0001558370-24-01530410-Q Voyager Therapeutics, Inc. 20241112202411121601461601461601460 0001558370-24-015304 10-Q 65 20240930 20241112 20241112 Voyager Therapeutics, Inc. 0001640266 2836 000000000 DE 1231 10-Q 34 001-37625 241447779 75 HAYDEN AVENUE LEXINGTON MA 02421 857-259-5340 75 HAYDEN AVENUE LEXINGTON MA 02421 10-Q 1 vygr-20240930x10q.htm 10-Q 44038333false0001640266--12-312024Q3Todd Carter, Ph.D.Chief Scientific Officer5454204800001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember2024-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyNineteenMember2024-03-310001640266vygr:DrDinahSahMemberus-gaap:RelatedPartyMember2023-06-300001640266vygr:Facility75HaydenAvenueMember2023-08-112023-08-110001640266vygr:NovartisPharmaAgMembervygr:NovartisCollaborationAgreement2023Member2023-12-280001640266vygr:NonProfitAgreementMember2016-01-012016-12-310001640266vygr:NonProfitAgreementMember2016-12-310001640266vygr:NonProfitAgreementMember2017-12-310001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember2024-09-012024-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember2024-04-012024-04-300001640266vygr:NovartisPharmaAgMembervygr:OptionAndLicenseAgreementMember2024-09-032024-09-030001640266vygr:NovartisPharmaAgMembervygr:NovartisCollaborationAgreement2023Member2023-01-012023-12-310001640266vygr:NovartisPharmaAgMembervygr:OptionAndLicenseAgreementMembervygr:SalesMilestoneMember2024-09-032024-09-030001640266vygr:NovartisPharmaAgMembervygr:OptionAndLicenseAgreementMembervygr:DevelopmentRegulatoryAndCommercializationMilestoneMember2024-09-032024-09-030001640266vygr:PreFundedWarrantsMemberus-gaap:OverAllotmentOptionMember2024-01-092024-01-090001640266vygr:NovartisPharmaAgMembervygr:NovartisCollaborationAgreement2023Member2023-12-282023-12-280001640266us-gaap:AdditionalPaidInCapitalMembervygr:NovartisCollaborationAgreement2023Member2024-01-012024-03-310001640266vygr:NovartisCollaborationAgreement2023Member2024-01-012024-03-310001640266us-gaap:AdditionalPaidInCapitalMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember2023-01-012023-03-310001640266vygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember2023-01-012023-03-310001640266us-gaap:CommonStockMember2024-07-012024-09-300001640266us-gaap:CommonStockMember2024-01-012024-03-310001640266us-gaap:CommonStockMember2023-07-012023-09-300001640266us-gaap:CommonStockMember2023-01-012023-03-310001640266us-gaap:CommonStockMember2024-04-012024-06-300001640266us-gaap:CommonStockMember2023-04-012023-06-300001640266us-gaap:CommonStockMembervygr:NovartisCollaborationAgreement2023Member2024-01-012024-03-310001640266us-gaap:CommonStockMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember2023-01-012023-03-310001640266us-gaap:RetainedEarningsMember2024-09-300001640266us-gaap:AdditionalPaidInCapitalMember2024-09-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001640266us-gaap:RetainedEarningsMember2024-06-300001640266us-gaap:AdditionalPaidInCapitalMember2024-06-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001640266662024-06-300001640266us-gaap:RetainedEarningsMember2024-03-310001640266us-gaap:AdditionalPaidInCapitalMember2024-03-310001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001640266620242024-03-310001640266us-gaap:RetainedEarningsMember2023-12-310001640266us-gaap:AdditionalPaidInCapitalMember2023-12-310001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001640266us-gaap:RetainedEarningsMember2023-09-300001640266us-gaap:AdditionalPaidInCapitalMember2023-09-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001640266us-gaap:RetainedEarningsMember2023-06-300001640266us-gaap:AdditionalPaidInCapitalMember2023-06-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001640266620232023-06-300001640266us-gaap:RetainedEarningsMember2023-03-310001640266us-gaap:AdditionalPaidInCapitalMember2023-03-310001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001640266620232023-03-310001640266us-gaap:RetainedEarningsMember2022-12-310001640266us-gaap:AdditionalPaidInCapitalMember2022-12-310001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001640266us-gaap:CommonStockMember2024-09-300001640266us-gaap:CommonStockMember2024-06-300001640266us-gaap:CommonStockMember2024-03-310001640266us-gaap:CommonStockMember2023-12-310001640266us-gaap:CommonStockMember2023-09-300001640266us-gaap:CommonStockMember2023-06-300001640266us-gaap:CommonStockMember2023-03-310001640266us-gaap:CommonStockMember2022-12-310001640266us-gaap:RestrictedStockUnitsRSUMember2023-12-310001640266us-gaap:OverAllotmentOptionMember2024-01-092024-01-090001640266vygr:NovartisPharmaAgMembervygr:OptionAndLicenseAgreementMember2024-07-012024-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember2024-04-012024-06-300001640266vygr:SidneyStreet75And64LeasesMember2024-09-300001640266vygr:DrDinahSahMemberus-gaap:RelatedPartyMember2024-07-012024-09-300001640266vygr:DrDinahSahMemberus-gaap:RelatedPartyMember2024-01-012024-09-300001640266vygr:DrDinahSahMemberus-gaap:RelatedPartyMember2023-07-012023-09-300001640266vygr:DrDinahSahMemberus-gaap:RelatedPartyMember2023-01-012023-09-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001640266us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001640266vygr:Facility75HaydenAvenueMember2024-02-01000164026662024-09-012024-09-300001640266us-gaap:RetainedEarningsMember2024-07-012024-09-300001640266us-gaap:RetainedEarningsMember2024-04-012024-06-300001640266us-gaap:RetainedEarningsMember2024-01-012024-03-310001640266us-gaap:RetainedEarningsMember2023-07-012023-09-300001640266us-gaap:RetainedEarningsMember2023-04-012023-06-300001640266us-gaap:RetainedEarningsMember2023-01-012023-03-310001640266us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001640266us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001640266us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001640266us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001640266us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-09-300001640266us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001640266us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-09-300001640266us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-09-300001640266us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001640266us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001640266us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001640266us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001640266us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001640266us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001640266us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001640266us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001640266us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001640266us-gaap:RestrictedStockUnitsRSUMember2024-09-300001640266us-gaap:EmployeeStockOptionMember2024-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:DiscoveryProgramThreeMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborativeAgreementTwentyNineteenMember2024-09-01-012024-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember2024-07-012024-09-300001640266vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyNineteenMember2024-01-012024-03-310001640266vygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember2024-09-300001640266vygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborativeAgreementTwentyNineteenMember2024-09-300001640266vygr:NeurocrineCollaborativeAgreementTwentyNineteenMember2024-09-300001640266vygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborativeAgreementTwentyNineteenMember2023-12-310001640266vygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborativeAgreementTwentyNineteenMember2024-01-012024-09-300001640266us-gaap:OverAllotmentOptionMember2024-01-040001640266vygr:PreFundedWarrantsMemberus-gaap:OverAllotmentOptionMember2024-01-090001640266vygr:PreFundedWarrantsMemberus-gaap:OverAllotmentOptionMember2024-01-040001640266620232023-09-300001640266620222022-12-310001640266us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001640266us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001640266us-gaap:MoneyMarketFundsMember2024-09-300001640266us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001640266us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001640266us-gaap:MoneyMarketFundsMember2023-12-310001640266us-gaap:CommercialPaperMember2023-12-310001640266us-gaap:USTreasurySecuritiesMember2024-09-300001640266us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001640266us-gaap:CorporateBondSecuritiesMember2024-09-300001640266us-gaap:CommercialPaperMember2024-09-300001640266us-gaap:CertificatesOfDepositMember2024-09-300001640266us-gaap:USTreasurySecuritiesMember2023-12-310001640266us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001640266us-gaap:CorporateBondSecuritiesMember2023-12-310001640266us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001640266us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001640266us-gaap:FairValueMeasurementsRecurringMember2024-09-300001640266us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001640266us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001640266us-gaap:FairValueMeasurementsRecurringMember2023-12-310001640266vygr:Facility75HaydenAvenueMember2023-08-110001640266us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001640266us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001640266us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001640266us-gaap:RestrictedStockMember2023-07-012023-09-300001640266us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001640266us-gaap:RestrictedStockMember2023-01-012023-09-300001640266us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001640266us-gaap:StockCompensationPlanMember2024-07-012024-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001640266us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001640266us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001640266us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001640266us-gaap:StockCompensationPlanMember2024-01-012024-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001640266us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001640266us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001640266us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001640266us-gaap:StockCompensationPlanMember2023-07-012023-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001640266us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001640266us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001640266us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001640266us-gaap:StockCompensationPlanMember2023-01-012023-09-300001640266us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001640266us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001640266us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001640266us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001640266us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001640266us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001640266620242024-04-012024-06-300001640266us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001640266620242024-01-012024-03-310001640266us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001640266620232023-07-012023-09-300001640266us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001640266620232023-04-012023-06-300001640266us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001640266620232023-01-012023-03-310001640266620232023-09-300001640266620242024-09-300001640266620232023-12-310001640266vygr:ToddCarterPh.d.Member2024-09-300001640266vygr:ToddCarterPh.d.Member2024-07-012024-09-300001640266620242024-07-012024-09-300001640266620242024-10-280001640266620242024-01-012024-09-30xbrli:sharesiso4217:USDutr:sqftiso4217:USDxbrli:sharesvygr:Programvygr:multiplexbrli:pureTable of Contents â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549â€‹â€‹FORM 10-Qâ€‹â€‹â€‹â˜’QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended SeptemberÂ 30,Â 2024â€‹â€‹â˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____ to _____Commission file number: 001-37625â€‹â€‹Voyager Therapeutics, Inc.(Exact name of Registrant as specified in its charter)â€‹â€‹â€‹Delawareâ€‹46-3003182(State or other jurisdiction ofincorporation or organization)â€‹(I.R.S. EmployerIdentification No.)â€‹â€‹â€‹75 Hayden Avenue, Lexington, Massachusettsâ€‹02421(Address of principal executive offices)â€‹(Zip Code)(857) 259-5340(Registrantâ€™s telephone number, including area code)â€‹â€‹Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, $0.001 par valueVYGRNasdaq Global Select Marketâ€‹Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜§ Â Â No Â Â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes Â Â˜§ Â Â No Â Â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Large accelerated filerâ˜Accelerated filerâ˜Non-accelerated filerâ˜Smaller reporting companyâ˜‘â€‹â€‹â€‹â€‹Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes Â Â˜ Â Â No Â Â˜The number of outstanding shares of the registrantâ€™s common stock, par value $0.001 per share, as of October 28, 2024 was 54,625,586. â€‹â€‹ Table of ContentsForward-Looking StatementsThis Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations,

future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.â€‹The words â€œanticipate,â€ â€œbelieve,â€ â€œestimate,â€ â€œexpect,â€ â€œintend,â€ â€œmay,â€ â€œmight,â€ â€œplan,â€ â€œpredict,â€ â€œproject,â€ â€œtarget,â€ â€œpotential,â€ â€œcontemplate,â€ â€œanticipate,â€ â€œgoals,â€ â€œwill,â€ â€œwould,â€ â€œcould,â€ â€œshould,â€ â€œcontinue,â€ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about:â€‹â€”our plans to develop and commercialize our product candidates based on adeno-associated virus, or AAV, gene therapy and our proprietary antibodies;â€‹â€”our ability to continue to develop our proprietary gene therapy platform technologies, including our TRACERTM (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) discovery platform and our vectorized antibody platform, our proprietary antibody program, and our gene therapy and vectorized antibody programs;â€‹â€”our ability to identify and optimize product candidates and proprietary AAV capsids;â€‹â—our strategic collaborations and licensing agreements with, and funding from, our collaboration partners Neurocrine Biosciences, Inc. and Novartis Pharma AG, and our licensee Alexion, AstraZeneca Rare Disease (successor-in-interest to former licensee Pfizer Inc.);â€‹â€”our planned and initiated clinical trials and ongoing and planned preclinical development efforts, related timelines and studies;â€‹â€”our ability to enter into future collaborations, strategic alliances, or option and license arrangements;â€‹â—the timing of and our ability to submit applications and obtain and maintain regulatory approvals for our product candidates, including the ability to submit investigational new drug, applications for our programs;â€‹â—our estimates regarding future revenues, expenses, contingent liabilities, existing cash resources, capital requirements and cash runway; â€‹â—our intellectual property position and our ability to obtain, maintain and enforce intellectual property protection for our proprietary assets; â€‹â—our estimates regarding the size of the potential markets for our product candidates and our ability to serve those markets; â€‹â—our need for additional funding and our plans and ability to raise additional capital, including through equity offerings, debt financings, collaborations, strategic alliances, and option and license arrangements; â€‹â—our competitive position and the success of competing products that are or might become available for the indications that we are pursuing;â€‹2 Table of Contentsâ—the impact of government laws and regulations including in the United States, the European Union, and other important geographies such as Japan; andâ€‹â—our ability to control costs and prioritize our product candidate pipeline and platform development objectives successfully in connection with our strategic initiatives.These forward-looking statements are only predictions, and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. You should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. We have included important factors in the cautionary statements included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2024, particularly in â€œPart I, Item 1A â€” Risk Factors,â€ and, if applicable, our Quarterly Reports on Form 10-Q, particularly in â€œPart II, Item 1A â€ Risk Factors,â€ that could cause actual future results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, strategic collaborations, licenses, joint ventures or investments we may make.â€‹You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.â€‹We obtained the statistical and other industry and market data in this Quarterly Report on Form 10-Q and the documents we have filed as exhibits to the Quarterly Report on Form 10-Q from our own internal estimates and research, as well as from industry and general publications and research, surveys, studies and trials conducted by third parties. Some data is also based on our good faith estimates, which are derived from managementâ€™s knowledge of the industry and independent sources. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, while we believe the market opportunity information included in this Quarterly Report on Form 10-Q and the documents we have filed as exhibits to the Quarterly Report on Form 10-Q is reliable and is based upon reasonable assumptions, such data involves risks and uncertainties and are subject to change based on various factors, including those discussed under â€œRisk Factorsâ€ and in the documents we have filed as exhibits to the Quarterly Report on Form 10-Q. In addition, statements that â€œwe believeâ€ and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. â€‹We own various U.S. federal trademark registrations and applications and unregistered trademarks, including our corporate logo. This Quarterly Report on Form 10-Q and the documents filed as exhibits to the Quarterly Report on Form 10-Q contain references to trademarks, service marks and trade names referred to in this Quarterly Report on Form 10-Q and the information incorporated herein, including logos, artwork, and other visual displays, that may appear without the Â® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks or trade names. We do not intend our use or display of other companiesâ€™ trade names, service marks or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. All trademarks, service marks and trade names included or incorporated by reference into this Quarterly Report on Form 10-Q and the documents filed as exhibits to the Quarterly Report on Form 10-Q are the property of their respective owners.â€‹3 Table of ContentsVOYAGER THERAPEUTICS, INC.FORM 10-QTABLE OF CONTENTSâ€‹â€‹â€‹â€‹â€‹PagePART I. FINANCIAL INFORMATIONITEM 1.Â Â Â CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)5â€‹â€‹CONDENSED CONSOLIDATED BALANCE SHEETS5â€‹â€‹CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) Income 6â€‹â€‹CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY7â€‹â€‹CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS8â€‹â€‹NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS9ITEM 2.â€‹MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS19ITEM 3.â€‹QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK33ITEM 4.â€‹CONTROLS AND PROCEDURES33â€‹â€‹â€‹PART II. OTHER INFORMATIONITEM 1.â€‹LEGAL PROCEEDINGS33ITEM 1A.â€‹RISK FACTORS34ITEM 2.â€‹UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSâ€‹ITEM 5.â€‹OTHER INFORMATION34ITEM 6.â€‹EXHIBITS35â€‹â€‹SIGNATURES36â€‹â€‹â€‹4 Table of ContentsPART I. FINANCIAL INFORMATIONâ€‹Voyager Therapeutics, Inc.Condensed Consolidated Balance Sheets(amounts in thousands, except share and per share data)

| (unaudited)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â Â â€‹Â Â Â 2024Â Â Â Â 2023Â Assetsâ€‹â€‹Â Â Â Â â€‹â€‹Â Â Â Â â€‹Current assets:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Cash and cash equivalentsâ€‹$ 112,525â€‹$ 68,802â€‹Marketable securities, currentâ€‹Â 232,835â€‹Â 162,073â€‹Accounts receivableâ€‹â€‹ 15,954â€‹â€‹ 80,150â€‹Related party collaboration receivableâ€‹â€‹ 3,714â€‹â€‹ 3,341â€‹Prepaid expenses and other current assetsâ€‹Â 8,415â€‹Â 5,318â€‹Total current assetsâ€‹Â 373,443â€‹Â 319,684â€‹Property and equipment, netâ€‹Â 15,201â€‹Â 16,494â€‹Deposits and other non-current assetsâ€‹Â 2,874â€‹Â 1,593â€‹Operating lease, right-of-use assetsâ€‹Â 34,523â€‹Â 13,510â€‹Total assetsâ€‹$ 426,041â€‹$ 351,281â€‹Liabilities and stockholdersâ€™ equityâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Current liabilities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Accounts payableâ€‹$ 3,160â€‹$ 1,604â€‹Accrued expensesâ€‹Â 11,442â€‹Â 16,823â€‹Other current liabilitiesâ€‹â€‹ 6,979â€‹â€‹ 3,200â€‹Deferred revenue, currentâ€‹Â 22,629â€‹Â 42,881â€‹Total current liabilitiesâ€‹Â 44,210â€‹â€‹ 64,508â€‹Deferred revenue, non-currentâ€‹Â 12,153â€‹Â 32,359â€‹Other non-current liabilitiesâ€‹Â 39,368â€‹Â 18,094â€‹Total liabilitiesâ€‹Â 95,731â€‹â€‹ 114,961â€‹Commitments and contingencies (see noteÂ 7)â€‹â€‹â€‹â€‹â€‹â€‹â€‹Stockholdersâ€™ equity:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Preferred stock, $0.001 par value: 5,000,000 shares authorized at SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023; no shares issued and outstanding at SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023â€‹â€‹ â€”â€‹â€‹ â€”â€‹Common stock, $0.001 par value: 120,000,000 shares authorized at SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023; 54,542,048 and 44,038,333 shares issued and outstanding at SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023, respectivelyâ€‹Â 55â€‹Â 44â€‹Additional paid-in capitalâ€‹Â 621,985â€‹Â 497,506â€‹Accumulated other comprehensive lossâ€‹Â (33)â€‹Â (48)â€‹Accumulated deficitâ€‹Â (291,697)â€‹Â (261,182)â€‹Total stockholdersâ€™ equityâ€‹Â 330,310â€‹Â 236,320â€‹Total liabilities and stockholdersâ€™ equityâ€‹$ 426,041â€‹$ 351,281â€‹â€‹The accompanying notes are an integral part of these condensed consolidated financial statements.â€‹5 Table of ContentsVoyager Therapeutics, Inc.Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (amounts in thousands, except share and per share data) (unaudited)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

66,862â€‹Supplemental disclosure of cash and non-cash activitiesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Operating lease right-of-use asset obtained in exchange for operating lease liabilityâ€‹$ 26,751â€‹$ â€”â€‹â€‹The accompanying notes are an integral part of these condensed consolidated financial statements.â€‹8 Table of ContentsVOYAGER THERAPEUTICS INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS1. Nature of businessVoyager Therapeutics, Inc. (the â€œCompanyâ€) is a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. The Companyâ€™s pipeline includes programs for Alzheimerâ€™s disease; amyotrophic lateral sclerosis; Parkinsonâ€™s disease, and multiple other diseases of the central nervous system. Many of the Companyâ€™s programs are derived from its TRACERâ„¢ adeno-associated virus (â€œAAVâ€) capsid discovery platform, which the Company has used to generate novel capsids (â€œTRACER Capsidsâ€) and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of the Companyâ€™s programs are wholly-owned, and some are advancing with licensees and collaborators including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG, (â€œNovartisâ€); and Neurocrine Biosciences, Inc. (â€œNeurocrineâ€). The Company has a history of incurring annual net operating losses. As of SeptemberÂ 30,Â 2024, the Company had an accumulated deficit of $291.7 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities, funding from fees, option exercise payments, and milestone payments, and cost reimbursements associated with its prior and ongoing collaborations and license agreements.As of SeptemberÂ 30,Â 2024, the Company had cash, cash equivalents, and marketable securities of $345.4 million. Based upon the Companyâ€™s current operating plans, the Company expects that its existing cash, cash equivalents, and marketable securities at SeptemberÂ 30,Â 2024 to be sufficient to meet the Companyâ€™s planned operating expenses and capital expenditure requirements for at least twelve months from the issuance of these consolidated financial statements.There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Companyâ€™s business, results of operations, and financial condition. 2. Summary of significant accounting policies and basis of presentationBasis of PresentationThe accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31,Â 2023 as filed with the Securities and Exchange Commission (â€œSECâ€) on February 28, 2024. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Companyâ€™s financial position and results of operations for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.Principles of ConsolidationThe unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary as disclosed in Note 2, under the heading â€œSummary of Significant Accounting Policies and Basis of Presentation,â€ within the â€œNotes to Consolidated Financial Statementsâ€ accompanying the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31,Â 2023. Intercompany balances and transactions have been eliminated.9 Table of ContentsUse of EstimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Companyâ€™s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, incremental borrowing rate for leases, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.Summary of Significant Accounting PoliciesThere have been no changes in the Company's significant accounting policies as described in Note 2, â€œSummary of Significant Accounting Policies and Basis of Presentation,â€ within the â€œNotes to Consolidated Financial Statementsâ€ accompanying the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023.3. Fair value measurementsAssets and liabilities measured at fair value on a recurring basis as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023 are as follows:â€‹â€‹â€‹â€‹â€‹â€‹

Company announced that the joint steering committee with Neurocrine selected a development candidate in a gene therapy program for the potential treatment of an undisclosed neurological disease under the 2023 Neurocrine Collaboration Agreement, which triggered a $3.0Â million milestone payment to the Company which was received in October 2024. The Company included the $3.0 million that had previously been constrained in the transaction price allocated to the programâ€™s performance obligation in the three months ended September 30, 2024, accordingly, which resulted in a cumulative catch-up adjustment to collaboration revenue of approximately $2.0 million.â€‹2023 Novartis Stock Purchase Agreementâ€‹Under the stock purchase agreement entered into in December 2023 (the â€œ2023 Novartis Stock Purchase Agreementâ€), Novartis purchased 2,145,002 shares of common stock of the Company (the â€œNovartis Sharesâ€) for an aggregate purchase price of approximately $20.0 million. The issuance of the Novartis Shares to Novartis pursuant to the 2023 Novartis Stock Purchase Agreement in January 2024 resulted in a premium of $0.7 million. The premium was allocated to the development and commercialization licenses granted to Novartis for two programs pursuant to the license and collaboration agreement with Novartis entered into in December 2023 and was recognized as collaboration revenue during the first quarter of 2024, upon the issuance of the Novartis Shares under the 2023 Novartis Stock Purchase Agreement.â€‹14 Table of Contents2019 Neurocrine Collaboration Agreementâ€‹In February 2024, the Company announced that the joint steering committee with Neurocrine selected a lead development candidate for the gene therapy program for Friedreichâ€™s ataxia (the â€œFA Programâ€) under the collaboration and license agreement with Neurocrine entered into in January 2019 (the â€œ2019 Neurocrine Collaboration Agreementâ€), which triggered a $5.0Â million milestone payment to the Company that was received in the first quarter of 2024. The Company included the $5.0 million that had previously been constrained in the transaction price allocated to the FA Program performance obligation in the three months ended March 31, 2024, accordingly, which resulted in a cumulative catch-up adjustment to collaboration revenue of $4.4 million.â€‹Related Party Collaboration Receivable â€‹The following table presents changes in the balances of the Companyâ€™s related party collaboration receivable and contract liabilities for the 2023 Neurocrine Collaboration Agreement and the 2019 Neurocrine Collaboration Agreement during the nine months ended SeptemberÂ 30,Â 2024:â€‹â€‹â€‹

reductions. For a further description of the 2023 Novartis Collaboration Agreement, refer to Note 9, Significant Agreements, to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 under the caption â€œ2023 Novartis Collaboration Agreement.â€â€‹2023 Novartis Stock Purchase Agreementâ€‹We and Novartis also entered into a stock purchase agreement on December 28, 2023, or the 2023 Novartis Stock Purchase Agreement, for the sale and issuance of 2,145,002 shares of our common stock, or the Novartis Shares, to Novartis at a price of $9.324 per share, for an aggregate purchase price of approximately $20.0 million. In accordance with the terms and conditions of the 2023 Novartis Stock Purchase Agreement, we issued and sold the Novartis Shares to Novartis on January 3, 2024, or the 2023 Novartis Investment Closing Date.â€‹2023 Novartis Investor Agreementâ€‹We and Novartis also entered into an investor agreement on December 28, 2023, or the 2023 Novartis Investor Agreement, which became effective as of the 2023 Novartis Investment Closing Date, providing for standstill and lock-up restrictions. Pursuant to the terms of the 2023 Novartis Investor Agreement, Novartis has agreed not to, without the prior written approval of us and subject to specified conditions, directly or indirectly acquire shares of our outstanding common stock, publicly seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents to vote any voting securities that we have issued, or undertake other specified actions related to the potential acquisition of additional equity interests in us. Further, Novartis has also agreed not to, and to cause its affiliates not to sell or transfer any of the Novartis Shares without our prior approval, subject to specified conditions.â€‹2022 Novartis Option and License Agreementâ€‹On March 4, 2022, or the 2022 Novartis Option and License Effective Date, we entered into the 2022 Novartis Option and License Agreement. Pursuant to the 2022 Novartis Option and License Agreement, we granted Novartis options, or the Novartis License Options, to license TRACER Capsids, or the Novartis Licensed Capsids, for exclusive use with certain targets to develop and commercialize AAV gene therapy candidates comprised of Novartis Licensed Capsids and payloads directed to such targets, or the Novartis Initial Licensed Products. Effective as of March 1, 2023, Novartis exercised its Novartis License Options to license TRACER Capsids for use in gene therapy programs againstÂ twoÂ undisclosed programs targeting specified genes, or the Initial Novartis Targets. Novartis elected not to license a capsid for one Initial Novartis Target prior to the expiration of the applicable Novartis License Option. As a result, the non-exclusive research license that we granted to Novartis in connection with this third Initial Novartis Target terminated, and all capsid rights with respect to that Initial Novartis Target returned to us.â€‹On SeptemberÂ 3, 2024 we entered into the Novartis Amendment. Pursuant to the Novartis Amendment, we agreed to amend the 2022 Novartis Option and License Agreement to incorporate the grant to Novartis of the Novartis Direct License to the Novartis Direct Licensed Capsid for exclusive use with the Novartis Direct License Target to develop and commercialize the Novartis Direct Licensed Capsid as incorporated into Novartis Direct Licensed Products. We refer to the Novartis Initial Licensed Products and Novartis Direct Licensed Products collectively as Novartis Licensed Products. As a result of the Novartis Amendment, the Novartis Direct License Target is now deemed a Licensed Target under the 2022 Novartis Option and License Agreement, as such term is defined therein, and the Novartis Direct License is subject to all other terms and conditions applicable to other licenses granted to Novartis under the 2022 Novartis Option and License Agreement. Novartis agreed to pay us a one-time fee of $15.0 million in consideration for the rights granted under the Novartis Amendment which we received in October 2024. In connection with the Novartis Amendment, the parties acknowledged that Novartisâ€™ prior rights to exercise options for any initial targets and additional targets as described in the 2022 Novartis Option and License Agreement, other than those that had previously been exercised, had expired as of the effective date of the Novartis Amendment.â€‹We are eligible to receive specified development, regulatory, and commercialization milestone payments of up to an aggregate of $125.0 million for the first Novartis Initial Licensed Product for each Initial Novartis Target for which 21 Table of Contentsa Novartis License Option has been exercised to achieve the corresponding milestone. Additionally, we are eligible to receive specified development, regulatory, and commercialization milestone payments of up to an aggregate of $130.0 million for the first Novartis Direct Licensed Product to achieve the corresponding milestone. On a Novartis Licensed Product-by-Novartis Licensed Product basis, we are also eligible to receive (a)Â specified sales milestone payments of up to an aggregate of $175.0 million per Novartis Licensed Product and (b)Â tiered, escalating royalties in the mid- to high-single-digit percentages of annual net sales of each Novartis Licensed Product. For a further description of the 2022 Novartis Option and License Agreement, refer to Note 9, Significant Agreements, to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 under the caption â€œ2022 Novartis Option and License Agreement.â€â€‹2023 Neurocrine Collaboration AgreementIn January 2023, we entered into a collaboration agreement, or the 2023 Neurocrine Collaboration Agreement, with Neurocrine for the research, development, manufacture and commercialization of certain of our AAV gene therapy products. Under the 2023 Neurocrine Collaboration Agreement, we agreed to collaborate on the conduct of four collaboration programs, which we refer to collectively as the 2023 Neurocrine Programs: a glucocerebrosidase 1, or GBA1, gene therapy program for Parkinsonâ€™s disease and other GBA1-mediated diseases, or the GBA1 Program, and three new programs focused on the research, development, manufacture and commercialization of gene therapies designed to address central nervous system diseases or conditions associated with rare genetic targets, or the 2023 Discovery Programs. Neurocrine has agreed to be responsible for all costs we incur in conducting preclinical development activities for each 2023 Neurocrine Program, in accordance with JSC-agreed upon workplans and budgets.â€‹The 2023 Neurocrine Collaboration Agreement provides for aggregate development milestone payments from Neurocrine to us for the research, development, manufacture, and commercialization of gene therapy products, or the 2023 Collaboration Products, under (a) the GBA1 Program of up to $985.0 million; and (b) each of the three 2023 Discovery Programs of up to $175.0 million for each 2023 Discovery Program. We may be entitled to receive aggregate commercial milestone payments for up to two 2023 Collaboration Products under the GBA1 Program of up to $950.0 million per 2023 Collaboration Product and for one 2023 Collaboration Product under each 2023 Discovery Program of up to $275.0 million per 2023 Discovery Program. In September 2024, we announced that the JSC with Neurocrine selected a development candidate in a gene therapy program for the potential treatment of an undisclosed neurological disease under the 2023 Neurocrine Collaboration Agreement, which triggered a $3.0Â million milestone payment to us. We received the $3.0 million during October 2024.â€‹Neurocrine has also agreed to pay us tiered royalties, based on future net sales of the 2023 Collaboration Products.Â Such royalty percentages, for net sales in and outside the United States, range from (a)Â for the GBA1 Program, the low double-digits to twenty and the high single-digits to mid-teens, respectively, and (b)Â for each 2023 Discovery Program, high single-digits to mid-teens and mid-single digits to low double-digits, respectively.Â For a further description of the 2023 Neurocrine Collaboration Agreement, refer to Note 9, Significant Agreements, to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 under the caption â€œ2023 Neurocrine Collaboration Agreement.â€â€‹2019 Neurocrine Collaboration Agreementâ€‹In January 2019, we entered into a collaboration and license agreement with Neurocrine, or the 2019 Neurocrine Collaboration Agreement for the research, development and commercialization of certain of our AAV gene therapy products. Under the 2019 Neurocrine Collaboration Agreement, we agreed to collaborate on the conduct of four collaboration programs, which we refer to collectively as the 2019 Neurocrine Programs: the NBIb-1817 (VY-AADC) program for the treatment of Parkinsonâ€™s disease, or the VY-AADC Program; a frataxin gene therapy program for Friedreichâ€™s ataxia, or the FA Program, and two other undisclosed programs, which we refer to as the 2019 Discovery Programs. Neurocrine has agreed to be responsible for all costs we incur in conducting preclinical development activities for each 2019 Neurocrine Program, in accordance with JSC-agreed upon workplans and budgets.â€‹The 2019 Neurocrine Collaboration Agreement provides for aggregate development milestone payments from Neurocrine to us for the research, development, manufacture, and commercialization of gene therapy products, or the 22 Table of Contents2019 Collaboration Products, under (a) the FA Program of up to $195.0 million, and (b) each of the two 2019 Discovery Programs of up to $130.0 million per 2019 Discovery Program. We may be entitled to receive aggregate commercial milestone payments for each 2019 Collaboration Product of up to $275.0 million, subject to an aggregate cap on commercial milestone payments across all 2019 Neurocrine Programs of $1.1 billion. We are no longer eligible to receive milestone or royalty payments for the VY-AADC Program in light of the partial termination of the 2019 Neurocrine Collaboration Agreement with respect to the VY-AADC Program. The JSCâ€™s selection of a lead development candidate for the FA Program in February 2024 triggered a $5.0 million milestone payment to us, which we received in March 2024.â€‹Neurocrine has also agreed to pay us royalties, based on future net sales of the 2019 Collaboration Products. Such royalty percentages, for net sales in and outside the United States, as applicable, range (a) for the FA Program, from the low-teens to high-teens and high-single digits to mid-teens, respectively; and (b) for each 2019 Discovery Program, from the high-single digits to mid-teens and mid-single digits to low-teens, respectively. For a further description of the 2019 Neurocrine Collaboration Agreement, refer to Note 9, Significant Agreements, to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 under the caption â€œ2019 Neurocrine Collaboration Agreement.â€â€‹Alexion Option and License Agreementâ€‹In October 2021, we entered into an option and license agreement with Pfizer Inc., or Pfizer, pursuant to which we granted Pfizer options to receive an exclusive license to certain TRACER Capsids to develop and commercialize certain AAV gene therapy candidates comprised of a capsid and specified transgene. Effective as of September 30, 2022, Pfizer exercised one option with respect to a capsid for a specified transgene for potential treatment of a rare neurological disease, and we granted Pfizer an exclusive, worldwide license, with the right to sublicense, under certain of our intellectual property, the rights to develop and commercialize rare neurological disease products utilizing the capsid candidate and incorporating the specified transgene. â€‹Effective upon the closing of a transaction on September 20, 2023, Alexion (via Alexion Pharma International Operations Limited, or APIO) acquired all of Pfizerâ€™s rights under the option and license agreement, which we refer to as the Alexion Agreement, and became the successor-in-interest to Pfizer thereunder.Â APIO subsequently assigned the Alexion Agreement to its affiliate AstraZeneca Ireland Limited, or AstraZeneca. Neither the acquisition by Alexion nor the subsequent assignment from APIO to AstraZeneca impacted the material terms of the Alexion Agreement. â€‹Pursuant to an amendment to the Alexion Agreement effective as of September 30, 2024, we agreed to extend the research term thereunder until April 1, 2025, during which period we may, at our sole discretion and expense, conduct further research activities to identify additional TRACER Capsids for potential use in the development of AAV gene therapies under the Alexion Agreement. For a further description of the Alexion Agreement, refer to Note 9, Significant Agreements, to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 under the caption â€œAlexion Option and License Agreement (Formerly Pfizer Option and License Agreement).â€ â€‹2024 Underwritten Public OfferingIn January 2024, we issued and sold 7,777,778 shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 3,333,333 shares of common stock in a public offering, or the 2024 Public Offering, at a public offering price of $9.00 per share of common stock and $8.999 per pre-funded warrant. The 2024 Public Offering resulted in net proceeds to the Company of approximately $93.5 million after deducting underwriting discounts and commissions and offering expenses.Each pre-funded warrant has an exercise price of $0.001 per share and is exercisable for one share of common stock from the date of issuance until the pre-funded warrant is exercised in full. Under the terms of the pre-funded warrants, we may not effect the exercise of any such warrant, and a holder will not be entitled to exercise any portion of any such warrant, that, upon giving effect to or immediately prior to, would cause: (1) the aggregate number of shares of our common stock beneficially owned by such holder (together with its affiliates) to exceed 9.99% of the number of 23 Table of Contentsshares of our common stock outstanding immediately after giving effect to the exercise; or (2) the combined voting power of our securities beneficially owned by such holder (together with its affiliates) to exceed 9.99% of the combined voting power of all of our securities outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants. However, any holder of a pre-funded warrant may increase or decrease such percentage to any other percentage not in excess of 19.99% provided that any such increase will not be effective until the 61st day after notice from the holder is delivered to us.Accumulated Deficit; ExpensesDespite reporting $132.3 million in net income for the year ended December 31, 2023, we have a history of incurring significant losses. As of SeptemberÂ 30,Â 2024, we had an accumulated deficit of $291.7 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially in connection with our ongoing activities, as we:â—conduct clinical trials in connection with our anti-tau antibody program;â—conduct preclinical development activities and initiate IND application-enabling studies and clinical trials in connection with our SOD1 ALS gene therapy program;â—continue investing in our proprietary antibody program, gene therapy and vectorized antibody platforms and programs, and other research and development initiatives; â—increase our investment in and support for TRACER, our proprietary discovery platform to facilitate the selection of AAV capsids and expand our investment to discover TRACER Capsids with broad tropism in CNS and other tissues with cell-specific transduction properties for particular therapeutic applications;â—increase our investment in the discovery and development of modalities for receptor-mediated non-viral delivery of therapeutic payloads to the CNS;â—conduct joint research and development under our strategic collaborations for the research, development, and commercialization of certain of our pipeline programs, including our FA Program pursuant to the 2019 Neurocrine Collaboration Agreement, our GBA1 Program pursuant to the 2023 Neurocrine Collaboration Agreement, and the Novartis HD Program pursuant to the 2023 Novartis Collaboration Agreement;â—initiate additional preclinical studies and clinical trials for, and continue research and development of, our other programs; â—continue our process research and development activities, as well as establish our research-grade manufacturing capabilities; â—identify additional diseases for treatment with our AAV gene therapies and develop additional programs or product candidates; â—seek marketing and regulatory approvals for any of our product candidates that successfully complete clinical development;â—maintain, expand, protect and enforce our intellectual property portfolio; â—identify, acquire or in-license other product candidates and technologies;â—expand our operational, financial and management systems and personnel, including personnel to support our clinical development, manufacturing and commercialization efforts; â—increase our clinical trial insurance coverage as we expand our clinical trials and increase our product liability insurance once we engage in commercialization efforts; and 24 Table of Contentsâ—continue to operate as a public company.Financial Operations OverviewRevenueTo date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales for the foreseeable future. For the three months ended SeptemberÂ 30,Â 2024, we recognized $15.0 million of collaboration revenue from the Novartis Amendment, $7.7 million of collaboration revenue from the 2023 Neurocrine Collaboration Agreement, $0.9 million of collaboration revenue from the 2019 Neurocrine Collaboration Agreement, and $1.0 million of collaboration revenue from the 2023 Novartis Collaboration Agreement. For the nine months ended SeptemberÂ 30,Â 2024, we recognized $15.0 million of collaboration revenue from the Novartis Amendment, $46.8 million of collaboration revenue from the 2023 Neurocrine Collaboration Agreement, $8.6 million of collaboration revenue from the 2019 Neurocrine Collaboration Agreement, and $3.4 million of collaboration revenue from the 2023 Novartis Collaboration Agreement.For additional information about our revenue recognition policy related to the 2023 and 2019 Neurocrine Collaboration Agreements and the 2023 Novartis Collaboration Agreement, refer to Note 9 of the December 31, 2023 consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023.For the foreseeable future, we expect substantially all of our revenue will be generated from our current strategic collaborations and out-licensing arrangements with Neurocrine, Novartis, and Alexion, and any other strategic collaborations and out-licensing arrangements we may enter into in the future. If our development efforts are successful, we may also generate revenue from product sales in the future.ExpensesResearch and Development ExpensesResearch and development expenses consist primarily of costs incurred for our research activities, including our program discovery efforts, and the development of our proprietary antibody program and gene therapy and vectorized antibody platforms and programs which include:â€‹â—employee-related expenses including salaries, benefits, and stock-based compensation expense;â€‹â—costs of funding research performed by third parties that conduct research and development, preclinical and clinical activities, manufacturing and production design on our behalf;â—the cost of purchasing laboratory supplies and non-capital equipment used in designing, developing and manufacturing preclinical and clinical study materials;â—consultant fees;â—facility costs including rent, depreciation and maintenance expenses; â—the cost of securing and protecting intellectual property rights associated with our research and development activities; andâ—fees for maintaining licenses under our third-party licensing agreements.Research and development costs are expensed as incurred. Costs for certain activities, such as manufacturing, preclinical studies, and clinical trials, are generally recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and collaborators.Research and development activities are central to our business model. We are in the early stages of development of our product candidates. During the nine months ended SeptemberÂ 30,Â 2024, our research and development expenses have increased as compared to the amounts recorded in the same period in the prior year. As our 25 Table of Contentsresearch and development programs progress and as we identify product candidates and initiate preclinical studies and clinical trials, including our SAD clinical trial to evaluate VY7523 (formerly referred to as VY-TAU01) which we initiated in the first half of 2024, we expect research and development costs to continue to increase. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of our product candidates.Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses. Our expenses will increase if:â—we are required by the FDA or the European Medicines Agency or other regulatory agencies to redesign or modify trials or studies or to perform trials or studies in addition to

those currently expected;â—there are any delays in the receipt of regulatory clearance to begin our planned clinical programs; or â—there are any delays in enrollment of participants in or completing our clinical trials or the development of our product candidates.General and Administrative ExpensesGeneral and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, information technology, business development, legal and human resource functions. Other significant costs include corporate facility costs not otherwise included in research and development expenses, legal fees related to patent and corporate matters and fees for accounting and consulting services.Other Income, NetOther income, net consists primarily of interest income on our marketable securities.Critical Accounting Policies and EstimatesWe believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate. There were no changes to our critical accounting policies during the nine months ended SeptemberÂ 30,Â 2024, as compared to those identified in our Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023.Â It is important that the discussion of our operating results that follow be read in conjunction with the critical accounting policies disclosed in Item 7 â€œCritical Accounting Policies and Estimatesâ€ in our Annual Report on FormÂ 10-K, as filed with the SEC on February 28, 2024.26 Table of ContentsResults of Operations Comparison of the three months ended SeptemberÂ 30,Â 2024 and 2023The following table summarizes our results of operations for the three months ended SeptemberÂ 30,Â 2024 and 2023, together with the changes in those items in dollars:â€‹â€‹â€‹

particularly because our investments, including cash equivalents, are in the form of money market funds and marketable securities and are invested in U.S. Treasury notes. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we believe an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.We are not currently exposed to market risk related to changes in foreign currency exchange rates; however, we may contract with vendors that are located in Asia and Europe in the future and may be subject to fluctuations in foreign currency rates at that time.Inflation generally affects us by increasing our costs of labor, goods, and services. We do not believe that inflation had a material effect on our business, financial condition, or results of operations during the nine months ended SeptemberÂ 30,Â 2024.ITEM 4. CONTROLS AND PROCEDURESManagementâ€™s Evaluation of Disclosure Controls and ProceduresWe maintain â€œdisclosure controls and procedures,â€ as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act of 1934, or Exchange Act, to mean controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commissionâ€™s rules and forms. Our disclosure controls and procedures include, without limitation, controls and other procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.â€‹Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of SeptemberÂ 30,Â 2024. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of SeptemberÂ 30,Â 2024, our disclosure controls and procedures were effective at the reasonable assurance level. â€‹We continue to review and document our disclosure controls and procedures and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.â€‹Changes in Internal Control over Financial Reportingâ€‹During the three months ended SeptemberÂ 30,Â 2024, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.â€‹PART II. OTHER INFORMATIONITEM 1. LEGAL PROCEEDINGSIn the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to intellectual property, commercial arrangements and other matters. While the outcome of any such matters cannot be predicted with certainty, as of SeptemberÂ 30,Â 2024, we were not party to any 33 Table of Contentsmaterial pending proceedings. No material governmental proceedings are pending or, to our knowledge, contemplated against us. We are not a party to any material proceedings in which any director, member of senior management or affiliate of ours is either a party adverse to us or our subsidiaries or has a material interest adverse to us or our subsidiaries.ITEM 1A. RISK FACTORSWe are subject to a number of risks that could adversely affect our business, results of operations financial condition and future prospects including those identified in our Annual Report on FormÂ 10-K for the year ended DecemberÂ 31,Â 2023, filed with the SEC on February 28, 2024.ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSOn July 8, 2024, we issued to an executive non-statutory stock options to purchase an aggregate of 200,000 shares of our common stock at an exercise price of $7.79 per share. On July 22, 2024, we issued to an executive non-statutory stock options to purchase an aggregate of 36,000 shares of our common stock at an exercise price of $8.77 per share. On August 28, 2024, we issued to an executive a non-statutory stock option to purchase an aggregate of 40,000 shares of our common stock at an exercise price of $6.49 per share. Each of these options was made outside of our 2015 Stock Option and Incentive Plan as an inducement material to the recipientâ€™s acceptance of an offer of employment with us in accordance with Nasdaq Listing Rule 5635(c)(4). On August 6, 2024, we filed a registration statement on Form S-8 under the Securities Act to register the shares of our common stock underlying these options.â€‹ITEM 5.OTHER INFORMATION(c) Director and Officer Trading Arrangementsâ€‹A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act,â€ is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or our other securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, for diversification or other personal reasons.â€‹Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.â€‹The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a non-Rule 10b5-1 trading arrangement, as defined in Item 408(c) of Regulation S-K.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Type ofNature ofDuration of TradingAggregateâ€‹Action TakenTradingTrading TradingNumber ofName (Title)(Date of Action)Arrangement Arrangement Arrangement Securities Todd Carter, Ph.D.(Chief Scientific Officer)Adoption(September 9, 2024)Rule 10b5-1 trading arrangement for exercises of options and sales of sharesSaleUntil August 15, 2025, or such earlier date upon which all transactions are completed or expire without executionUp to 79,000 sharesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹34 Table of ContentsITEM 6.EXHIBITSThe exhibits filed or furnished as part of this Quarterly Report are set forth on the Exhibit Index, which is incorporated herein by reference.INDEX TO EXHIBITSâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â

Voyager of such assignment and assumption of the Agreement pursuant to a written notice dated October 12, 2023;WHEREAS, under the Agreement, Pfizer (i) exercised its Option with respect to the CNS Capsid during the Option Period and (ii) did not exercise its Option with respect to the Cardiology Capsid during the Option Period; and WHEREAS, Alexion desires to extend the Research Term for the CNS Capsid, and the Parties have agreed to amend the Agreement in accordance with Section 11.11 thereof. NOW, THEREFORE, in consideration of the premises and mutual covenants set forth in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:1.Amendment of the AgreementThe Parties hereby agree that the Agreement is amended as set forth below, effective as of the Amendment Effective Date. â€‹Page 1 of 4Exhibit 10.2â€‹1.1Amended Definitions. Section 1.82 and Section 1.103 and of the Agreement are hereby deleted in its entirety and is replaced with the following:1.82 â€œPfizerâ€ means AstraZeneca Ireland Limited, a limited company incorporated in Ireland, with its registered office at [**].1.103â€œResearch Termâ€ means, (i) for any TRACER Capsid Candidate designed to target the central nervous system, the period commencing on the Effective Date and ending on April 1, 2025, and (ii) for the Cardiology Capsid, the period commencing on the Effective Date and ending on the first (1st) anniversary of the Effective Date.References in the Agreement to Pfizer shall be deemed references to Alexion (as assignee). 1.2Amendment of Section 11.7 (Notices): Â Section 11.7 of the Agreement is hereby amended, replaced and superseded by the following as of the Amendment Effective Date:11.7Notices. Any notice or request required or permitted to be given under or in connection with this Agreement will be deemed to have been sufficiently given if in writing and personally delivered or sent by certified mail (return receipt requested), or overnight express courier service (signature required), prepaid, to the Party for which such notice is intended, at the address set forth for such Party below: If to Voyager:Voyager Therapeutics, Inc.Attention: Chief Executive Officer75 Hayden Avenue, Lexington, MA 02421â€‹Copy to (which copy will not constitute notice):â€‹Voyager Therapeutics, Inc.Attention: Chief Legal Officer75 Hayden Ave, Lexington, MA 02421Email: [**]â€‹Wilmer Cutler Pickering Hale and Dorr LLP60 State Street, Boston, MA 02109Attention:Brian A. Johnson, Esq.Sarah T. Hogan, Esq.Email:brian.johnson@wilmerhale.comsarah.hogan@wilmerhale.comâ€‹If to Alexion:AstraZeneca Ireland Limited[**]Attention: [**]Email: [**]â€‹â€‹With a copy to:Alexion, AstraZeneca Rare Disease Legal â€‹Page 2 of 4Exhibit 10.2â€‹[**]â€‹If delivered personally, the date of delivery will be deemed to be the date on which such notice or request was given. If sent by overnight express courier service, the date of delivery will be deemed to be the next Business Day after such notice or request was deposited with such service. If sent by certified mail, the date of delivery will be deemed to be the third (3rd) Business Day after such notice or request was deposited with the U.S. Postal Service.1.2Capsid Substitution During Research Term; Reporting. The Parties acknowledge and agree that during the Research Term, pursuant to the terms and conditions of Section 2.3 and Section 2.5 of the Agreement (without limiting the terms of Sections 2.3 and Section 2.5 except as amended by this Amendment), (i) Alexion may conduct additional Evaluation of TRACER Capsid Candidates that are CNS Capsids during the Research Term, and (ii) Alexion may elect to substitute any TRACER Capsid Candidate for any Licensed Capsid during the Research Term by providing written notice to Voyager in accordance with Section 11.7 of the Agreement, identifying the Substitute Capsid and the specific Pfizer Transgene for which the Substitute Capsid will replace the previously designated Licensed Capsid. Â Alexion will provide to Voyager written reports summarizing all results (including the Pfizer Evaluation Data) of the Evaluation conducted by Alexion during the Research Term; provided that Alexion, in its sole discretion, may choose to redact, mask, or not provide any information related to a Pfizer Transgene or Manufacturing, in each case, pursuant to Section 2.3.2 of the Agreement, and Alexion will provide the foregoing results within thirty (30) days following the completion of the Research Term.1.3No Further Options. The Parties acknowledge and agree that Pfizerâ€™s rights to exercise the Option set forth in Section 2.4 have been exercised or expired as of the Amendment Effective Date, and accordingly no further Option rights exist under the Agreement as of the Amendment Effective Date. For clarity, an Option does not include the substitution rights under Section 2.5, which continue to apply as set forth herein.2.Miscellaneous2.1Scope. This Amendment supersedes all proposals, negotiations, conversations and/or discussions between or among Parties relating to the subject matter of this Amendment and all past dealing or industry custom. This Amendment shall be integrated in and form part of the Agreement effective as of the Amendment Effective Date. Except for the foregoing modifications, the Agreement is hereby ratified and confirmed in accordance with its original terms. 2.2Counterparts. This Amendment may be executed in one or more counterparts, each of which will be an original and all of which together will constitute one instrument.â€‹[Remainder of this page is intentionally left blank]â€‹â€‹Page 3 of 4Exhibit 10.2â€‹IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this Amendment to be executed by their duly authorized representatives as of the Amendment Effective Date.â€‹VOYAGER THERAPEUTICS, INC.â€‹â€‹â€‹By:/s/ Alfred W. Sandrock, Jr., M.D., Ph.D.Name: Alfred W. Sandrock, Jr., M.D., Ph.D.Title: Â President and CEOâ€‹â€‹ASTRAZENECA IRELAND LIMITEDâ€‹â€‹By: /s/ Becky JorgensonName: Becky JorgensonTitle: Director[Signature page to First Amendment to Option and License Agreement] EX-31.1 4 vygr-20240930xex31d1.htm EX-31.1 Exhibit 31.1 Certification I, Alfred Sandrock, certify that:â€‹1.I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2024 of Voyager Therapeutics, Inc.;â€‹2.Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹3.Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;â€‹4.Â Â Â Â The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:â€‹a.Â Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹b.Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹c.Â Â Â Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹d.Â Â Â Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andâ€‹5.Â Â Â Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Â â€‹â€‹â€‹â€‹â€‹Date: November 12, 2024â€‹/s/ Alfred Sandrock, M.D., Ph.D.â€‹â€‹Alfred Sandrock, M.D., Ph.D.â€‹â€‹Chief Executive Officer, President, and Director(Principal Executive Officer)â€‹ EX-31.2 5 vygr-20240930xex31d2.htm EX-31.2 Exhibit 31.2 Certification I, Nathan Jorgensen, certify that: â€‹1.I have reviewed this Quarterly Report on Form 10-Q for the period ended September 30, 2024 of Voyager Therapeutics, Inc.;â€‹2.Â Â Â Â Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;â€‹3.Â Â Â Â Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;â€‹4.Â Â Â Â The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:â€‹a.Â Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;â€‹b.Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;â€‹c.Â Â Â Â Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andâ€‹d.Â Â Â Â Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; andâ€‹5.Â Â Â Â The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):â€‹a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹â€‹â€‹â€‹â€‹Date: November 12, 2024â€‹/s/ Nathan Jorgensen, Ph.D.â€‹â€‹Nathan Jorgensen, Ph.D.â€‹â€‹Chief Financial Officer(Principal Financial and Accounting Officer)â€‹ EX-32.1 6 vygr-20240930xex32d1.htm EX-32.1 ExhibitÂ 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTIONÂ 1350, AS ADOPTED PURSUANT TO SECTIONÂ 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on FormÂ 10-Q of Voyager Therapeutics, Inc. (the â€œCompanyâ€) for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), each of the undersigned officers hereby certifies, pursuant to 18 U.S.C. SectionÂ 1350, as adopted pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002 that to his knowledge: Â 1)the Report which this statement accompanies fully complies with the requirements of SectionÂ 13(a)Â or 15(d)Â of the Securities Exchange Act of 1934, as amended; and Â 2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. â€‹â€‹â€‹â€‹Â â€‹â€‹Date: November 12, 2024Â /s/ Alfred Sandrock, M.D., Ph.D.â€‹Â Alfred Sandrock, M.D., Ph.D.â€‹Â Chief Executive Officer, President, and Director(Principal Executive Officer)â€‹â€‹â€‹Date: November 12, 2024Â /s/Â Nathan Jorgensen, Ph.D.â€‹Â Nathan Jorgensen, Ph.D.â€‹Â Chief Financial Officer(Principal Financial and Accounting Officer)â€‹ EX-101.SCH 7 vygr-20240930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Fair value measurements - Assets and liabilities measured on a recurring basis - (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, cash equivalents, and marketable securities (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Commitments, contingencies, and other liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - Net (loss) income per share - Basic and diluted weighted average shares outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Accrued expenses link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Commitments, contingencies and other liabilities link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Stock-based compensation link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Net (loss) income per share link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Related party transactions link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Accrued expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Significant agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Stock-based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - Net (loss) income per share (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Nature of business (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Lease obligation (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Significant Agreements - Narratives (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Significant Agreements - Novartis Option and License Agreement & Stock Purchase Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Significant Agreements - Neurocrine Collaboration Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - Significant Agreements - Neurocrine Collaboration receivables and contract liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Stock-based compensation - Compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Stock-based compensation - Restricted Stock - (Details) link:presentationLink link:calculationLink link:definitionLink 99940903 - Disclosure - Stock-based compensation - Stock Options - (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Net (loss) income per share (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Underwritten public offering (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Related party transactions (Details) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Nature of business link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of significant accounting policies and basis of presentation link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Fair value measurements link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Lease obligation link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Significant agreements link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Underwritten public offering link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Commitments, contingencies and other liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 vygr-20240930_cal.xml EX-101.CAL EX-101.DEF 9 vygr-20240930_def.xml EX-101.DEF EX-101.LAB 10 vygr-20240930_lab.xml EX-101.LAB Document and Entity Information Document Information [Table] Document Information [Line Items] Document Type Document Quarterly Report Document Transition Report Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Common Stock, Shares Outstanding Condensed Consolidated Balance Sheets Statement [Table] Statement [Line Items] Assets Abstract Assets Assets, Current Abstract Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current. Marketable securities, current Receivables, Net, Current Accounts receivable Contract with Customer, Asset, Net, Current Related party collaboration receivables, ending balance Related party collaboration receivables, beginning

balance Related party collaboration receivable Prepaid expenses and other current assets Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Deposits and other assets that are expected to be realized or consumed after one year. Deposits And Other Non-Current Assets Deposits and other non-current assets Operating Lease, Right-of-Use Asset Operating lease, right-of-use assets Assets Total assets Liabilities and Equity Abstract Liabilities and stockholders' equity Liabilities, Current Abstract Current liabilities: Accounts payable Accounts payable Accrued Liabilities, Current Accrued expenses Total Other Liabilities, Current Other current liabilities Total other current liabilities Contract with Customer, Liability, Current Deferred revenue, current Liabilities, Current Total current liabilities Contract with Customer, Liability, Noncurrent Deferred revenue, non-current Other Liabilities, Noncurrent Total other non-current liabilities Other non-current liabilities Liabilities Total liabilities Commitments and contingencies (see note 7) Commitments and contingencies (see note 7) Stockholders' Equity Attributable to Parent Abstract Stockholders' equity: Preferred stock $0.001 par value: 5,000,000 shares authorized at June 30, 2019 and December 31, 2018; no shares issued and outstanding at June 30, 2019 and December 31, 2018 Preferred stock, $0.001 par value: 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023 Common stock, $0.001 par value: 120,000,000 shares authorized at June 30, 2019 and December 31, 2018; 36,677,608 and 32,364,895 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively Common stock, $0.001 par value: 120,000,000 shares authorized at September 30, 2024 and December 31, 2023; 54,542,048 and 44,038,333 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Additional paid in capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Stockholders' Equity, Ending Balance Stockholders' Equity, Beginning Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Par value of common stock (in dollars per share) Common Stock, Shares Authorized Common stock shares authorized Common Stock, Shares, Issued Common stock shares issued Common Stock, Shares, Outstanding Common stock share outstanding Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income Revenue from Contract with Customer, Excluding Assessed Tax Collaboration revenue Collaboration revenue Operating expenses: Research and development expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Operating (loss) income Interest and Debt Expense [Abstract] Other income: Interest income Interest income Other financing expense Other income Interest and Debt Expense Total other income, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (Loss) income before income taxes Income Tax Expense (Benefit) Income tax provision (benefit) Net (loss) income Net income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Other comprehensive (loss) income: Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Net unrealized gain (loss) on available-for-sale securities Unrealized gain (loss) on available-for-sale securities, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive (loss) income Earnings Per Share, Basic Net (loss) income per share, basic Earnings Per Share, Diluted Net (loss) income per share, diluted Weighted Average Number of Shares Outstanding, Basic Weighted-average common shares outstanding, basic Weighted average shares outstanding-basic Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares outstanding, diluted Weighted average shares outstanding-diluted Condensed Consolidated Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock Common stock Additional Paid-in Capital Additional paid-in capital Accumulated Other Comprehensive Loss Accumulated other comprehensive loss Accumulated Deficit Accumulated deficit Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents information pertaining to 2023 Neurocrine collaboration agreement. 2023 Neurocrine Collaborative Agreement Neurocrine Collaborative Agreement 2023 Represents the member information pertaining to 2023 Novartis Collaboration Agreement. Novartis Collaboration Agreement 2023 [Member] 2023 Novartis Collaboration Agreement Shares, Outstanding Shares, Outstanding, Ending Balance Shares, Outstanding, Beginning Balance Stock Issued During Period, Value, Stock Options Exercised Exercises of vested stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Exercises of vested stock options (in shares) Represents the value of vested restricted common stock. Vesting Of Restricted Common Stock Vesting of restricted stock units Represents the number of vested restricted common stock. Vesting Of Restricted Common Stock In Shares Vesting of restricted stock units (in shares) Stock Issued During Period, Value, New Issues Issuance of common stock Stock Issued During Period, Shares, New Issues Issuance of common stock, shares Issuance of common stock (in shares) Equity impact of the value of new stock and pre-funded warrants issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Stock And Pre-Funded Warrants Issued During Period, Value, New Issues Issuance of common stock and pre-funded warrants in connection with underwritten public offering Equity impact of the shares of new stock and pre-funded warrants issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Stock And Pre-Funded Warrants Issued During Period, Share New Issues Issuance of common stock and pre-funded warrants in connection with underwritten public offering (in shares) Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Issuance of common stock under ESPP Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Issuance of common stock under ESPP (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Stock based compensation expense Condensed Consolidated Statement of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flow from operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net (loss) income Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: Stock-based compensation expense Stock-based compensation expense Depreciation Depreciation Operating Lease, Impairment Loss Impairment charge on leased facility Impairment charge Accretion (Amortization) of Discounts and Premiums, Investments Amortization of premiums and discounts on marketable securities Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of fixed assets Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from Collaboration agreements. Increase (Decrease) in Collaboration Receivables Related party collaboration receivable Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets The increase (decrease) during the reporting period in operating lease, right-of-use assets. Increase Decrease In Right Of Use Assets Operating lease, right-of-use asset Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Operating Lease Liability Operating lease liabilities Increase (Decrease) in Contract with Customer, Liability Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flow from investing activities Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Marketable Securities Purchases of marketable securities Represents the information of proceeds from sales of marketable investments, Proceeds from Sales of Marketable Investments Proceeds from sales and maturities of marketable securities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flow from financing activities Proceeds from Stock Options Exercised Proceeds from the exercise of stock options Proceeds From Issuance Of Stock Net Of Discount And Issuance Costs Proceeds from the issuance of common stock in connection with the underwritten public offering The cash inflow from the capital issued in connection with the 2023 Novartis Collaboration Agreement. Proceeds From Issuance Of Common Stock In Connection With 2023 Novartis Collaboration Agreement Proceeds from the issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement The cash inflow from the capital issued in connection with the 2023 Neurocrine Collaboration Agreement. Proceeds From Issuance Of Common Stock In Connection With 2023 Neurocrine Collaboration Agreement Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options Proceeds from the purchase of common stock under ESPP Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents, and restricted cash, end of period Cash, cash equivalents, and restricted cash, beginning of period Total cash, cash equivalents, and restricted cash Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of cash and non-cash activities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating lease right-of-use asset obtained in exchange for operating lease liability Nature of business Nature of Operations [Text Block] Nature of business Summary of significant accounting policies and basis of presentation Significant Accounting Policies [Text Block] Summary of significant accounting policies and basis of presentation Fair value measurements Fair Value Disclosures [Text Block] Fair value measurements Cash, cash equivalents, restricted cash, and available-for-sale marketable securities Schedule of Cash and Cash Equivalents [Table] Cash and Cash Equivalents [Line Items] Cash, cash equivalents, and restricted cash Cash and Cash Equivalents Disclosure [Text Block] Cash, cash equivalents, restricted cash, and available-for-sale marketable securities Accrued expenses Accrued Liabilities Disclosure [Text Block] Accrued expenses Lease obligation Lessee, Operating Leases [Text Block] Lease obligation Commitments, contingencies and other liabilities Commitments and Contingencies Disclosure [Text Block] Commitments, contingencies and other liabilities n/a Significant agreements Collaborative Arrangement Disclosure [Text Block] Significant agreements Stock-based compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-based compensation Net (loss) income per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share Earnings Per Share [Text Block] Net (loss) income per share No definition available. Underwritten public offering The entire disclosure of underwritten public offering. Underwritten Public Offering [Text Block] Underwritten public offering Related party transactions Related Party Transactions Disclosure [Text Block] Related party transactions Basis of Presentation Basis of Presentation Consolidation, Policy [Policy Text Block] Principles of Consolidation Use of Estimates Use of Estimates Summary of Significant Accounting Policies Summary of Significant Accounting Policies Assets and liabilities measured at fair value on a recurring basis Schedule of assets and liabilities measured at fair value on a recurring basis Marketable Securities [Table Text Block] Schedule of money market funds and marketable securities Tabular disclosure of the components of cash, cash equivalents, and restricted cash. Schedule of Cash Cash Equivalents And Restricted Cash [Table Text Block] Reconciliation of cash, cash equivalents, and restricted cash Schedule of accrued expenses Schedule of accrued expenses Summary of other current and non-current liabilities Summary of other current and non-current liabilities Represents information pertaining to the Neurocrine collaborative agreements for 2023 and 2019. 2023 Neurocrine Collaborative Agreement and 2019 Neurocrine Collaborative Agreement Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Schedule of collaboration receivables and contract liabilities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Compensation cost recognized for all stock-based compensation awards Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Summary of stock-based compensation expense by type of award Summary of status and changes in unvested restricted stock Summary of stock option activity Outstanding potentially dilutive securities excluded in the calculation of diluted net (loss) income per share Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of weighted average number of shares, basic and diluted Counterparty Name [Axis] Counterparty Name [Domain] Represents information pertaining to Novartis Pharma, AG. Novartis Pharma, AG Represents information pertaining to an option and license arrangement. Option and License Agreement Cash, Cash Equivalents, and Short-term Investments Cash, cash equivalents, and marketable securities Represents the amount of upfront payment to be received under collaborative arrangement. Collaborative Arrangement Upfront Payment to be Received Upfront payment Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Money market funds Money market funds Certificates of Deposit [Member] Certificates of deposits Financial Instrument [Axis] Financial Instruments [Domain] U.S. Treasury notes U.S. Treasury notes U. S. Government agency securities U. S. Government agency securities Corporate bonds Corporate bonds Commercial paper Commercial paper Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Level 1 Level 1 Level 2 Level 2 Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair value, measurements, recurring Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Assets, Fair Value Disclosure [Abstract] Assets, Fair Value Disclosure [Abstract] Marketable Securities. Marketable securities Assets, Fair Value Disclosure, Total Total money market funds and marketable securities Debt securities Amortized Cost Basis [Abstract] Amortized Cost Available-for-sale Debt Securities, Amortized Cost Basis Marketable securities, Amortized cost Represents the value of money market funds and marketable securities on amortized cost basis. Money Market Funds And Marketable Securities, Amortized Cost Basis Total money market funds and marketable securities Debt Securities, Available-for-sale, Unrealized Loss Position Debt securities, unrealized loss position Fair Value Disclosure [Abstract] Fair Value Cash and cash equivalents Cash and cash equivalents, fair value Available-for-sale Securities, Debt Securities Marketable securities, fair value Represents the fair value of money market funds and marketable securities. Money Market Funds And Marketable Securities Fair Value Total money market funds and marketable securities n/a Unrealized Gain and Loss [Abstract] Unrealized Gains and Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Marketable securities, unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Marketable securities, unrealized losses Restricted Cash Restricted cash included in deposits and other noncurrent assets Employee compensation costs Employee compensation costs Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs . Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research And Development Costs Current Research and development costs Represents the amount of expenses incurred but not paid for goods and services, due within one year or the normal operating cycle, if longer. Accrued Goods And Services Current Accrued goods and services Professional services Professional services Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Represents information pertaining to 75 and 64 Sidney Street leases. 75 and 64 Sidney Street Represents the lease at 64 Sidney Street. 64 Sidney Street Represents the lease at 75 Hayden Avenue 75 Hayden Avenue 75 Hayden avenue Area of Real Estate Property Area of additional facility leased The cash inflow from proceeds received from lessor related to leasehold improvements. Proceeds From Lessor For Leasehold improvements Leasehold improvements amount Operating Lease, Liability, Noncurrent Lease liability Sublease Income Other income from sublease Operating Lease, Expense Lease expense Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term Weighted average incremental borrowing rate for operating lease. Operating Lease Weighted Average Incremental Borrowing Rate Weighted average incremental borrowing rate Collaborative Arrangement and Arrangement Other than Collaborative [Table] Agreement made with a non-profit organization. Non-profit organization agreement Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Commitments contingencies and other liabilities Other Liabilities, Current [Abstract] Other current liabilities Operating Lease, Liability, Current Lease liability Other Liabilities, Noncurrent [Abstract] Other non-current liabilities Amount of miscellaneous liabilities classified as other, due after one year or the normal operating cycle, if longer. Miscellaneous Other Liabilities Noncurrent Other Reflects the amount of maximum funding available from non-profit organization, for research and development under arrangement. Non Profit Organization Research And Development Maximum Funding Capacity Maximum funding Reflects the multiple to be used for future funding following successful development and commercialization. Non Profit Organization Research And Development Multiple Funding multiple Reflects the value of the milestone payment received from the non-profit organization recognized as a liability as it is probable that the Company will repay the amount. Non Profit Organization Milestone Payment Liability Milestone payment liability Represents the number of programs under collaborative arrangement. Collaborative Arrangement Number of Programs Number of collaboration programs In the aggregate, the maximum milestone payments to be received from the collaborative partner. Collaborative Arrangement Aggregate Maximum Milestone Payments To Be Received From Collaborative Partner Aggregate maximum milestone payments to be received from collaborative partner Information by categories of milestones achieved. Milestone Achievement [Axis] Categories of milestones achieved. Milestone Achievement [Domain] Information pertaining to development, regulatory, and commercialization milestones achieved. Development, regulatory and commercialization milestone Sales milestone achieved. Sales milestone

Represents the number of shares agreed to be issued. Number of Shares Agreed to be Issued Shares of common stock Represents the aggregate purchase price pf number of shares agreed to be issued. Number of Shares Agreed to be Issued, Aggregate Purchase Price Aggregate purchase price Represents the amount of premium on shares issued Amount of Premium On Shares Issued Amount of premium Represents the amount of revenue performance obligation allocation of transaction price. Revenue Performance Obligations Allocation of Transaction Price Allocation of transaction price Represents information pertaining to 2019 Neurocrine collaboration agreement. 2019 Neurocrine Collaborative Agreement Neurocrine Collaborative Agreement 2019 Represents information pertaining to Neurocrine Biosciences Inc. Neurocrine Product and Service [Axis] Product and Service [Domain] Represents information pertaining to discovery program three. Discovery program 3 Represents the amount of cash flow on milestone payments. Milestone Payments Milestone payments Contract with Customer, Liability, Revenue Recognized Deductions Contract with customer liability revenue recognized Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract Cumulative catch up of revenue recognized Amount of increase to contract with customer assets during the reporting period. Additions To Contract With Customer Assets Additions Amount of decrease to contract with customer assets during the reporting period. Deductions To Contract With Customer Assets Deductions Contract with Customer, Liability Deferred revenue, ending balance Deferred revenue, beginning balance Amount of increase to contract with customer liabilities during the reporting period. Additions To Contract With Customer Liabilities Additions Income Statement Location [Axis] Income Statement Location [Domain] Research and development General and administrative Unvested restricted common stock units Restricted stock awards and units Employee stock purchase plan Employee stock purchase plan awards Stock-based compensation. Stock-based compensation Shares Balance, beginning (in shares) Balance, ending (in shares) Balance, beginning (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in shares) Vested (in shares) Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited (in shares) Weighted Average Grant Date Fair Value Per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Balance, ending (in dollars per share) Balance, beginning (in dollars per share) Restricted stock granted, original issued price (in dollars per share) Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Restricted stock disclosures Vesting period Unrecognized stock-based compensation expense Remaining weighted-average remaining vesting period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding, ending balance (in shares) Outstanding, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Cancelled or forfeited (in shares) Cancelled or forfeited (in shares) Exercisable (in shares) Weighted Average Exercise Price Outstanding (in dollars per share) Outstanding (in dollars per share) Outstanding (in dollars per share) Granted (in dollars per share) Exercised (in dollars per share) Cancelled or forfeited (in dollars per share) Exercisable (in dollars per share) n/a Remaining Contractual Life Abstract Remaining Contractual Life Outstanding Exercisable n/a Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Exercisable Options disclosures Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Unvested restricted common stock awards Antidilutive Securities Excluded from Computation of Earnings Per Share (in common stock equivalent shares) Antidilutive securities Earnings Per Share Reconciliation [Abstract] Numerator: Net loss attributable to common stockholders Net (loss) income Weighted Average Number of Shares Outstanding, Basic [Abstract] Denominator for basic net (loss) income per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Denominator for diluted net (loss) income per share: Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Common stock options and restricted stock units Subsequent Event [Table] Sale of Stock [Axis] Sale of Stock [Domain] Over-Allotment Option Underwriting Agreement Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents the member information pertaining to Pre-Funded Warrants. Pre-Funded Warrants [Member] Pre-Funded Warrants Subsequent Event [Line Items] Underwritten public offering Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of warrants issued to purchase common stock Sale of Stock, Price Per Share Offering price for common stock Class of Warrant or Right, Exercise Price of Warrants or Rights Price per warrant The number of warrants issued. Class of Warrants And Rights Outstanding, Number of Warrants Issued Issuance of Pre-Funded Warrants Sale of Stock, Consideration Received on Transaction Net proceeds received Schedule of Related Party Transactions, by Related Party [Table] Information pertaining to former executives of the entity. Former Executives Person designated as former Chief Scientific Officer, Dr. Dinah Sah, Ph.D. Dr. Sah Related Party [Axis] Related Party [Domain] Related Party Related Party Transaction [Line Items] Related party transactions Total amount of services received The amount of advisory fee payable per month in a related party transaction. Related Party Transaction, Advisory Fee Payable Per Month Advisory fee amount per month Represents the information pertaining to Todd Carter, Ph.D. member. Todd Carter, Ph.D. [Member] Todd Carter, Ph.D. EX-101.PRE 11 vygr-20240930_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Oct. 28, 2024 Document and Entity Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Sep. 30, 2024 Â Entity File Number 001-37625 Â Entity Registrant Name Voyager Therapeutics, Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 46-3003182 Â Entity Address, Address Line One 75 Hayden Avenue Â Entity Address, City or Town Lexington Â Entity Address, State or Province MA Â Entity Address, Postal Zip Code 02421 Â City Area Code 857 Â Local Phone Number 259-5340 Â Title of 12(b) Security Common Stock, $0.001 par value Â Trading Symbol VYGR Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Central Index Key 0001640266 Â Amendment Flag false Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Entity Common Stock, Shares Outstanding Â 54,625,586 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 112,525 $ 68,802 Marketable securities, current 232,835 162,073 Accounts receivable 15,954 80,150 Related party collaboration receivable 3,714 3,341 Prepaid expenses and other current assets 8,415 5,318 Total current assets 373,443 319,684 Property and equipment, net 15,201 16,494 Deposits and other non-current assets 2,874 1,593 Operating lease, right-of-use assets 34,523 13,510 Total assets 426,041 351,281 Current liabilities: Â Â Accounts payable 3,160 1,604 Accrued expenses 11,442 16,823 Other current liabilities 6,979 3,200 Deferred revenue, current 22,629 42,881 Total current liabilities 44,210 64,508 Deferred revenue, non-current 12,153 32,359 Other non-current liabilities 39,368 18,094 Total liabilities 95,731 114,961 Commitments and contingencies (see note 7) Stockholders' equity: Â Â Preferred stock, $0.001 par value: 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023 Common stock, $0.001 par value: 120,000,000 shares authorized at September 30, 2024 and December 31, 2023; 54,542,048 and 44,038,333 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 55 44 Additional paid-in capital 621,985 497,506 Accumulated other comprehensive loss (33) (48) Accumulated deficit (291,697) (261,182) Total stockholders' equity 330,310 236,320 Total liabilities and stockholders' equity $ 426,041 $ 351,281 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are

statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB

-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of nonredeemable preferred shares and preferred shares redeemable solely at option of issuer, held by shareholders. Excludes preferred shares repurchased and held as treasury shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_ReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDeposits and other assets that are expected to be realized or consumed after one year. + ReferencesNo definition available. + Details Name: vygr_DepositsAndOtherNonCurrentAssets Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Condensed Consolidated Balance Sheets Â Â Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock shares authorized 120,000,000 120,000,000 Common stock shares issued 54,542,048 44,038,333 Common stock share outstanding 54,542,048 44,038,333 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income Â Â Â Â Collaboration revenue $ 24,629 $ 4,614 $ 73,723 $ 159,947 Operating expenses: Â Â Â Â Research and development 30,241 25,863 91,785 66,416 General and administrative 8,168 8,258 26,926 25,580 Total operating expenses 38,409 34,121 118,711 91,996 Operating (loss) income (13,780) (29,507) (44,988) 67,951 Other income: Â Â Â Â Interest income 4,579 3,429 14,334 8,567 Other income 200 Â 220 3 Total other income, net 4,779 3,429 14,554 8,570 (Loss) income before income taxes (9,001) (26,078) (30,434) 76,521 Income tax provision (benefit) 43 (177) 81 586 Net (loss) income (9,044) (25,901) (30,515) 75,935 Other comprehensive (loss) income: Â Â Â Â Net unrealized gain (loss) on available-for-sale securities 489 (115) 15 (29) Total other comprehensive income (loss) 489 (115) 15 (29) Comprehensive (loss) income $ (8,555) $ (26,016) $ (30,500) $ 75,906 Net (loss) income per share, basic $ (0.16) $ (0.59) $ (0.53) $ 1.85 Net (loss) income per share, diluted $ (0.16) $ (0.59) $ (0.53) $ 1.78 Weighted-average common shares outstanding, basic 57,851,110 43,864,838 57,564,413 40,962,116 Weighted-average common shares outstanding, diluted 57,851,110 43,864,838 57,564,413 42,610,724 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22))

-Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. +

ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands Common stock 2023 Neurocrine Collaborative Agreement Common stock 2023 Novartis Collaboration Agreement Common stock Additional paid-in capital 2023 Neurocrine Collaborative Agreement Additional paid-in capital 2023 Novartis Collaboration Agreement Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit 2023 Neurocrine Collaborative Agreement 2023 Novartis Collaboration Agreement Total Stockholders' Equity, Beginning Balance at Dec. 31, 2022 Â Â $ 38 Â Â $ 452,713 $ (219) $ (393,512) Â Â $ 59,020 Shares, Outstanding, Beginning Balance at Dec. 31, 2022 Â Â 38,613,891 Â Â Â Â Â Â Â Â Exercises of vested stock options Â Â Â Â Â 185 Â Â Â Â 185 Exercises of vested stock options (in shares) Â Â 51,993 Â Â Â Â Â Â Â Â Vesting of restricted stock units (in shares) Â Â 374,417 Â Â Â Â Â Â Â Â Issuance of common stock $ 5 Â Â $ 31,116 Â Â Â Â Â $ 31,121 Â Â Issuance of common stock (in shares) 4,395,588 Â Â Â Â Â Â Â Â Â Â Stock based compensation expense Â Â Â Â Â 2,504 Â Â Â Â Â 2,504 Unrealized gain (loss) on available-for-sale securities, net of tax Â Â Â Â Â Â 87 Â Â Â 87 Net income (loss) Â Â Â Â Â Â Â 124,044 Â Â 124,044 Stockholders' Equity, Ending Balance at Mar. 31, 2023 Â Â $ 43 Â Â 486,518 (132) (269,468) Â Â 216,961 Shares, Outstanding, Ending Balance at Mar. 31, 2023 Â Â 43,435,889 Â Â Â Â Â Â Â Â Stockholders' Equity, Beginning Balance at Dec. 31, 2022 Â Â $ 38 Â Â 452,713 (219) (393,512) Â Â 59,020 Shares, Outstanding, Beginning Balance at Dec. 31, 2022 Â Â 38,613,891 Â Â Â Â Â Â Â Â Unrealized gain (loss) on available-for-sale securities, net of tax Â Â Â Â Â Â Â Â Â (29) Net income (loss) Â Â Â Â Â Â Â Â Â 75,935 Stockholders' Equity, Ending Balance at Sep. 30, 2023 Â Â $ 44 Â Â 494,001 (248) (317,577) Â Â 176,220 Shares, Outstanding, Ending Balance at Sep. 30, 2023 Â Â 43,909,161 Â Â Â Â Â Â Â Â Stockholders' Equity, Beginning Balance at Mar. 31, 2023 Â Â $ 43 Â Â 486,518 (132) (269,468) Â Â 216,961 Shares, Outstanding, Beginning Balance at Mar. 31, 2023 Â Â 43,435,889 Â Â Â Â Â Â Â Â Exercises of vested stock options Â Â $ 1 Â Â 1,228 Â Â Â Â 1,229 Exercises of vested stock options (in shares) Â Â 198,348 Â Â Â Â Â Â Â Â Vesting of restricted stock units (in shares) Â Â 62,828 Â Â Â Â Â Â Â Â Issuance of common stock under ESPP Â Â Â Â 418 Â Â Â 418 Issuance of common stock under ESPP (in shares) Â Â 62,344 Â Â Â Â Â Â Â Â Stock based compensation expense Â Â Â Â 2,627 Â Â Â 2,627 Unrealized gain (loss) on available-for-sale securities, net of tax Â Â Â Â Â (1) Â Â Â (1) Net income (loss) Â Â Â Â Â (22,208) Â Â (22,208) Stockholders' Equity, Ending Balance at Jun. 30, 2023 Â Â $ 44 Â Â 490,791 (133) (291,676) Â Â 199,026 Shares, Outstanding, Ending Balance at Jun. 30, 2023 Â Â 43,759,409 Â Â Â Â Â Â Â Â Exercises of vested stock options Â Â Â Â 415 Â Â Â 415 Exercises of vested stock options (in shares) Â Â 127,252 Â Â Â Â Â Â Â Â Vesting of restricted stock units (in shares) Â Â 22,500 Â Â Â Â Â Â Â Â Stock based compensation expense Â Â Â Â 2,795 Â Â Â 2,795 Unrealized gain (loss) on available-for-sale securities, net of tax Â Â Â Â Â (115) Â Â Â (115) Net income (loss) Â Â Â Â Â Â (25,901) Â Â (25,901) Stockholders' Equity, Ending Balance at Sep. 30, 2023 Â Â $ 44 Â Â 494,001 (248) (317,577) Â Â 176,220 Shares, Outstanding, Ending Balance at Sep. 30, 2023 Â Â 43,909,161 Â Â Â Â Â Â Â Â Stockholders' Equity, Beginning Balance at Dec. 31, 2023 Â Â $ 44 Â Â 497,506 (48) (261,182) Â Â 236,320 Shares, Outstanding, Beginning Balance at Dec. 31, 2023 Â Â 44,038,333 Â Â Â Â Â Â Â Â Exercises of vested stock options Â Â Â Â 78 Â Â Â Â 78 Exercises of vested stock options (in shares) Â Â 32,500 Â Â Â Â Â Â Â Â Vesting of restricted stock units (in shares) Â Â 324,520 Â Â Â Â Â Â Â Â Issuance of common stock Â $ 2 Â Â $ 19,303 Â Â Â Â $ 19,305 Â Issuance of common stock (in shares) Â 2,145,002 Â Â Â Â Â Â Â Â Â Issuance of common stock and pre-funded warrants in connection with underwritten public offering Â Â $ 8 Â Â 93,465 Â Â Â Â 93,473 Issuance of common stock and pre-funded warrants in connection with underwritten public offering (in shares) Â Â 7,777,778 Â Â Â Â Â Â Â Â Stock based compensation expense Â Â Â Â 3,498 Â Â Â 3,498 Unrealized gain (loss) on available-for-sale securities, net of tax Â Â Â Â Â (458) Â Â Â (458) Net income (loss) Â Â Â Â Â Â (11,330) Â Â (11,330) Stockholders' Equity, Ending Balance at Mar. 31, 2024 Â Â $ 54 Â Â 613,850 (506) (272,512) Â Â 340,886 Shares, Outstanding, Ending Balance at Mar. 31, 2024 Â Â 54,318,133 Â Â Â Â Â Â Â Â Stockholders' Equity, Beginning Balance at Dec. 31, 2023 Â Â $ 44 Â Â 497,506 (48) (261,182) Â Â $ 236,320 Shares, Outstanding, Beginning Balance at Dec. 31, 2023 Â Â 44,038,333 Â Â Â Â Â Â Â Â Â Exercises of vested stock options (in shares) Â Â Â Â Â Â Â Â Â 86,100 Unrealized gain (loss) on available-for-sale securities, net of tax Â Â Â Â Â Â Â Â Â Â $ 15 Net income (loss) Â Â Â Â Â Â Â Â Â (30,515) Stockholders' Equity, Ending Balance at Sep. 30, 2024 Â Â $ 55 Â Â 621,985 (33) (291,697) Â Â 330,310 Shares, Outstanding, Ending Balance at Sep. 30, 2024 Â Â 54,542,048 Â Â Â Â Â Â Â Â Stockholders' Equity, Beginning Balance at Mar. 31, 2024 Â Â $ 54 Â Â 613,850 (506) (272,512) Â Â 340,886 Shares, Outstanding, Beginning Balance at Mar. 31, 2024 Â Â 54,318,133 Â Â Â Â Â Â Â Â Exercises of vested stock options Â Â Â Â 90 Â Â Â Â 90 Exercises of vested stock options (in shares) Â Â 25,958 Â Â Â Â Â Â Â Â Vesting of restricted stock units (in shares) Â Â 56,549 Â Â Â Â Â Â Â Â Issuance of common stock under ESPP Â Â Â Â 639 Â Â Â 639 Issuance of common stock under ESPP (in shares) Â Â 71,473 Â Â Â Â Â Â Â Â Stock based compensation expense Â Â Â Â 3,959 Â Â Â 3,959 Unrealized gain (loss) on available-for-sale securities, net of tax Â Â Â Â Â (16) Â Â Â (16) Net income (loss) Â Â Â Â Â (10,141) Â Â (10,141) Stockholders' Equity, Ending Balance at Jun. 30, 2024 Â Â $ 54 Â Â 618,538 (522) (282,653) Â Â 335,417 Shares, Outstanding, Ending Balance at Jun. 30, 2024 Â Â 54,472,113 Â Â Â Â Â Â Â Â Exercises of vested stock options Â Â Â Â 92 Â Â Â Â 92 Exercises of vested stock options (in shares) Â Â 27,642 Â Â Â Â Â Â Â Â Vesting of restricted stock units Â Â $ 1 Â Â Â Â Â Â Â Â 1 Vesting of restricted stock units (in shares) Â Â 42,293 Â Â Â Â Â Â Â Â Â Stock based compensation expense Â Â Â Â Â 3,355 Â Â Â Â 3,355 Unrealized gain (loss) on available-for-sale securities, net of tax Â Â Â Â Â Â 489 Â Â Â 489 Net income (loss) Â Â Â Â Â Â Â (9,044) Â Â (9,044) Stockholders' Equity, Ending Balance at Sep. 30, 2024 Â Â $ 55 Â Â $ 621,985 $ (33) $ (291,697) Â Â $ 330,310 Shares, Outstanding, Ending Balance at Sep. 30, 2024 Â Â 54,542,048 Â Â Â Â Â Â Â Â X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-

2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEquity impact of the shares of new stock and pre-funded warrants issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesNo definition available. + Details Name: vygr_StockAndPreFundedWarrantsIssuedDuringPeriodShareNewIssues Namespace Prefix: vygr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock and pre-funded warrants issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesNo definition available. + Details Name: vygr_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the value of vested restricted common stock. + ReferencesNo definition available. + Details Name: vygr_VestingOfRestrictedCommonStock Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the number of vested restricted common stock. + ReferencesNo definition available. + Details Name: vygr_VestingOfRestrictedCommonStockInShares Namespace Prefix: vygr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flow from operating activities Â Â Net (loss) income $ (30,515) $ 75,935 Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: Â Â Stock-based compensation expense 11,048 8,108 Depreciation 3,720 3,106 Impairment charge on leased facility 2,776 Â Amortization of premiums and discounts on marketable securities (6,456) (1,832) Loss on disposal of fixed assets 478 143 Changes in operating assets and liabilities: Â Â Accounts receivable 64,196 Â Related party collaboration receivable (373) (2,996) Prepaid expenses and other current assets (3,097) (342) Operating lease, right-of-use asset 3,423 1,459 Accounts payable 1,556 704 Accrued expenses (5,381) 3,236 Operating lease liabilities (1,698) (2,102) Deferred revenue (40,458) 16,260 Net cash (used in) provided by operating activities (781) 101,679 Cash flow from investing activities Â Â Purchases of property and equipment (3,366) (2,501) Purchases of marketable securities (334,667) (194,975) Proceeds from sales and maturities of marketable securities 270,377 29,000 Net cash used in investing activities (67,656) (168,476) Cash flow from financing activities Â Â Proceeds from the exercise of stock options 261 1,829 Proceeds from the issuance of common stock in connection with the underwritten public offering 93,473 Â Proceeds from the issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement 19,305 Â Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement Â 31,121 Proceeds from the purchase of common stock under ESPP 402 235 Net cash provided by financing activities 113,441 33,185 Net increase (decrease) in cash, cash equivalents, and restricted cash 45,004 (33,612) Cash, cash equivalents, and restricted cash, beginning of period 70,395 100,474 Cash, cash equivalents, and restricted cash, end of period 115,399 $ 66,862 Supplemental disclosure of cash and non-cash activities Â Â Operating lease right-of-use asset obtained in exchange for operating lease liability $ 26,751 Â X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease)

during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from Collaboration agreements. + ReferencesNo definition available. + Details Name: vygr_IncreaseDecreaseInCollaborationReceivables Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in operating lease, right-of-use assets. + ReferencesNo definition available. + Details Name:

vygr_IncreaseDecreaseInRightOfUseAssets Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the capital issued in connection with the 2023 Neurocrine Collaboration Agreement. + ReferencesNo definition available. + Details Name: vygr_ProceedsFromIssuanceOfCommonStockInConnectionWith2023NeurocrineCollaborationAgreement Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the capital issued in connection with the 2023 Novartis Collaboration Agreement. + ReferencesNo definition available. + Details Name: vygr_ProceedsFromIssuanceOfCommonStockInConnectionWith2023NovartisCollaborationAgreement Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the information of proceeds from sales of marketable investments, + ReferencesNo definition available. + Details Name: vygr_ProceedsFromSalesOfMarketableInvestments Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Nature of business 9 Months Ended Sep. 30, 2024 Nature of business Â Nature of business VOYAGER THERAPEUTICS INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS1. Nature of businessVoyager Therapeutics, Inc. (the â€œCompanyâ€) is a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. The Companyâ€™s pipeline includes programs for Alzheimerâ€™s disease; amyotrophic lateral sclerosis; Parkinsonâ€™s disease, and multiple other diseases of the central nervous system. Many of the Companyâ€™s programs are derived from its TRACERâ„¢ adeno-associated virus (â€œAAVâ€) capsid discovery platform, which the Company has used to generate novel capsids (â€œTRACER Capsidsâ€) and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of the Companyâ€™s programs are wholly-owned, and some are advancing with licensees and collaborators including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG, (â€œNovartisâ€); and Neurocrine Biosciences, Inc. (â€œNeurocrineâ€). The Company has a history of incurring annual net operating losses. As of SeptemberÂ 30,Â 2024, the Company had an accumulated deficit of $291.7 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities, funding from fees, option exercise payments, and milestone payments, and cost reimbursements associated with its prior and ongoing collaborations and license agreements.As of SeptemberÂ 30,Â 2024, the Company had cash, cash equivalents, and marketable securities of $345.4 million. Based upon the Companyâ€™s current operating plans, the Company expects that its existing cash, cash equivalents, and marketable securities at SeptemberÂ 30,Â 2024 to be sufficient to meet the Companyâ€™s planned operating expenses and capital expenditure requirements for at least twelve months from the issuance of these consolidated financial statements.There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Companyâ€™s business, results of operations, and financial condition. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies and basis of presentation 9 Months Ended Sep. 30, 2024 Summary of significant accounting policies and basis of presentation Â Summary of significant accounting policies and basis of presentation 2. Summary of significant accounting policies and basis of presentationBasis of PresentationThe accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31,Â 2023 as filed with the Securities and Exchange Commission (â€œSECâ€) on February 28, 2024. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Companyâ€™s financial position and results of operations for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.Principles of ConsolidationThe unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary as disclosed in Note 2, under the heading â€œSummary of Significant Accounting Policies and Basis of Presentation,â€ within the â€œNotes to Consolidated Financial Statementsâ€ accompanying the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31,Â 2023. Intercompany balances and transactions have been eliminated.Use of EstimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Companyâ€™s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, incremental borrowing rate for leases, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.Summary of Significant Accounting PoliciesThere have been no changes in the Company's significant accounting policies as described in Note 2, â€œSummary of Significant Accounting Policies and Basis of Presentation,â€ within the â€œNotes to Consolidated Financial Statementsâ€ accompanying the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurements 9 Months Ended Sep. 30, 2024 Fair value measurements Â Fair value measurements 3. Fair value measurementsAssets and liabilities measured at fair value on a recurring basis as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023 are as follows:â€‹â€‹â€‹

gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CashAndCashEquivalentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued expenses 9 Months Ended Sep. 30, 2024 Accrued expenses Â Accrued expenses 5. Accrued expensesAccrued expenses as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023 consist of the following:â€‹â€‹â€‹

compensation expenseâ€‹$ 3,434â€‹$ 2,878â€‹$ 11,048â€‹$ 8,108â€‹â€‹Restricted Stock UnitsA summary of the status of and changes in unvested restricted stock unit activity under the Companyâ€™s equity award plans for the nine months ended SeptemberÂ 30,Â 2024 was as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹Â Â Â Â Weightedâ€‹â€‹â€‹â€‹â€‹Averageâ€‹â€‹â€‹â€‹â€‹GrantÂ Dateâ€‹â€‹â€‹â€‹â€‹FairÂ Valueâ€‹â€‹Â Â Â Â UnitsÂ Â Â Â PerÂ Unitâ€‹Unvested restricted stock units as of DecemberÂ 31,Â 2023Â 1,370,897â€‹$ 6.65â€‹GrantedÂ 867,558â€‹$ 8.15â€‹VestedÂ (423,362)â€‹$ 6.23â€‹ForfeitedÂ (198,076)â€‹$ 6.68â€‹Unvested restricted stock units as of SeptemberÂ 30,Â 2024Â 1,617,017â€‹$ 7.56â€‹â€‹Stock-based compensation of restricted stock units is based on the fair value of the Companyâ€™s common stock on the date of grant and is recognized over the vesting period. All of the restricted stock units granted in the nine months ended SeptemberÂ 30,Â 2024 vest in equal amounts, annually over three years. The stock-based compensation expense related to restricted stock units was $1.0 million and $3.5 million for the three and nine months ended SeptemberÂ 30,Â 2024, respectively. The stock-based compensation expense related to restricted stock units was $0.8 million and $2.3 million for the three and nine months ended SeptemberÂ 30,Â 2023, respectively.As of SeptemberÂ 30,Â 2024, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $9.1 million, which is expected to be recognized over the remaining average vesting period of 2.1 years.Stock OptionsThe following is a summary of stock option activity for the nine months ended SeptemberÂ 30,Â 2024:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹Â Â Â Â WeightedÂ Â Â Â RemainingÂ Â Â Â Aggregateâ€‹â€‹â€‹â€‹â€‹Averageâ€‹Contractualâ€‹Intrinsicâ€‹â€‹â€‹â€‹ at DecemberÂ 31,Â 2023Â 7,425,444â€‹$ 8.52â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹GrantedÂ 2,325,226â€‹$ 7.79â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ExercisedÂ (86,100)â€‹$ 4.11â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Cancelled or forfeitedÂ (793,242)â€‹$ 11.69â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Outstanding at SeptemberÂ 30,Â 2024Â 8,871,328â€‹$ 8.08Â 7.5â€‹â€‹â€‹ 3,756â€‹Exercisable at SeptemberÂ 30,Â 2024Â 4,604,321â€‹$ 8.51Â 6.4â€‹â€‹â€‹ 2,777â€‹â€‹As of SeptemberÂ 30,Â 2024, the Company had unrecognized stock-based compensation expense related to its unvested stock options of $20.1 million which is expected to be recognized over the remaining weighted-average vesting period of 2.7 years. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Net (loss) income per share 9 Months Ended Sep. 30, 2024 Net (loss) income per share Â Net (loss) income per share 10. Net (loss) income per shareThe following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net (loss) income per share because to include them would be anti-dilutive:â€‹Three Months Ended SeptemberÂ 30,Â â€‹â€‹Nine Months Ended SeptemberÂ 30,Â â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â â€‹2023â€‹Â Â Â Â 2024Â Â Â Â â€‹2023â€‹Unvested restricted common stock awardsâ€‹Â â€”â€‹â€‹ 22,500â€‹Â â€”â€‹â€‹ 22,500â€‹Unvested restricted common stock unitsâ€‹â€‹ 1,617,017â€‹â€‹ 1,312,727â€‹â€‹ 1,617,017â€‹â€‹ 714,164â€‹Outstanding stock optionsâ€‹Â 8,871,328â€‹â€‹ 7,745,593â€‹Â 8,871,328â€‹â€‹ 6,695,548â€‹Totalâ€‹Â 10,488,345â€‹â€‹ 9,080,820â€‹Â 10,488,345â€‹â€‹ 7,432,212â€‹â€‹Basic and diluted net (loss) income per share and diluted weighted-average shares outstanding are as follows for the three and nine months ended SeptemberÂ 30,Â 2024 and 2023:â€‹Three Months Ended September 30,â€‹â€‹Nine Months Ended September 30,â€‹â€‹â€‹â€‹2024â€‹â€‹2023â€‹â€‹2024â€‹â€‹2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 shares Trading Arrangements, by Individual Â Material Terms of Trading Arrangement (c) Director and Officer Trading Arrangementsâ€‹A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act,â€‹ is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or our other securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, for diversification or other personal reasons.â€‹Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.â€‹The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a non-Rule 10b5-1 trading arrangement, as defined in Item 408(c) of Regulation S-K.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Type ofNature ofDuration of TradingAggregateâ€‹Action TakenTradingTrading TradingNumber ofName (Title)(Date of Action)Arrangement Arrangement Arrangement Securities Todd Carter, Ph.D.(Chief Scientific Officer)Adoption(September 9, 2024)Rule 10b5-1 trading arrangement for exercises of options and sales of sharesSaleUntil August 15, 2025, or such earlier date upon which all transactions are completed or expire without executionUp to 79,000 sharesâ€‹ Todd Carter, Ph.D. Â Trading Arrangements, by Individual Â Name Todd Carter, Ph.D. Title Chief Scientific Officer Rule 10b5-1 Arrangement Adopted true Adoption Date September 9, 2024 Aggregate Available 79,000 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd_IndividualAxis=vygr_ToddCarterPh.d.Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of significant accounting policies and basis of presentation (Policies) 9 Months Ended Sep. 30, 2024 Summary of significant accounting policies and basis of presentation Â Basis of Presentation Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31,Â 2023 as filed with the Securities and Exchange Commission (â€œSECâ€) on February 28, 2024. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Companyâ€™s financial position and results of operations for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board. Principles of Consolidation Principles of ConsolidationThe unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary as disclosed in Note 2, under the heading â€œSummary of Significant Accounting Policies and Basis of Presentation,â€ within the â€œNotes to Consolidated Financial Statementsâ€ accompanying the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31,Â 2023. Intercompany balances and transactions have been eliminated. Use of Estimates Use of EstimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Companyâ€™s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, incremental borrowing rate for leases, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Summary of Significant Accounting Policies Summary of Significant Accounting PoliciesThere have been no changes in the Company's significant accounting policies as described in Note 2, â€œSummary of Significant Accounting Policies and Basis of Presentation,â€ within the â€œNotes to Consolidated Financial Statementsâ€ accompanying the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Fair value measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair value measurements Â Schedule of assets and liabilities measured at fair value on a recurring basis Assets and liabilities measured at fair value on a recurring basis as of SeptemberÂ 30,Â 2024 and DecemberÂ 31,Â 2023 are as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

3,985â€‹Total money market funds and marketable securitiesâ€‹$ 227,583â€‹$ 93â€‹$ (13)â€‹$ 227,663â€‹ Reconciliation of cash, cash equivalents, and restricted cash â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of SeptemberÂ 30,Â â€‹As of DecemberÂ 31,Â â€‹â€‹â€‹2024Â Â Â Â 2023â€‹â€‹â€‹Â Â (in thousands)â€‹Cash and cash equivalentsâ€‹$ 112,525â€‹$ 68,802â€‹Restricted cash included in deposits and other non-current assetsâ€‹â€‹ 2,874â€‹â€‹ 1,593â€‹Total cash, cash equivalents, and restricted cashâ€‹$ 115,399â€‹$ 70,395â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash, cash equivalents, and restricted cash. + ReferencesNo definition available. + Details Name: vygr_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock Namespace Prefix: vygr_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued expenses (Tables) 9 Months Ended Sep. 30, 2024 Accrued expenses Â Schedule of accrued expenses â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of SeptemberÂ 30,Â â€‹As of DecemberÂ 31,Â â€‹â€‹â€‹2024Â Â Â Â 2023Â â€‹â€‹(in thousands)â€‹Employee compensation costsâ€‹$ 5,927â€‹$ 6,614â€‹Research and development costsâ€‹â€‹ 3,972â€‹â€‹ 5,225â€‹Accrued goods and servicesâ€‹â€‹ 530â€‹â€‹ 4,229â€‹Professional servicesâ€‹Â 1,013â€‹Â 755â€‹Totalâ€‹$ 11,442â€‹$ 16,823â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments, contingencies and other liabilities (Tables) 9 Months Ended Sep. 30, 2024 Commitments, contingencies and other liabilities Â Summary of other current and non-current liabilities â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹As of SeptemberÂ 30,Â â€‹As of DecemberÂ 31,Â â€‹â€‹2024Â Â Â Â 2023â€‹â€‹(in thousands)â€‹Other current liabilitiesâ€‹â€‹â€‹â€‹â€‹â€‹Lease liabilityâ€‹ 6,979â€‹â€‹ 3,200â€‹Total other current liabilities$ 6,979â€‹$ 3,200â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Other non-current liabilitiesâ€‹â€‹â€‹â€‹â€‹â€‹Lease liability$ 38,368â€‹$ 17,093â€‹Otherâ€‹ 1,000â€‹â€‹ 1,001â€‹Total other non-current liabilities$ 39,368â€‹$ 18,094â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of other liabilities. + ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Significant agreements (Tables) 9 Months Ended Sep. 30, 2024 2023 Neurocrine Collaborative Agreement and 2019 Neurocrine Collaborative Agreement Â Schedule of collaboration receivables and contract liabilities â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Balance at â€‹Â Â Â Â â€‹â€‹â€‹Balance at â€‹â€‹ December 31, 2023â€‹Additionsâ€‹Deductionsâ€‹September 30, 2024â€‹â€‹â€‹(in thousands)Related party collaboration receivablesâ€‹$ 3,341â€‹$ 11,895â€‹$ (11,522)â€‹$ 3,714Contract liabilities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Deferred revenueâ€‹$ 75,240â€‹$ 1,592â€‹$ (42,050)â€‹$ 34,782 X - DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=vygr_NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborativeAgreementTwentyNineteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation (Tables) 9 Months Ended Sep. 30, 2024 Stock-based compensation Â Compensation cost recognized for all stock-based compensation awards â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended â€‹â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹â€‹2024Â Â Â Â 2023Â 2024Â Â Â Â 2023Â â€‹â€‹(in thousands)Â Research and developmentâ€‹$ 1,590â€‹$ 919â€‹$ 4,495â€‹$ 2,472â€‹General and administrativeâ€‹Â 1,844â€‹Â 1,959â€‹Â 6,553â€‹Â 5,636â€‹Total stock-based compensation expenseâ€‹$ 3,434â€‹$ 2,878â€‹$ 11,048â€‹$ 8,108â€‹ Summary of stock-based compensation expense by type of award â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Ended â€‹Nine Months Ended â€‹â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹â€‹2024Â Â Â Â 2023â€‹2024Â Â Â Â 2023â€‹â€‹â€‹(in thousands)â€‹Stock optionsâ€‹$ 2,373â€‹$ 2,021â€‹$ 7,357â€‹$ 5,587â€‹Restricted stock awards and unitsâ€‹â€‹ 983â€‹â€‹ 774â€‹â€‹ 3,454â€‹â€‹ 2,339â€‹Employee stock purchase plan awardsâ€‹Â 78â€‹Â 83â€‹â€‹ 237â€‹â€‹ 182â€‹Total stock-based compensation expenseâ€‹$ 3,434â€‹$ 2,878â€‹$ 11,048â€‹$ 8,108â€‹ Summary of status and changes in unvested restricted stock â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

bonds | Level 2 | Fair value, measurements, recurring Â Â Assets, Fair Value Disclosure [Abstract] Â Â Marketable securities 102,083 23,970 Commercial paper | Fair value, measurements, recurring Â Â Assets, Fair Value Disclosure [Abstract] Â Â Marketable securities 22,715 3,985 Commercial paper | Level 2 | Fair value, measurements, recurring Â Â Assets, Fair Value Disclosure [Abstract] Â Â Marketable securities 22,715 3,985 Money market funds Â Â Assets, Fair Value Disclosure [Abstract] Â Â Cash and cash equivalents 106,492 65,589 Money market funds | Fair value, measurements, recurring Â Â Assets, Fair Value Disclosure [Abstract] Â Â Cash and cash equivalents 106,492 65,589 Money market funds | Level 1 | Fair value, measurements, recurring Â Â Assets, Fair Value Disclosure [Abstract] Â Â Cash and cash equivalents 106,492 $ 65,589 Certificates of deposits | Fair value, measurements, recurring Â Â Assets, Fair Value Disclosure [Abstract] Â Â Marketable securities 5,461 Â Certificates of deposits | Level 2 | Fair value, measurements, recurring Â Â Assets, Fair Value Disclosure [Abstract] Â Â Marketable securities $ 5,461 Â X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, cash equivalents, and marketable securities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Amortized Cost Â Â Cash and cash equivalents $ 112,525 $ 68,802 Total money market funds and marketable securities 339,232 227,583 Debt securities, unrealized loss position 96,000 44,200 Fair Value Â Â Total money market funds and marketable securities 339,326 227,663 Unrealized Gains and Losses Â Â Marketable securities, unrealized gains 158 93 Marketable securities, unrealized losses (64) (13) Money market funds Â Â Amortized Cost Â Â Cash and cash equivalents 106,492 65,589 Fair Value Â Â Cash and cash equivalents, fair value 106,492 65,589 Certificates of deposits Â Â Amortized Cost Â Â Marketable securities, Amortized cost 5,449 Â Fair Value Â Â Marketable securities, fair value 5,461 Â Unrealized Gains and Losses Â Â Marketable securities, unrealized gains 12 Â U.S. Treasury notes Â Â Amortized Cost Â Â Marketable securities, Amortized cost 77,846 102,966 Fair Value Â Â Marketable securities, fair value 77,920 103,044 Unrealized Gains and Losses Â Â Marketable securities, unrealized gains 74 81 Marketable securities, unrealized losses Â (3) U. S. Government agency securities Â Â Amortized Cost Â Â Marketable securities, Amortized cost 24,644 31,068 Fair Value Â Â Marketable securities, fair value 24,655 31,075 Unrealized Gains and Losses Â Â Marketable securities, unrealized gains 13 10 Marketable securities, unrealized losses (2) (3) Corporate bonds Â Â Amortized Cost Â Â Marketable securities, Amortized cost 102,077 23,975 Fair Value Â Â Marketable securities, fair value 102,083 23,970 Unrealized Gains and Losses Â Â Marketable securities, unrealized gains 55 2 Marketable securities, unrealized losses (49) (7) Commercial paper Â Â Amortized Cost Â Â Marketable securities, Amortized cost 22,724 3,985 Fair Value Â Â Marketable securities, fair value 22,715 $ 3,985 Unrealized Gains and Losses Â Â Marketable securities, unrealized gains 4 Â Marketable securities, unrealized losses $ (13) Â X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRepresents the value of money market funds and marketable securities on amortized cost basis. + ReferencesNo definition available. + Details Name: vygr_MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the fair value of money market funds and marketable securities. + ReferencesNo definition available. + Details Name: vygr_MoneyMarketFundsAndMarketableSecuritiesFairValue Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Definitionn/a + ReferencesNo definition available. + Details Name: vygr_UnrealizedGainLossAbstract Namespace Prefix: vygr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Cash, cash equivalents, restricted cash, and available-for-sale marketable securities Â Â Â Â Cash and cash equivalents $ 112,525 $ 68,802 Â Â Restricted cash included in deposits and other noncurrent assets 2,874 1,593 Â Â Total cash, cash equivalents, and restricted cash $ 115,399 $ 70,395 $ 66,862 $ 100,474 X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of

cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued expenses (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued expenses Â Â Employee compensation costs $ 5,927 $ 6,614 Research and development costs 3,972 5,225 Accrued goods and services 530 4,229 Professional services 1,013 755 Total $ 11,442 $ 16,823 X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the amount of expenses incurred but not paid for goods and services, due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: vygr_AccruedGoodsAndServicesCurrent Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs . Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: vygr_AccruedResearchAndDevelopmentCostsCurrent Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Lease obligation (Details) $ in Thousands 3 Months Ended 9 Months Ended Aug. 11, 2023 USD ($) ftÂ² Sep. 30, 2024 USD ($) Jun. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Feb. 01, 2024 USD ($) Dec. 31, 2023 USD ($) Operating lease, right-of-use assets Â $ 34,523 Â Â $ 34,523 Â Â $ 13,510 Lease liability Â 38,368 Â Â 38,368 Â Â 17,093 Restricted cash included in deposits and other noncurrent assets Â 2,874 Â Â 2,874 Â Â $ 1,593 Impairment charge Â Â Â Â Â 2,776 Â Â Â Other income from sublease Â 200 Â Â 200 Â Â Â Â Lease expense Â $ 1,900 Â $ 900 $ 8,000 $ 2,700 Â Â Weighted average remaining lease term Â 4 years 10 months 24 days Â Â Â 4 years 10 months 24 days Â Â Â Weighted average incremental borrowing rate Â 6.80% Â Â 6.80% Â Â Â 75 and 64 Sidney Street Â Â Â Â Â Â Â Â Restricted cash included in deposits and other noncurrent assets Â $ 2,900 Â Â $ 2,900 Â Â Â 64 Sidney Street Â Â Â Â Â Â Â Impairment charge Â Â $ 2,800 Â Â Â Â Â 75 Hayden avenue Â Â Â Â Â Â Â Â Area of additional facility leased | ftÂ² 61,307 Â Â Â Â Â Â Â Leasehold improvements amount $ 1,800 Â Â Â Â Â Â Â Operating lease, right-of-use assets Â Â Â Â Â Â $ 26,700 Â Lease liability Â Â Â Â Â Â $ 26,700 Â X - DefinitionArea of a real estate property. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfRealEstateProperty Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of sublease income excluding finance and operating lease expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_SubleaseIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average incremental borrowing rate for operating lease. + ReferencesNo definition available. + Details Name: vygr_OperatingLeaseWeightedAverageIncrementalBorrowingRate Namespace Prefix: vygr_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from proceeds received from lessor related to leasehold improvements. + ReferencesNo definition available. + Details Name: vygr_ProceedsFromLessorForLeaseholdImprovements Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=vygr_SidneyStreet75And64LeasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=vygr_Sidney64StreetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=vygr_Facility75HaydenAvenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments, contingencies, and other liabilities (Details) $ in Thousands 12 Months Ended Dec. 31, 2016 USD ($) multiple Sep. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Dec. 31, 2017 USD ($) Other current liabilities Â Â Â Â Lease liability Â $ 6,979 $ 3,200 Â Total other current liabilities Â 6,979 3,200 Â Other non-current liabilities Â Â Â Â Lease liability Â 38,368 17,093 Â Other Â 1,000 1,001 Â Total other non-current liabilities Â $ 39,368 $ 18,094 Â Non-profit organization agreement Â Â Â Â Other non-current liabilities Â Â Â Â Maximum funding $ 4,000 Â Â Â Funding multiple | multiple 2.6 Â Â Â Milestone payment liability Â Â Â $ 1,000 X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of miscellaneous liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: vygr_MiscellaneousOtherLiabilitiesNoncurrent Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReflects the value of the milestone payment received from the non-profit organization recognized as a liability as it is probable that the Company will repay the amount. + ReferencesNo definition available. + Details Name: vygr_NonProfitOrganizationMilestonePaymentLiability Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReflects the amount of maximum funding available from non-profit organization, for research and development under arrangement. + ReferencesNo definition available. + Details Name: vygr_NonProfitOrganizationResearchAndDevelopmentMaximumFundingCapacity Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReflects the multiple to be used for future funding following successful development and commercialization. + ReferencesNo definition available. + Details Name: vygr_NonProfitOrganizationResearchAndDevelopmentMultiple Namespace Prefix: vygr_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=vygr_NonProfitAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Agreements - Narratives (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Collaboration revenue $ 24,629 $ 4,614 $ 73,723 $ 159,947 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606

-SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Agreements - Novartis Option and License Agreement & Stock Purchase Agreement (Details) $ in Thousands 3 Months Ended 9 Months Ended 12 Months Ended Sep. 03, 2024 USD ($) Dec. 28, 2023 USD ($) shares Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2023 Program Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Collaboration revenue Â Â $ 24,629 $ 4,614 $ 73,723 $ 159,947 Â Novartis Pharma, AG | 2023 Novartis Collaboration Agreement Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Number of collaboration programs | Program Â Â Â Â Â Â Â 2 Shares of common stock | shares Â 2,145,002 Â Â Â Â Â Aggregate purchase price Â $ 20,000 Â Â Â Â Â Amount of premium Â $ 700 Â Â Â Â Â Novartis Pharma, AG | Option and License Agreement Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Collaboration revenue Â Â $ 15,000 Â Â Â Â Upfront payment $ 15,000 Â Â Â Â Â Â Â Novartis Pharma, AG | Development, regulatory and commercialization milestone | Option and License Agreement Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Aggregate maximum milestone payments to be received from collaborative partner 130,000 Â Â Â Â Â Â Novartis Pharma, AG | Sales milestone | Option and License Agreement Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Aggregate maximum milestone payments to be received from collaborative partner $ 175,000 Â Â Â Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the amount of premium on shares issued + ReferencesNo definition available. + Details Name: vygr_AmountOfPremiumOnSharesIssued Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIn the aggregate, the maximum milestone payments to be received from the collaborative partner. + ReferencesNo definition available. + Details Name: vygr_CollaborativeArrangementAggregateMaximumMilestonePaymentsToBeReceivedFromCollaborativePartner Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the number of programs under collaborative arrangement. + ReferencesNo definition available. + Details Name: vygr_CollaborativeArrangementNumberOfPrograms Namespace Prefix: vygr_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the amount of upfront payment to be received under collaborative arrangement. + ReferencesNo definition available. + Details Name: vygr_CollaborativeArrangementUpfrontPaymentToBeReceived Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the number of shares agreed to be issued. + ReferencesNo definition available. + Details Name: vygr_NumberOfSharesAgreedToBeIssued Namespace Prefix: vygr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresents the aggregate purchase price pf number of shares agreed to be issued. + ReferencesNo definition available. + Details Name: vygr_NumberOfSharesAgreedToBeIssuedAggregatePurchasePrice Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_CounterpartyNameAxis=vygr_NovartisPharmaAgMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=vygr_NovartisCollaborationAgreement2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=vygr_OptionAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: vygr_MilestoneAchievementAxis=vygr_DevelopmentRegulatoryAndCommercializationMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: vygr_MilestoneAchievementAxis=vygr_SalesMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Agreements - Neurocrine Collaboration Agreements (Details) - USD ($) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Sep. 30, 2024 Apr. 30, 2024 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Collaboration revenue Â Â $ 24,629 Â Â $ 4,614 $ 73,723 $ 159,947 2019 Neurocrine Collaborative Agreement | Neurocrine Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Milestone payments Â Â Â Â $ 5,000 Â Â Â Allocation of transaction price Â Â Â Â 5,000 Â Â Â Cumulative catch up of revenue recognized Â Â Â Â $ 4,400 Â Â Â 2023 Neurocrine Collaborative Agreement | Neurocrine Â Â Â Â Â Â Â Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Â Â Â Â Â Â Â Collaboration revenue Â Â Â $ 3,000 Â Â Â Â Milestone payments $ 3,000 $ 3,000 Â Â Â Â Â Â Allocation of transaction price $ 3,000 Â 3,000 Â Â Â $ 3,000 Â Cumulative catch up of revenue recognized Â Â $ 2,000 Â Â Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the amount of cash flow on milestone payments. + ReferencesNo definition available. + Details Name: vygr_MilestonePayments Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRepresents the amount of revenue performance obligation allocation of transaction price. + ReferencesNo definition available. + Details Name: vygr_RevenuePerformanceObligationsAllocationOfTransactionPrice Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_TypeOfArrangementAxis=vygr_NeurocrineCollaborativeAgreementTwentyNineteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=vygr_NeurocrineBiosciencesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=vygr_NeurocrineCollaborativeAgreementTwentyTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Agreements - Neurocrine Collaboration receivables and contract liabilities (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Related party collaboration receivables, beginning balance $ 3,341 Related party collaboration receivables, ending balance 3,714 2023 Neurocrine Collaborative Agreement and 2019 Neurocrine Collaborative Agreement Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Related party collaboration receivables, beginning balance 3,341 Additions 11,895 Deductions (11,522) Related party collaboration receivables, ending balance 3,714 Deferred revenue, beginning balance 75,240 Additions 1,592 Deductions (42,050) Deferred revenue, ending balance 34,782 Discovery program 3 | Neurocrine | 2023 Neurocrine Collaborative Agreement and 2019 Neurocrine Collaborative Agreement Â Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Â Additions 1,600 Deductions $ (42,100) X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to contract with customer assets during the reporting period. + ReferencesNo definition available. + Details Name: vygr_AdditionsToContractWithCustomerAssets Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase to contract with customer liabilities during the reporting period. + ReferencesNo definition available. + Details Name: vygr_AdditionsToContractWithCustomerLiabilities Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of decrease to contract with customer assets during the reporting period. + ReferencesNo definition available. + Details Name: vygr_DeductionsToContractWithCustomerAssets Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=vygr_NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborativeAgreementTwentyNineteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=vygr_DiscoveryProgramThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=vygr_NeurocrineBiosciencesIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Compensation expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Stock-based compensation $ 3,434 $ 2,878 $ 11,048 $ 8,108 Employee Stock Option [Member] Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Stock-based compensation 2,373 2,021 7,357 5,587 Restricted stock awards and units Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Stock-based compensation 983 774 3,454 2,339 Employee stock purchase plan awards Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Stock-based compensation 78 83 237 182 Research and development Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Stock-based compensation 1,590 919 4,495 2,472 General and administrative Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Stock-based compensation $ 1,844 $ 1,959 $ 6,553 $ 5,636 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Restricted Stock - (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restricted stock disclosures Â Â Â Â Â Stock-based compensation. $ 3,434 $ 2,878 $ 11,048 $ 8,108 Unvested restricted common stock units Â Â Â Â Â Shares Â Â Â Â Â Balance, beginning (in shares) Â Â 1,370,897 Â Granted (in shares) Â Â 867,558 Â Vested (in shares) Â Â (423,362) Â Forfeited (in shares) Â Â (198,076) Â Balance, ending (in shares) 1,617,017 Â 1,617,017 Â Weighted Average Grant Date Fair Value Per Share Â Â Â Â Â Balance, beginning (in dollars per share) Â Â $ 6.65 Â Granted (in dollars per share) Â Â 8.15 Â Vested (in dollars per share) Â Â 6.23 Â Forfeited (in dollars per share) Â Â 6.68 Â Balance, ending (in dollars per share) $ 7.56 Â $ 7.56 Â Restricted stock disclosures Â Â Â Â Â Vesting period Â Â 3 years Â Stock-based compensation. $ 983 $ 774 $ 3,454 $ 2,339 Unrecognized stock-based compensation expense $ 9,100 Â $ 9,100 Â Remaining weighted-average remaining vesting period Â Â 2 years 1 month 6 days Â X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes

share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based compensation - Stock Options - (Details) - USD ($) $ / shares in Units, $ in Thousands 9 Months Ended Sep. 30, 2024 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Â Outstanding, beginning balance (in shares) 7,425,444 Granted (in shares) 2,325,226 Exercised (in shares) (86,100) Cancelled or forfeited (in shares) (793,242) Outstanding, ending balance (in shares) 8,871,328 Exercisable (in shares) 4,604,321 Weighted Average Exercise Price Â Outstanding (in dollars per share) $ 8.52 Granted (in dollars per share) 7.79 Exercised (in dollars per share) 4.11 Cancelled or forfeited (in dollars per share) 11.69 Outstanding (in dollars per share) 8.08 Exercisable (in dollars per share) $ 8.51 Remaining Contractual Life Â Outstanding 7 years 6 months Exercisable 6 years 4 months 24 days Aggregate Intrinsic Value Â Outstanding $ 3,756 Exercisable 2,777 Employee Stock Option [Member] Â Options disclosures Â Unrecognized stock-based compensation expense $ 20,100 Remaining weighted-average remaining vesting period 2 years 8 months 12 days X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Definitionn/a + ReferencesNo definition available. + Details Name: vygr_AggregateIntrinsicValueAbstract Namespace Prefix: vygr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definitionn/a + ReferencesNo definition available. + Details Name: vygr_RemainingContractualLifeAbstract Namespace Prefix: vygr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Net (loss) income per share (Details) - shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share Â Â Â Â Antidilutive securities 10,488,345 9,080,820 10,488,345 7,432,212 Unvested restricted common stock awards Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share Â Â Â Â Antidilutive securities Â 22,500 Â 22,500 Unvested restricted common stock units Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share Â Â Â Â Antidilutive securities 1,617,017 1,312,727 1,617,017 714,164 Employee Stock Option [Member] Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share Â Â Â Â Antidilutive securities 8,871,328 7,745,593 8,871,328 6,695,548 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Net (loss) income per share - Basic and diluted weighted average shares outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Numerator: Â Â Â Â Net (loss) income $ (9,044) $ (25,901) $ (30,515) $ 75,935 Denominator for basic net (loss) income per share: Â Â Â Â Weighted average shares outstanding-basic 57,851,110 43,864,838 57,564,413 40,962,116 Denominator for diluted net (loss)

income per share: Â Â Â Â Weighted average shares outstanding-basic 57,851,110 43,864,838 57,564,413 40,962,116 Common stock options and restricted stock units Â Â Â 1,648,608 Weighted average shares outstanding-diluted 57,851,110 43,864,838 57,564,413 42,610,724 Net (loss) income per share, basic $ (0.16) $ (0.59) $ (0.53) $ 1.85 Net (loss) income per share, diluted $ (0.16) $ (0.59) $ (0.53) $ 1.78 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareReconciliationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Underwritten public offering (Details) - USD ($) $ / shares in Units, $ in Millions Jan. 09, 2024 Sep. 30, 2024 Jan. 04, 2024 Dec. 31, 2023 Underwritten public offering Â Â Â Â Par value of common stock (in dollars per share) Â $ 0.001 Â $ 0.001 Underwriting Agreement Â Â Â Â Underwritten public offering Â Â Â Â Issuance of common stock, shares 7,777,778 Â Â Â Par value of common stock (in dollars per share) Â Â $ 0.001 Â Offering price for common stock Â Â 8.46 Â Net proceeds received $ 93.5 Â Â Â Underwriting Agreement | Pre-Funded Warrants Â Â Â Â Underwritten public offering Â Â Â Â Number of warrants issued to purchase common stock 3,333,333 Â Â Â Price per warrant Â Â $ 8.459 Â Issuance of Pre-Funded Warrants 3,333,333 Â Â Â Â X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -

Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants issued. + ReferencesNo definition available. + Details Name: vygr_ClassOfWarrantsAndRightsOutstandingNumberOfWarrantsIssued Namespace Prefix: vygr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=vygr_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Related party transactions (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Jun. 30, 2023 Related party transactions Â Â Â Â Â Related party collaboration receivable $ 3,714,000 Â $ 3,714,000 Â $ 3,341,000 Â Dr. Sah | Related Party Â Â Â Â Â Related party transactions Â Â Â Â Â Â Total amount of services received 150,000 $ 157,500 450,000 $ 541,300 Â Â Advisory fee amount per month Â Â Â Â Â $ 50,000 Neurocrine Collaborative Agreement 2019 Â Â Â Â Â Related party transactions Â Â Â Â Â Related party collaboration receivable 400,000 Â 400,000 Â Â Â Neurocrine Collaborative Agreement 2023 Â Â Â Â Â Related party transactions Â Â Â Â Â Related party collaboration receivable $ 3,300,000 Â $ 3,300,000 Â Â Â X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of advisory fee payable per month in a related party transaction. + ReferencesNo definition available. + Details Name: vygr_RelatedPartyTransactionAdvisoryFeePayablePerMonth Namespace Prefix: vygr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_CounterpartyNameAxis=vygr_DrDinahSahMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=vygr_NeurocrineCollaborativeAgreementTwentyNineteenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=vygr_NeurocrineCollaborativeAgreementTwentyTwentyThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ÿ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

TB=)2E):AM!RE%2A-4;1V3!NW)3CA.44#IXBP M(P?G$E5=4%J,TA*4)@-=LG"GOK931!46E):CM *EJ;ZMVXY;([$=H'EE110 M>]7!B41U%I06H[0$I4F4E@8&\\71QA;1.5M06H'25_ F:.4Q; 2:T"
[0G*1V MVAE#TX72(I06H[0$I4F4EJ*T+#1,7^*,': [*$RT:H'25'\?VAEKK)?P'.M% MM]3RAZ7=4K/7&9Q#5'D)3U!>T(H)2I.A27F9^&YWRC%#NTM?=$R6S-1*3$3@ MN]U
H,H+2E.&3KBN[SGAD4 TRDMXAO)R3AY0WP6E1:')=_%"X3C=2R1HM92 M2926HK0,I>4HK4!IBJ*UX]KX+N$K^"YVYN!LHKX+2HM16H+29&AP,D1WCX;Z M+B@M1VD%2E/V;=O.6N.
[A* LN]CY@W.'^BZAP7<) T]T=XBH[X+2)$I+45]& MTG*45J T1=':(6U\E_"%OHLQF*CC@M*BT/!@FVXH4;%I4F4EJ*T#*7E**U M:2K41:ECETX::26T2RLO-LOL ,&I0_654/<./"&FVODAZ]6@-
(G24I26H;0< MI14H35&T=D@;TR6TFR[G#*';D8-SB:HM*"U&:0E*DZ$N\;AN]U[[%*V9H;0< MI14H3?5MW7;<&F,EM!LKKS2$;]\Z.)&HU(+28I26H#2)TM)0ESB\R;0[5H$Z
M+2BM0&FJ9W.T\]@H+:%=:3EM"!T55%!:A-)BE):@-(G24I26A0:_8SKNSE'< MHT4+E*9ZN]!*V*215"8]L[Q0LQ[9ZPQ-(4J+#C3KK$=HQ02E2H3VH4!IRM)VZQ'DT8HF?0()="L1_8R@^.
^B0373XX,NL16C=! M:1*EI2@M0VDY2BM0FJ)HW^)ZM;FMJFU4;LMW;^[+F^K/Y?IFOMR,%M7G&C_^ M>7<===#V_N7UZL5W=0[VH5^'3:KM=W>U_O*W*>F>V:U#__?-JM?W^XJKF/Z[6
M?^QKO/L. 4$L#!!0 (#. ;%F]0Y]'CP< "\A 8 >&PO=V]R:W-H M965T&ULK5IK<]LV%OTK&+6SD\Q8$0'P(7IMS3A*.^W,-NN) MM]O/% E):$A"!4#9WE^_%Z0L2@(V*F^Q*)T<7GN
_<<@KEY%/*KVC*FT5-5 MUNIVLM5Z=SV;J7S+JDQ]$#M6PR]K(:M,PZ7E:O]%CP?;8(+R1FE1'18#@HK7W=_LZ9"(DP7@ MQ[V '!:0X8)P9 $]+*!MH!VR-JQ/F-/R!:FF%Q!HM,
[5%/T/%%9]BWQ\^H7<_MOD<_(EZC_VQ%H[*Z4#]O03X"@.%_@RB. MH9'T4#X2K\,'MON :'"%2$!"!Y[EZY=3#QQZS"QM_=&QS)JDK2%I:"U%A6#C MR4SS>M-U+M><.9/6.0W=3LVFOE:
[+&>W$]BUBLD]FRS^\0..@W^Z(KZ0L[/X MPV\H<_[XC/,H'>E4.H]-$HN*N:*MG,1MR[,Q-DOIC2(<'0SVY_&89LE44I[MJS. T1%@Y"W07?$G[*^NR;6
F92+.NHY,Z8AR$\T&U:LY#N;N8B=M(D7[2<&* #8>"OO M[(_T&%CJ#>RN$E+S_W4] 20"MZAX4RD$=($*KG+1M/12 YW)KTQG*]ZBN6- M')V-J!7S- ZC8= .*SRGQ%TF'/1$&7CC^1<,!
(,6H.^$RDH3TYH_09DRI9AV M,V!@80F38;L[C'!(1^">\#KVT\\VJS=,&9(^F4TMTK8")<]6IKG&YM3!_84& MU:6\G2>#],D@_E[,#]T&,X#QO6DU9\S$JD0?&%E
MJ]%VF=3/,'K+,EL)V>VS;\1'[:U!$SH,SV%%TG1DSN%>#V"_(+B7#$9=\<(/ M71L*O642A*Z49@)Z=E+H@!ZDR1"[RRP)EW\^[B#VLE\A:1Y.IB*
M]13$0(?:"3JR"2,D5KYM*QO&Z0CFGIZQGY^//;_+GD<;PD'(D350'59)$({@ MZPD9^QD9\,F&]>W@Q&?V)K!+BI@!NQ9W;CK[>#&, @C"Z-MAV,2!VZ,I.=0 MXN?
0SV\7T:XPB,V8T\3J"H<5#G"*MM#.5 S(R$YW]U?"=T;/.'-@,.Z4T'DX\CFRFFQP M/ ^3$5(@/:V2^"V;?\WKK,Y? =Q+UF_>_!?R=IZ#GK]G)K/NQ$4') XDSD' MCH0N5.9@ &:Y$:3N7-
AT36)K>MM&>$[&9G?/Z<3/Z39TKE0#6RAYZ*J0$5W M$4!;YJ*N#^?-CUQO6_NF+IA\A+VE68UVS:KD.2P%[H4F<$9K\WU*0TMU^W%_M;TE[]4#\ZN'OY\41C(V2@D-MI#08'@+Z(_C. M#-
%>NU" _=KE4AE@#CJ!9&%]>/;IY4^3']N9C85L948$*W+27AA1K^API&CW MT@##%+6[*/WT<'_O#!?;YR8G"OD0A6UQLZ:2]LJ%_8'*GI5)B*=LJ36[=@ M3,-P.-P<=I3B^1CXDU<.?
GUCP/,ZE^WCRKN"=9_>MPT),5UUD1F%M@<) 0^' M5ZV*@);1DN?F4,$8.".SI4T8!2=/@8? G%(IQB-/[070-0O@):OAW^%5FS# MZ]J4RXA3F,RB<,9DJQL00>EP[CC,,$2>C#P!TUX%4;*>E-
,S!R6>*-Q'"/@ MB*;I,)S(>ID2Q-XK$*],*)^8?30['9E.\"RLCW?+85J9+?S38@FJEK4T^[" MOXTN*I8NY>T\+[U8HGZQ-#Q%L(^.D%CI#%:U2I@]Y>W)+5H+>?) ?'X"X?PC M<, 1G\FJ)+)FCQ?
N6],Q.WGU7#&Y=_(*0!0>/76O;H_?'M_ZW[7ON@???\37 MR^[=?>^F^Z\$OV42MK."%*S!9? A@0:6W=OY[D*+7?N">R6T%E7[<&PO=V]R:W-H965T&ULI5=K;^.V$OTK _>B: '7=IQL]Y$'
MX#AN&Z#K!+%W+VZ_T=+48(I8B59*RX_[ZG]%DQ;N;#5K<+[9$##6?.S)R9(2]V MSG*!7.DQ]+8<-DK8JS>#8]MOBR=KY4$:]^,PR59Y6G3:49CD>C MGX>ETK9W=9'6[OW5A:NCT9;O/86Z+)7?
7[-QN\O>2>^P* W192%X=5%I3:\ MX/BANO=X&W9:23Q9.?=)7F[SR]Y(M +'A+(H&A\M3]D84008?[8Z>YU)V7C\?-#^2_(=OJQ4X*DS_]5Y+"Y[;WJ4 M\UK5)CZXW6_<^O-
*]&7.A/+1^NT;VY&V/LCI$5[:;@:#4MOE7CVT4BNIMT IZTD91$]OFKLBU=S%6O/Y-:T MJ@.^A7 QC- K7X=9J^.ZT3'^AHZW]-[96 2:V9SSS_O:3!R)\4_6_RZ^R!EK_-'B;WLP_+V^F";N?3
WD=UHLL?!^ M-E\NZ 0JOD)-']T>M>QI6;!7%==19Z%/MS8;T ^Q8/K^NS?C\>A\ZLI*V7UZ M.SG_D70@12OM(F>%=<9M]I0U(K0K7&!0/Z0^ ,'HR/ 6ZC=,HK)R.Q@$B*(N ME:4-
6Q:K(E>Z7*_W22ISM0\)][(YH68U2IH-[(@+EFLO9G6F#.4Z, H]#,0+ M.H)Z\OH\4*4KEM"3MIFI<\:*=QNORD#HD30Q?Q6,MN6[#:VZ^4_:1N<_7)G/T$N!7-EX +<\1U(\2CYQS:*0HN\NSI0 MV(?
(Y8#>2PQ;F:]<.0!7"$'.'OTQI[5W)>D8:/DPF('SV9@SP.5OWDPK! M91K8<]IJ#S_ M F=3#YVR5;93.QD" 8C90&AFF10I\W:N6 41QJ]">B M$\./0-VG20"]P [4 0GZFX.M)N[K?(1A7-?*,PQFOS:
(T)Z^'8(YGDR-I=J MR+R0_%]D&FV&7=E?-C:"1TV?U8O*;$*0<8(\XF! %U[+Z"5M76B:B2<+B3N M6#0N1J[;)$IC!(^^Q#], ?Z7] FAQH,]:Q&8:1\8Q8C5U%V_V?\]F3PB&DW# M&
3G:US6Q8YLHF^ZMBFGJ0+7 M+$NN2ISD1_89\DF5VB^^5ZYH)XHLN5]+S&[%%A)'H)!J!#QY(= MSFZ8!: -AW)7E8XHD;28ZS1FO:#5;3IE MU *&08G#P([-%C.R.84E^HA-C,Q:R-
LVIB!#$//%Z#S1H*&VEB$4L=*F5@8W M!%%;*^G#PIO:)RTI84Y.[JVZ&:,TZ^<,XRT#N1#D1PQO$08 MO9WE^,'H#O#C&T0^G*+Z\"Y@W*=B>&HZ#26?TH9L-I$>T'-T.'1K0#GD4VZ
M^P0!:&-S0>A6N^O5I+E5/(DW=[/WRF]P- '=UM@Z&KQ^U2/?W'>:E^BJ=,=8 MN8@;2WHL<$5D+P+XOG:8O^V+&.@NG5=_ U!+ P04 " S@&Q9@6; B>P% M "'$ &
'AL+W=ORZ9DY5UM[X@"N*^U,:?#HH0JC?CL<**J4?V8H,OBRL*V7 JUN.?>5(MYE&HU./I9/)R7$IE!FW:G9W8.FAEZ-H)7Y>E=.L+TG9U.M@?M N?U;((MO#
^.ZGDDF84;JIKA[=QIR57)1FOK!&.%J>#_TW%X>\/V[X0]*JYX%1S*W M]I9?/N2G@PD[1)JRP!HD?N[HDK1F17#C:Z-ST)EDP?YSJ_U=C!VQS*6G2ZO_ M5'DH3@=' Y'30M8Z?
+:K7ZF)YP7KRZSV\:]8I;TO7P]$5OM@RT88'I3*I%]Y MW^2A)W T^8; M!&81K^3H>CE6QGDV8FS*^%X-[3Q0PPU2L,Y9;@HL^#P54$N MG,U2,81="*^61BU4)DU LC);FZ#,4E16JTR1%]+DG
#E>3,0X,D$R:D]&0=X MPOK&66/U(EF=?L/J: '1FE!X<65RRK?EQXB@"V/:AG$Q?53AC*J1.)@,Q70R M/7Q$WT&7EH.H[^ _3DNR>KC;*C?@&U _)C$X49&[H\'9\V?[+R?'C\1TV,5T
M^)CV'Q;3XU:G(_%O&!87[>IU?_5+05%/64FS9DVUD76N N4BL\"6\>G)PT N M>7FAC#29DEIXZ"#P2XAJ S1=)CVBD\4 M=%8:$2S)D)-:K_D[52')LO8;$_V:L5DO?G[^[&@ZG1R_/S^_CH_[Q[\
(D"QV M!W*][#D*ZQC.R-Q'GW HUX/6>E:Y%88&R*5Z3I',K1NHU$F<78D/^1U86W M5MAV]+56'-5\+=A^M,M)U!1H9X9& APH%K6#8M?7/&1FQE*PT>;3]=[VI'&[MRU%3 4[(_JMC+\Z-J2'_.69
(!"F8K$_V?LM^LPB"^4S;%F3=(*83L1;RJB< MPZF#_4@(!T)Z;-/X% O'4C/*:J=*B[FK^ZR09AD=*)6/(Z>MT.SJLBL0>T!S M5S.);D:,0D]=X?X!(9MW+92AFVB=*4TF(;\.>:6QU>LJN&4,QC@N&/0
MR?POS(>458.0O6>O."U2+*1RV_VS#?$NP1NO*NM5AQ5(8JS%QL#>U&[U*. M%65SWQJ@'.!$VT0D$/=`B@HY254&.&.I15H<7E7)-8UBIU$?JY)&8"?-]"D:Q#
M85$=R1/[0=_LZ*_=C<@UQW('K?/-+J@RN72(X-+FD8ZZP'?NNJGR:+O)X;LN M9SMW7UC\C,!3G2N0N^R@T-+6AJEZP'FB>=HN#PWMU3O(BZ-06%X5%EG:LRL# M;;Z>>Y4K!@CRDJ-
EM/6I[3ZA1&(ZA#\YI?(6.-QQ2"W^- 0]Z]%W+_;K/GWO M).IATT&Q 9N"-.H_M1"Y[(>_R?&L"[_5L47X/XXU1N(#%Z:QA;&D&;4IR."D M\3)+;;$9%Z05SF@R=L0-X(\L7/F@RH@>+GJ:)UU'?
D_%>1/3K0KK1%^1L1L* M]SVZX!R6\I8$=2;95>EQX*Z2IZ&0()^@CDE8JA,$$H39D/#WT?C6W6(G3X2 MOW,;(>5+RXMPD JWUJCG-]U)74=_&;>=]T- 6&5%"_JAF-=PWD52$9QH=B[8
M82]>1UJF53S>D:F)^=("M&E6096+-A',W#HCQ3+JM+%)0AS>>*4,?ADFB_E#A8J 53\L+9$A)@B[[KKF]XZX3W%$4@ M*RCAIF6,%6GT^@=G@)_\TZ=%4!GYS*GY-
I7]GXGK4<;:=4L8]RZ');EEO)[M$7.0[HG=:G?+/D^7R\WV=$7_*-U2 6B:%A"=C%Z]& B7KKWI)=@J7C7G-N+B MA&A]YF)#C#?C.?[_VA0UT_WLX^QM02P,$% @ ,X!L6:#V+/^/! 5Q$ M !@
!X;"]W;W)K M?B:V@21=NP(KEC7))IF63C81B51(*J[_^QTI65;\2%1DZ+8O)GFZ^]U#=Z>C MIVLA[]4*0)/O><;5S%EI79QYGHI7D%/5$P5P?)(*F5.-1[GT5^&!)E8HS[50 M]X=>3AEWYE-
+NY;SJ2AUQCA<2Z+*/*=R'+\G,\8U! MD$&L#0+%Y1&N(,L,$)KQ4&,ZC4HCV-YOT3]9W]&7!55P);* 6*)7,V?LD 12 M6F;ZFUC_"K4_ X,7BTS97[*N>,..^0^)2:9'7PFA!SGBUTNJU'%H"8_^$0%@+
MA-;N2I&U\B/5=#Z58DVDX48TL[&N6FDTCG'S4FZTQ*<,Y?3\$V02/-*L!(# M5:4$C+A64T\CN&'QXAKHL@(*3P!-R%?!]4J17W@"R5-Y#XUJ+ NWEEVC&$+?> M0-$CD>^2T _[S^!%C:>1Q8M>
[VD%U#\,9,KD3!4TAIF#=:! /H(S?_5%6]"/$-36PU(A0"48D%1EV 75&WKT9AWYT M_I];_RB%Q@!<2Q9C0+;4&[;D+&4QY?K5&A@G%[83-93?]01#]1=7ZF\-R\4 M>_0.=6$RDRZRG:([+@Z)+ZU?
$DP9-"?;9DWS@!?EZ6/-?"LT2K[_#1XA(\&' M[2YL=M&'8TFT17F/T=(K42K,*O7!=!C88/O=],BMM.6X M(1Q3+_%D\@N2F%1#\[O)XTW+RP):P[PX'@Z[D8_J/ MT:] :IOEQC5L)
D40K'#C!^X_6'064LW[BLA"R%1,UD(DT+[_($?NOXXZJRU M* ^5R'.0,<."&C1*ODFIJ$["KK'M"-[58+Y8>F82LF/)7HC^I9$T<2-PF&+ M$OH3UQ^.6I0 RS8<3%J4?1,.OP< _JY)>T3&&
W;M"7+GCO)"58>1.QGYG>$[LK]8TP@S'KRH[9#K'Z_D,!RY MPV'4H@23B3ORQVT>)_BTFOIAGO];Z^T*3*@+RC?;*57A8 !/QM3T2&CD6%@7$K+8D-9@6BM+\#;;.W:?\EJ7771X
M::_T"A%+KJM[;T-M_C6X["+. ;J+P=LVTMT@620HJC?&PT<(JMK?'70HK!7 MYX70>!&WVQ5@%*5AP.>IP/C4!Z.@^2]E_C=02P,$% @ ,X!L65#D$C;4 M!P 8AH !D
!X;"]W;W)K&ULS5EMC^*V%OXK M%EU5,U(60GC?G1EI=MKMK70KK*E_6P2]8Z-K4=6/KK[W.<$ (!=GJK,OMA M!G#L_H\QS[.W=;8SVXEA&=?[L+8._MP9PJOI!;O+'-%GG.[>R.4V=YW^IW]
MP'NY7'D:Z#W+263N=!.&LVL6-QW'ONOW@QI?ICPJQ1; MU_C.R).Y,9_IQ_9?2+ M84$N=?G)OU1Q>,Z"I%]0!+M+1<'*'[CG#W?6;)FEV9!&7X*K836,DŸJ2\L%;
M/)58YQ^>N%M%+,5_)GXOY(8KH;V+$&_GK4R]R,+#B'&=,;[A4O&Y$B^!AI<. M=V,89?]+99X9=6Z>[)E].!23#:#QLZ^L/VD!);L^N'HT.V!/ \4*FG)P$?#*Q M-D[ZUK)1-!S.VCJ39[L- >-^
_)V;2R4LKDAG+4$QTD43R9M*:.VD\-9V\NP M?CIHZ,MS85/)%5OSM6AS,$FBR1FJM9$=N^H,S0<7J_L&TC\9#4=ZFT^6B>"## M8#"+DD&30OW1M/'K9CRV9D^2 Z(+*M
JV1^RR(P'D6CZ:PQ\)P:<++H7UP" M"%NS<;L&3/NMH9L&5OKQ((H;O/WSQ$E4G)I_%C*7R)ADDP QT%C9-;\<50$RMGC
M<39MCCTH1&>F<@Q"LN=X%TR>OW04#^*4M?,4W@G&6XD!OT705Y!GWM&Q'*^ D MVPENF;%,">> W8-.'/ VU"B!OAL<]?+ UNU*: 'LE84XTW8R:L8>9<#%8 M!^_QH'0^$RD=EJFX-
>*P0BIP,$8?"D<7UN0LM2+#QJC*$QH";8*(!=)A+#3! M&(=FR^ MHPB5S\KJ49W=,\01@8!%L!C1<:4(#XJ36Y7TO;R(3"$U3;\09]CJ
M"9OPVY68.$ES,S;P6[IJY$, A04UML*NL<")G^;!ILJ,.1FK5/D[1/O(46A/ M*8?V8/0)"N?<27<:H,KV_],.KP$_J(S..E]F :FEWH83,=!$G0!(NH!X2_LJ M/24-34FF5$HY%-
H%I=H9);.0NCE706ZXI(B8DKD,P[N]I42LD)P3?C_+JRY[M! @E(BYM2'B05/.T1D]E;^7*4@V2C%U24^=//*32>U27
MYD))V. "8*$K"/*Y5%5Y)RBU^_%C>N@%Y2JCPA04"!F24%$BQ424)BJH2VXS MJAA2A_H4@H=CG"V=0E:=P+8%F;GPQ_O(2JB,O9B-NS'+I5+A A"Q?#$<=I-Z M!-$[O[<%#&V%#;F
1\6A.PZ9"GU'D'EI$SQ[%Q#N+XC"R*/:E0:?B*:L//]R MH;21>V_EO"B](*@?\$]!HSL3*KVBY'IF*FKL*\T1@H^CF!E1$BDD(*LC7FY> MS<, 'LJ:=J"I ,_P\F2O#18\A)A1?"I>E69/!*:X\'"5!P"2W85)E
2SG/_ MX]&U3!F!P+B,C IB= IL!N#OJ^FE*Z"3RZ5G$.RHM%6P<46^+_P^'.OVE9[G M^%=@=RU+'C:ZE=E]]DP*N^.]X.]K+\Y=S5QIV"Z):]V\U=N!)Z>LZ533^) M1LFH,3*>1M/X<-!_?
Y+"9CM871>48"W+OC;Z)3!L0T\#^/LSO44T/7-ATH]& MC4-V>7$_,!!JNC2*!K-F!SJ),=#J,,Y=[_8:] YH6I;&[0856,"K? 50C]8O M4![+]P:'Z>7;%_2P2[K44V*!I7%W,NHP6[[1*']XLPYO$>;&>Y.'KRO!
<8:D M"7B^,&@\JQ^DH'ZM]/ _4$L#!!0 (#. ;%G0=37?N@($<' 9 M>&PO=V]R:W-H965T[%$BN?HD+*HR8:+9YD#*+*M M2B:G5JY4/78<&>=04=GC-3!<2;FHJ$)39(ZL!=#$@*K2\5VW[U2T8-
9L8GQ+ M,9OPM2H+!DM!Y+JJ]'A=0,DW4\NS=H[(LN5=CBS24TS> +ULUX*M)R.)2DJ M8++@C A(I];<&R]"'6\"?A6PD0=SHC-9_)U"*U("@A5I]!XO "MU"6
MF@AE_&DYK6Y+#3R<[]B FMPQEQ65<,O+WT6B\JPDM%@*"5V7ZI%OOD&;3Z3Y M8EY*\R6;)M8;6"1>2\6K%HP*JH(U]VV=3@ #-UW 'X+\(WN9B.\HXJ.IL(MOB%"1R.;GIA4#1K%%4P?
RI,2N%H@3LWF<2S6D!#8XC%+D!-'(:M><^*68=$P M^.\PC,@#9RJ7Y)XED+S%.ZBFD^3O)"W\BX1/4/=(X-K$=_WP E_0I1@8ON # M*38,X7D&?3'&LJ8Q3"W\\R6(%[!FUU=>W[VYH"_L]
(67V/])WV6&]$>.24X= M5!*>$BRN@FH%HJLPH2PA=Q"W7L]X Q)SO'A2:8S*@:2\Q/M;L&Q,KJ^&OAO< M_/=Q?D;@V[4W*H_A)A_<,5,9S218%[X@N1;-192\%3D+J#TO*4Q[-=;U^N0;07\8,K
M!.RS]CP[#/U#1]\>GBGU!\=SM\DY:&X5B,RT<(D%7C/5]+G.V[T2\Z8Y[L.; M)^:!BJQ@ID(M3M#2*+B*9M-X;BM6F5*ZZP\9IICB\="!V ZRGG:F?H#,JW M<_874$L#!!0 (#. ;%GE9L')YP4 *D/ 9
>&PO=V]R:W-H965T M0CE MZ^'0ISD5T@]LJ208K<^L*&?#]%D-?.I)9%"KT,!F-#H>%5*9W?AJ_7;OS4UL% MK0Q=.^&KHI!N?4G:KLYZXU[[X;-:Y($_#,]/2[F@&PI_EM<.;\-.2Z8*,EY9 M(QS-
SWH7X]>74]X?- RE:.6WG@5[,K/V"[^\SYZ(P9$FM+ &B1^EO2&M&9% M@/&UT=GK3++@]G.K_2KZ#E]FTM,;]_]66L<]D=%<5CI\MJMWU/CSDO6E M5OOX7ZSJO>.CGD@K'VS1" -
!H4S]*V\;'K8$CDAD#[YIAV^Z3_NC\.W7<#@0 M=Y6(3R4Y/)E%O>3%A1=V+D!NH&)&KF.X+T)-XHTM2FG6(I=>2*&C-I2\T")F MH<>ZM9 F@X:Y2DE$,H0,XNBE>"?7&1EQL213D5 &]FYA-
EC3%Q^E]S+-*T\A M>-AQMEKDXH,T%1J F(P9P60<-6\;E5FFV FI6X.\8PM*9_]P*FY49F@MP ?W M,-A_(XN94]F"[MI_QHX^?7*<)*.3;I.XDJG2*JSCPOCD>0?S=[O<80HL?X*? MU0)5*
<81>S+998],(&<94 0+C^;*8:M$#\OP%W8 7,6UBW9M8]T*!:S@T,?H M_2^AZ(NRTYIR&E8@GMQH<%\"$"#&QRJ3X M@0"2UWN;*@#-T$E#[=8=KG=-
+3"YL#E%$W.6L4>1&BQL7M',1:!UP*?1*\"S M#MT.,3Y 7AQU"!T/@1=V_J)BUCS(;I[=YOMBK/F5RLYBTG8QYABU5C2>*DC M@SG%0RSB^H[_ZYQ3HV/3GP;1 XJ;_?0^+52CG9BCF#S$ _X
]Y4^AS3K;1> M(;I.*.=H:5,YTXPA(,V9J13)KF+1L2:Y@ 6T'SP5MC(Q*PZ2P:O.[5*NHX(F MQS6HT7"6@R8\I94# S'561LHBF<.PW8 1X%>-. BPK!Q&TI\]-RWIJ$2[FW" MQ"
[[X%3*>1%]BV%Q7"6IKK)8LZV_QJXOZ';"6/,"P!RS'./I.V\1,@*MK3YKXII(8* MPQDCE8L)D^;2+:@)T*; $)A-:M)MR2YYD2$P>()E0>RIX,IO4J"N"1X:8!A' MH;: 4NEX5E?- EVB!(04?:@UCI
KGW)XVR#.<:;T G7P#\'(MSITM@*0$ZUS3OIK5J=]8GS>MOJ;H6SJ0S57*?>]GX9^M=_C='B#)?=.7;E$% MH4%P%_VW(VL@KN6ZK>BF86[JHI._F^9U9N.++:C-Y@<2V ?\U!: HLD-+C]V MG?/?
4.MML?:#XX'H_9#GTNEI'@?2 MT3\ 9_)X.*.[<)+---J%TX\-^,Z 0E/9?WQF0+(FZ>H4NE<6CKB8=#A*H+APG&8]C@=+*Y>MC24:LD"EB#0^.TVCQ<'#\ MRR
>NT:3>_KPZWK4T%H!'Q)")VFOHFU7WM[$7]?5KL[V^Q'Y$'U&&6_@< MHJ/!T?29H7X(MXV5L9@.N=O$QQUV:'&_ ^MS:T+ZP@>YV?OX?4$L#!!0 M (#. ;%DV;?(XS ('$(9 >&PO=V]R:W-
H965T2:6#AV9KL4_OW. M3IJEI:W$V+[$OO/=\SQGR[Y,UE+=ZQS D,>""SWU"ZHXL0>#* M4J]"&C15%NA2 4U=4L&#* S[04&9\&83Y[M1LXE<& M>EUOX[AE66ZL(YA-2IK!'9COY8U"*VA04E:
T$P*HF Y]>;=\4/7QKN 'PS6 MNC4GMI*%E/?6^)Q.O= * @Z)L0@4AP>X!,XM$,KX56-Z#:5-:,\WZ!]=[5C+ M@FJXE/PG2TT^]88>26%)5]SW&Q![/#B M_[@%%4-O/X.]6&-=T@2F'MX<#>H!O-
GIFVX_/#^BO]?H[QU#_R?ZCS,,.N2E M)&2NB5P2/"L#Q0+7-@?FPJ\@J;U=Y]W]&X6-Z#6\9*84<+DA(\7YCMY&173-M(+4$ MF$66DN/;@H+&Y/3-, KC\U>/^]1OKVV5L)ON"K5U/5MYRP1JEBN-
%>IWC?OK M5O7M:E^J_O@&]4@/#7^OC\:C)Y%QSZ^WHWU31K*=TZBK>5D!^5D)_]OQZKZ M0^?]VAU E4,_[@];LKL#/QS%._P;J^N'>VJRWN[>G3JD&WE'N[Q#Y.T=J'^>
M*0!WPYZ7A(@9=6VL=NU[-X)6&Ra 9:[9V?NR$];]"(VWZ:?SJWH\":^:\355 M&1.:<%AB:M@9G'E$50VN,HPL75-92(,MRDUS_"< 90-P?2FEV1B6H/G+F/T& M4$L#!!0 (#. ;%G_9?REO H (TE 9
>&PO=V]R:W-H965T9D66]'-N)[1G;V6S3=C<>.]M^ADA(M0D(27 "TK/[ZG@L0?.AE*3MIQ@B"=SGN2^05PNEOYFY$):]I$EFKCMS: -W MIZG*9=9Y^;*W7O0-U>J MLG,G,Q(-
FIDA3KI=W(E&+Z\Z@$VX\RMG=V\.YN3.O=@G])L3"-WXPTF2CUC2X^Q=>=/@DD$A%9HL#Q[UG< MBR0A0A#CSY)FIV))&YN__6/3G?H,N%&W*ODWS*V\^O.18?%8LJ+Q#ZJQ=]$
MJ<\9T8M48MQ?M0!KAZ,.BPIC55INA@2IS/Q_E+:H;'AHK]EP[#<,'1R>T9. MR@_<\ILKK19,TVI0HQ].5;<;PLF,G/)D-9Y*[+,W3W*6R:F,>&89GVDA8'1K MKDXM:-.*TZBD<^?I#+?0N62_J%X!
[U1I>C(T1O]944]G?%F.A0D[TS.(W'=0108H9]%Y^;GGP9O^^]W M24#FNI!SOHGZ E+OI7/389E+LRURP>Y7F/%O^_-/%<'#^WC"S>2G7 @ WD983 M$3.9L=^5%>R2J2FSH\)!1"*=",U&
^>E$8M49E0B8VZQ?BHSGD62)\Q8W/ D M918E1>RI25S?9EF!%8\B5]HR1'F%&AOT3_[!D' CSZG4"3+;>6D.K2'BBXH#^90DQ9H4G::,ZSF3#,*D]5 MZ-0$E5<-A^A+^$1I[C-
;;;]%M'/VNRBT@O4R+U6# (LEI%06TH$^C %F=#M# M%FO3A!$2&2$)B@;Y'ON<-55J:%1Q<)2=H1UMQK$SIMVD&)E>O$ACR78[J]# MQ#56I2+JF6LK#?>_8WK:.[&CNN0'1-7LLBP_]
[=]%9_K@G_LR1\&PB[#8/W M;WI-0"++1TJ3OI&T.)99(4+QP-Q[VW2(1)$D@?-6_$]W!X!06. B&I"R8F M%9Z%&),N#I3H?]<[;4@W.+GN7F^3:!YQ;Q=K?P!LATG+6;86(7Z93SX*AAHC@
MFC:>B$G%>#NXF@RJY16G0#H$U_[J]-A#H4W!/7YI[SKU'0([0,>TU8EZ(',7 M,AE D)/OA=L]TR3+5*NTQ14K*Y(!MDFCB611FH)X;712!\D<&8#\Z:E.(MX M;I Q8FDB>PL#W2K8C;?F)6^/-
[>__)8K5ZR/.&6^K=]&,?LWC&K!* \+%Z0 MM@T!I(#X+B= **$MNCXV$]E>*K2O7,]$"P,Q0BA1N;-ZI-)4:"H8\C^B[>'- M$C)NFEXIT9AK%1>1I=R MJ-A\CSJ]31$.7P?W5KD
K84XL9@FV%3XC#TXZ_6K] P44^\B(8'/[:'YT-34 MU_+6,F[RZ6(N8=@%+ R#"42+:W,^1U91"J;\VZXXIDGA4/N9HHEN]NG>_:V M_]99H"I%;?GY:BL2:A\X[U\+#:+)1U[;&)B3DC)]\ S=7!;S!
9E&*$ZE-G9[4BQ3D2,8S27$ M*UVIJ86@D(05*S%<"\E?I78R69ZA%A3L33MXDL!F1BUT8;'_$W#CH9#H@/_M<][$/L#PNE'(*<<3U!Q) .HR3#4<#B.3:+7D">Z;$"RIC$^([QRQ?X*8F"7B M)
(8:EEB!KN4T'KCB[H:7#+G8:X%[K9_59R>]Y3]T7L_-C7FA/M6%-<-R"=< M(,J2#8T^I% %(B'V$4>/OBJ40Z]$*[K)#1'BZNUL<2:CKCJTL SV@V@A4*R MPMXL*2*%@B\F6B$S<
3.P!=^BE>>+ZGN(DNF;L<#U]\D1L&L:DG0BPC:1'[P MY>+7N]O!"0J;= FP?&Y;?00M"72KKJ&.\97A:\?X4BO<:ESA[[]SN! =DO/# MRB2SCV/:8\Q6N]>G4
2;5VSMU'XHS6F1R&9.9,Z.1@W8KT7,2LW;,L+0BA= MK:6C,;(8026=_0E3T;@*'7PQ^]0<,?['R)24OK8BD'CERF(+C?16"V[=?M^2 M T/HC1-%(9D1ST3-T*4D%4Q;O<@^.
C%_[O==7#S4)VDK'G4&7N.9C>'*Z4J M3+)D$R%\BV,U=^U>: S0V!CNH>FK.!HZ%?%&B]P(0!?*FXOO09T&BF1$>*3< MN@RF\SVS%PW#19%21:5Z 6FB^0EJ 8^_%L8&XVT=QM%S:O4BZ4
'FA\-:].L MYMV0II^LBK[1@!G>6ON"\O_J'!@W-(\+*TSS6IF]6A6((AO(#M\ZK-T]F3V]J:\UJEME*R:N]6+=MOFI; M*0V-Z'4ON,*KU>_G#_/\GBYI)^WQ"FP ^506J6L3^O61C)(VT[;-N-**)39@LURS
RQWNE:#27L[) 25DU\S0JV%72[RMG9 MCRMGM3\.KV3^X+M\^?"#]JC1N#=>KUN/(G'*H,.VRQ6//CJKN[.6L)PL/,4B MM7#QQ[YZYMU8T8(47':6^PQL,36=QVZ9)TU[JMR5ZS+ R!X H-
/(OE$)M)- M5R&>]AUY>'5,NU_>./"(_5UEI/_7_SMO<"2-O(]T_2U<>'(;AU.X>BU-GZU; M&XZ!M@EQ[)&""(1KS)L*B[L!4;,Z8J/N:#QH7 \&W8O+L\:-8]PY&P[?M/:< M#\9P^CJB?
KP'/XBIT)0)0US68IV?=8?C?E.7[MGEL*G*>-CMG_5;[RH[YQ?U M&@I.'X,A!/<,L3)2JXC:ZXT2=5P:K9N6R)^Q1DK*V 1U-$49I=.619TB0TXF M^I0L7-
:C<&P62GKS+2E=H"0^RY@.5=1T:H1M4B45?*EM1"?2KE18WDH(_H77 M7I%N>NN.<1]W2+NLAS_')054YJW3-?^%*GQVA#7\2K)0U_9!>?!B%/Y0C^V M%2-?
9"+M3CR:9CL:#WN#IE";JT.CY2N[-OB 7J#[MTS-LI:J6"3KQO]^VX,FK=SD341\S]S9]AW':^$0&??W,?0A$ 5._=&DF7)5^-M=_NR+Y:&FODXG-L\6PCY3>6, M:?)8\DJ=#W*MIZ?
#H4IS5E)EBRFKX,M8R))(.5DJ*:2T7RBG&Q.!^X@]7"73')-2X,+\ZF=,+NF?X\ MO95 #5N4K"A9I0I1$,8\(>*E@BOS2Q8UKQ<.2#I36I2-,&A0%E7]I(^-'3H"B;-'P&L$ M/*-WO9'1\@W5].),B@61R
UH^&*.:J1!N:)"IQK"5\+D-,7]UJDWU2N4#2 MBA)\K2B:ZVRH 1UYAFF#=%4C>7N01N2#J'2NR$V5L:PO/P2M6M6\E6I7WD' M>S:UB>]8Q'.\X ">WQ[5-WC^3SAJC13L1L)$.553FK+S
62"8G+.!A?/G[F1 M_J GD&K9W (_2@]#R.-;+(/K/EP93Y<=S_<*'42\"#9486%'@4:,&AM*A3\OQ9XCG^ZU_^_)1+QGK9 MT'[Z SRT^\OF$Z(?K/+ I$F!/K7BP<3 '[_SMHGSPAA?
S!18$TQW!^%*99H; MXV9L#E5YBK9O^4^(:X4CIT./W%&"]QQ%'9HSPIBKZ7?L0K%4JC M.\%W*Q;72H*@0XW"-7QDA>'Z"*$5^=':JB8>]X8:\)VK9EO!7[0TS2)D^XY M75856 M6^J-
DFW5XSC86H- #[=705M_G5DWY92+);BFWGLZ@QH (4VFG+9ENMUCG00[M-/#\>&O-3=8EX%?E:<>^M0, &Z->KN9-3##,1$RYF4DWDV,YK2;,H^A*9-0<(M$)>;GD+WU/-CH9= 91"#"
(5]DU9+U,"-7RO"_IPA0UT%T+++*M$ADK3#XRSKX MF0G^?CB;8/VWD_JKF5$/)-[F\W(.!6G"GLS_3E)H)3"(/EWD+2TD^4+Y;%ND M=N M6 C?.LN'_&0L",Y]P]+&NJY55P$7TM>QDE$W12,["OO:
U@2Q="'>A%G MNVNV+_7N+P+/M_S(>]F#ZU0;^-)Y<11GS5*CCS2CHAQK2?F-# ME /;V!(&)65#1V/?KV:2<=//M=BG+.;VB6L[\">.[DGLJUN@)&< M8H_L1,TQ)\3C'*[M1H>3D>VN#F>115[D
RABH!I@ _3 =D:N9'C[@;%+FWK9 MCV5$]P"\":BZ.WULQ@OT5UWP40 VI-V&I3JCR+H#'=

#L50?!W%90S?&(.L$?*USA#3Y'?O/5A=+? M^"=POM3W(/4-8!8K4:1ZB?&O\'KP_4GO"%LQD0 Q:61&U/'C0]P?->CL7>(\Y1.[;4C7;Q^:V7[9T7O-'YNO,CH4F,EKQD MB$7C(*3AV#]!-J+1&&6#'>>6*U;N/'9HD"34#*!ZI@ZB4-Q?8IP3 /?HW@= M \XEDT6*Y9-MZ[" 7IFN!MDY%K/)MV5H]Q[#71],KE^/\R38:I M_O!?UX5$GBZD\\[-QYIA3)/0I:[K#%B!3Y,HH(D_?%A0*T16X Y3(W#H./(0 M,!H$ZH16_'\-U?M^2]HT _UH]=K6L7[U5#=\+AU[6)#0R$E.BM/F0E\^4A[V M5@>[[O!]^O?>DVV2TJ[D=[F*KX4SQ MWG4AM(@=]GM7_1?[[NC0J&+WYDEL#TLS-4O\5=;6]ALMM]3M8/ZNFT=WXMU4 M_XF)98&54L("59U1'%I$=)-RMU&\,=/IG"N<=)(X0",^L0&#T>>8M".""B\7^/ M&0PI7>!X?$" \=I)RXX9W"KQE>>V6@>+ '(L6"OL9[5_C[V>,X>7*6'\+^P[MW_0B@*PU5M5],#&HN>R>[%M?AU' (OE)0-H'I)YWE\BS_(M9MEEIM0?MO G- M#;Q4'TWDN'2+ M]#?)[=!FQ]'<@;DT#34Y3Y8GN,X&KK-3Z+_,]33:9!+!
M*41X\VJ1)M,E "OA'R9;.J$PZ^H>@JT0MJINF'P"E!8UYL"E5< DM =0!* MC4AGUL(?+L9AILGR?NQR=7#QQLGR3]KQMH(M64NMV@;>";5C CXQ_8#6P >9 M190GAW=M6:*LD-=PAUGKX-"$\/'C-@1FZ(;P:R M<^?%Z@;D>()Q>#+*N.I(Z&]8_C]T0\>@BKU&7OEVY M?=)*V]WIP]NA(UYUC>#9O6NG=`Q*+@(T"@TB>9G >BN1743JQK?%G;*4I/Q MPXJZ.FKG0/9"*7N8N 3#_X3-=U!+ P04 " S@&Q9IGS:0^X# !<"@ M&0 'AL+W=O@G3Y)E MITE3VX"3;%@'= V2M?M\EDX648E422].]^MW1_FU>5DW%-@'RZ)X]JQS+^3=
M9&7L%U<1>7AH:NVF4>5]>Y$D+J^H01>;EC3OE,8VZ'EIEXEK+6$1E)HZR=+T M3=*@TM%L$K[=V-G$=+Y6FFXLN*YIT*XOJ3:K:32,MA]NU;+R\B&935I-L8LT*K$@SFKP$5X,VDU-:DG+G+>\]UO.S6ZK14P$M6K\&;U$[M#/%RD\SOD@E^0;KL!?<GL%Z"Q^,]I6#GW5!Q;%^PKQVY+(MNM7PS?1N0>8 MCG=,QR^A_TNF+V,-LQ@V>#)\]QH(KSB]]!%\1_RP1H"Y ,P8T?
39)L@F<"T_- M@NPN(8.@!:::$@#JL!W%3Q=7QD[/6K\VQX]HY%^6 RW%6EJ(2[/>C'DI]D8_A# MO#(>:\#&=-J#*:$D-M*B*G@'KEF(K0C2GD%KS;T2IXO_'IL5.C@9GJ:#-$V#
MVLFX7PPX5*ZE.ZXBQF*I M'5>"0&TYXY(I!2]0G!*%PDTU,6M8/%(-CSY7!!J?MK\D9NR-(?)=S6RCX%9]/ M%0:S=`PO"^U (\C)1'N1!4,Y-PH6*
ZS57[CO;LHK"H<"N/@]=^3G:,_GGV%)6DJ&++9K:=@,V=T M5?!5X6*8AW)T7&'4)^. ,EJ2EBR]E4ES(=FC"^LX+/W5@(LZH#HA]4^W286,
MVC*K!\6=EZL03D;QB!M@70NBTM]KD+DYPX$2T9 3L1+*_\";JR/M^:Y@)-3? ML$CC\8]C,7S['2SBI]I)!FDI63>.STPAL/\OT"V_:,#\LC.=I)+Q6//Z1%0'>+XWQVX48V V4L[\! M4$L#!!0 (#.
;%FOP3N?Z0(%$+ 9 >&PO=V]R:W-H965TVQ)+37.=UBEJUNTSM4ELU08/ M<-+^^P%VW*0ED=7E2P+X?5XXYF!.?TOH$XL1XN Y2S$;&#'G><\T61BC#+)K MDB,LGJP(S2
77;HV64X1C!24I:9C62TS@PDV@KX:6]"@3PJ>)A@M*&!%ED'Z M,D0IV0X,V]@-W"?XF,L!,^CG<(V6B#_D"RIZ9NT2)1G"+"$84+0:&#=V;^Y) MO1+\3M"6[;6!C.21D"?9F4<#PY(+0BD*N72
XF^#;E&:2B.QC+^5IU%/*<'] M]LY]HF(7L3Q"AFY)^B>)>#PP.@:(T H6*;\GVQFJXO&E7TA2IG[!MM3ZO@'" M@G&25;!809;@\A\^5^]A#["/ 4X%.&\![PC@5H#;%/ JP&L*^!7@-P5:%=!J
M"K0KH-WT+74JH--TAFX%=%4ZE/NG-G\$.OSZE&P!E6KA)ALJ@Q0M]CS!,M>7 MG(JGB>!XL(O8,/ E%U;G"(P"AA84I801&X @_+$;B\^ (N0(+!KY@4#.*(M]4TNYI8.9EC-
,RSG<8[,XX([@GG,P!A'*-+PL]-\]P1OBICKP)U=X$/GI.$2 MY=? M;X"QW(\S7IN3^/?"WP2'YW&[R 5N'T4'S=?O*O!)\T7K\.GS1>OPV?_ M]^;G'X[](!'<^@2XRL_]R G0)7IIY^GMY-W48SD,T< 0EP]#=
(.,X/,GNV5] MTV79.T:"D+609M@JNNY8E3N-E/2HW*MFS//I2-=#+;=:U#V5@C<_RN]<9M MHI,YCM4YE$W?RVS'>Q?"3./F6K[M'\KF[V5MO^N^JLJ=,/?NUPS1M2K.& A)
M@7GYH:E'Z_KO1I4];\:'=FJ]:\9GHEXLR[M7^[+8%- :=8(92-%*3&5=MT4= M00/!@)A$!D !X;"]W;W)K&UL MM5C;;MLX$/T5P@L4">#8LIUKFQAPFEULL&@WJ)/=9UH:6T0H424I._G[/4)
MBMS:*M!%7ZP;Y\R9XN-L<\N)?+B)=.YN^FEWA?OAT,7IY1)-S %Y?BR M-#:3'HJV-72%)9D$HTP/QU%T/LDRDGO3Z_ #NP4ZO3>FURNG!"E=FF;2OMZ3- MYJ8WZFU??%&KU/.+X?
2ZD"N:DW\]'BR>A@U*HC+*G3*YL+2\ZR,.:9'^Z3FU[CA3[!E"XK*FCZ0U(X''UQJTU_ADP_;]%OV/ M$#R"64A''XW^5R4^O>E=]D1"2UEJ_\5L_J0ZH#/&BXUVX5=LJK$3#(Y+YTU6 M&X-
!IO+J*E_J1+0,+J,#!N/:8!QX5XX"RSOIY?3:FHVP/!IH?!-"#=8@IW*> ME;FW^*I@YZ?WR&]"5CQ:F:A\)6;6RGQ%R+MWUT,/#SQN&-=HMQ?:^ #:1'PR MN4^=^#U/*-
FU'X)90V^\I7<[[@2<4S$0DZ@OQM'X5+A46G(=L),FZDF G1R MW1=M7RQ>Q7V>]+5*2JGW!5^!GNX'Y?YY[PH9TTT/#>+(KJDW???;Z#SZT$'Y
MM*%\VH4^_20]626U>"2;.6&6^Z9L'^ENV*/X6-PIBQXQ5L@\$7\OERH^4!#B MW6^7XVCR0.I..V 8]$J%Q\ M*36)T;D\&1TMCT69V&>NX]$'H1R[X<^L86Q/7TOE7X7<2)L$RL7*
<2*0(@:\1J$*\]71N.11X;7*4.0?-V[0U,-C.WQ.3=EFS(UU M()OLWE*=#T2S((A;$M(KX]C81.8D50EE3%6KE:^+LS!:Q:]]!*CB= ODD'#I M0]9WIF6QV8U86!3#D E7X-)@/Q)+@
#&VZ&NYJ3$+:U*U4+XA ,3<;WD\2Y ?$\#VP +M=&H5)B@UQ9F,@%5G4,PW!0 MX>K;*?]?RT130:$_-38) 3G,!Z*/K5IPR2_K#O]:2@M _V&P!T56Y])6G
M#G4+F0,/4J%ECD;'R"I2""K0)"Y@;\MXVU<;>/+HS4)CEE7N@YSM=#68[IM] M("J2CQXM\H)>A[D4.[4V)Y$A%%'8Z:'J3GYX>A=U;[WE(G3Z)*7#R9 JU)7 M:C$_^>MM5O_O]?&U"!/S6?
K2AKN[TC:+3+-$K5:6H'7TMCY5&7Z4STCN=MBW MU\]EML 4!7@(_]&C\IJ.Q=$=(^%M!7+<7@$/WK=6JT>3).)C*-.^>$@'=P,Q MXT)B0C_(:3$K5]@JBM%9V"B=A;FM M5A1IM4*0"
<=4%)[!02:74>K=]68AY$==45SR]%*CPH)'<]F 5ER&&IX(+].*J M'T71EDJ=]XYMSEFSS3GKW(]\G[U]>YI.C)_M['Z=NJQ]-Q0Z5RX;*93K MUH%QU,VJ4=O96BK-*_5>;A7*64#A_P;6TXLK2,;U<-
UV/VP=73.RJW! YTU' MF?OJ%-N\;?X$F%5'W[?AU3\(GZ1=87T5FI8PC087\&VK0WGUX$T1#L(+XW&L M#K0"^+XWQVP=VT/PU,OT/4$L#!!0 (#. ;%G@E3&PO=V]R:W-
H965TIGWY9OAT"49%=(-3$D:7Q;&%M+CU2Z'KK0DTR!4 MY,/Q:'0R+*32OH>]9N&S6F:>%X:3 M\U(N:4;^IIQ:O U;+:DJ2#MEM+"TN.A=`KZY.N7]8<-?BE:N\RPXDKDQM_SR
M(;WHC=@ARBGQK$'BWQU=4YZS(KCQM=;9:TVR8/>YT?X^Q(Y8YM+1MR*EA:QR_]FL?JL+S&Y"W_%JMX[ZHFDG M"(QK@7'P.QH*7KZ57D[.K5D)R[NAC1]"J$$:SBG-
19EYBZ*;T0&.M)/=5AF+;UPI$[KH!47VCGJ3Y\\.3T9G>V(Z;F,Z MWJ=]/WL]'H _?KN\G(;'P[.7 L2'W9ZL*CJ. MP@=CV*HYFO!]H-=3F).GG9F:" # 2V)162BV71-L/I[J;4]JM]LCGOEQJ74%^<\A
P*!,#V*P]'!'\%G%EDHEV#+FJ05Q+@6;RFA8@ZGC@X# M,H^$=-B6XU,H'$O-*'FL\@V2WMTGF=3+X$"A7!@#385F[Z[; K$'-+<5@W3\ M.N)^P%WHJ"W<=S1>OXG;E$JS392ND!H3BC^'W/)
("575G')N!CANN>ED^@\X M.V95(V3GV"M.BQ0+J>PV;VZW>)O@C5>E<:KM%4ABU 1@8";;H,*U*<>*.JEK M#%"*Q@1L0B<0XR-&A9S$*J,Y9%F"N.0\)[&L5$01\%P0\QN^;W61K'QF4!W)
M4_0!;G;@:S<0N>98;EOKYCS5GC1[#)^19E2(#@W+K+)W2,&/?A3TJQVS*<_SC#*1PW M,W+6F9&=4DR[,W+GW.C7@ Y\4/=`K?Y3T['7W? W)9^UX3+*W@VZ 9^3QG?.J8#CL MZL'OTQ
:+X[8EJ2>TG6\B2>0\NO(Z&&(U5/-=1B4ZUC(6Q+4FN1T28=[01FS MY3,)?ETLF&9#'Q>QC>/0W4RFITVVK5X(Y#<0?S*SH.Q>PXOAS-;?V2<=O.E. MYE7PE[':9%C%22-
<#KBWD%YVW@6<'%9N>\Z7?BM93+N(K'.)(5\0@Q $X< MWU!E@TT$,S<6/<%>HAX4FC,G7$-@%X'9"FKHON39AA5<%Y+; [ZEI.'L@.58 MQ'I+/T)?
XQL80MYS*KYTB($E'X3'V,@4%%O%:&!%5H6!PJI,.'L ^[?D#UQ) M"4-?P,?X 8$B:WQ:?EA=Y0&'7"'Z .PY9T ZH\,TVO!,HFQ2%2@HPXJ/6KX* M\S9.PD+BK*46/*46UA20 &-
U7;==P_OP=MKB[70O6IY.=+N0^%_IYIJAP3:D MHHV(9R7WX-#WOUVT@*R)Y=8-=\F^_\SM>_E]%UM,NS.CM$L%&.2T@.AH<(HS@HV_'<O7;\IP7Y\;C]M_>.1Q M2Y8WX#.N?U)L7-
M#^@#/Y%U!+ P04 " S@&Q9 3&U#P@$![#P &0 M 'AL+W=O!H%.5U P?2)+$/AF(57!#%[5,M"E I8YHR(/:!@. M@H)QX4W'3G:EIF-9F9P+N%)$5T7!U-T%Y'(S\2)O)_C.ERMC!<%T7+(ES,#<
ME%<*;T&#DO$"A.92$ 6+B7<>G5[TK+Y3^(O#1K?.Q&8RE_+67CYG$R^T 4$. MJ;$(#!]KN(0\MT 8QH\MIM>XM(;M\P[]D\L=DGQA59L[P"4@#3 ME0*LN-'DZ)K-
<]#'X\"@%ZL;I%O$BQJ1/H&8D"]2F)4FOXD,LH?V 4;7A$AW M(5[09P%G4)Z0./0)#6GO&;RZ33EV>/&OI7PHTQJH=QC(\N54ERR%B8>$T*#6 MX$T_O(L&X=DS8?::,'O/H4]GR+^LRH'(!6%:
WX4)C*2^""G+MQ MU4B^FA66ZC6^OC!U:S\H#O)[U+GM6LOT1G0CY+[PI>?G#!F$X>1DVS7-"U%6 M3U^WRM?2H.71G["&G$3'NQ-M3O'QH2;.H1QAM85#B-;UY3IE>L_=X ?%
<<&=B/O/8G"@=]+Z(.3]1+1L];I84%=G;1M M?,>/M^O:FY/9";E6CHYW1&!+WA=V./03&CYU?9S(X[M# _EVN00D[&0G^.(OT MKI7D7BRTYP_Z :[B0_X/R2]!&=?E-
C4<)!F44O/]CN_[O4'4V4LW[4NI2JG0 M,YE+VT*/]:.0^N$H[NRUJ_ZE+ I0*4=*"E*QL4;ZI*?6'4?>:=E2O*5CL4Q+'B1_304M"P\0/!\.6)$+:TG[2DCP.8? WX*V8]GJ),>C[_5'2
M/OPOY\5]E\9^7V.MUEG=E\J]/%&R"<+C?MT^(.T^4%UA-8S\9AIWA.ZJ_R&F$ M&?5?]+:O]:\SF=*A/QC$+4F4)/XP'+5U\,>D-=3W^_R-GX?^U0Y:"Q&6?NG6 M/DU260E3[T:-M-
DLS^N%ZEZ]7DN1M4LN-,EA@:;AR;#O$56O>O7%R-*M5W-I M<%ESQQ5NQZ"L KY?2*3:]F(=-/OV!]02P,$% @ ,X!L652Z;%21! M[1 !D !X;"]W;W)K&ULS5C;;N,V$/T50ELL M$")>KJQ#:09+O;
@T0Y+)]IB7:)B*17I**-_WZ#B5'EBU9<5 T[8M%CCCW M.:.AQVLAG224HU^YAE7$VNI]>I\.%3)DN9$G8D5Y?!F+F1.-&SE8JA6DI*T M9,JS(7:<<)@3QJWIN*3=RNE8%#ICG-
Y*I(H\)_+EBF9B/;%ZL?5K83=L):2LIQRQ01'DLXGUJ5[?A68\^6![XRN56.-C"O-6<=":2:&TR#?,8$'.>/4D/S=Q M.(8!;QAP:7>EJ+3R"]%D.I9BC:0Y#=+,HG2UY ;C&#=)N=<2WC+@T]-KHI8V M2N
7T1\%>R89Y5K9$&^E)4LT329L(S,,GH*U7"JX"R8(I^H-C2D M:%)(IAE5:/!@*.ID/-1@H]$T3#;V7%7VX /VC-"-X'JIT*\I>DN_Q!]QW$ MKPY>X5Z!]W1UACS'1MC!?H\\KPZ85\KS/C)@77&JS'
[S3!8/5#T96,VFA<\5:5K1_O1K^E0 M. ^J0(PG60&U@?22HKG(H*TPOD!$(TBUIOF,RCK?I9@O--E0W9+JG://GV+L M>!?_V?,R%U*SO\')5\HCAY::O47Z2IAL";L62J-OT\'\5^D,H!2'Z3K*"'E0^
M8!QB)PH%P5$G6YN4R79'#(]UZJ9=*'6N0&698Y./_637 GY!KA/:_@@W*&;E MXHMX>RC[735?=?%S2\'_NS] #Y$X5\(5QH>G6Q2BR8S]LL43=46ZZV9 PPLZN MLF_BF4H.GTJ-
X$/*DYU1J..Y2XAQ$LHG MI2NAF&ZQ!;;OC]HZ\=%N@X#0;92\7 D)2M%,F#IK"7:P[4116TK0=M(?M;TL M^6.OH2_/J4P8R="*K&@;@QC;40=4VI2!ZW4$%;C=K6D/0H.B]_3=!A@\;V1C MKPDA-
X@;NT'HG^P=]_"V(JLNT&J9']D$PL .XE&#<$P/V&/Z'[< 4UNCL-T# M8K=%&C1JQ74\VVG@JOW AUPZ8=PBNTZOWB9WU #^&PC$GCV*VFAK WX0=>#! M,#L-76^@#X[';5V'6LDA^JZ4?
P1"C",H1Z!&34W.TV@.AV&]8&>^2VHY[>@ M=ZJZHXG@"R*B8!@ZR$)L%/H9)DB668XG0'INRX M8U!P[:!7%79O$/;.RX%MC=J=M[(4(+65T%.FQ<00&LB_*BK5 B"JZKVVA-
MK>_RE]45=GN\^B, >O?"#+,9G0.K6L3 MI*3MM'VH%#7=]MF!2T UF-FF:?_]SH:0=$FS2=L7[#O?_@'Y'SZ/-T(^JPQ
MD]>"EVKB9%I7UYZGD@P*IJY$!26NK(0LF$93KCU526"I!17BUCPO82Z)JHN"R;<9<+&9.(&S=3SFZTP;AQ>/*[:&!>AOU5RBY74L M:5Y J7)1$@FKB3,-KF>1B;PQY@Z'\ H"V 6MW-1E;E'=,L
M'DNQ(=)$(YN9V%0M&L7EI2G*0DM)%Q =45"WR74I]$) MOK#+-;1\5_F>BS%AB$ZSF!NR+6J6 (3!Z^ OD"3GQ^%O3]FQ/ZHDY?=(H] M7N"-2VL.1*SP; VSUM-LYV=#ZH ,@B2C,63!
[FQ.AM.IB/I&>.Z:#/;OO M]H.HLQ^Q5DPF&4%JO+,OV(LJ["SZ-YKM&+JC 3WP]EQ*>[M4VP*MA4B5Y36_ M0Y[(5TO]]\$9*-.FLNQ0J4:72,'_($KA_LCFO0VXEX$AH!TOMNP@T(TBNN_H
MN\,C1_V/X[%_W=OK007(M>VT"@^X+G73CCIOU\RG30_;A3&PO=V]R:W-H965T2NEA382A4V;-#1$V?;93:Z-A6-GMD/AW^^< MMX72=MK8E]AWOGN>Y\ZQ/5E+]: S
$.>%+Y;E4\D:7A3,"M(KK,9\#E>NH$ M3NNX8ZO,(<73PJZ@CF8;\6M0LOK4%*6@!',"J)@.74N@_/9P,97 =\9K'5O M3FPE"RD?K/$YG3J^%00<$2L,1* Z/< 6<6R"4\;/!=#I*F]B?M^@?J]JQE@75
M<"7Y#Y:::,J,')+"DI;2Z^I)U'7N*P4FICL'-=T 2F#AXA#>H1G/CP73#T+_;H'W3Z!_O0XWE] ML(A<-EJ34BFLIE(OI'C?VG^H83_+X;M1Z$<7Y*WCI;9"<0\-Y L4:S?RY=HU
M),U2X+Y*MWMN/]&KE2,FB,EDJ;%L?=RYO[YH2?^7_EOE7P"O@0[AN?,/W?'9 M^%5TY.(%V5GWTE"^L3U]+0<;* <;^?\ZUM7O^ G>W %4.7*CX:@G.SAS_7&T MP=]:@>MOJ<>;O"/D';2.,:?
ZJV6.:A5]29H//"E,/7%V7F[M9^>RO/A=]@ U5^R8YX8;#$5/_D[-0AJGX':L/(HKI[%]+@35Y-,WPZ0=D M7%]:5K#$G2/&PO M=V]R:W-H965T2U]H:W4PJ;M M Q.B>_GL)I?
&PK$SVZ'P[W=VTI!J4"%-TI[XD]OGN\?/?93JH'70 8\E1R MH>=>84PU]7V=%E!2?2K+B22U52@U.U]76E@&8NJ.1^% 27?DF9\!8S9[M3 MBYFL#6<"
[A31=5E2];P"+G=S+_3VAGNV+8PU^(M91;>P!O.]NE,X\SN4C)4@ M-).'*,CGWC*_9/3CEHV5,.UY#]99HJY-_9(!CFMN;F7N_0ZAE:O%1R M[;YDU_H&'DEK;639!B.#DHGF3Y_:/+PG(&H#(L>
[V3L&]UPT.)@0*(@2H[@Q9WB MV.$E;^ A3$R^0JUDJG")8#TYW4A%[?$@RWT.'!49;AE.WN'[6I:.DK!7;:HK_MFL+L-YJ;<@")QZ Y; MW*TLLXS9].F>;U:GAR8IZ:-;P_KFR3."!/$%++66 -
]3NZ!4P,9J:@RST1@.QI-ASW*&EF$4G1_$C,($C_"?%9_^\PK=0 Y*H40%CR!J MZ-$:#0=1$O2U#(:3]"\EB0;!,#B0D@QX^BUF^+W6F):NL:OL:44V3;R9&5JZQ;J3!-NV&!;Z+H*P#
MKN=2FOW$;M"]M(O?4$L#!!0 (#. ;%G_MO#/\00 .41 9 >&PO M=V]R:W-H965T$?>@E2W,^&ZV%**XF$QZN28;YF!8DAS,X$@-RM*)J>ON),-)
M/II/E>Z>S:>T%&F2DWN&>)EEF&UO2$HWSY&QVBL>DG@MI&(RGQ8X)@KZUW M#*1)C1(E&$[+AK6']P;\M&V:)@I'&>_ V. Q\13E/$3VT@WF 6
M\;Z8AF=]_\XW=>L#>NO[MS4CI)-*]:L_P.7^-X=W2!U!LB5A*G^ZTMY&9I6\ M6*VG0YR+)$=B34N.\XA?H@?8:\S"-0(1:L SU+8"*I6H[7]!AN8$>DL.C* E MV9H=."W9U&S/K.7)"<,IPH=1\#ZA
N&9?FJ30S-M^V6%#@-O*LY3A."H[F6 MVZPJ%7@@:&!:WI'.\)LB\]A MJELSU7T]4[$HJSV!]&H3_ -]KKAWS""4./."V/AWQ7B7X/')9/+?6)!=XQ W.Y.1]) MN.._H57$-H"1NN8';=:Y8]?I>@]@ONM!
<^DDT=AHS!ZKV2]LT](LU[SLP+4* M"'Q0KTBB3(W UW3/[9JZ_IDA=6N:J&EB&YAJ>IAOMF+RQ4[?"@83WZH3WSFI- MNUI7'342L>U+ZV'$MVHW=?H_$'F22_(87<?7'CGGV.N]Y!$T%
$W3;0%Z8R\X&W"_.L DWX5Z MKK>)9(\-XVS$6YR'<$@&1#AAK!JB>H&EF7:'TX8Q=L]W^6"U>ZCK0^>"DF1V MZPST*N!O3]?V&E+OUT.>74^ VYJKVP!N=/?2@++3U_P]RXK@?
15CTCIZ9X3% MZ@<4#AU9=YJ(ZA=?:^A_&=75T;\RK'R!?,8N!&B@E*QBJCSWX4F753X5*$+10 M!_DE%8)FZG%-<$28-(#W*TK%7I 3U'JVYO\ 4$L#!!0 (#. ;%DS,PBP M- 0)<0 9 >&PO=V]R:W-
H965T+4]M DZ[8'IH%3;H^T]*Q)#80 9**TW^_0TF^Q8YF8\LZ8"^6 M>*[?(<]%]'@IY(/* 31Y'GFE)E:N=7UIVRK-H53U0M10(6& M8$_'-5O '>BO]:W$E;VVDA4E5*H0%9$PGU@?W,NKT,BW
K\7L%1;[\1$,A/B MP2Q^S2:68P !AU0;"PP?CW -G!M#"../WJ:U=FD4M]]7UC^UL6,L,Z;@6O!O M1:;SB958(,Y:[C^(I:_0!]/"S 57+6_9-G+.A9)&Z5%V2LC@K*HNB=[ZO?A M&
6O5_!:W)VC%N5'IMET+,622"..ULQ+&VJKC>"*RAS*G9;(+5!/3V_PW,^X M4.J<%%4J2B UX)GE3 (YNV7 MJF8I3"PL# 7R$:SIVS=NY+P?@!JLH09#UQ>_-5II5F5%M2"UT%#I@G'^G60%
M;TQ&$P5I(PM=@"+PE/(&=QR#(CH'DC*>-IRU^2_FG0IRJ].B\9WCW[F@F-U M&X3:I Q"T@J)4N[%WI V%+)C.UX\OU#OCV:.@XIXKJI?>F M*K3:L^+2R(VIX\8'.+[KT=@[Q'E))W8#ZD:;_=DNV
Z%J$V^;G D-(G1DY?L MVZ)Q$-)PY!\A&]%HA++!AG,O-.;;Q X-DH3Z0;BG.J).XE!\T8XIH'O43R. M%66@J87KIA8.-HT[_+C(&NP46,/+=G+BR6'12_P0(%73IBJRV@)6U,S=(L4Z MS58%?ZA-
#7O\T57\8ZOY8.V>+GGL\Z8\2BUD*_?3?E MTQ7,]L!]U\%\KAG&- E=ZKK.'BOP:1(%-/'W6PYJA<@*W/W4"!PZBCPT&.UM MU!%#^O^Z5=?;PVHU)DR?VQIH0Y/LI3EY*AVG6Y#0R$F.VJ?5@;
[^3GDX=1V< MQ_O]Z=_K)^LD[>?0)E>Q6S@7;G2^2PA'SPG^-L&]2),A+_WV_FT <7)H4MM; MET7LTHOV2JSPLZFI='=O7%/7M^X/W65S(]Y=V3\SN2@P83G,4=6YB'$$R^X: MW"VTJ-
NKYTQHO,BVKSFP#*010/Y&PO=V]R:W-H965TLFEJ-J_0ET$D"EHW:>M06;?//)AS$JA.GM@.MM!_VTDC:"%] M);XD/ON>YWQ/SN?TUUP\R!11P5/&528H9D6>\P%RO++C(B-*F
M6+JR$$CF%I0Q- "\GIL1FCMQW\Y-1-SGI6(TQXD 6689$<_7R/AZX/C.R\0= M7:;*3+AQOR!+G**Z+R9"6V[#,J<9Yi+R' 0N!L[0OQIWC;]U^$-Q+3?&8*9
M.9#2'#1!D&HE\K"%CADAOX['F=)J0!K@Y?F' _:G/7N*^X&L0QENSF8$5TZ)U^C0W MGWVJA%ZE&J?B6Z)*@< 7,"NE7I,2CL>H"&7R!$[A?CJ&XZ,3. *:P^^4EY+D M<]EWE0YM"-RD#G-
=A0GVA)EB<09>V("Z(=\-$[X*&W%SYNAX\QT7#?PL-M MN*OU:D0+&M$"RQ?MX1LF29F5C"B?Y2A8DP8&C#ZQ$L4(G M_OS)[WE?=@E4D?4LF3G+J _@TN/1[E^=]=[6IQ"Z_GN]?!(W?
5LIADW+8FO*(MR+0#B7X/!9T11CF2G9 EX,N1_&@2V;&$"0FI:"*XLX::0WQ44"-XF&43?R MO%=Z'"CFEFA1(UK4*MHM7Q&AJ(1)2G2/ZL#P!O[!KZ+J>%JY'S31'11AN1<
MNIGN+*/6&!]5[9!DXP.1;6G;;;3MMFI[7RP$SQ44Y'F?<-TW%>)WO=<%,FH- M\U%%#D16*>)NM'5S\ \D8DES^0P7FMX[.]?11'6O58;BA>WT,Z[TO6&']?X5 M0&$<]/]"<_5BF,NC^;F(_P-02P,$%
@ ,X!L6=A+J(I=!@ GS(!D M !X;"]W;W)K&ULO5MA;^(V&/XK%CM-=U)7$MM) M2$>1[]CN-FF33M?K[<.T#P9,B9K$G&WH5=J/GQTHQB2XI#C[4A)XW\?VXX?T
MX7V3X2/C#V)!J00_BKP4U[V%E,NK?E],%[0@XI(M::D^F3-$*E.^7U?+#DE MLRJIR/LP".)^0;*R-QI6[WWFHR%;R3PKZ6<.Q*HH"'_Z0'/V>-T+>\]O?,GN M%U* T1\-
E^2>WE)YM S,U5E_AS++"EJ*C)6 T_EU[WUX-8ZJA"KB6T8?Q=XQ MT$N9,/:@3WZ??<"/2.:TZG4$5]2L.F8YKE&4O/XO@7M[<;4B?O'S^@?J\6K MQ4R(H&.6_Y7-Y.*Z-^B!&9V352Z_L,??
Z'9!D<:;LEQ4?\'C-C;H@>E*2%9L MD]4,BJSN&2#(:R&H.B#E#.09 MF61Y)C,JGJ-F0.^!VLCIBO.LO-=<9CKM[0V5),O%.W5\=WL#WKYY!]Z K 1? M%VPE%)H8]J6:N!Z^/]U.\L-FDO#/()&_I\A*@X +
.*&]+$[_89.57I8I2,[MO:_HVG$&=YS!"@\=P=LPOQ),Z75/?2D%Y6O:&_W\4Q@'OS8MVQ.810+:D8!NIA\6 0P%V4-5&\FRAV3M0H_,*2 M^(41;].4G:!M-\H3F+7^:+?^J#.UC1Y)\ 1FD1#O2(B=
(OC*),E!P4KZI*Z> M_$']?YROV+6H4O#F#3+)*!:$M6%KHF.S1C1GCX12A&,#V1<#X,PB6/4K.-D MMX3$N80_Z)KF(3_@E#F*I%@4P2@_$W1 'DS2*CHC;&*30[9#N+F\OP5=> MB?
D)E$PJ]_QZH3O'-KV_GM!L9HPC"W%W0O=JS'RAV408:Q8Z3<_HSY.U'-4T MFB0I# ZE7 \+ Q1@?$3+QCZ%;O_4K.6S+8E[U-:;Z0G-YLCXLS#I3M5>S9DO M-
)L(8\]"I_%IN+K!:;JNASE5;2Q4Z/90=Y= R?H36U->:KD"K,^0 MMG/HUCOJ"+9HO-)L(8]&@T_F<+NTMCF4J(!]RK4+D=U$G*/OOR[9Y$ZZWMHIP%C5V#]#N->W5GOM!L(HP[@^Z"V>D:
MQZ=IO![FTK@Q3]!MGL:,+QDGDH()TS\.7B]CKV4N7V@V*\:IP;@[&7NU8[[0 M;"*,'8/N>MGI,DX:[4,!NA0Q_4XB-(D.*)C8Y>@VR[5=7QV6<0]8NN-[*+.
M!8U+@VEWBO;JPGRAV0T7X*0NUIVLJ*W."\JNB'.H6AD7!)RNZ0Q*PK*IQG) MP9(L*7^]D-T#M=T_7V@V+<:4H>[ZALBXJ?*%9A.QUSIT5\9.%S)J:J6$M;YA M/0RE@R,& QDCA-
Q&J$'&9U^9W4.VWL35=OM!L(HSI0N[R MV.F";NP-U@7=T&D\+FACB= +EJA646^\G&7*'N>H7(JXORA683 M85P4ZVMVOT=#P"V*N2.#>-T\ M.I][Z>?45USU4ZSLY
MNJ@_8>.L<'Z]6%YX*&T^%7ZAJM1)V4[^O2=A1_XZ@MBK"_.%9A-A M7!CVU!'$]59?A./P4,Y=6"ELK!1^P4H=5_W9OP_=0[?>]BX*5I&Q<5%W;&PO=V]R:W-H965TI7EY,UD+L7DSG9;QFF6T
MO.(;ELMO5KS(J)!OB\=IN2D87=:3LG2*/"^89C3))_/K^K./Q?R:;T6:Y.QC M 5R+ZH/I_'1#']D=$_>;CX5\-SVH+),.Y67" MLŰJ*P\O/G\F;B51&Q6,6BDJ#RSXXM
M6)I62C*.;XWHY/";U<3VZQ_J[VOSTLP#+=F"I_\D2[&^F403L&0KNDW%)_[T M!VL,^95>S-.R_A<\-6.]"8BW!>!9,UE&D"7Y_B JWBQ$:P(D Q-0,P$=.P$W
M$W!M=!]9;>N6"CJ_+O@3**K14JUZ4:]-/5NZ2?(JC7>BD-\FP;]MD1U.6B_)"9J@411(+MMQ_2?,EH#N:I/0A99=R^UR6B.1?N:0+7@J3G?U\8IY?'=%OR@V-VSN%C"YWDL%M51UVMG-
(40^\J^GN[:?_K @BCQT M&*4%2@Z!$FN@G[F@*JR<'^-_Q6:!C/$$8=! UA"(5^ MA,T6_(,%WVKAECV(5GP78)O+$WI:;[24ER78\#*ISIFFR/U>2+/ \[Q.X/U1 MA*#6*"WNX!!W8#T+ 9_@\[+#3M,
(R"3]+Z MP^0."X*!'18=+$363-VK#?5!DL$^]+_DUC+'&KE,G2,QS??LX'MF3=W?INQH MQ]=CM1RF-9CU$@']J).L_IC90**@I\JY=V;(Z6#>&NEV0)WP\0(RZQ94 MP[C]Z/9P'944
#)&:4)6I'BY+PX4M.M*GB =GH8S,L%6%6KL!MG-.%*33>N> *&YYXXK$1R MLEU':KI=Q1[06N*'*II:A7AH%:+>QO,)F76WYTL !E2$ 6?GG&FL?')R(AVI MZ1>_"DW0*#2QGV50'S=\$L!.$NV /-
:9HA<$7?(QAI4;SF'D M1EFK(-WJ8?_UX>X4M2 [M=Q?W5V!S])*N2V>0<[%0$:M*B=GU)&:[EG!#[+# MSQ%M*]< Y$I-MZU "-D!:'1]07VP"<.(=`)#<.@AV9!8 8@I (G=,.U1CY) MQY6:,E4A#
[+W4,:5CGXS) QGJ-O;,@R#'O8(&**C08QEHL6 %*=C>8KF_ K*6 M?> [5N29O, #])'E\?-/^HYVT9.-O02K8,4J^-R6"W;:P41%RIZ=X5B.!1('),7<,&SL#=E)E89"!? MBD/PJ ;*
**<76MWT.Y[%ZBF<8,52L%$-@.$ M>;'A!!0,/?.!N@%WAY(WU$LT1 MHN"#>&>6)N(4,5RIZ785C)"?W.\96YH:W<[5E!>&W5OM_7$(SX9.?D0A!+$C MA+TV$:?XX$I-
MZKP@8$"!WMMQJ8[-\B+NFU>%]M_U=^T];!X]:2^#/^QVHXI6TEYRJ42UWL M'W[?OQ%\4S_L"%X%G]Q+;V @ 2 H !D !X;"]W;W)K&ULK59M;]HP$/XK5E9-Q42;=PH=1%]!:?
LPJ8)V^VR2@UAUXM1VH/OWLYTT M@I BT/B2^.6>Y^Z>.]D>;1E_$2F 1&\9S<782J4L[FU;Q"ED6-RR G*ULV(\ MPU)-^=H6!0><&%!&;<]Q^G:&26Y%([/VR*,1*R4E.3QR),HLP_SO
U"V'5NN M];XP)^M4Z@4[&A5X#0N0S\4C5S.[84E(!KD@+$<<5F/KFWL_"[6],?A-8"MV MQDAGLF3L14]^)F/+T0$!A5AJ!JQ^&Y@ I9I(A?%:YJUR6
M6,"$T3\DD>G8&E@H@14NJ9RS[0^H\S$!QHP*\T7;VM:Q4%P*R;(:K"+(2%[] M\5NMPP[#3X >#7 .Q7@UP#_5$!0 X)3 6$-,*G;5>Y&N"F6.!IQMD5<6RLV M/3#J&
[32B^2Z3Q:2JUVB<#*:8)'V4*R^"%Y+LL$4K/&Z%,523\!:1>0P+BDA-)0* ;

!X;"]W;W)K&ULK95?;YLP%,6_BL6JJ96V N9?VR5(;;)]>Y@4->WV[,)-L&HPLYVD M_?:S#4%I(*@/>TELN.?X=\"^3'9N*[,"2B(O>0V5 MOK/BHB1*3\7:E;4
DEM1R5SL>;%;$EHYZ<1>6XATPC>*T0H6 LE-61+Q=@>, M[Z:.[^PO/-!UH]2K5/I;9:)#>0(7O6^D"#1^1P4H4Q>H*_H:3E'YV<7Z S1"CT6 M?"-)EQZO]2Z6ZC3J(U?=$ 17"?X"+5?
%&$<#:-& M'6HTBKK?/VO.IHP[RGB4O]F!JO@*!T=,[D%K M-)^E7T2L:241@Y76>9>)CB2:5M],%*]MMWSF2O=>.RSTUQ&$*=#W5YRK_<0T MX.Y[F_X#4$L#!!0 (#. ;%F\
W72(P8 !&PO=V]R:W-H 9655T-U!^_,T"P,60*$Z/]$G,[SSD37LY<#BR?*/M6[GAZ'N6 MYL7-9,_YX7HZ+:(]R?!Q10\D%V>/VE&68BUVVFQ8'1G!<&F7IU- T>YKA))^L
MEN6Q3VRUI$>>)CGYQ%!QS#+,GN](2I]N)OKDY<#G9+?G\L!TM3S@'7D@_,OA M$Q-[TX82)QG)BX3FB)'MS>16OP[UA30HK_@[(4_%V3:23=E0^DWNA/'-1),1
MD91$7"*P^`DD]R1-)4G$\4\-G30^I>'Y]@O=*QLO&K/!!;FGZ=/2=QC[ZGM%PK[J6AFTU;CI:UWAA)X>]Q=(5U_CPS-,-&7AS5Z^^8=VO)?
M?]&=^6]]#53S'IC'AA"IE:R9N]\'HP:S7F]V,^",.,C\948##R81OPT1Rt$'S*EP4A/<].'=*JNS?KHL#CLC-1'1@!6&/9+(2(K6U7I%6,+N$R;[M<67. M+,-
<3A_/-0CITH6$>8/B]R%=!I"PL!N_;EJZUL3?4M:L4=9,J:PJ+Z<)WB1I MPI_[1*0$C!51:,/.,\+@@/;J0,&](^#ZDQP 2%EK=Q&6)CF[D9RME%R8'7#" M,JFA:(_9CO1I2(D8JR%
(V!H2YD+"/+NK-<>Q+[0&Z3& A(5 L)8FG4:3CGJ4 M5F8WD?QH1M"6T4Q,[3?E@*U/G$K66'$ZW;NF:1?Y#=*A"PGS!D3O0SH,(&$A M$*PEN7DCN?F X1OY?B!YO\J4YF-5-N\F\D5'9I
>W:['CD.O>\UY'A M7%X40(8> L%:LE@TLE@H9?&U7'L3 S#*":..X(8D0N2S002<<*R/KDHL6/E MHHYQAIX)9@72-915ZR]BYAWCY[[1X!HR+A<2YL$UTH>,*X"$A4"PEI9U[;1T
MJ(U3L^ABA:#%V ^G:$.9 $IE,\Q[4Z":/E;4-6UQEDFT*S75UZH+2O&%- M\$&=!J"$(K65N398K:N5*1CE=-9>X8>DC@GO5H<)(3WJD)&]T^2-H:E.:"
MTCQ0F@]*"T!(12MK67CI&7C?U^\4;L<++7]C.WCKCCM!?;J@-&]0"WQ0GP$H M+82BM45ZJG_HZ@+(H$P+6NT I:U!:2XHS0.E^:"T)060M':(CZ56G1UK670
MFJ6:,5K%D+1U36NEL?EE&G-!?7]@-!^4%H#20BA:6YVG&HZN+N*(,6V GV.2 MRVE6?NP7)VA5!I2V!J6YH#0/E..#T@)06@A%:XOX5!72U66A6T8PHEN$XSB1
MKQGA%&UQ5):VJY6O&/U0O8ESIW?K'[9N:DX6]VKPQ@M7=!R$'C- Z7YH+0 ME!9*]=K2/16/=*7UJ%S*W]-43+RR Z./Y0*7F'EE)\CWCW>=[G)\IS>^5WL= MK530(A(HS0.E^:"T
)060M':2CW5G'1UT>F_OHVFQHX>/4#2UJ T%Y3F@=)\ M4%J@JQ36[$YE+81RVE;LJ1RFJ\LP]YR4Q-&BQ.2M@:EN: T#Y3F@]*"FO93 M<8*6MZ9G+\EG1,SRY1<6!8ID-UZ]\=L<;;
[BN"V_7;@X?J}?NWK/<4^_]JMO M-$[XZI.1CY€MDKP0:7DK7&E7CAC&LNHKC&]'TT/YBOZ&\A3_@,_-H5 9 >&PO M=V]R:W-H965T$I)LDTBW
M@5,K==O5[5W[V@N3Q#JPJ>UL=JM^^-I 2 BLE:A^DV"8^7G\'JLPGN\9_RZV M !*]%#D5"VG\NO? EW.VDSFA\,"1V!4%Y]JWD+/]PO&=PXTO9+.5^H:[G)=X X\@OY4/
M7+7^Z\6NV<#P=$>20 M2HW ZN\95I#GFJ3B^+N!.FV?VO'T^D#_7 U>#>8)"UBQ_"^2R>W"F3HH@S7> MY?(+V_\"S8#&FI>R7%2_;%_;3L8.2G=*LJ)Q5A$4A-;_^*41XL0A]-]P"!J'
MX,PA"-YP'!N'\%*'4>,PNM1AW#A40W?KL5?"Q5CBY9RS/>+:6M'T1:5^Y:WT M(E1/E$?)U5.B_.1RQ8J"2)5Y*3ZBE%%)Z 9H2D U,1$JMOH M?0P2DUQ\0.\0H>CKENV$LA1S5ZIX-
-5-F[[OZKZ#-_KV W2O>MP*E-,LB[M50-I1Q,<1G,7&(DQI#/;C*,Z:@6MG,@K+CA&]P_JARG.\[5-#C-]5!*:]1H M&*6WM5M1XA06CMJW!/!G<)8__N!'WL]#ZMN$Q39AB258)Q^C-
A\C$WWY&ZB= MK\W#ZU 6C(!KLU##H@JF7RS/RV@VFAEUC1)+8754&[>JC8VJ M?642Y\U^=>%<-@*O5;&&CL?B/T6B5G_5?, MK#_O^E;^U)N-SK2T%%A'2)\[?
E1[1C5_5PJ6G*V)1*J&PY3\@^NR:,,;!],?V MX,>RD7FMF%9H.55:8HO6S/;?<4G2^G6F_WY&RK_+ZI#A4%2MF.ROJ8]W;'EQ^JH]K MW*-Y?>IYC_F&4(%R6"M7!T8?
$_+Z(+%N2%96)V5/3$I6$;=;P!EP;;">KQF3 MAX;NH#W.7?X'4$1.#!!0 (_4(9 >&PO=V]R M:W-H965T&\3N1 4AT7^143*Q. MXG)LVR+.H,#BG)5
U6I+4H..#&@(K<]QQG8!2;4BD(CN^91R"J9 M$PK7'(FJ*##_/8.<[2:6.^T%-R3-I!;845CB%%8@;\MKKFYVRY*0 J@@C"(. MFXDU=3JE2BT3,?..$JZ@/$>^ M\P9YCA?T^#-_/MSO"^?
_K"__V?!I.ORV*WS#Y$_!I_YV.5ZSN@'05'4"34UG M(%7M@_L7F0%',L.4'8)^?%*^4+MN'HE_;6O%^05YBFA N6P4:.<\Z$: MN[Q>.O5%LM),U363:D:.8Z;V-'"MH-XWC.G]11MH-
W_T!U!+ P04 " S M@&Q9EXR@#PD& !H- &0 'AL+W=OMH=A#XQ.VT(E424I.QWZX4== M(IFUPMC=&9*'6!>>'X_$O\E#'G.VH^P+WQ BT$,2I_RRMQ$BN^CW>;@A">;G M-
".IO+.B+,%"GK)UGV>,X&5IE,1]RS!&_01':6\^*Z_=LOF,YB*.4G++$,^3 M!+-OUR2FN\N>V7N\\#E:,T1QH3^?97A-%D3<9;=,GO4;HCFB)&5I>]
M*_BL(S"H"SQ1T1V?,\8%8]R3^F7XN3]\K)G%!Z1F(2B0&#YL24W)(X+DO3C M:PWM-746AOO'CW2O?'CY,/>8DQL;.QDMQ>:R-^FA)5GA/!:?Z2X@]0,-"UY(M8U[^1[NZK-
%##8_HM_H%C,1]H[>?/F MO'GK\-8I]WB,K<%X,-[X,-X$1[QIVZPQMXRN&4XT0K";KZ!=_/4OYLAXUZ5'2)@#"7,A81XDS(>$!4 P1:R# M1]P#'7U?
K&7PLB5I3KHDI\6<*CE(F%/!1B6L".VVE!B-S MH!;R#@N-I;%EJZ7\PU+F<#H=C-5B =!#*LTZ;)IUJ&W69K2_E0-'@L_0E8^^ M5QU=!$\N9<:I"L4*GUE5L6*7':IG6%CI4,M
M^U0=0L(<2)@+"?,@83XD+*A@P_THHQGO%7%-&G%-M.);E%.Z2EQ)(E7%RUGW M]Z?G>M=:X*F*FAP^D#D8&H:EAC$.9*4N),R#A/F0L (INAJVNAJJM75U5I& M%W
R%H6=0;V6=*J@IH=QN"'_?I 39)4N),R#A/F0L (ILC)--H5 M14,OJ(3F,AZ3'97$)U'>.=CI&:.=*J:8I${$#)8%6Z8+2/%":#TH+H&BJG/86 MJ,V?F)KJ5J4[]::MY&2]0=(<4)H+2O-
:3XH+8"BJ<*T6F%:+STUK3V 4BTD MS0&EN: T#Y3F@K[""}]VC;98&J7AX]?P-5S3M8>:.:@IJE+]@>QHPM:]0=* M\T% I1-%56;%##U68&[;,6H[.@R_.W) ;AK%?
R@R6[T%9VL$TB:"TKS0&D^ M*"V HJER:I,1YL]D(QS95\4T*P1V)CNN=1YC0=FW8^H1&NS:8X(ZSD2%-T3V2&'1*ITB60D MD.SG/[9%4292PCI%>[A.;MJ'RX W>D=/EB-
H1@.4YH'2?%!; $53Y=AF0$QJ M"J0[+EA@*: T'Y060-%4J;9)%7/ZXN,];#8&E.; MTEQ0F@=*\T%I 11-_45RF[JQGDG=_,_CO768]3"'>L >D=/E2,HS06E>: T M'Y060-$J.?;WMBG(V?
]ZW++"I7;R5%0_EVZN-MMBKLK-(#]<=\P+U^RXHD7 M?K7H<57>W ^8K.4HYBLD)5&>=C&7"R:EM+=2)H5FZ2N*=*T*0\W!"\)*PH M(.^O*!6/)T4%S>.B;)02P,$% @
,X!L68'ELXH1!0 &ULQ9IK;]LV%(;_"]$50PMLT=5VG-D& MG.@Z+%O0K-N'81\8F;:$2])&478[[,>/ND26:H6UVP[TW4QW^<<22]%4N3B M0-G[(B*$HP]IDA5+)>
(\OU'5(HQ(BHLKFI-,_+.E+,5<'+*=6N2,X$TM2A/5 MT+2IFN(X4U:+^MP#6RUHR9,X(P\,%%66:8O;QEB3TL%1TY?G$VW@7\>]$NEKD M>$<>"7^7/S!QI':439R2K(AIAAC9+I6U?
A/HDT0E_@C\H>BMX^]2WFBl'UU M$&R6BE9E1:(2\@]'Q69/fDB25"21QS\M5.EB5L+_C/=K2]>7,P3+L@=3?Z, M-SQ:*M<*VI M+A/^EAY\TEY0G6!
(DZ+^18>VK*:@L"PX35NQR""-LV:+/[0W MHB<0G'&!T0J,3P76"P*S%9CG1K!:@75NA$DKF)PKF+:"Z;F"62N8G7L-UZW@ M^MP(\U8PK^W0/+_ZX=N8X]6"T0-B56E!JW9J!!5J\??
M/=KH]:LWZ!6*,_1]1,L"9YMBH7*19!5*#=N$;IN$C!<2TM$]S7A4("?;D,V(MWI;KS<_I?;E^+M&KXN9V=]AXOL.WAA3X2/(K9&H_($,SK)%\[N3R=-=H3 MM&8,9[NZ(B%14P;'O_&
(,,0CG*&AZ*]?JOH8<)(6?X]5K28!:SR!JMV*7(< MDJ4B&L."L#U15M]_IT^UG\9\"0FS(6$.),R%A'F0,!\2%@#!!LZW.N=;,OIJ MV(PLB=92<;*\58+==\W)F1(%Q+FG>9O375K
MF+Y_6FAFSJIW7]!4<%I*G\SGUJPK-O#(I//(1.H10]/G+W0ZJK?E2)@-"7,@ M8>!LI"&>;)HV;*TJR(@^)"P @@U,>=V9\EIJRG62T+#ICM(MXN+M6^#FZUO. MXG"T8R$%7NI02)@-
"7,@86X#F\@=*"AG1AX0%0+"!0^>=0^?R,5.9EDG3\ NC MAA$]\\JJ!>!);$.ZR^),1SIQW4K1EWH5$F9#PAQ(F#L_'2%9)UZ%C.A#P@(@ MV,"KNG;\BJQI9O1FF!"C-WF82YT+2K-
!:0XHS06E>: T'Y060-&&1N]-E^C? M>AS79@!5!R!I-BC- :6YH#0/E.:#T@(HVK.&,'%B)_:'=GE;+E"5UL)] 9 M+E":!TKS06D!%&UHN^,TERZ?Y_J"KPKZZ6S*F =!Y[):VD0:TP&-
Z8+2/%"; M?]8S"*!B#KUUG!{3Y?-C7_4]0,Z^N"$&G19K&P(=(\4)H/2@N@ M:(UKU=Y"LY2P7;U*L4 A+3/>+ ?HSG8K<?U^K]/SM_J-W?ZR'E;O_'&SOO5
MBLIZP=LQ;+,.<\QZS79P5*"%;D8)V-1,7S)H5CLT!WF[,V)C$-8 M54#\OZ64/O]4 ;IU]JO_5!+ P04 " S@&Q9GNC.FZ\# "L#@ &0 M 'AL+W=ORS'SCS/S,Z+ M9W7BXI-,
13ZG&=,KJU4J>+:MF640D[D%2^ Z2\'+G*B]%8DMBP$D+@2RC/; M=9RYG1/*K'!5O;L5X8J7*J,,,@6299X3<7\#&3^M+6R=7[S1)%7FA1VN"I+
M#M3'XE;HG=UJB6D.3%+.D(##VMK@ZQL<&(']QO\43K*W1L:4/>>2S.9]O+8< MPP@RB)110?3C"G\ARXPFS>/?1[G58AK!_OJL_5UEO#9F3R2\Y=E?-%;IVEI: M*(8#*3-
UQT^_0&.0;_1%/)/5+SHU9QT+1:54/&^$-8.,Z FX[HB MVPBX%>\;J&*Y)8J$*\%/2)C36IM95*96TIH<9>96=DKHKU3+J7!'$T8/-"), MH4TB +3'E41OT&]0"AX)?
1QIBS.RYX*H^BHBH$>RST BPF(4<::$=B[**-G3 MC"]J/[S<@B(TDZ_0"T09^B/EI=2'Y2LTCL;T=OS MTA'01@C"DLJ;E9?Z^]]5"@*IE##T4.CO7XV[WRO(Y3]#GJH)>,,$3/Y>RX)$
ML+9T@DH01[#"'W_ <^>G"?,\UCQO2GMX!QE1$*,"''6O+WTD)%ZC/224,

**C60WZ>WP-XPO7E+ M;SY)3X?;;"2K3+R<5EC(VF0- R#"89;N*8&CJ#=3:X ,1X&?C#B-CI&H@SB;F%N(Q&01OA/NH;
MC'W7'8'M]2W\7-G>(#TMW;';,70?<"0VO,O8\%S''S.U:P1XNA-<>OX)03!0 M\
[W%!OT1UPUQ[P='^8SK#+>J^!QT*]*_AXNN(_DF'!Q?\LG6'X M;N#1 YB*0: MDZ2NJB53]2S1OFU'L4T]@'3'ZSGN
Q&ZR$F4P4&+.E<+;;&H1Z-ZHWA1C2-[MKO1P4RU3/4Z", ?T]P/GZKPQ .V &OX'4$L#!!0 (#. ;%D?C3IZJ@0 M *\= 9
>&PO=V]R:W-H965T0C0)9':PMVNM&I5N[N]N-H+-[@)*F!F.TW[[6<;2@(XJ-DL]4T# MY)R??
7P.__K$\QVACVR#,0?/95&QA;7AO#ZW;;;:X!*Q,U+C2GSS0&B)N+BE M:YO5%*-,.96%
[3K.S"Y17EG+N7IV0Y=SLN5%7N$;"MBV+!%]N<0%V2TL:+T^ MN,W7&RX?V,MYC=;X#O-O]0T5=W9'R?
(25RPG%:#X86%=P/,4QM)!6?R9XQT[MN 8RE'M"'N7-UVQA.7)&N, K+A%(?#SA*UP4DB3F\4\+M;HQI>/A]2O]BPI>
M!'./&+XBQ5]YQC<+*[) AA_0MN"W9/FX7XL!!Z^"]+=02_=?#?.D+0.JC0[29VM7) MXF@YIV0'J+06-
'FA5E]YB_7**UDH=YR*;W/AQY=WG*P>/\NESL"*E*+^&%(9 M_ RN#F_QL[S&X&.".%,XY], ^\<3_K98CVY1W-
=%N70G@7>X/@.>\Q-P M'=?7S.?J[>Z>+IS_-WKZGT?O+8;758BG>-XQW@91W%9(KR0N*$75&@O5X.#^ M!1S:W: 7]?
ABAV@&OO\FD. KQR7[6U<=S?B^?GRIE.>L1BN\L(04,DR?L+7\ M\0DGTNR3Z4_2CK[DN'0UIIDCR_\S3TO,]48A/A\L\
M-G*C,.H;)6,C"!U_8)6.K2+H[(UZ\09=O,%DO&E9%^0%8Z "![_7JF*_7^/R M'E-
M$4[R3BU"D[#$)"PU!.LE9=8E9?;.2C(SF423L,0D+#4$ZR4Q[)(8&E.2 MAA0@,ET1@Y+APHR=@H]()P("1CHR"
(0KV01%VXT62XMYAQFJ^XB)8I M*4&R$!D0.QVPK7*NW>Y,(D\M0Y.PQ"0L-03KY27N\A*_LY;$)I-H$I:8A*6&
M8+TD0F???3C&U*1%';[?<314$XU1& XV+XG&R/.#@56JL7(]+];K"3QHN.#; MMB:-
GM1;NMJ(^$%=H*I5%VWTD]13Z]$H+3%*2TW1^OEQ]_EQWUE9V@F82J5) M6F*4EIJB]5.Y[USA9$]UFKIX8^&
(AN(RMAD*4**Q$9N>H;2,C6#D'E&6?8\' MIYL\L5?!2*B)VIQD^ D7I)9EJ0UW$G5R#9JD)49IJ2E:/RG[1A0&[RTG1EM7
MH[3$*"TU1>NG MTY1]MP>GV[U?<(4I*I2DH*S,JUST0TC^N*^->A)VG#1T3[O3Q0MUIC9X?@G/KZ#F>2)/
M(]6!UQ[?'&5>([K.*P8*_""&&WR7U!+ P04 " S@&Q92=CFK&D% #D(0 &0 'AL M+W=O&P<(-3A$;DRW.Q)-
G0E/$Q2U=&VQ+,8IRHS0Q+--TC!3% MV6AQG9?=T<4UV?$DSO =!6R7IHB^+7%"#O,1'+T7W,?K#9<%QN)ZB]9XA?
G# M]HZ*.Z-"B>(49RPF&:#X>3ZZ@5>!94F#O,9CC ^L<0UD5YX(>9$W?T;SD2E; MA!,<<@F!Q-
\>W^(DD4BB'7^7H*/*IS1L7K^C?\\[+SKSA!B^)<.!]QM+BFY "HK"W0 MY$7.?FXM^(HS&2@K3L736-
CQQ8J3\.524AV!D*0B_AC*1_ 2W&/&:1QR\22O M)8K.?,Q1G+!S,ABSBY$H;C^:T-V#&41NS:X M:*IT:
(1ELY9%LZP/FF6#'R3C&P:"+,)1C[VOMI\I[U!4<63]<[3TE("KO!V M#&SS EBF->EIS^UP<[NO._/>_"?O;?
(L*N@L7,\^P.\1F2P/#*BF(4)83L1 M!'UC7:!-^M%D*KQB6Q3B^4CD.H;I'H\6O_X"'?.W/J)U@ODZP0)-8*TAF51# M,E&A?
SB/QWWC44 Y.91\D^P7]LO6<;5O\GQZ)NRDPENUVY/9'.@VT.6VS:95LVDI
M5QP_\QT!$;DW>TS1&H,*P.AB3'XCF(*'E&RP^ .4Y O3GHIMK1&M4XT7RM: MH NM/5BU?(1**?31"B4B28(H
ULQ2/E,Z)\(6M6D5C2_1/,:L\49.]/N5/D* MH0AKI0C54K&Y7AE(N1+P9,IUHODE&H3-Y[NM$J+P?Y#'3Y;%-
:RTOH:=UMA5J5IE8T M7RM:H NM/3"U)H6?BU(9XR*N8])W2+%4 YP\%%HEZ2>=L\$;%I.VE_:O4*E6
MK5(MM4H]::N[Q&KN/<^\SIOJMJ>2ZW;VP_V>2O9DVJD5]-02.G_6O]=MU6+1 M4HO%AXSBD*RS^)_W+-!W9H=?
Y76OMBGQ6SQ T^P2H54[#O(9Z/+99K86CI92
MZXCL*H_3Y30^E!+R$I42DE:/]I_.=+674V>Z5C3_$P:L8J8#"%)Y9@H<$*&W MWHFOJUG%4!F-4^L4TW7^N0
3$;W+>'$66956GR34^O J* M#PYJ^.+[AQ^("N')0(*?A2MS[(JE*BT^*2AN.-GF9^9/A'.2YI<;C"),907Q M_)D0_GXC'50?
=BS^!5!+ P04 " S@&Q9O]213Z<$ %$@ &0 'AL M+W=O M/PC=000I MQ,JHH/IO"
[>0ID:3QO%/I=2I;1K!X_9!^Z^%\]J9.95PR]-O+%&KJ3-R4 (+ MNDG5(]_]#I5#@=$7\U06OVA7S?
4<%&^DXEDEK!%D+"__Z6L5B",]$G0(D$J M%+A+0P7*.ZKH;"+X#@DS6VLSC<+50EJ#8[G)RI,2^BO3?
SM$GY"*YH@(D8CEZSIF2 M%WI0M_]:\8VD>2(GKM(XC34WKC#=E)A(!Z8QNN>Y6DGT.4\@>2OO:O]J)\G! MR1MB5?
@ZP:>A>(>,2WZ!O601L6^H9=^HS'5=!NCX-V+03-EZ"K5J'Y'AW/ M>Z#[8OAZ1T5R<0BK;FR45#I.+%^B[X\\39&N-
C/G[[; E;C\=EQF!5_)-8UA MZN@E*D%LP9G]_!,.O5\L7ONUU]Y-^^P(Z06:PY+EN0$]IRG-8T!G.NEE*9RW
M(2]U!X5N0Q7;6>23P/=U/K8MH((:5& %]9L.N-+A?<=Z<&*=#$E 2-AN/:RM
MAU;KGU]!Q$R^;S\\L7\Y"K'GM9N/:O.1U?RM"7R::O-<(,W0"V]8A&=8HG& M0^*3=C"C&LRH?WE 6=]:V-

T@F@TBO"0C-H1C6M$XS[9H?/T703C$P1^Z/E# M@ML18*^A5\]*%=^*;4$GY7H+0F]SZ% RZ$&P&%K)T?
L!BQP?;0BX;QZ+J"6: MDZB0: VBC&!K "NEH^,<#H*.DL*D 4-Z+^^>0$J%&!\SS2 :=R!I*!];N?5_M2[TGEN$I%G^
NXJJ(6)L9V++NN\)S#\%AO$@[(I2P\;83LP1R236!N]>E&Z./HAJ;H#[9H)P$K
M\W^4!!HNQ[W)O!6=73I">S!Q#E%6',1LD!HRQ[W9O!6273JL(/D5)$1\E-"]-M#1H2){82?YZN12PI K0%YU9I]\L,?
I*TTTK4/(CZ)TT]$YZTWLKNE(Z/"K^ M811T')-(P^/$SN/O)*^2?G,^BZ*HPVK#V>0=SL[6*=\#O+G*H._WD,U!M)ZO
M[0H_FIR&V(EO+:3#92MA,DZYW&@;K2BMV\-'438D3^PD_YP+B/DR9__J34=V M72#AU;3;TQV<%!GQ.D_#I.%[8N?
[AF)WU;'KDE;'+E%_VH)4YE]O HPGK?#L
M5DA%):,#E6#2227NT&ULQ9A?;Z,X$,"_BL5)JUWIKH"!0+I)I#9PVGOH;;71WCV<]L$% M)[$*F+--TOWV9QM*0T*Y9-
=27QIL9G[C^<,49K:G[)%O,1;@JV0E37 MMLW3+2X0OZ(5+N6=-64%$G+)-C:O&$:95BIR&SK.Q"X0*:W%3._=L\6,UB(G
M);YG@-=%@=CW6YS3_=QRK>>-+V2S%6K#7LPJM,$K++Y6]TRN[(Z2D0*7G- 2 M,+R>6S?N=>)Z2D%+_$7PGA]<
^7* Z6/:O%'-K<<=2*:Y(M\AS_ME"KLZD4#Z^?Z;]KYZ4S#XCC)HSH77^C^$VX="A0O MI3G7?
\&^D0VA!=*:"UJTRO($!2F;7_34!N) 07*&%6"K (\5_%<4O%;!.]>"
MWRKXYUH(6@7MNMWXK@,7(X$6,T;W@"EI25,7.OI:6\:+E*I05H+)NT3JB<6? MLA;?
YY3S#X"4*2TPJ+"LHRUB&+R/L4 DE[=^:W;XS!;2IM*TTY9_V_#A*WP/ MW-%2;#E(R@QG _KQN/YT1-
^6OG8.PV>';^$H<(6K*^ YOP+H0'_@/,OSU;TA M=W[.>O+#UGO!\+KL>YKGO<*
[*07)2%ZKAQ6L<%HS(@B6P7Y*\UK&&ZP9+<"2
M%E4MD'ZPZ1HDB)6DW'!P+RMEI>IBJ"P;P_ZP8=7^KGF%4CRW9'_CF.VPM7CW MBSMQ/@[EQ"0L-@E+#,%ZV?.
[I/EC]'[V>)>]H6PTH$"#U/^.W<)U_"CR_&!F M[PXC?2HX=2(G@DY?+CX7F)P*AKX'H0L[N9[O0>=[,.K[UW*'N9
5*L,J&$G5 MI6Q?A2Q1V3/31X#VB&6#L1@%7UJ9)F&Q25AB"-;+SJ3+SN2M^LK$9/9,PF*3
ML,00K)>]L,M>:*JOC((NS49XTBH@#)SCSF/29/)_)GOQB[KX13_7F^J2B,%P MCG(O#:=)6&P2EAB"]9(S[9(S?:O6-
#69/9.PV"0L,03K9<]U7KY7'%/-J27U M7E(F;NBXX=%+SY"@Y\(0'@G&YQ*3 <'0]=V)/]Q9W(//-7?
4_:2H1SI4OTGSMR"Y,E*7HID2=+O=U.]&S[J.]F_=ZZ4[L!^K*:$>1+W@
MFQ'C'6(;4G*0X[4TY5R%\K2LF=HU"T$K/99ZH$+00E]N,(_4$L#!!0 (#. ;%GJ#-;_^@, !<2 9 >&PO=V]R:W-H
M965T/'(EMEA'^[YRF;#\UL'%H^)RL-U(UF+-)0=;TB+S$M@HH$5\2NA1A,B]$T 5+OR:QW$R-P$ Q79%M*C^S_9^T
MGI"G^'"*6BO(7[6NL9:!H*R3+ZF 809;DU3_Y7@MQ$@ \^@"[#K O]PK 4X= MX-S:@UL'N+?VX-4!Y=3-:NZE<"&19#;A;
(^X0@.;*I3JE]&@5Y(KHSQ)#D\3 MB).SO\&+=RD3X@-*\HAE%!44?+0AG*('-"LX3*>ZA$V9;M:L:SN#W6"?7:G
FM0MC>R\#DLU, .6S9A@V]D7-$ MGK[K8N?" MM1I&:^3;&/MZXPX;/89O,N[A4_M6ZP[M&Z?9&&?
9,N>R,Y2%32I"GZ==8-; MK=L&7K&NCE%K70UCIW5'C1ZC3CT6+,M@MP^[U.@5L4)M_46Y7011)$\B)57U M<*MV?
#I5.CMXJVO[) O[)%N.6AG D%'?"O0)P-9Q_V[]M"7K%46[P;9N=:4& M><666DZM+W6U>T>7D7(/?
MODYKI[WZ.H[6I,&ISL8:W#RFM1::&'> MZ%((/:RE0AN&!\&5[1"VCPK8/ZY
ER7LVS30PMH:Z&$M#=HP/!A>OAWFR4$7 M#A?K\H9!H(AMM1'JR/]-65R2?"UPFL M;BE=05?68
BFY=4M1%61K"B/V2],PJ&]+&XHB2E7 'B^8DP>*JJ#YBYH]A]0 M2P,$% @ ,X!L687&'RT)! ZA< !D
!X;"]W;W)K&ULM9AMCYLX$,>_BD6K:E?:!DC(TS9!:A>J:Z6V45=[?>W)+$6 M,+6=I"?=A[\QL"QL63:I?+Q(>)K?
V/^Q/1X61R[NY0Y D5]IDLFEM5,JO[9M M&>T@I7+
<\CPR8:+E"J\%%M;Y@)H7!BEB3UTG(F=4I99_J*XMQ+^@N]5PC)8 M"2+W:4K%/Q\@X<>EY5H/-[ZS[4[I&
[:_R.D6;D'=Y2N!5W9-B5D*F60\(P(V M2^N]>QVZGC8HWOB;P5$VSHGNRIKS>WWQ*5Y:CFX1)! IC:#X=X ;2!)-PG;\
MK*!6[5,;-L\?Z!^+SF-GUE3"#4]^L%CMEM;,(C%LZ#Y1W_GQ+Z@Z--:\B">R
M^"7'ZEW'(M%>*IY6QMB"E&7E/_U5"=$PP(YV&PPK@^&I!J/*8'2J@5<9>*<: MC"N#HNMVV?="N(
JZB\$/Q*AWT::/BG4+ZQ1+Y;I@7*K!#YE:*?\NRP&<11, M*4UL(G=4@"0L(W<94_(*
M;^+Y%Y8D&'NYL!4V3./MJ&K$A[(1PV<:\9EF ^+,K\C0&7H=YC?]YK>0#\C(
M>=8\.,6[]ZQYV&\>0(3>W<)\U#:W,1AU1(9U1(8%;_0'$>F2MJ1YW32]SES+ MG$:PM' AD2
.8/EO7KD3YUV7T"9A@4E8: C6"LFH#LFHC^ZOJ" 'FNP! T$B MGJ:XPN',C.[)!8[[F"
<)%9+D(.J9<=D5IEX/YX:IA$T+F$X%!]\9.(Z[L]- M_4VZ#%]RV1+6JX7U>H6MQ[I>;=YO!0#F(-4E7R_G7/E,P@*3L-
0K!6,<1V, ML=&%9VPR)"9A@4E8: C6"LFD#LFD=WY\DG)/L^BW=>>J2L%=82F)X\9$G1;'
MK+TZW/1Z/E=QD[#0$*RE^+16?/J_+_6]'LZ=&"9AP?24O!$: 002RP"(\ 2+NY2O,2XPT:_YJ/!^,D"T^OL7"E-PD)#L);(KO-
8 M<3E_L.DA_Y*5@+++*0];?F[$@8+8M-T=J1>"R,W1CQ_DI9-.6W+_%@FN_UU*>.;J/5L%%::(I6RFXW/I/J MK^!?J-BR3)
($-HAW!E,42Y0?ELL+Q?/BR^F:*\73XG0'%)."?@&?;SA7#Q?Z M8VS]>=__#U!+ P04 " S@&&Q9332XT#0$ #%'@ &0
'AL+W=O&9$['-,LI?IY"R_5@SM4/#2[):RZ)!GXPV= 5SD%\WSUR=Z0TE M3C+(1<)RPF$YUI[,Q]!T"D%YQ=\)
[,7),2FZLF#L6W'R1SS6C.*.((5(%@BJ MWG8P@S0M2.H^_JVA6E.S$)X>'^A!V7G5F045,&/I/TDLUV/M7B,Q+.DVE2]L
M_SO4'7(+7L124;Z2?76M,]1(M!629;58W4&6Y-4[_5Y_$2<"Q>D66+7 .A7*UH MQ4'I;ZE6CB1Y$<6YY.K31.GDY
52*B$F&\KE*Y&2)JGX2'XE M7^<>^?#SQY$N5QJ[XV';8. M'9Y:O< Y;.Z(;7PBEF$Y'?1$INOBD/^^6?M_E;
MU5M6V$WV[))GWYR]KIQ5+*>;58S8CV)#(QAK:D@6P'>@37[YR1P8OW69C GS M,&$^)BS
A(5(L%94G"8J3A_]+"IJT$OI@G$JJPDQ@F1'%RETQ:;B#DIN,2_O M)O;0= S#&.F[TT3TUK\U$5<6]3&+!AU%;
<>*!HB%6WYZ#8^NKT^>OR.S.F: M_$<.CCX7CG89UPNZ]?>."?,P83XF+,"$A4BP5DX&34X&B%/# #,JF# /$^9C
MP@),6(@$:T5EV$1EV#ND_,4D30G-V#:7A"U)P4\B$/6\T/G0.:V0[LE8:,K& MY:0PO!A237?HGE_F7=*
<#II_27,=TSZ_+.CM[JW.(,%:SMPWSMSW.O,4[Q+! M^"M9 AP,V@ G6?%$W^5*+^[6WS$FS,.$^9BP
!,6WE\FM)7C5@P>FA@\],;@ M3]AR%G'52F;'![<=D*<5!\A I<(RS(>N0/2";PT$)LS#A/F8L 3%B+!6KDQ
MC>/:A('X%%##D-*"2O-0:3XJ+4"EA5BT=F1.EK/,'_1'L0:W9G&CXYF@_P9N M#L9U57W4J@$J+<2BM2VWCI9;[Y]?.M>
[IOWDFX<,3)J'2O-1:0$J+<2BM?-S M7(4T,96]9' M+1N@TD(L6F6Z?K)IE@%?E?NA0IFI_J96>QA-:[/G^E3N-
)ZU3\W'F=G1[IF/ M?K6C>L17&[Q?*%\EN2 I+%4IXVZHIG]>[9E6)Y)MRBV[!9.29>7A&F@,O+A M?;YD3!Y.B@+-SO7D?
U!+ P04 " S@&Q9]_42N3D# #N$P #0 'AL M+W-T>6QEF
M^!"&Y73.J8))BV1*Y]38KIZ%9:$934L@Y2+L=3IQF%,NR6@@%_E=;LI@ MJA;2#$GS=V5GGZ?)V-WY1 M
9'R!ZU>G@P@!BXO%AXONT,>F;;>EF^+G5:KGG&+GO)6]0,6)RT(3V MS*<2#NO]'@TR)=?;'A$7L)EISH)G*H9D3 6?:
ZLC.9U(/WP&:'ACD0K0&>\0%1H."&L.TO+.= M:G 5? $%=?MQ55B',TU7W=XU61.JFTTR43IENDW3)4UH-! L SN:S^9P-
ZH(M 31&Y;:1&D;=L+)3)L0#/*??LRWM9;:QIQW84=DVK:&ZZ61Q=5I48C51\%G,F=N M\@<8DTU1LFK:U?
\RK_&K'T3U*9B,3\'D2=1D__A- M1LGQ>ZR/=4=G,JP/&1LGF:US3!L-X+PX)-_@9"K628/)@@O#9=V;\S1E\L5Q
MQLH;.K%_S&SIV_$IR^A"F,<6'))U^RM+^2)/VE'WL!#UJ'7["TRO&[>'59N+
MRY0M63JNNWHVJ9J!;=BL]06$7>2NNOP(QG&8'P$,RX,YP#B.A>7YG^;31^?C M,,Q;WXOT44X?
Y3B6#QE7'RR/GY/8RS_3)(FB.,96=#SV.AACZQ;'\.-7P[P! M \L#F?YLK?'=QBMD?QU@>[JO0K"9XI6(S11?:T#\ZP:,)/'O-
I8'&-@N8+4# M^?UYH*;\G"B"7<6\84\PCB0)AD M^FLTCI'5B>'CWQ_L*8FB)/$C@/D=1!&& MP-.((Y@#\(A452]!W?
>1V'SG@K7_^$;_0902P,$% @ ,X!L69>*NQS M $P(L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/ M:(7-
>=I3W;+T]!;X"O M.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_ M'_V!8I MT9^.(K\C]>
])NH>5M0_B6]L8/\^V(717TZE76VBE_\5V8+!F;5TK QZZS=1W M#F3MMP"A:;;%;'8Y;:4VV?MW^[;NW#0]L %4T-
9@82SXJN')_ZB/A^)1>[W2 MC0[/\VSXW4 F6FUTJ[]#/<]FF?!;^_2[=?J[-4$V2^5LT\RS?%?Q%5S0ZJ!X M&2&_R)4?
2H)7,VQPK9T/PQE#^Q(9'P%/WAWUP7[230"WD %^<[;O MM-G$9O NILEM#''8?
^^">.7^2QCM>JT5+*SJ6S!A%T<'300T?JL[GPDC6YAG M^U.$-+7XU00,DK@QNZ;PW'BG^-ZN ^(F,717&BO<33V
\T%^M*8&XZ$6 M^,O;1M?(48L/LI%&@4@@"P*R."'D7T4"61*0Y4D@EQ$'+TT@*P*R.B'D*)(7
M!.3%*2'+!/*2@+SDA;R5H7<@[%JL>J\->)]PO2:X7O-R+?NVE>XY@GF],1HO MDW$.4LKV. \D)^D=N)1-

CV(%J3'0,8+T@B^)>#>,C]^TF_/A<)/-M-7_W&C$CV[EPX(/3*IVW9]3$/>/%O%;*]3@LX%L7!TL:O)P4"K-1/F.'XKA8-M-7ISX#G*(3F[1-I6AW;7EPJ3$.3=]#)E#ER9G7<8KMGC?7^E=-&-4%TX)!-.D@1*6_D-MS.+X$^7FGIP.-8SH>APG"B?K-3A\'E-&RB$YLT3N8R%V<2<=)JW!2>SF82DP-M>A
I@>3,!KF3S^+1BSMPP^4Q5UUHK[#K^W%74R+)F4UR8[S&SA9?G*RQ=\6U-MPTAN#D9T06FD8-8(F2^,,L*"LDK!;)4C&8,XPX5?,Y)?02Y4N"5#Y0[C:%*2-M*9@E\W/NL_CJQ20\DS!ODXA9#V.
(Z6;@EDW+\OZQ6A2RBF8E7/,VO^"IIB4-M=0IFZQ#RCJ0I)J6>@ED]ARL_<;:-('4S[G'*/-6S>8Y-EQ-Q[3V$=,>$DD_)
M+!]ZNDQ7^B4EGY)[DXS$K%),2CXELWP.9_47'LN2W")C]L[/:\.7"2GQE"<3-MSWE<)J:8E'C*_U$\US_$,Q&W$G/,T?
BFQ%-RB^WB0:QIYB4A:K!0M/]&]D:UIA5U[?X%Q[+E6S4G1/Q:[>'7%W$39UU-MWS0?
L>P/\]G*>O^"=_]R^OT_4$L#!!0-(-#.-;%G]+-6EK@$-,$;-:-M->&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V;MNPD
0A>%707X-EIE9-M;A%0I:&-> $+EHLPV/)N%'C[("C@6"G2H#V5M;8_AM_LM:SKU"5Z5"?X_[0-MQ-[E5)WCO-
BGU'PX%]?[<"ICOV["^79E6[>G,MV6[ZG;H]Q'T(J>JNRW84T+]RE>IZ.
M[GZ0_FURT5MNYD6[W$CA<@BOJK01Z*^JM!'HK
MZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01Z6V>SA$!O-M0[V-0&]#O8U-;T.]C4!O0[V-0&]#O8U
;T.]C4!OCWI[-KT]ZNT)]/:HMR?0-MVZ/>GD!OW]GL)M#;H]Z>0&^/>OMWZAW3M0KQV?-8X_/?276ZW1N>C[\O'R<[
M[_@=9P=_[!:_4$L#!!0-(-#.-;%DF^H>GM0$-P;-3-6T-O;G1E-M;G1?5'EP97-=+GAM;,V9S6[",!"$7P7EBHBQG=(?
9>VUY9#7\!--B0BB2W;-M4'C[.N%':D6C(BIU+K$2[\Z,O=)WR?1M9\@-MG75N%E4>&\>&'-I0;5RL3;4
MA)U7T<$A#IU=C2M*XX:A(&)G'=J=GPT.?:\;-MLK;,:+!0UK^H.E2Q;<6H?K_=!VU&PO=&AE;64O
M=&AE;64Q+GAM;%!+-0(4-Q0-(-#.-;%FIW:NGS@4-/X>-8-M-"-@0T(-!X;"]W;W)K&PO=V]R:W-H-M965T&UL4$L!-A0#%
@-,X!L67],L8[=-@-#@H-!@-M-("!;A0-'AL+W=O&PO=V]R:W-H965T&UL-M4$L!-A0#%-@-,X!L6;U#GT>/!P-+R$-!@-("!\C$
M-'AL+W=OP%-"'$-&-M@(%O0->&PO=V]R:W-H965T&UL4$L!-A0#%-@-,X!L-M6:#V+/^/!-5Q$-!@-("!D48
'AL+W=O&UL4$L!-A0#%-M-@-,X!L6=!U-=^Z-@-1P<-!D-("!85,-'AL+W=O&UL4$L!-A0#%-@-,X!L6?]E_*6\-M"@-C24-!D
("!&PO=V]R:W-H965T&UL4$L!-A0#%-@-,X!L6:^"P*I<-P-,P@-!D-M-("!<'4-'AL+W=O0->&PO=V]R-M:W-H965T&UL
M4$L!-A0#%-@-,X!L6=];9>0/!@-)A$-!D-("!2(-M-'AL+W=O&PO=V]R:W-H965T&UL4$L!-A0#%-@-M,X!L652Z;%2!!-[1-!D
("!')$-'AL+W=O&PO=V]R:W-H965T&UL4$L!-A0#%-@-,X!L626-4H7&-@-M=0<-!D-("!G9L-'AL+W=O&PO=V]R:W-
H965T&UL4$L!-A0#%-@-,X!L6?;T]EJV-@-:-@-!D-M-("!+:@-'AL+W=O&PO=V]R:W-H-M965T&UL4$L!-M-A0#%-@-
,X!L65'>Q+;V-@-2-H-!D-("!N+@-'AL-M+W=O&PO=V]R:W-H965T&UL4$L!-A0#%-@-,X!L-M67I[R%/^-P-VA4-!D-("!&<4
'AL+W=O&PO=V]R:W-H965T&UL4$L!-A0#%-@-,X!L68'ELXH1!0-&PO=V]R:W-H965T&UL4$L!-A0#%-@-
,X!L64G8YJQI!0-Y"$-!D-M-("!AN-'AL+W=O&PO=V]R:W-H965T-M&UL4$L!-A0#-M%-@-,X!L6>H,UO_Z-P-%Q(-!D-("!%N\
'AL+W=O-M&PO=V]R:W-H965T-9-"-@8?W-M-!X;"]W;W)K&UL4$L!-A0#%-@-,X!L6??U-M$KDY-P-[A,-T-(-!\OL-'AL+W-
T>6QE&PO=V]R:V)O;VLN>&UL4$L!-A0#%-@-,X!L6?TLU:6N-M-0-P1L-!H-(-!E-0!-'AL+U]R96QS+W=OU-0-W!L-!,-M-(
!>@8!-%M#;VYT96YT7U1Y<&5S72YX;6Q02P4&-#8-@"Q#@-8-@!-#-end-XML-60-Show.js-IDEA:-XBRL-DOCUMENT-//
Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function()
{Show.LastAR.style.display='none'};Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var
d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}e.style.display=d;if(a.textContent)
{a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 191 232 1 false 40 0 false 7 false false R1.htm 995200090 - Document - Document and Entity Information Sheet
http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - Condensed Consolidated Balance Sheets Sheet
http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet
http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income Sheet
http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensi Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income Statements 4 false false R5.htm 995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet
http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity

Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 995200400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995210101 - Disclosure - Nature of business Sheet http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusiness Nature of business Notes 7 false false R8.htm 995210201 - Disclosure - Summary of significant accounting policies and basis of presentation Sheet http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation Summary of significant accounting policies and basis of presentation Notes 8 false false R9.htm 995210301 - Disclosure - Fair value measurements Sheet http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurements Fair value measurements Notes 9 false false R10.htm 995210401 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities Sheet http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketa Cash, cash equivalents, restricted cash, and available-for-sale marketable securities Notes 10 false false R11.htm 995210501 - Disclosure - Accrued expenses Sheet http://www.voyagertherapeutics.com/role/DisclosureAccruedExpenses Accrued expenses Notes 11 false false R12.htm 995210601 - Disclosure - Lease obligation Sheet http://www.voyagertherapeutics.com/role/DisclosureLeaseObligation Lease obligation Notes 12 false false R13.htm 995210701 - Disclosure - Commitments, contingencies and other liabilities Sheet http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilities Commitments, contingencies and other liabilities Notes 13 false false R14.htm 995210801 - Disclosure - Significant agreements Sheet http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreements Significant agreements Notes 14 false false R15.htm 995210901 - Disclosure - Stock-based compensation Sheet http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensation Stock-based compensation Notes 15 false false R16.htm 995211001 - Disclosure - Net (loss) income per share Sheet http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShare Net (loss) income per share Notes 16 false false R17.htm 995211101 - Disclosure - Underwritten public offering Sheet http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOffering Underwritten public offering Notes 17 false false R18.htm 995211201 - Disclosure - Related party transactions Sheet http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactions Related party transactions Notes 18 false false R19.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 19 false false R20.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm 99920202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) Sheet http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation Summary of significant accounting policies and basis of presentation (Policies) Policies 21 false false R22.htm 99930303 - Disclosure - Fair value measurements (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsTables Fair value measurements (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurements 22 false false R23.htm 99930403 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketa Cash, cash equivalents, restricted cash, and available-for-sale marketable securities (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketa 23 false false R24.htm 99930503 - Disclosure - Accrued expenses (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesTables Accrued expenses (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureAccruedExpenses 24 false false R25.htm 99930703 - Disclosure - Commitments, contingencies and other liabilities (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesTables Commitments, contingencies and other liabilities (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilities 25 false false R26.htm 99930803 - Disclosure - Significant agreements (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsTables Significant agreements (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreements 26 false false R27.htm 99930903 - Disclosure - Stock-based compensation (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables Stock-based compensation (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensation 27 false false R28.htm 99931003 - Disclosure - Net (loss) income per share (Tables) Sheet http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareTables Net (loss) income per share (Tables) Tables http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShare 28 false false R29.htm 99940101 - Disclosure - Nature of business (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails Nature of business (Details) Details http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusiness 29 false false R30.htm 99940301 - Disclosure - Fair value measurements - Assets and liabilities measured on a recurring basis - (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri Fair value measurements - Assets and liabilities measured on a recurring basis - (Details) Details 30 false false R31.htm 99940401 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, cash equivalents, and marketable securities (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketa Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, cash equivalents, and marketable securities (Details) Details 31 false false R32.htm 99940402 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarketa Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details) Details 32 false false R33.htm 99940501 - Disclosure - Accrued expenses (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails Accrued expenses

(Details) Details http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesTables 33 false false R34.htm 99940601 - Disclosure - Lease obligation (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails Lease obligation (Details) Details http://www.voyagertherapeutics.com/role/DisclosureLeaseObligation 34 false false R35.htm 99940701 - Disclosure - Commitments, contingencies, and other liabilities (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails Commitments, contingencies, and other liabilities (Details) Details 35 false false R36.htm 99940801 - Disclosure - Significant Agreements - Narratives (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails Significant Agreements - Narratives (Details) Details 36 false false R37.htm 99940802 - Disclosure - Significant Agreements - Novartis Option and License Agreement & Stock Purchase Agreement (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStockl Significant Agreements - Novartis Option and License Agreement & Stock Purchase Agreement (Details) Details 37 false false R38.htm 99940803 - Disclosure - Significant Agreements - Neurocrine Collaboration Agreements (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDetail Significant Agreements - Neurocrine Collaboration Agreements (Details) Details 38 false false R39.htm 99940804 - Disclosure - Significant Agreements - Neurocrine Collaboration receivables and contract liabilities (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndCo Significant Agreements - Neurocrine Collaboration receivables and contract liabilities (Details) Details 39 false false R40.htm 99940901 - Disclosure - Stock-based compensation - Compensation expense (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails Stock-based compensation - Compensation expense (Details) Details 40 false false R41.htm 99940902 - Disclosure - Stock-based compensation - Restricted Stock - (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails Stock-based compensation - Restricted Stock - (Details) Details 41 false false R42.htm 99940903 - Disclosure - Stock-based compensation - Stock Options - (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails Stock-based compensation - Stock Options - (Details) Details 42 false false R43.htm 99941001 - Disclosure - Net (loss) income per share (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareDetails Net (loss) income per share (Details) Details http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareTables 43 false false R44.htm 99941002 - Disclosure - Net (loss) income per share - Basic and diluted weighted average shares outstanding (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareBasicAndDilutedWeightedAverageShares Net (loss) income per share - Basic and diluted weighted average shares outstanding (Details) Details http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareTables 44 false false R45.htm 99941101 - Disclosure - Underwritten public offering (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails Underwritten public offering (Details) Details http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOffering 45 false false R46.htm 99941201 - Disclosure - Related party transactions (Details) Sheet http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails Related party transactions (Details) Details http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactions 46 false false All Reports Book All Reports vygr-20240930.xsd vygr-20240930_cal.xml vygr-20240930_def.xml vygr-20240930_lab.xml vygr-20240930_pre.xml vygr-20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vygr-20240930x10q.htm": { "nsprefix": "vygr", "nsuri": "http://www.voyagertherapeutics.com/20240930", "dts": { "schema": { "local": ["vygr-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["vygr-20240930_cal.xml"] }, "definitionLink": { "local": ["vygr-20240930_def.xml"] }, "labelLink": { "local": ["vygr-20240930_lab.xml"] }, "presentationLink": { "local": ["vygr-20240930_pre.xml"] }, "inline": { "local": ["vygr-20240930x10q.htm"] } }, "keyStandard": 197, "keyCustom": 35, "axisStandard": 16, "axisCustom": 1, "memberStandard": 21, "memberCustom": 17, "hidden": { "total": 15, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 8, "http://xbrl.sec.gov/ecd/2024": 2 }, "contextCount": 191, "entityCount": 1, "segmentCount": 40, "elementCount": 467, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 558, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 6 }, "report": { "R1": { "role": "http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements",

"order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R3": { "role": "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_sYBu54XDg02B9AkLmz4-Rw", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_sYBu54XDg02B9AkLmz4-Rw", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens "longName": "995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R5": { "role": "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2eEUuRJFE0Ki2Xc6W0Sw5Q", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ymQdRRwLNk6PnOJXf-E8lg", "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R6": { "role": "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusiness", "longName": "995210101 - Disclosure - Nature of business", "shortName": "Nature of business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentatio "longName": "995210201 - Disclosure - Summary of significant accounting policies and basis of presentation", "shortName": "Summary of significant accounting policies and basis of presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-

gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurements", "longName": "995210301 - Disclosure - Fair value measurements", "shortName": "Fair value measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "longName": "995210401 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities", "shortName": "Cash, cash equivalents, restricted cash, and available-for-sale marketable securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpenses", "longName": "995210501 - Disclosure - Accrued expenses", "shortName": "Accrued expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligation", "longName": "995210601 - Disclosure - Lease obligation", "shortName": "Lease obligation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilities", "longName": "995210701 - Disclosure - Commitments, contingencies and other liabilities", "shortName": "Commitments, contingencies and other liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreements", "longName": "995210801 - Disclosure - Significant agreements", "shortName": "Significant agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensation", "longName": "995210901 - Disclosure - Stock-based compensation", "shortName": "Stock-based compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":

"Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShare", "longName": "995211001 - Disclosure - Net (loss) income per share", "shortName": "Net (loss) income per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOffering", "longName": "995211101 - Disclosure - Underwritten public offering", "shortName": "Underwritten public offering", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "vygr:UnderwrittenPublicOfferingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "vygr:UnderwrittenPublicOfferingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactions", "longName": "995211201 - Disclosure - Related party transactions", "shortName": "Related party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentatio "longName": "99920202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies)", "shortName": "Summary of significant accounting policies and basis of presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsTables", "longName": "99930303 - Disclosure - Fair value measurements (Tables)", "shortName": "Fair value measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "longName": "99930403 - Disclosure - Cash, cash equivalents, restricted cash, and available-for-sale marketable securities (Tables)", "shortName": "Cash, cash equivalents, restricted cash, and available-for-sale marketable securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables",

"order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesTables", "longName": "99930503 - Disclosure - Accrued expenses (Tables)", "shortName": "Accrued expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesTables", "longName": "99930703 - Disclosure - Commitments, contingencies and other liabilities (Tables)", "shortName": "Commitments, contingencies and other liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:OtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsTables", "longName": "99930803 - Disclosure - Significant agreements (Tables)", "shortName": "Significant agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_vygr_NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborati "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_vygr_NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborati "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables", "longName": "99930903 - Disclosure - Stock-based compensation (Tables)", "shortName": "Stock-based compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareTables", "longName": "99931003 - Disclosure - Net (loss) income per share (Tables)", "shortName": "Net (loss) income per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_8LzUHnGMMUihNkv50_vBoQ", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "longName": "99940101 - Disclosure - Nature of business (Details)", "shortName": "Nature of business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-5",

"ancestors": ["p", "us-gaap:NatureOfOperations", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R30": { "role": "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri "longName": "99940301 - Disclosure - Fair value measurements - Assets and liabilities measured on a recurring basis - (Details)", "shortName": "Fair value measurements - Assets and liabilities measured on a recurring basis - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_njAnOSw_lk29Uyt_tBQKvw", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R31": { "role": "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "longName": "99940401 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, cash equivalents, and marketable securities (Details)", "shortName": "Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Cash, cash equivalents, and marketable securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "vygr:MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R32": { "role": "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "longName": "99940402 - Disclosure - Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details)", "shortName": "Cash, cash equivalents, restricted cash and available-for-sale marketable securities - Reconciliation of cash, cash equivalents, and restricted cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails", "longName": "99940501 - Disclosure - Accrued expenses (Details)", "shortName": "Accrued expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails", "longName": "99940601 - Disclosure - Lease obligation (Details)", "shortName": "Lease obligation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:SubleaseIncome", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["us-gaap:SubleaseIncome", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R35": { "role": "http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails", "longName": "99940701 - Disclosure - Commitments, contingencies, and other liabilities (Details)", "shortName": "Commitments, contingencies, and other liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:OtherLiabilitiesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1,

"baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails", "longName": "99940801 - Disclosure - Significant Agreements - Narratives (Details)", "shortName": "Significant Agreements - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc "longName": "99940802 - Disclosure - Significant Agreements - Novartis Option and License Agreement & Stock Purchase Agreement (Details)", "shortName": "Significant Agreements - Novartis Option and License Agreement & Stock Purchase Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_srt_CounterpartyNameAxis_vygr_NovartisPharmaAgMember_us-gaap_TypeOfArrangementAxis_vygr_NovartisCollaborationAgreement2023Member_AV10rAGD90WWCrw5cKaJ2g", "name": "vygr:CollaborativeArrangementNumberOfPrograms", "unitRef": "Unit_Standard_Program_z4VHT8sdTEWb3YCxGjh5eg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R38": { "role": "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "longName": "99940803 - Disclosure - Significant Agreements - Neurocrine Collaboration Agreements (Details)", "shortName": "Significant Agreements - Neurocrine Collaboration Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_3_31_2024_srt_CounterpartyNameAxis_vygr_NeurocrineBiosciencesIncMember_us-gaap_TypeOfArrangementAxis_vygr_NeurocrineCollaborativeAgreementTwentyNineteenMember_N86cv1zXmk2t-zv5kTXQ_w", "name": "vygr:MilestonePayments", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R39": { "role": "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC "longName": "99940804 - Disclosure - Significant Agreements - Neurocrine Collaboration receivables and contract liabilities (Details)", "shortName": "Significant Agreements - Neurocrine Collaboration receivables and contract liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2023_wCSWQ_s-VECLrFFx7I6Oeg", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_TypeOfArrangementAxis_vygr_NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborati "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R40": { "role": "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "longName": "99940901 - Disclosure - Stock-based compensation - Compensation expense (Details)", "shortName": "Stock-based compensation - Compensation expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_iTfITRk0tkKBYiM8uKQUnQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCosts "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R41": { "role": "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "longName": "99940902 - Disclosure - Stock-based compensation - Restricted Stock - (Details)", "shortName": "Stock-based compensation - Restricted Stock - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA",

"xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Wm14g6XU1E2v7S1jzxoWNg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonve "unitRef": "Unit_Standard_shares_JgAfG4QeM02tz9-QhUViUg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R42": { "role": "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "longName": "99940903 - Disclosure - Stock-based compensation - Stock Options - (Details)", "shortName": "Stock-based compensation - Stock Options - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_12_31_2023_wCSWQ_s-VECLrFFx7I6Oeg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_JgAfG4QeM02tz9-QhUViUg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_wCSWQ_s-VECLrFFx7I6Oeg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_JgAfG4QeM02tz9-QhUViUg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareDetails", "longName": "99941001 - Disclosure - Net (loss) income per share (Details)", "shortName": "Net (loss) income per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_JgAfG4QeM02tz9-QhUViUg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_JgAfG4QeM02tz9-QhUViUg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareBasicAndDilutedWeightedAverageShare "longName": "99941002 - Disclosure - Net (loss) income per share - Basic and diluted weighted average shares outstanding (Details)", "shortName": "Net (loss) income per share - Basic and diluted weighted average shares outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_BZNN8_M6bUanOedNHiZdXg", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails", "longName": "99941101 - Disclosure - Underwritten public offering (Details)", "shortName": "Underwritten public offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_sYBu54XDg02B9AkLmz4-Rw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_9_2024_To_1_9_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_JOchZz2xcE-NAE1wY2whWw", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_JgAfG4QeM02tz9-QhUViUg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "vygr:UnderwrittenPublicOfferingTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } }, "R46": { "role": "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99941201 - Disclosure - Related party transactions (Details)", "shortName": "Related party transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_9_30_2024_YkQ6giVBhUy9G3lQaExYDQ", "name": "us-gaap:ContractWithCustomerAssetNetCurrent", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"

], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_vygr_DrDinahSahMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_QRDUdcRopUK4V7Ak9XkLqg", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "Unit_Standard_USD_HtomFABm3UaSkpWUGJAckA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "vygr-20240930x10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of significant accounting policies and basis of presentation" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureAccruedExpenses"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued expenses", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": ["r282"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts payable", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r33", "r542"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premiums and discounts on marketable securities", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r57"] }, "vygr_AccruedGoodsAndServicesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "AccruedGoodsAndServicesCurrent", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the amount of expenses incurred but not paid for goods and services, due within one year or the normal operating cycle, if longer.", "label": "Accrued Goods And Services Current", "terseLabel": "Accrued goods and services" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r35"] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Professional services", "terseLabel": "Professional services", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r35"] }, "vygr_AccruedResearchAndDevelopmentCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "AccruedResearchAndDevelopmentCostsCurrent", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs . Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Research And Development Costs Current", "verboseLabel": "Research and development costs" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r15", "r16", "r48", "r95", "r410", "r437", "r438"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Loss", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to

owners." } } }, "auth_ref": ["r1", "r8", "r16", "r305", "r308", "r354", "r433", "r434", "r657", "r658", "r659", "r664", "r665", "r666", "r667"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r596"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid in capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r43", "r542", "r741"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r446", "r664", "r665", "r666", "r667", "r691", "r742"] }, "vygr_AdditionsToContractWithCustomerAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "AdditionsToContractWithCustomerAssets", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC], "lang": { "en-us": { "role": { "documentation": "Amount of increase to contract with customer assets during the reporting period.", "label": "Additions To Contract With Customer Assets", "terseLabel": "Additions" } } }, "auth_ref": [] }, "vygr_AdditionsToContractWithCustomerLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "AdditionsToContractWithCustomerLiabilities", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC], "lang": { "en-us": { "role": { "documentation": "Amount of increase to contract with customer liabilities during the reporting period.", "label": "Additions To Contract With Customer Liabilities", "terseLabel": "Additions" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r609"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r609"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r609"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r609"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitic { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition", "terseLabel": "Stock based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by operating activities:", "terseLabel": "Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:" } } }, "auth_ref": [] }, "vygr_AggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "AggregateIntrinsicValueAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r642"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r568", "r578", "r588", "r620"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r571", "r581", "r591", "r623"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember",

"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r643"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r609"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r616"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r572", "r582", "r592", "r616", "r624", "r628", "r636"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r634"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Stock-based compensation.", "verboseLabel": "Stock-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r276", "r281"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "vygr_AmountOfPremiumOnSharesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "AmountOfPremiumOnSharesIssued", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "documentation": "Represents the amount of premium on shares issued", "label": "Amount of Premium On Shares Issued", "terseLabel": "Amount of premium" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share (in common stock equivalent shares)", "terseLabel": "Antidilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r146"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r20"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r20"] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "label": "Area of Real Estate Property", "terseLabel": "Area of additional facility leased", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsTables",

"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r296"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r67", "r76", "r94", "r114", "r150", "r152", "r157", "r158", "r194", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r298", "r302", "r337", "r405", "r468", "r517", "r518", "r542", "r559", "r685", "r686", "r704"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets Abstract", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r91", "r96", "r114", "r194", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r298", "r302", "r337", "r542", "r685", "r686", "r704"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current Abstract", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure, Total", "totalLabel": "Total money market funds and marketable securities", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r315", "r316", "r531"] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Marketable securities, unrealized gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r167"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Marketable securities, unrealized losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r168"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Available-for-sale Debt Securities, Amortized Cost Basis", "terseLabel": "Marketable securities, Amortized cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r164", "r202", "r404"] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Amortized Cost Basis [Abstract]", "terseLabel": "Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Available-for-sale Securities, Debt Securities", "terseLabel": "Marketable securities, fair value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r165", "r202", "r315", "r398", "r531", "r534", "r674", "r695", "r696", "r697"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r631"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r632"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]",

"terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r627"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r627"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r627"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r627"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r627"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r627"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r630"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r629"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r628"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r628"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentatio], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash, cash equivalents, restricted cash, and available-for-sale marketable securities" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r18", "r93", "r508"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r93"] }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsDisclosureTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "Cash, cash equivalents, restricted cash, and available-for-sale marketable securities", "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and

equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify." } } }, "auth_ref": ["r93", "r408"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "terseLabel": "Cash and cash equivalents, fair value", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r693", "r694"] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Line Items]", "verboseLabel": "Cash, cash equivalents, and restricted cash", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents, and marketable securities", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r656"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r18", "r55", "r112"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeR { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateE "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r55"] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposits", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": ["r7", "r553", "r554", "r555", "r556"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r607"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":

"http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r604"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r602"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r26"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Price per warrant", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r229"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Number of warrants issued to purchase common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r229"] }, "vygr_ClassOfWarrantsAndRightsOutstandingNumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "ClassOfWarrantsAndRightsOutstandingNumberOfWarrantsIssued", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued.", "label": "Class of Warrants And Rights Outstanding, Number of Warrants Issued", "terseLabel": "Issuance of Pre-Funded Warrants" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r608"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r608"] }, "vygr_CollaborativeArrangementAggregateMaximumMilestonePaymentsToBeReceivedFromCollaborativePartner": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "CollaborativeArrangementAggregateMaximumMilestonePaymentsToBeReceivedFromCollaborativePartner", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "documentation": "In the aggregate, the maximum milestone payments to be received from the collaborative partner.", "label": "Collaborative Arrangement Aggregate Maximum Milestone Payments To Be Received From Collaborative Partner", "verboseLabel": "Aggregate maximum milestone payments to be received from collaborative partner" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreements"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Significant agreements", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": ["r80", "r82", "r88"] }, "vygr_CollaborativeArrangementNumberOfPrograms": { "xbrltype": "integerItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "CollaborativeArrangementNumberOfPrograms", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "documentation": "Represents the number of programs under collaborative

arrangement.", "label": "Collaborative Arrangement Number of Programs", "terseLabel": "Number of collaboration programs" } } }, "auth_ref": [] }, "vygr_CollaborativeArrangementUpfrontPaymentToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "CollaborativeArrangementUpfrontPaymentToBeReceived", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "documentation": "Represents the amount of upfront payment to be received under collaborative arrangement.", "label": "Collaborative Arrangement Upfront Payment to be Received", "terseLabel": "Upfront payment" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Commitments contingencies and other liabilities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r296"] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Commercial paper", "terseLabel": "Commercial paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r62", "r213", "r553", "r554", "r555", "r556"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (see note 7)", "terseLabel": "Commitments and contingencies (see note 7)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r39", "r68", "r407", "r455"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments, contingencies and other liabilities" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilities"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments, contingencies and other liabilities", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r61", "r211", "r212", "r505", "r681", "r682"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock", "terseLabel": "Common stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r549", "r550", "r551", "r553", "r554", "r555", "r556", "r664", "r665", "r667", "r691", "r740", "r742"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "verboseLabel": "Par value of common stock (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r42"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r42", "r456"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r42"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock share

outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r9", "r42", "r456", "r474", "r742", "r743"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value: 120,000,000 shares authorized at June 30, 2019 and December 31, 2018; 36,677,608 and 32,364,895 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively", "terseLabel": "Common stock, $0.001 par value: 120,000,000 shares authorized at September 30, 2024 and December 31, 2023; 54,542,048 and 44,038,333 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r42", "r409", "r542"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r613"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r612"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r614"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r611"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens
], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive (loss) income", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r17", "r101", "r103", "r107", "r399", "r420", "r421"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens
], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive (loss) income:" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentatio
], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r30", "r512"] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsTables"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of collaboration receivables and contract liabilities", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r687"] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails",
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, Net, Current", "periodEndLabel": "Related party collaboration receivables, ending balance", "periodStartLabel": "Related party collaboration receivables, beginning balance", "terseLabel": "Related party collaboration receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": ["r231", "r233", "r236"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC
], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "periodEndLabel": "Deferred revenue, ending balance", "periodStartLabel": "Deferred revenue, beginning balance", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } },

"auth_ref": ["r231", "r232", "r236"] }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract", "terseLabel": "Cumulative catch up of revenue recognized", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r522"] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "verboseLabel": "Deferred revenue, current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r231", "r232", "r236"] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Noncurrent", "verboseLabel": "Deferred revenue, non-current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r231", "r232", "r236"] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Revenue Recognized", "negatedLabel": "Deductions", "verboseLabel": "Contract with customer liability revenue recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r237"] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Corporate bonds", "terseLabel": "Corporate bonds", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r117", "r118", "r223", "r227", "r361", "r379", "r403", "r509", "r511"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "terseLabel": "Debt securities, unrealized loss position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": ["r77", "r204", "r519"] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Debt securities", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } }, "auth_ref": ["r24", "r551", "r744"] }, "vygr_DeductionsToContractWithCustomerAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "DeductionsToContractWithCustomerAssets", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC], "lang": { "en-us": { "role": { "documentation": "Amount of decrease to contract with customer assets during the reporting period.", "label": "Deductions To Contract With Customer Assets", "negatedTerseLabel": "Deductions" } } }, "auth_ref": [] }, "vygr_DepositsAndOtherNonCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "DepositsAndOtherNonCurrentAssets", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Deposits and other assets that are expected to be realized or consumed after one year.",

"label": "Deposits And Other Non-Current Assets", "terseLabel": "Deposits and other non-current assets" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r5", "r25"] }, "vygr_DevelopmentRegulatoryAndCommercializationMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "DevelopmentRegulatoryAndCommercializationMilestoneMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "documentation": "Information pertaining to development, regulatory, and commercialization milestones achieved.", "label": "Development, regulatory and commercialization milestone" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-based compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r245", "r249", "r277", "r278", "r280", "r527"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-based compensation" } } }, "auth_ref": [] }, "vygr_DiscoveryProgramThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "DiscoveryProgramThreeMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to discovery program three.", "label": "Discovery program 3" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r563"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r595"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "vygr_DrDinahSahMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "DrDinahSahMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "Person designated as former Chief Scientific Officer, Dr. Dinah Sah, Ph.D.", "label": "Dr. Sah" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r606"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net (loss) income per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareBasicAndDilutedWeightedAverageShare "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net (loss) income per share, basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r108", "r124", "r125", "r126", "r127", "r128", "r129",

"r134", "r137", "r143", "r144", "r145", "r149", "r292", "r295", "r312", "r313", "r400", "r422", "r514"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareBasicAndDilutedWeightedAverageShare "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net (loss) income per share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r108", "r124", "r125", "r126", "r127", "r128", "r129", "r137", "r143", "r144", "r145", "r149", "r292", "r295", "r312", "r313", "r400", "r422", "r514"] }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareBasicAndDilutedWeightedAverageShare], "lang": { "en-us": { "role": { "label": "Earnings Per Share Reconciliation [Abstract]", "terseLabel": "Numerator:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net (loss) income per share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r133", "r146", "r147", "r148"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesDetails"], "lang": { "en-us": { "role": { "label": "Employee compensation costs", "terseLabel": "Employee compensation costs", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r35"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r279"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodFo { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRec "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Remaining weighted-average remaining vesting period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r279"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r561"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": {

"label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] },
"dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": {
"label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] },
"dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": {
"label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r561"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": {
"label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": {
"xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory",
"presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": {
"en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r561"] },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": {
"label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype":
"yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent",
"presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": {
"en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r645"] }, "dei_EntityRegistrantName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName",
"presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": {
"en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r561"] },
"dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityShellCompany", "presentation": [
"http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": {
"label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r561"] }, "dei_EntitySmallBusiness": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": {
"label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r561"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": {
"label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r561"]
}, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
"en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r600"] },
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r641"] },
"ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role":
{ "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [
"r641"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r641"] },
"us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EquityComponentDomain", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"],
"lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the

parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r9", "r89", "r104", "r105", "r106", "r119", "r120", "r121", "r123", "r128", "r130", "r132", "r151", "r195", "r196", "r207", "r230", "r286", "r287", "r289", "r290", "r291", "r293", "r294", "r295", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r347", "r354", "r418", "r433", "r434", "r435", "r446", "r498"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r610"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r568", "r578", "r588", "r620"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r565", "r575", "r585", "r617"] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r616"] }, "vygr_Facility75HaydenAvenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "Facility75HaydenAvenueMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the lease at 75 Hayden Avenue", "label": "75 Hayden Avenue", "terseLabel": "75 Hayden avenue" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r224", "r238", "r239", "r240", "r241", "r242", "r243", "r314", "r316", "r317", "r318", "r319", "r328", "r329", "r331", "r367", "r368", "r369", "r520", "r521", "r524", "r525", "r526", "r531", "r534"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r315", "r316", "r317", "r319", "r531", "r696", "r699"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair value measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r324", "r326", "r327", "r328", "r331", "r332", "r333", "r334", "r335", "r397", "r531", "r535"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Level 1", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r224", "r238", "r243", "r316", "r329", "r367", "r524", "r525", "r526", "r531"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Level 2", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r224", "r238", "r243", "r316", "r317", "r329", "r368", "r520", "r521", "r524", "r525", "r526", "r531"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri

```
], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r315", "r316", "r317", "r319", "r531", "r696", "r699" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r224", "r238", "r239", "r240", "r241", "r242", "r243", "r314", "r316", "r317", "r318", "r319", "r328", "r329", "r331", "r367", "r368", "r369", "r520", "r521", "r524", "r525", "r526", "r531", "r534" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurements, Recurring", "terseLabel": "Fair value, measurements, recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r531", "r693", "r694", "r695", "r696", "r697", "r699" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r320", "r321", "r323", "r324", "r325", "r330" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r325", "r330" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r197", "r198", "r199", "r200", "r201", "r203", "r205", "r206", "r225", "r228", "r310", "r336", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r419", "r519", "r531", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r543", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r676", "r677", "r678", "r679", "r692", "r695", "r696", "r697", "r698", "r699" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r572", "r582", "r592", "r624" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r572", "r582", "r592", "r624" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r572", "r582", "r592", "r624" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r572", "r582", "r592", "r624" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r572", "r582", "r592", "r624" ] }, "vygr_FormerExecutivesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "FormerExecutivesMember", "presentation": [ "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to former executives of the entity.", "label": "Former Executives" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
```

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r605"] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of fixed assets", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": ["r5"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r51", "r478"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r51"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "(Loss) income before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r49", "r71", "r75", "r401", "r415", "r516", "r517", "r669", "r670", "r671", "r672", "r673"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r208", "r209", "r210", "r321", "r325", "r330", "r431", "r432", "r483", "r506", "r533", "r711"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r209", "r210", "r321", "r325", "r330", "r431", "r432", "r483", "r506", "r533", "r711"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "verboseLabel": "Income tax provision (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r78", "r86", "r131", "r132", "r150", "r155", "r158", "r284", "r285", "r288", "r423", "r528"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r4"] }, "vygr_IncreaseDecreaseInCollaborationReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "IncreaseDecreaseInCollaborationReceivables", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from Collaboration agreements.", "label": "Increase (Decrease) in

Collaboration Receivables", "negatedLabel": "Related party collaboration receivable" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r395", "r661"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r646", "r661"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r4"] }, "vygr_IncreaseDecreaseInRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "IncreaseDecreaseInRightOfUseAssets", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in operating lease, right-of-use assets.", "label": "Increase Decrease In Right Of Use Assets", "negatedLabel": "Operating lease, right-of-use asset" } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareBasicAndDilutedWeightedAverageShare], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Common stock options and restricted stock units", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r138", "r139", "r140", "r145", "r248"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r572", "r582", "r592", "r616", "r624", "r628", "r636"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r634"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r564", "r640"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r564", "r640"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r564", "r640"] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "Interest income", "terseLabel": "Interest income", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r517", "r660", "r670"] }, "us-gaap_InvestmentsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosureAbstract", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Fair Value Disclosure [Abstract]", "terseLabel": "Fair Value" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Lease obligation" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureLeaseObligation"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease obligation", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r346"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [

"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r14", "r34", "r35", "r36", "r37", "r38", "r39", "r40", "r114", "r194", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r299", "r302", "r303", "r337", "r454", "r515", "r559", "r685", "r704", "r705"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r47", "r69", "r412", "r542", "r663", "r680", "r700"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity Abstract", "terseLabel": "Liabilities and stockholders' equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r36", "r92", "r114", "r194", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r299", "r302", "r303", "r337", "r542", "r685", "r704", "r705"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current Abstract", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri
], "lang": { "en-us": { "role": { "label": "Marketable Securities.", "terseLabel": "Marketable securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": ["r70", "r655"] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current.", "terseLabel": "Marketable securities, current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r655"] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket
], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table Text Block]", "terseLabel": "Schedule of money market funds and marketable securities", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r608"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r608"] }, "vygr_MilestoneAchievementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "MilestoneAchievementAxis", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc
], "lang": { "en-us": { "role": { "documentation": "Information by categories of milestones achieved.", "label": "Milestone Achievement [Axis]" } } }, "auth_ref": [] }, "vygr_MilestoneAchievementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "MilestoneAchievementDomain", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc
], "lang": { "en-us": { "role": { "documentation": "Categories of milestones achieved.", "label": "Milestone Achievement [Domain]" } } }, "auth_ref": [] }, "vygr_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "MilestonePayments", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta
], "lang": { "en-us": { "role": { "documentation": "Represents the amount of cash flow on milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments" } } }, "auth_ref": [] }, "vygr_MiscellaneousOtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "MiscellaneousOtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of miscellaneous liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Miscellaneous Other Liabilities Noncurrent", "terseLabel": "Other" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed

for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r627"] }, "vygr_MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "documentation": "Represents the value of money market funds and marketable securities on amortized cost basis.", "label": "Money Market Funds And Marketable Securities, Amortized Cost Basis", "totalLabel": "Total money market funds and marketable securities" } } }, "auth_ref": [] }, "vygr_MoneyMarketFundsAndMarketableSecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "MoneyMarketFundsAndMarketableSecuritiesFairValue", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "documentation": "Represents the fair value of money market funds and marketable securities.", "label": "Money Market Funds And Marketable Securities Fair Value", "terseLabel": "Total money market funds and marketable securities" } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Money market funds", "terseLabel": "Money market funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r689"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r635"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r609"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusiness"], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of business", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r79", "r87"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r111"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flow from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r111"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flow from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash (used in) provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r55", "r56", "r57"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [

"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flow from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "verboseLabel": "Net income (loss)", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r50", "r57", "r72", "r90", "r99", "r102", "r106", "r114", "r122", "r124", "r125", "r126", "r127", "r128", "r131", "r132", "r141", "r194", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r292", "r295", "r313", "r337", "r417", "r476", "r496", "r497", "r557", "r685"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareBasicAndDilutedWeightedAverageShare], "lang": { "en-us": { "role": { "label": "Net loss attributable to common stockholders", "terseLabel": "Net (loss) income", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": ["r109", "r124", "r125", "r126", "r127", "r134", "r135", "r142", "r145", "r295"] }, "vygr_NeurocrineBiosciencesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "NeurocrineBiosciencesIncMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Neurocrine Biosciences Inc.", "label": "Neurocrine" } } }, "auth_ref": [] }, "vygr_NeurocrineCollaborativeAgreementTwentyNineteenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "NeurocrineCollaborativeAgreementTwentyNineteenMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2019 Neurocrine collaboration agreement.", "label": "2019 Neurocrine Collaborative Agreement", "verboseLabel": "Neurocrine Collaborative Agreement 2019" } } }, "auth_ref": [] }, "vygr_NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborativeAgreementTwentyNineteenM { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborativeAgreementTwentyNineteenMeml "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsTables"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Neurocrine collaborative agreements for 2023 and 2019.", "label": "2023 Neurocrine Collaborative Agreement and 2019 Neurocrine Collaborative Agreement" } } }, "auth_ref": [] }, "vygr_NeurocrineCollaborativeAgreementTwentyTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "NeurocrineCollaborativeAgreementTwentyTwentyThreeMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2023 Neurocrine collaboration agreement.", "label": "2023 Neurocrine Collaborative Agreement", "verboseLabel": "Neurocrine Collaborative Agreement 2023" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentatio], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r608"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r572", "r582", "r592", "r616", "r624"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r599"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r598"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r616"] }, "vygr_NonProfitAgreementMember": { "xbrltype": "domainItemType", "nsuri":

"http://www.voyagertherapeutics.com/20240930", "localname": "NonProfitAgreementMember", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails"],
"lang": { "en-us": { "role": { "documentation": "Agreement made with a non-profit organization.", "label": "Non-profit organization agreement" } } }, "auth_ref": [] }, "vygr_NonProfitOrganizationMilestonePaymentLiability": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname":
"NonProfitOrganizationMilestonePaymentLiability", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails"],
"lang": { "en-us": { "role": { "documentation": "Reflects the value of the milestone payment received from the non-profit organization recognized as a liability as it is probable that the Company will repay the amount.", "label": "Non Profit Organization Milestone Payment Liability", "terseLabel": "Milestone payment liability" } } }, "auth_ref": [] },
"vygr_NonProfitOrganizationResearchAndDevelopmentMaximumFundingCapacity": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname":
"NonProfitOrganizationResearchAndDevelopmentMaximumFundingCapacity", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails"],
"lang": { "en-us": { "role": { "documentation": "Reflects the amount of maximum funding available from non-profit organization, for research and development under arrangement.", "label": "Non Profit Organization Research And Development Maximum Funding Capacity", "terseLabel": "Maximum funding" } } }, "auth_ref": [] },
"vygr_NonProfitOrganizationResearchAndDevelopmentMultiple": { "xbrltype": "decimalItemType", "nsuri":
"http://www.voyagertherapeutics.com/20240930", "localname":
"NonProfitOrganizationResearchAndDevelopmentMultiple", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails"],
"lang": { "en-us": { "role": { "documentation": "Reflects the multiple to be used for future funding following successful development and commercialization.", "label": "Non Profit Organization Research And Development Multiple", "terseLabel": "Funding multiple" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag",
"presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label":
"Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } },
"auth_ref": ["r635"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [
"r635"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens
], "lang": { "en-us": { "role": { "label": "Interest and Debt Expense", "totalLabel": "Total other income, net",
"documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r52"]
}, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens
], "lang": { "en-us": { "role": { "label": "Interest and Debt Expense [Abstract]", "terseLabel": "Other income:" } } },
"auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": {
"label": "Summary of status and changes in unvested restricted stock", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": ["r13"] },
"vygr_NovartisCollaborationAgreement2023Member": { "xbrltype": "domainItemType", "nsuri":
"http://www.voyagertherapeutics.com/20240930", "localname": "NovartisCollaborationAgreement2023Member",
"presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"],
"lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to 2023 Novartis Collaboration Agreement.", "label": "Novartis Collaboration Agreement 2023 [Member]", "terseLabel": "2023 Novartis Collaboration Agreement" } } }, "auth_ref": [] }, "vygr_NovartisPharmaAgMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname":
"NovartisPharmaAgMember", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails",
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc
], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Novartis Pharma, AG.",
"label": "Novartis Pharma, AG" } } }, "auth_ref": [] }, "vygr_NumberOfSharesAgreedToBeIssued": { "xbrltype":
"sharesItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname":
"NumberOfSharesAgreedToBeIssued", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc
], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares agreed to be issued.", "label":
"Number of Shares Agreed to be Issued", "terseLabel": "Shares of common stock" } } }, "auth_ref": [] },
"vygr_NumberOfSharesAgreedToBeIssuedAggregatePurchasePrice": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.voyagertherapeutics.com/20240930", "localname":
"NumberOfSharesAgreedToBeIssuedAggregatePurchasePrice", "crdr": "debit", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc
], "lang": { "en-us": { "role": { "documentation": "Represents the aggregate purchase price pf number of shares agreed to be issued.", "label": "Number of Shares Agreed to be Issued, Aggregate Purchase Price", "terseLabel":
"Aggregate purchase price" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens
], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses",
"documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling,

general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Operating (loss) income", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r75", "r516", "r669", "r670", "r671", "r672", "r673"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r702"] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment charge on leased facility", "verboseLabel": "Impairment charge", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": ["r701"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "verboseLabel": "Lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r349"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r349"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease, right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r348"] }, "vygr_OperatingLeaseWeightedAverageIncrementalBorrowingRate": { "xbrltype": "percentItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "OperatingLeaseWeightedAverageIncrementalBorrowingRate", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted average incremental borrowing rate for operating lease.", "label": "Operating Lease Weighted Average Incremental Borrowing Rate", "terseLabel": "Weighted average incremental borrowing rate" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r352", "r541"] }, "vygr_OptionAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "OptionAndLicenseAgreementMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to an option and license arrangement.", "label": "Option and License Agreement" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Nature of business" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss)", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r3", "r8", "r66", "r100", "r103", "r128"] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens

"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Net unrealized gain (loss) on available-for-sale securities", "verboseLabel": "Unrealized gain (loss) on available-for-sale securities, net of tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r97", "r98", "r193"] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "totalLabel": "Total other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r35", "r542"] }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrentAbstract", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current [Abstract]", "terseLabel": "Other current liabilities" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "totalLabel": "Total other non-current liabilities", "verboseLabel": "Other non-current liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r38"] }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrentAbstract", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent [Abstract]", "terseLabel": "Other non-current liabilities" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesTableTextBlock", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "Summary of other current and non-current liabilities", "terseLabel": "Summary of other current and non-current liabilities", "documentation": "Tabular disclosure of other liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "Other financing expense", "terseLabel": "Other income", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": ["r53"] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": ["r608"] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r570", "r580", "r590", "r622"] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": ["r573", "r583", "r593", "r625"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r573", "r583", "r593", "r625"] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OverAllotmentOptionMember", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Over-Allotment Option", "terseLabel": "Underwriting Agreement", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r597"] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": ["r675"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r54"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],

"lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": ["r607"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r607"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r599"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r616"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r609"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r598"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r600"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r644"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r599"] }, "vygr_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the member information pertaining to Pre-Funded Warrants.", "label": "Pre-Funded Warrants [Member]", "terseLabel": "Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r41", "r226"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r41", "r456"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r41", "r226"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r41", "r456", "r474", "r742", "r743"] }, "us-gaap_PreferredStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValueOutstanding", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred stock $0.001 par value: 5,000,000 shares authorized at June 30, 2019 and December 31, 2018; no shares issued and outstanding at June 30, 2019 and December 31, 2018", "terseLabel": "Preferred stock, $0.001 par value: 5,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023", "documentation": "Value of nonredeemable preferred shares and preferred shares redeemable solely at option of issuer, held by shareholders. Excludes preferred shares repurchased and held as treasury shares." } } }, "auth_ref": ["r41", "r456"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r656"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": {

"en-us": { "role": { "label": "Proceeds From Issuance Of Stock Net Of Discount And Issuance Costs", "verboseLabel": "Proceeds from the issuance of common stock in connection with the underwritten public offering", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r2"] }, "vygr_ProceedsFromIssuanceOfCommonStockInConnectionWith2023NeurocrineCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockInConnectionWith2023NeurocrineCollaborationAgreement", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the capital issued in connection with the 2023 Neurocrine Collaboration Agreement.", "label": "Proceeds From Issuance Of Common Stock In Connection With 2023 Neurocrine Collaboration Agreement", "terseLabel": "Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement" } } }, "auth_ref": [] }, "vygr_ProceedsFromIssuanceOfCommonStockInConnectionWith2023NovartisCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockInConnectionWith2023NovartisCollaborationAgreement", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the capital issued in connection with the 2023 Novartis Collaboration Agreement.", "label": "Proceeds From Issuance Of Common Stock In Connection With 2023 Novartis Collaboration Agreement", "terseLabel": "Proceeds from the issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options", "terseLabel": "Proceeds from the purchase of common stock under ESPP", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": ["r2", "r12"] }, "vygr_ProceedsFromLessorForLeaseholdImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "ProceedsFromLessorForLeaseholdImprovements", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "documentation": "The cash inflow from proceeds received from lessor related to leasehold improvements.", "label": "Proceeds From Lessor For Leasehold improvements", "terseLabel": "Leasehold improvements amount" } } }, "auth_ref": [] }, "vygr_ProceedsFromSalesOfMarketableInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "ProceedsFromSalesOfMarketableInvestments", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Represents the information of proceeds from sales of marketable investments,", "label": "Proceeds from Sales of Marketable Investments", "terseLabel": "Proceeds from sales and maturities of marketable securities" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r2", "r12"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r159", "r396", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r507", "r523", "r544", "r545", "r546", "r547", "r548", "r683", "r684", "r688", "r710", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r159", "r396", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r507", "r523", "r544", "r545", "r546", "r547", "r548", "r683", "r684", "r688", "r710", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net (loss) income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r90", "r99", "r102", "r110", "r114", "r122", "r128", "r131", "r132", "r194", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r292", "r295", "r297", "r300", "r301", "r313", "r337", "r401", "r416", "r445", "r476", "r496", "r497", "r529", "r530", "r558", "r659", "r685"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r6", "r353"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": {

"role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r6", "r353", "r402", "r414", "r542"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r60", "r353"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r597"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r597"] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrent", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Receivables, Net, Current", "terseLabel": "Accounts receivable", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": ["r542"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r565", "r575", "r585", "r617"] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r162", "r244", "r358", "r359", "r406", "r413", "r449", "r450", "r451", "r452", "r453", "r473", "r475", "r503"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r115", "r116", "r358", "r359", "r360", "r361", "r406", "r413", "r449", "r450", "r451", "r452", "r453", "r473", "r475", "r503"] }, "vygr_RelatedPartyTransactionAdvisoryFeePayablePerMonth": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "RelatedPartyTransactionAdvisoryFeePayablePerMonth", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of advisory fee payable per month in a related party transaction.", "label": "Related Party Transaction, Advisory Fee Payable Per Month", "terseLabel": "Advisory fee amount per month" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Total amount of services received", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": ["r32", "r358"] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related party transactions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r162", "r479", "r480", "r483"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related party transactions" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r162", "r244", "r358", "r359", "r406", "r413", "r449", "r450", "r451", "r452", "r453", "r473", "r475", "r503", "r703"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related party transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions

include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r355", "r356", "r357", "r359", "r362", "r442", "r443", "r444", "r481", "r482", "r483", "r501", "r502"] }, "vygr_RemainingContractualLifeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "RemainingContractualLifeAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Remaining Contractual Life Abstract", "verboseLabel": "Remaining Contractual Life" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": ["r117", "r118", "r223", "r227", "r361", "r379", "r403", "r510", "r511"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "Research and development expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r283", "r506", "r517", "r706"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r566", "r576", "r586", "r618"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r567", "r577", "r587", "r619"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r574", "r584", "r594", "r626"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash", "verboseLabel": "Restricted cash included in deposits and other noncurrent assets", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r654", "r662", "r707", "r709"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r93"] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Unvested restricted common stock awards", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": ["r20"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Unvested restricted common stock units", "terseLabel": "Restricted stock awards and units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit",

"documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r44", "r63", "r411", "r436", "r438", "r441", "r457", "r542"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "terseLabel": "Accumulated deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r89", "r119", "r120", "r121", "r123", "r128", "r130", "r132", "r195", "r196", "r207", "r286", "r287", "r289", "r290", "r291", "r293", "r294", "r295", "r304", "r306", "r307", "r309", "r311", "r345", "r347", "r433", "r435", "r446", "r742"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaboration revenue", "verboseLabel": "Collaboration revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r73", "r74", "r150", "r153", "r154", "r156", "r158", "r159", "r160", "r161", "r234", "r235", "r396"] }, "vygr_RevenuePerformanceObligationsAllocationOfTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "RevenuePerformanceObligationsAllocationOfTransactionPrice", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "documentation": "Represents the amount of revenue performance obligation allocation of transaction price.", "label": "Revenue Performance Obligations Allocation of Transaction Price", "terseLabel": "Allocation of transaction price" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease right-of-use asset obtained in exchange for operating lease liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r351", "r541"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r635"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r635"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "verboseLabel": "Net proceeds received", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "verboseLabel": "Offering price for common stock", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "vygr_SalesMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "SalesMilestoneMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "documentation": "Sales milestone achieved.", "label": "Sales milestone" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureAccruedExpensesTables"], "lang": { "en-us": { "role": { "label": "Schedule of accrued expenses", "terseLabel": "Schedule of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r20"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareTables"], "lang": { "en-us": { "role": { "label": "Outstanding potentially dilutive securities excluded in the calculation of diluted net (loss) income per share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r20"] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." } } }, "auth_ref": [] }, "vygr_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and restricted cash.", "label": "Schedule of Cash Cash Equivalents And Restricted Cash [Table Text Block]", "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r296"] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCosts { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPl "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]", "terseLabel": "Summary of stock-based compensation expense by type of award", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Compensation cost recognized for all stock-based compensation awards", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r29"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Assets and liabilities measured at fair value on a recurring basis", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r693", "r694"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r31", "r32", "r479", "r480", "r483"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r246", "r247", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Summary of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes,

but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r10", "r11", "r64"] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of weighted average number of shares, basic and diluted", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": ["r19"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r560"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r562"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Stock-based compensation expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r527"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditi
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalI
"presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Restricted stock disclosures" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfei
{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedIn
"presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r266"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfei
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitures
"presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r266"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrants
{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPe
"presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r264"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrants
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPe
"presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Restricted stock granted, original issued price (in dollars per share)", "terseLabel": "Granted (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r264"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonve
{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedI
"presentation": [

"http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Balance, beginning (in shares)", "periodEndLabel": "Balance, ending (in shares)", "periodStartLabel": "Balance, beginning (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r261", "r262"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonve { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvested "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonve { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvested "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Balance, ending (in dollars per share)", "periodStartLabel": "Balance, beginning (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r261", "r262"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonve { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvested "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Grant Date Fair Value Per Share" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPe "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Vested (in shares)", "negatedLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r265"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVested { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPe "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r265"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r246", "r247", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Options disclosures" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Exercisable (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r255"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercis { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePri "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Exercisable (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options

outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": ["r255"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Cancelled or forfeited (in shares)", "negatedLabel": "Cancelled or forfeited (in shares)", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": ["r690"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodW { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeigh "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Cancelled or forfeited (in dollars per share)", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": ["r690"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r257"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r27"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r253", "r254"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExerc { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePr "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Outstanding (in dollars per share)", "periodEndLabel": "Outstanding (in dollars per share)", "periodStartLabel": "Outstanding (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r253", "r254"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExerc { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePr "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverag { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExe "presentation": [

"http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r258"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageEx
{ "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExerci
"presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r257"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r27"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemain
{ "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingC
"presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Exercisable", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r27"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemai
{ "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemaining
"presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r65"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Shares, Outstanding, Ending Balance", "periodStartLabel": "Shares, Outstanding, Beginning Balance", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "vygr_Sidney64StreetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "Sidney64StreetMember", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the lease at 64 Sidney Street.", "label": "64 Sidney Street" } } }, "auth_ref": [] }, "vygr_SidneyStreet75And64LeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "SidneyStreet75And64LeasesMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 75 and 64 Sidney Street leases.", "label": "75 and 64 Sidney Street" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentatio
], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies and basis of presentation", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r58", "r113"] }, "vygr_SignificantAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "SignificantAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Significant agreements" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r9", "r42", "r45", "r46", "r89", "r104", "r105", "r106", "r119", "r120", "r121", "r123", "r128", "r130", "r132", "r151", "r195", "r196", "r207", "r230", "r286", "r287", "r289", "r290", "r291", "r293", "r294", "r295", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r338", "r339", "r340", "r341", "r342", "r343", "r345", "r347", "r354", "r418", "r433", "r434", "r435", "r446", "r498"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails",
"http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails",
"http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsTables",
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r119", "r120", "r121", "r151", "r347", "r396", "r439", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r456", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r471", "r472", "r473", "r475", "r477", "r478", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r552"] }, "us-

gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statement of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsTables", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r119", "r120", "r121", "r151", "r162", "r347", "r396", "r439", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r456", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r471", "r472", "r473", "r475", "r477", "r478", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r552"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r569", "r579", "r589", "r621"] }, "vygr_StockAndPreFundedWarrantsIssuedDuringPeriodShareNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "StockAndPreFundedWarrantsIssuedDuringPeriodShareNewIssues", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Equity impact of the shares of new stock and pre-funded warrants issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock And Pre-Funded Warrants Issued During Period, Share New Issues", "terseLabel": "Issuance of common stock and pre-funded warrants in connection with underwritten public offering (in shares)" } } }, "auth_ref": [] }, "vygr_StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock and pre-funded warrants issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock And Pre-Funded Warrants Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock and pre-funded warrants in connection with underwritten public offering" } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Employee stock purchase plan", "terseLabel": "Employee stock purchase plan awards", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": ["r668"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, shares", "verboseLabel": "Issuance of common stock (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r9", "r41", "r42", "r63", "r440", "r498", "r504"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock under ESPP (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r9", "r41", "r42", "r63"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercises of vested stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r9", "r41", "r42", "r63", "r258"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"],

"lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r9", "r41", "r42", "r63", "r446", "r498", "r504", "r558"] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock under ESPP", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": ["r28", "r41", "r42", "r63"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercises of vested stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r9", "r42", "r45", "r46", "r63"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Stockholders' Equity, Ending Balance", "periodStartLabel": "Stockholders' Equity, Beginning Balance", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r42", "r45", "r46", "r59", "r458", "r474", "r499", "r500", "r542", "r559", "r663", "r680", "r700", "r742"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent Abstract", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureLeaseObligationDetails"], "lang": { "en-us": { "role": { "label": "Sublease Income", "terseLabel": "Other income from sublease", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": ["r350", "r541"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Underwritten public offering", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r344", "r363"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r344", "r363"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOfferingDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation": ["http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental disclosure of cash and non-cash activities" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r615"] }, "vygr_ToddCarterPh.d.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "ToddCarterPh.d.Member", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Todd Carter, Ph.D. member.", "label": "Todd Carter, Ph.D. [Member]", "terseLabel": "Todd Carter, Ph.D." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r607"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r614"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r634"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r636"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.voyagertherapeutics.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } },

"auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r225", "r228", "r310", "r336", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r419", "r531", "r532", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r543", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r676", "r677", "r678", "r679", "r692", "r695", "r696", "r697", "r698", "r699"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r637"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r638"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r638"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r636"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r636"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r639"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r637"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCommitmentsContingenciesAndOtherLiabilitiesDetails", "http://www.voyagertherapeutics.com/role/DisclosureNatureOfBusinessDetails", "http://www.voyagertherapeutics.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNarrativesDetails", "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationAgreementsDeta "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNeurocrineCollaborationReceivablesAndC "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsNovartisOptionAndLicenseAgreementStoc "http://www.voyagertherapeutics.com/role/DisclosureSignificantAgreementsTables", "http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r296"] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "U. S. Government agency securities", "terseLabel": "U. S. Government agency securities", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r513", "r524", "r708"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket "http://www.voyagertherapeutics.com/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurri], "lang": { "en-us": { "role": { "label": "U.S. Treasury notes", "terseLabel": "U.S. Treasury notes", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r513", "r524", "r526", "r531", "r708"] }, "vygr_UnderwrittenPublicOfferingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "UnderwrittenPublicOfferingAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Underwritten public offering" } } }, "auth_ref": [] }, "vygr_UnderwrittenPublicOfferingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.voyagertherapeutics.com/20240930", "localname": "UnderwrittenPublicOfferingTextBlock", "presentation": ["http://www.voyagertherapeutics.com/role/DisclosureUnderwrittenPublicOffering"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of underwritten public offering.", "label": "Underwritten

Public Offering [Text Block]", "terseLabel": "Underwritten public offering" } } }, "auth_ref": [] },
"ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "UndrlygSecurityMktPriceChngPct", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": ["r633"] }, "vygr_UnrealizedGainLossAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://www.voyagertherapeutics.com/20240930", "localname": "UnrealizedGainLossAbstract", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureCashCashEquivalentsRestrictedCashAndAvailableForSaleMarket
], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Unrealized Gain and Loss [Abstract]", "terseLabel": "Unrealized Gains and Losses" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentatio
], "lang": { "en-us": { "role": { "label": "Use of Estimates", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r21", "r22", "r23", "r81", "r83", "r84", "r85"] },
"vygr_VestingOfRestrictedCommonStock": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.voyagertherapeutics.com/20240930", "localname": "VestingOfRestrictedCommonStock", "crdr": "credit",
"presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"],
"lang": { "en-us": { "role": { "documentation": "Represents the value of vested restricted common stock.", "label": "Vesting Of Restricted Common Stock", "terseLabel": "Vesting of restricted stock units" } } }, "auth_ref": [] },
"vygr_VestingOfRestrictedCommonStockInShares": { "xbrltype": "sharesItemType", "nsuri":
"http://www.voyagertherapeutics.com/20240930", "localname": "VestingOfRestrictedCommonStockInShares",
"presentation": [
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"],
"lang": { "en-us": { "role": { "documentation": "Represents the number of vested restricted common stock.", "label": "Vesting Of Restricted Common Stock In Shares", "terseLabel": "Vesting of restricted stock units (in shares)" } } },
"auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r603"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareBasicAndDilutedWeightedAverageShare
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens
], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted", "totalLabel": "Weighted average shares outstanding-diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r136", "r145"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareBasicAndDilutedWeightedAverageShare
], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator for diluted net (loss) income per share:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation":
[
"http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareBasicAndDilutedWeightedAverageShare
"http://www.voyagertherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehens
], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding, basic", "verboseLabel": "Weighted average shares outstanding-basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } },
"auth_ref": ["r134", "r145"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [
"http://www.voyagertherapeutics.com/role/DisclosureNetLossIncomePerShareBasicAndDilutedWeightedAverageShare
], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Denominator for basic net (loss) income per share:" } } }, "auth_ref": [] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [
"r601"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A",
"SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-

20" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher":

"FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r61": { "role": "http://fasb.org/us-

gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808",

"Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB",

"URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r141": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r167": { "role":

~~"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r193": { "role":~~

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r219": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r245": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards

~~Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards~~

{"Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards

~~Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":~~

"https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r350": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r351": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r352": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r353": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r354": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r355": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r356": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r357": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r358": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r359": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r360": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r361": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r362": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r363": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r364": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r365": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r366": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r367": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r368": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r369": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r370": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r371": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r372": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r373": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r374": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r375": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r376": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, r402": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r428": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, r454": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r480": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r506": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r532": { "role":

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r558": { "role":

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":

"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r640": { "role":

"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r671": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r672": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r673": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r674": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r675": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r676": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r677": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r678": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r679": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r680": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r681": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r682": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification",
"Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r683": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r684": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r685": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r686": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r687": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r688": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r689": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r690": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r691": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting
Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r692": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r693": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r694": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r695": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r696": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r697": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting

Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting

Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" } } } ZIP 67 0001558370-24-015304-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-015304-xbrl.zip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

[DS4T)H50$4+T1X"YH^)W:&#XXA&;7NND @_4K(*L,<_MCQ&3Q;XM6RP2^)Y8.&ZQE,[W8(HQQV$A&BZ-F1[-?3&2
$K9W8T[@D3RQ(!LS^]K- UJQN0:Z!,]G)6'BTC3(1%J 9==1BU?-?E2OM#X$$K
M\'(8]!&&_7F*=3.>6=T@TQV#2<<_5,R(*17HL5DZ87?UD53.B1N,H+41?&$J MC<;OF7A<4L'0Z[9 B=?<"6
4_)7QQ1)^3]: :\$TB)P&"G=;<->OQCKVB=I@ M-L='Y:D$R),WC@[TN6:!K,!,)%* 4LV'-A\[Y(0\1ZS O*)Y"4$ABDRY&0S+
M:%C17F_\&S3]"3JLVMQZ,$F[6I3(3MI &I<%CL[U"G"\PYSYB*H-$9(,QD%O M.R_[WD.O\ +
(*!.YS7@?.T6"\)GVRP(DSPSX=HCTS,KL%.-5AWB#LLWY&# 'ZMQ)W/N$'I+UO4U01A6> MEU6H48UF.EO3RB ;5+55#-
XJFC8J"@+CDJ(: N-!5R9=/3 ''4X(+]3F25"P M<4MG&13550MGU-A)66,1,K)";$1ET T*,XZ#@0L^W ;B#
[[P^!S"04^!ZX#) MC##'W$,$$JMY.K_/-%)<6AHU]X&S>4D+,VE+2UH170QQ9$J9T(0T6478 M]:P9[ED#
<%;Q$!I',$-4O%U*Q!-& ^VR'"+09E6?0IA[VC9QX4V(_+2GO,3M()OD%U.P:Q-
;IK@C4I[[Q">37Q[*"^W0+,:NTU@1J4!S%N M27E-F[^#_EKKCRKX.9U?!I)[3-
:E@=2!F7(]CBO6)C0JC%EF$;)AS[V]OCY# MI,"F,X;;3K:P&PFS MX907I6H-)V*%A+SH.#3B)@4D?
Z/NZI^ALT5BMC+%@\GM:'(L$+XE8"J]\AV' MSOSP5%P*T,FXVB(SFU%CK)0WHX0HR5'-0@U6\BI6\L
LQM?:6]9'.#TEJ*7, M><&O0L-L4V]WMRF1B M_ER/N8))F14+?UFD9*6Q$C]".VAS]_RD&EV:P$V:
])2L-.AQ^Z5WTYJ[.66S MU6K[H)C7S"?;9QZ96>$5?7,?"62#B6R5-=8J7\RLU/9WW QZZKA=9M@G,^NF
MQ0[9H)2MUB=;+3":%638]DI3= 8U;1\UM \7S+GP'0.%06U[/)6D_?:&8$I M]>J'BM36CJ?!_D]2>O '+F]L#G1EY)?
X/W4'PXD=U<.WGJNOUOJJ]WQ9N]1 M?&OWOT'4PQ?7B4$0?
<,]ZMIFBJT3$8Y14&&5L)0N30HAD(T8;>"@_D+Q.L*5X/ING'%9#P66N2=>]"-!I@Y3,>8^8HF:#I9H\U[X+LP(1^/V
['M(7 M&=K1C^%#VOBNQ?8C0.YM@BW&'JA;23UZ04>[ISCG_#LZ(?, ;@M,$GC^ZIJM
MF>.OPMMI)#BL^ET1L#]D^<-!EPKG/APHJ') PNE/OT=SX?H>4U1L;A5S MT6<#(8.9A&DF0!%_%GZPBD$Y@,
\I#_#_,1]^TDC"GN8BHMFX5U&'PXLP6RN M&J6^XV":"EB86$L.[(=7:N%3![&8C1"56U Y$ MM-;2(%,F)6?-
)D)0\/[U%6$+"-!Q9+ZC+]P-W$2R>[H)3^KXERS,)V+VC?#= M'"+^V.!S M&6DKM0-
ND!93*;R%459;7=C[0F@PCY[M(>O)=]YX$A56CP.),N MH! ;S-DD0A^+V0)N=YWN6;9?H","V>D\<]
(VU58LF1'J3^J9+0;S9M9OO?!Z MS':"9J";%*EA]B)NTR0%S;H)3S_?!)Y==VOZQ 5_@O\'Q9!*;WDE<]@."/Z<
MJ=L\#K>4*=DGZM@6V7I];8+(_O9][48CTRLN<5J_+1ZJ-XZ9X__NH
M!&/JCKFSU/^H*>OEI/+5$XPZV+%^!NJ8Q%6<3AHA>C>1?/&]>^'/N9J*!?7X M?^+,THHX(/("L:?A9$DAT-%W7X9B[P-
1;ZVWBW"!H[A>"NS>+FG5AI:PF<5= MZKSV1)4X_[<>&J;DEAY"B]9N!NN=R3] BWL!IEWJNY#!!M*=;3EQG"@BG\XS
M66#WX%2PU&'<'D%O3;PJ-LZ&/PWE/8YX\/E<.W!8N]2]GXKI5BR\!&;S!H[D'H MR\1K*ZN.V:^KN8 H-5J R:Z_F,1LK-
G;%9KT=-HE]Z7%&=3#M/F"Z9J@>FG MUVSE2ZZ2? 'H@)$C'S[(%DO7 JZO40WH0&#:US4+?!]Z#_BRQ'3^5;*\D*T@
M^[M<$;VQZ2UTEEOA*0\M&\)3Y](7PG\&N =PF6+9MZULL&K :D&]?2B^DXKK MSK36J[JA1G]5?L>EQ8
[C_F!+";\0!^U\J%[>_#>NHC7XII[=/E(E_GAM^+[
M7@ZX>/&@3/S8PAI$=5DOY;B!J(.)3R_,"O1E)'E):DO[*0O%M^C4YH>S?]&-
MS;R)#JT*$C7#]%*NB6WKW"KYY,?;"K]RM0R?86ZMFW8- 9+56MS6 MT/T=_"M7=8K[H_$ W[Q&UE2KMU-
!N&0;+MC^< ;>Z;NWVGF152N[36!]ZKRQ M=28+<@]L@KGVT'V[0XKNWF%1<+D^D.VZ+84?YB4T>R]C-2
M<3T@OQH2V^/3,_S81#^7\&59Z]MBZ*%9M)/E"Y0KQKPMFZ)8O8?
M@.829IT;AGX%$KUGX@XZ^/(@NQ/2N>XK#P&)2V(; M >I]E-CSJ#@6E^Y*91R91K@==JM>0]GW@N&N*;-
_Q9LH@=.2^=9"]-!TXZFU M^@8]S/>OG8W-5?HH;[33$&8C:.YM7(C'M#1+3N>Y9#QP,SVF)QIT-+'/-O?
JW.CV"MA[T[8&4]I.>,,]I3LWKA'_M_TKSUA_.KG ;V@#WS'>H9SF3K=!"P ST[KD,.^FWUO=#8YUX=LD7"D?3ZP#%
MN-F/P1A^YO8QZ-MJQG8HX7M6+V<)LLN/?9R8A KKQ MA5ZNQ/>S;]V5\-?
9.SA*@Z:ITO^,85PY5,KI/%8EYCCAGK2#H\%-+!V" MS$A;4=8;L4QC_I-OVU<0)S%19ZR5Y7^NF897480GJ3_^%U!+
P04_" S M@&Q9A>&#H;D. "ZO@ %0 '9Y9W(M,C R-# Y,S!?8V%L+GAM;.U=6V_C MMA)^+W#^@X[[T@)U?
(NS<=#=PKGM"9"LC63W;-\6BDP[1&71AY21\,Z/A#"^CW_]XFYO:$E&&B?6QT3EI-S1D&62"K=G' MAF-/F^>-/S[]ZZ??
_]UL_GGY>*]-B.',D65K!D6ZC2;,*[9?M*]DL= M[0%1 MBDU3NZ1X,D.:UFF?
G)^T3P9]K=G\)/JXU!G0$$L3G75/.OX/5UYWQ+K0.IT6 M_.FVNZ?:^46O=!'M:^,'O^$#\#;%F2U-;/UUP?_W#"-J_-
)B'QLOMKVX:+5> M7U]/WIZI>4+H#(C;O9;?L.&VO'AC.-+ZM>>W[;3^?+A_,E[07&]BB]FZ9014
MO)LXNLY@,&B)7Z$IPQ=,T-\30[>%V#/YTA);\$]-OUF3?]7L=)N]SLD;F_A\ M;;&5 1Y^Q2GMU[__:1IKJ
I,=$CFFH"XX6]6J"/#8;G"Y-W*KY[H6CZL;%< MS6B3JZL]Z+4YBS_V:!V;E!7Q)H@"ZP#_L&(B2?<'"YUDX_T](*0S1H:'^;;
MXUV$MR59Z3-$[1=$]05R;&RP$X/,6[QM*U?OK?WC6?_*1M/1 CCF^F=#"QK- M%Q2]
%>HGO"V!T\A'-4.N3\#!Q8*E[DUR6OYVDX8I11\UY@9)F$.1;JR;&LB\SFVA7,!1VN#\X#0$:0+HAMQ%D..IA3E%QBN
M9,1?D!W,C6-$GUYTBKC'-("):VPZ8"O?$9Z]P-]#B*H!EFC"1H[-@R8>5IBQ9SY7#Q'30P3;"-3P'YO&Y$E]&CH
MIN&8;E^=$Q'#_KS9>XC;4/-[^.P-PGG:4X081H;>; 04D_6WV.;C#@9]GB6T MVUI36_<-_UYWKX7[U[P!-
&\$CLU'9Q(C,J#)TP5"XV4IY#C5V;,0IL.:,UU? MB,2HA4R;^=\(NQ9B];[XX48%?J?@-Y$)>=_&CZVJ^+J"F
3DE\J>U^;'6>_\ M[&S0/X44I7W>ZY_U/FPP'C*7(8UB %/VQ_"LNIC13RF9;XO/&XGDX9S0":*0 MD#:_'+@F("\]GJ8Z-
;B8Z\"7=SXK2O=$I7X&%$")J@ M.RE:976:IKEM;1?'FL*>I5806RDF_K8&8'M B8&
MX4>ZAF/;'HENY;%Y6NVE:;4*MPW!,]4-^SNV7ZX<9D,(284@,M4J07DD2BZ*
MU%/YJTS10L=^=NAG3S(!EP3ED>B_*%)/_WV5'?F8D@6D0ZLQI!XV0.,Q MR8*G*6#;B8I/)E%6X_%ZS0GD
#/S]H(#_^;'-5H0ANWU\L878GF6%YNS2='4 M0E?%DW#;D]5%V"JS$-5A M,2:$(3V(VVZHMA9CN4O581JL.JRH# V#.);-
QOJ*IYD9BZ"QC=56:1J3,8NE M\@CK*!ZFW/2SVMB^R/3<0Z0=5@NV]R23%=R0NMC4G$>B'4(Y..6B'QXJ_SK
M:)NDQZ3ZPGCK$/RG@H.TU2AN"@%U5#I]D,Z90M90AAED8*VCR\]4?C+!4>@[M)[PZ.'WIW'Z[H=HJECDO=
4H@45+*DPF+W M0/(BK4/^Q8\1$BO E#@Q1YL=DV:EL-7A"1Y,)MAE:ZSCR9UUI2^PS7F,SZ3C M6Q^39O- K,-
\.S0,9\Y%C]QMH,@U%??X*S\(^P79H^E7_2UY"25/+T=E$"5 MKT,6]LA/,UMHJX(.1$+36YE\R0*H
M0ZZ0A/N;19%NXK_1Y#_@A,&1?@:ORH4QLH(#OT.*&;]GX_!KE6,$4"893].^ MAE/0 /=A4?)VNQ>!UL&@ 4
@YP0KC+11T'1R^JYL.'7(=%T(-$[DGJ)+(C7 MDB:LA-8**C-;.]L:S8,N\Z%L5G,(/P!]"_)P[!,ZX&>"^/ 230E%:ZR(W;S9 M5
<\V-+IZ@XD*A;4^9X*,8&UV9UE(XI8NDWL9<2CLJO#24C&[U1Y0C5SIHAI M&07Z 8!N^LN#F*AU1H3ADC*22:"J-
(@_(("6>;@MU/0&&&15D:+$5'2JSC>? M88ZDNLGK8TSFV,+,YF"6R .3H-$,*I7UFZJE;>T60:KHX_J(& *1\2O'UVB) M3"
(NN*0KJ7FB-2<'Z>BD_0C<&\YR)_1-H_5W+P9IL,36WZQ OY,DA<="O2D MLD'D]NMEX5?
44"!P(5'9I'N"Q/8**KWZR"Z?M!0U$1]S!$ 86?+%4!E2!0TG MG]KB,L6"L!4-&?PKEKD\13K1$6J] &#I)UZMO=)0?
4SI#='38ANB?"C-':N: M"D99]02C7X1:NEL"8 .4WV6]1N[?\-F-%R!P>-&M&7H$M#?3*3(2CX ?F(EJ MMATXWV-
*EACLYW+U#:SBSEH';4,#.ISDC5;^N)LO=QY"BSO11#\A[T MGAN_S$'=BFZ\(Z&'.3_1\[<0Y&C*RQF+B_T0_HPIFF-
GSNZL)01"(CE(/LM= MH+/W8"XE2B;SO&]3@3(9H3-;$"J/II':7NO"7DD[6U+$[\%L=I"$9R9G)6]V
M)A1$V\Z!KH@):B7N6F^H+N>&SG-21Z$.^F?=_M$HO0Q1>%K_H+1SV,;HEY$) MX"4?E,HD/68;V5D.GH&A?2EI1
_SZ-)X\P_#6N]N%KMVXSOE'J4C)$V:0Z9J7O(@)?U>G'[M3S M#:D5<:0]1&HOQVPR98K$-R&E%T>30S*O.&+ND-
:C>Y]6(B,$WRZ47ER-A;91 M4#&/:6R01@0S:(-@3M^'=7; MN*MH UY?B07EKV1H@/0H2GS70M(&O70'"IK8C@J.V<#?
31I2]U"J]DI;&./> MFR5K+7&T[])0I 61Z55*L)&$!!G@&PA-Q+EMONW 1M. [>1-P%RTQZS\W06A
MZ,O)$B1TBRW=,G8(5&(Z4- ^E U49,57AY,HD<>&%](:"2[9S1NB!F;!\>;M M X3I= H:U([JC)EM"@FA#L<-
P\CN&'/X>YE'TU"I3 FSB*6+2J2C0CG!O9J% MO!#V64^$ 5FU[RNK2E[77%P"O+I:$TMX ^<":T)>="FX?8@%]<
M3D3!5C/@Q6\UT8BEZ1KU&=*>.4=]HO'U:\5W&QT65[+-0":=*PZN7T5-?K= M5'>^.26TR:"I-
E^SI;$U7RG=\F[B:7:80Q+RD@=BH94KMUO' MFB1)T;M$PJ,,9HLY-B[W*-S9CXJN(FU8VC5ZMD-L!M7P/U/"6%
FF%^2<&O) MI+QEHHR^%?)=NRMXV[7M3T:J%MXKBIA?R=F7Q47Z_L?B"LKHH*N7DE)91Q@[

M..MU'T=J&>7)0GH]L9XA%Z38Q#(@V_5NDL:'8-&N"P1?W0,%7U$XO/:0D1*. M;0Y693*_T[9P2IJ\0Y_5U#4-<9,
]I((0]6JBXW2IIF(5:TZMR!5WF.4_W% M!:%4;;I@ O".7?N%?7-//WM;-[K4D->G]6NS&X=*T]_67Q*^]*B2V^,^.K(
M/(Q*X#$?<=0*>RJ\TCY3&>N <3>4=5AU]1#RRF&(,<'?+9*TS@2BNFI\!W1U MJ+%U,U^89(70(Q*9K[0KRJ2KN[Z+
3S H<=TO_V9$)'!/B&ZQ$:2%B4HZJJ_ MHM#RO=FVHFR>S.?8/$ W+R9\ MS,@V>)7!U*8$TOU78NO*Z^&M[R9G
$@E4O#IS=!/HN)RT MT0"3 3)-W4+$8=+&FX?TF+2\,^XZ'.'X@NS@%>EC1/T3B-C@63 V'0B5OPMV
MT62XA+YFR#V[.')L9D/0P-^BFS,TZ;2W]P6 #^T74[PB'0M>-'BV-,:'@E\% M0R)$F;@L>2)$?)- ,.4V91H)V*HT>-
F0V1=G_HPH+]@IV-\288)7S=U+!3-& M H];S D=YL,9WX>"/J:@ML-SR>XBJ$/$)&XP\@1$-[WC^)?]#7@P2EH[_[S
MD%)^NS&M=/#N'1^G6>U)+N5.;=[W_'_/P,6G_P-02P,$% @ ,X!L67 ? M^A[%+ G?(" !4
!V>6=R+3(P,C0P.3,P7V1E9BYX;6SM?6MSX[:2Z/>M MVO_ .UMU]VS5\?@QF61F;N9LR:\
<5WDLE^U)=C^E:!*2>$(1"D#*5G[]!4B* MX@, ;X R:Q*/+;4 /H)-+H;P,___;KTK35 V(/!UW>G[T_>62!PH.L%\Z_O
MHG!V].G=?__CW__MY_]S=/0_YP^WE@N=: F"T'(0L$/@6B]>N+">X&IE!]8W M@)#G^]8Y\MPYL*S3D_>?
WI^__S1.CKZ1]S'N8U)&QA8<6=G[T^W7URDW<'@ MBW5Z>DS^.SLY^\'Z].7#AR]G'ZW[;UO
;P2WF5<+Z7O!'U_HCVCKY<)RUXD+0OXZV8$?THZ/3 MLZ,/I^]?L?O.(AP-<#RVQ"!;<()A ?KEPQ;V]/A_OMT^QL@?>0$.
[<#9M:J, MDK8[_?SY\W'\;09*AO<$"%6Z)M^Z8=8@#_SQ./GRW3_^S;)^1M '#V!FQ:-] M"3?/YQ03OW'8TA$3I7I @8N"
(AF MD%\P]#V7JD+V+9[.'D/H_+& ODL4]>K/R LW[RPZ[O>'FP)):[BQYP"%"X#L
M%8A"S\'O';@\IK#'[8:+N2(ET..6;+GTL.-#""PZ,T#HNR.'823.0()>D_V MLP]P _HE^]5!Z)T=DI_3V7F$O0!@?
E"V_/;$!U[:'?K7]"'P#-OT[MYO@$8T!^!NZM9S]{OA=Z *??N]/@ 3@1F4Z#.9DSO4XXTAT2.EAX8>,%_9\: MY-KV*>X/ (?
(KJC6QO.K0YV.#")V,NXC MY"SLW*?]\:HE/N8P%D0(.F1-(N;ADVD3HGA>V 'TQT+ID4UG%EG6 5E&J,-' M-
('.+G161S<_(_R6!+\5IKC[,"UD4M=@ B' M<#EY]? E7-H>V?;-[,@/LJ0H [K)J-Y4N$ID0V..K5S(G8(\X25=!M
2)YW3KX;"IB8B5+^O "\)C MUUMF"F+[?C,MR\6.:=3\8\R&N+?V2)'?*7-@<.3&,NX0PVK7': ;]W2T!,OG
MIC;+QK78;WM$%P0GY$3/X"AC0X?H,GOO5!D24^]'&[9])PB3/[W 2VPR^"/M MG*+3VK9SJ ,*YP(W^]0+Z0"
[YE:NO95,=]:W6!M49@E*$)4!= JC^S1[!E'C M&9!^LIL TP]^3T/0SSC>]&T])YM#X']]QP;Z_;3$ #[8L0HMU06%?O+
])5A! M[(59X.V.;,@BA,B&-AFOA+-4FPH)TJVV%.T4;H**M!$[V'8^0W IP46H,'Z$ MR1
PWG38V4J0FE[3F2]AP8ZB+SR,K2=H26,*$7%7OKXCOZV0!XE3O?GZ[D11 M)3I2;X*>DZ(GH^A\<*;"L\"-5?
RS1HI_UH'B"[@J;0!G6@R@BKF\(9R)#>'G MX^+*M5M]ZU>T?IQ[X5+W^?/GDQ/KR-
KU3/[8=FZ1WJVD>XOVOUT!LQ&V-A$K MK;+Y;_=^+O 2RR>_[R>_/'[95H?"EEPMQF$)0!".G8@!;05[%R-DY W?
$O+YKJ=%>N6PI>:.!O/G3VWE'.3!6U7 M2./;>%LNP]#N6GBN%R=LH8'B/!I,?><#PSHD!K,"":RI#8BQ MU6H+$_=?
9+6)4UO7$-V!EXGCP"C.U=\C&)!?G;3.AF\?2GWP=SZJO6C@UA/I M>SJ;N(EN?2MX0"6FL$"YM/. VUI34\G
>M0&MS%%6O)VQZ/!C%4HJ="D63$8 MU%B:L$W]:L1KI8'Z$BK"18D)RZ66"]W9TE3#?"B!B[X5BHU\WEJX2'=O+AB%
M.64A?^T4A?SQ^T6TC/RX0.IJ-@-.> _(YL_=63+#4F2;5=1'I:$AY#.-1KYA M(Q:T-Z<&$H*JN UF7O+$4 M3(V)X<\L=)
[@B"RNM6^*9& >4K5,"8(VD\K=#!!W7\R-JG[N2]*M7QX]%O7<[YA=R#://4W(G^KU>^8QLCMSEX"H6=9UTR1@\6&
MK3=O@V@&5"-J^&U?GUS(N[TRU&N=F])=+$)V, ><@+P0MB[\4(7682&B6CVS]!QT^7PSWSWC-^"G6X5--
!!=.09>0HW] MJ=!K:],EEW%M.VWKSTG)&G:'[^ >GHC O)O7EC"M)G[M!7;@>+9_$Q J>/50 M-=!<'17 Z]AH4I=
[!A!UQA\!6GL.V5%/9PPD,?7N,?LK8>"ERR'XV]J.!VD[M$]1K!>P/^<&G!2ZUA%M7)*ZO,DK4V6*3>?PO4;@
MSP@$SD;.H'DM9:Q9U-804\[P4C;@4DLELV6T[=!8)4168ZD,_'3:)Y^@.N-D M$&**26XO6-G$E;5RQEAM(V.&
[%8ZJ9>X[^Y[ )\Q\:KHO30WP2H*R=>0.$^^ M%V?+RE3)F6]?X]9+H<^1.YPZA K&FC3ZI$OGE,-B!'.RZ9,!6J>JW"P:
(TWW M,()9B@?.-0U1 T/(%4XJ_ 9*)'=GQA(2@+*X#&YZ?.3S5B=&VI25/8=E;/_* MCG;62M')+K33P(-[B&*-
#3/TLE]V)T:%472%'KB\4>RC'\>;)4+8&$=#G.\< M47FK5"1F\(SN ZW'X&1QL^_8"?_\MT-BRS22TK=\C-LK-
X\UD#G*H)G6'%I9 M04$1':WK0.Y \?GFP@[!'*+-=*8)GL.T,D\4>)%LS9W[%-IKX$U\1<+3P@Z> MP'(%D8TV-
\L5F2KB"A#B.'OQ=8, 4_]X'GA_?IQ. MZ*+U-AZ7_[V.V':E4E9RC^ *H'!S M[]/[M0.7EGRL8@=Y4Q,ED6C)W]?(M36)'[5!%
(F6ZOSH-JRB)C*HC-_@YB=% M4&%_)T=(&Y/D7('VS?/)2@D#,'$6'ECS3HX(82OZ4PO=*_I,AO=K+
M\A)*83&8@G5W8)D9W\- $,2TW%$*%AAS^\\#'):<7464X*0R M%U9$&!NZ392CAK508OA!PQ]L?
+>1$"&>FN,BVTU/C8M4!11$.UB@VHG;[O7^ MLFMO6JIO*$D\KVG[F(% &E 5&PW[_"KZ>==&#FW-AD-?
W\C.ETALSP4M!-HD M;&,.W<+MA+"-*NU=!MYD! (5,-)@2 (2BA95@_K@/M83)8I&W;:O@W"<+"8< MTQGA0NJBZ#
X<["%2@=]QK&UVZ4'_K*G_$_W^Q@[NU-O,.D MB.^P#UP:)ZF]OJ6/H;B\[6NPUM?$<#0#]H_Z\)?!%&G-
KYE]T:AU9OB5.-9> M,!?,"SD(KN:68/31(33F DP=+=V9#YN!4##BX%I?0#&O\Q74M"KK+\340A"[
MK9&H7J\"QQ4V$U(W94(E9D#*4=>=0HO8"VM''URY&>CF59R#IE9%Y[WW>+[) M?R.P /D.N,JCUH5F)@E-
I@HH171W!M-(&K ,J\$-286,XK4,+/1--#!UBVIB M0H;83
XC:?.IM%&EO7>CDK,B)D:F&)38@IBHZWUG('K&\0'.\&I=GSGB0/-W
MQ7QX,V@5!Q!X\"KT=OC"0"WSH20FP[\OP$.]L$<7H:S=2#S7L]'FT::QP]HG
MH7CP0L7AMM!!\0X+&O"8SF07G/J&?!Y(->W"BNID U61TF)0'"H*)B6%O>;D
M*Z',]B>KE>\EB:SDS8/R2P@QYEYM7K9)9X*T9=/N]H*1-8G>9MUUR,PNT\,M
M]0)V0X>&I'(SPHOYYN8$#W\2$>!M8IQW'K$(P3[C5X49'G_!%W*QC.+N0F0&:GI]R@5$X1- 2WHBJF[;Q8(5I"
(YT"9069.Q94++ M4]JAFUC#[!!7X"N8+=]\;G+^AK.P9 +N%S"(-[Y7$=AA, -QA$] M[;8]BLH[Y"+5D'U<1+KI<%3RS\)(-
FU(;4>G9%2% =7Q&_;\C"1!V6$:!4+T MGM=,*V-$!S-S(/P3AR4@C:2(3U7*585U7_%X2(4C3G\^<<"DH6#CF954#W9
MK\FU AC[IN8TH"0V(#VL&(U*8(I9.:.L/(0]53U*GB,UD)A:/J4.X\FB6%+J-G
MP#DP@M4D"LDFN>X>*19PS0DH%K@1A$J<^;J"*Q#;]4DO =\KA[S8>&@ZWU5%
MO'JTBXVPWC>LZ+6YT]EO\=.+X10]>/.%Z(D;+CQ79X0M3*%8:":"%FI4=V68LT' MZRRN=6<'SN97+
[1]]CV=8J!\I(H!U-2H:MD#^6.V-)U8EX^6+"IS9L-#,(LF M,1#;&<>*>&)TQ?GZ[J1#23[!Y\TU0/,(P^#;>_?]_8+\X,M4
CPO72%X[W(6 MCFZ&Q(4HIK(_ZT_VKDOVJB% M5(7 !;ES00<0-+,<4V1,1.Y5+H?6-+EKX'U MR]_+R\O[-=S8RZM@\Z^
MQ6EAV@+Z!%%,KSP+Y9;-SY_GIVS:>E1]P!X(M.+/R8_ZG ME8VZ] -<(#$3&QTJ9M>SC4&V3 ^3/=]B_D0?MN ES4M
QWI03#A)3]?" (C? MMZUILR5 RI"EK6U!6B(G>@9'F2.:7_U8WC.;_874OYB2TOPPK&1** FW+AS8 M?
B21VPBDXTB*0:1B>:EPJ-$JC5PB3WA=%0.N)RD45Q^Q"(2Z5-A!5M'7RO:)
MZWK)R/>VY]X$%_:*NK]"$=2T&5(<9RW%44.*7M$X3E) "MSXVF]*#@(+.C6L M01(($XM)OOV0(OO05F3R9&D5WP,
("07 W5Z_7O-T.QMX2,'\T%(P/!JT2H'6 M[TUGN7M,1+DW-NSP[A9G5JMWMS@4Z)W&B2$.LAQ>NJTBG"FB $1B$. M[<
E?BA/!%4X W9!DA*HXFZ0 *AZT"ILX%Y&] 'BI(0I?HLQ_FX:(X:O7HG_ MZ^%=\)IE(VK]&+!;4C A-=J,%W"BE!U(6-B1 ?
YA8P67T A[9VI ,=93.]# MG,[H85#D.6%\&>@V7,ER$>M:#"FMCTT,4HH*O7R_"1*E4.?_KJ5&JU'0+$F! M[,@R?
DZ,YX0[\!)_PW?5I=H.*<,?^UK<(W =T;J'M*(1*UI>V\Z&E.5/C9>U%@0:),A8R;H29+DSW>MB M:X5N(NPR$XR?
B!//FGE!?9.](Z>C(77A4V^;1PYQQLLXW?AT(&1Q3X8OPV(& MR&\@C5>#B?NO*'V _
ERJC#85.0WQP_@S\C#7@C2EP83'J2/GPM49[#1AU2W MSVTFE<$X8HX*\JI'O@<(V+[W%W#_"7T:7?V%,/L68CP-
'H%#;"WT)X@0F

'0BGLR?[E:-S_0TWZ)QVTD;+^N.!.6I%<$J(HOAS=*$$,Z@-6^7H2HC7-M=^-:O;JJ>]J6!J1)T!ONZ=36\XG,[.([(1 AA?
THI[7]K/_>'D-M].2T[.7;JO78ZW3J=VU\M($]5AB?K^PT=*>S.L+RLN0
M&MV_1KI4*1HO$S2>>!I//(W;ZSW87B=IB]CK<^C%&-D$P)_$:ILIIG;?OIM)&]-M@W(3K$&:&^:%"Q0ZV)M3-
BI$]5TP5PP0[B;S[RM"61#>VYMXTH#GX $X@,"4 MSUPT[L7X,S6-*3,@H'-M>RBN^_D&;/IWLF+32!3.A:(\@-
/OW6GP0//A- -^ M;F-//0+TH1H!HDA8:XJ%M"@65;:(N0]4PQ(LV, MCQ]E;+\#X25-Q+ICM:'49N$_'L>_:_ 9 [2FZ_--
L(I"6MT2.*1-7-TCBDCU M/^SPRP91T_(<*;CT6-# F/C74,I17FIXC-%\B4UV (>)(OO3FJMNVG1IQB:W M7O.+SF

;BK7*_QL,P.:;C?X (2TK%TN6!VS CK@+/J7C>>.!QQR5((M\'1V"580>^Q(AE0+ S9;78M-
2*]6V5U[@4T6"MN_"0C)44W>#R-M\T BC>/<5ET?+25@2RFL5/,_DK\R$ZG0YBQQ-881"$'T"GY6I7E
M^^,3BJUBLZM[%L[@H@8&K+M]*']>]"+R-0OR%[@&*(CU=@X(10#3]X2EQ2K; MW(!5NG\ARS)#\PW&:$4C4.
<4CY(R;FFC0&QTKZ%6\,![7=2T]M7Z#DHX@'5 MWDO-@#4@?-J_!)F4ZW6GM^[G^2;[]9\>0(2!B\TM6 -?Y%U+-
A[>V>;8J!9G M6Y))9JA!/KY>15?H7"OV88CWK*3_3+G*D6N&>&/%Q3%=I\)96MC" '^YD<(R MQ<V AM"#=B$M0*B\
(KKVL$9H;^O[.)LF>?$86J=WF$5; MLF(9BZ_Z+KZ2EX1Y151[?KZ/=X"_J<,_'M(;#^F-A_1Z]/7&0WKL674\I&?(
M(3TV)75I]=I6VC+BDO04+BB26SWW,"-="K+GWIVH24E+-#3 2AO(6H8RYU0+I-9W$9-EI L$7_1=XAP&%=-2-IF?
3<&6&HS$:N3VO>=567W MBY./K!5FV\X,B,>HB;0MP>:8<4D)2US8O?I$7Q.ZIVZ>QWVRK5E7!D2 FIES M,W+-
D7SN=CSU*C_9Q@98=@.W2I8ZU/N;D!KE5STJ]?>:2LQ[6 M0AO@WB@L@+7DF#LIEMRQW6W.OR!"09&F M?
PVAC.I+0TI]:UQP!]20M&U'3? AN#Z;/OS>,C.\H%US]6"Z[C+BV8];D' MA<_F/T1[C^"*2'-
S[]/'@P.7KE\KBLWYAI8*"@H=I%J;4^)<^XJ.%#U:IULN MAA0_8;FR5$LS*A84%%)*>GD*>_!C'SV7N-:/(0(@_.DC&?
C"'^)YBEV (-7$ M@/V_@JIE7FTM77WO*1($?OPA0:%. &4X [;FS;E>)]J9O5E_;3GR"]Z>/_[0W M+@@F:Q#0&P5X+!?#&
["Q;L)Z,5'FN.GC8U%&%UT0)WXZ>R">_!6FQ&PUD;N1)N;4! M4YKDTJ%)DSGTV)MI
=8#"/,7WPYHMP.ON.D\LE.&93T\: (**<[=308:J0 MLBL_[F!
;_I()M]Z03';#2FLC]T)BTF+.0(KEK!RI%,&&E(4/[8111EQ<_A> M5!(RY]H>BLF!F.>GB9L,*9.?NC./,AGF2.@Q(JXEQ3!PX)
(;QBL!#2F%3ZT\ MZ!+BYO"]J!]7KROZ#J^4262P0TKAVD.%OJC!^_]3S "[9\B)[#AX 9R!TLK8^#3L: M5':-
X@AMJ#,@S4:/S'I)/<@%#"@)R;'_2>!..=O<\ZG**;B?&'<>[8;[N^7D M!TPN*()TS,([J>;GZ':'>3COYZ;/QSN9-390 /?
JT/ZGLYR& FR M@QQ8<_*!O8F]<$\.FPMZBS8J)-ILJH0',I5[,2.[*%3A8HQ2D;X>5F\RZ#V" M,R^
8$/KI:;5+^M(>C&LVXU4* MT+KJU(!2F[Z6PZY89))J1'[HK2I![>;=&%"\8XSX,Z9H$?@WSPC!@,*@X<4LX($ MM1N#?
+$;9LP(CAG!,2,X9@3'C&"C>IZ838%[ZSFT0$PB,5C;Q("01=O\8"V- M?;A4($+00<1!*$X7VZ&?7LB/3?J3]"0X'-
>X*P.B&:U3NTUI'S._8^9WS/QF MIQOBHZ?T&!/:(B!GA(B_[G\:U<:]63 /-2W
MGC7B2]_;>A[1=Q%EV71&=]AS9%>F&,6V!D1?>]W*RW-"ESR_KP@[@C"-*CS! M<_
'$!@7!7)BGHY]*!L$Y[HDO9D3IR?N1V"-#Q\- CNSVSS]@((5P3%#W,W60]AM#YXSY"SL+.?=H@G'@F'TY,<;(2I.*S
M!RE:.T#K_]K+U?^S8O2L+7ZYK\= I.&!2(S"')O(7SL6D3^(/4;$(T>(,F;,.\P4V^J-*M;IY58F"@3UD@Y,
MIL_[A8V6]F0N.E; AM08-&RD2[F\'9N@7NJ94C]@XBP\L.;E1VI@37PSLH>) MJH8+ XF'.0'50NN=:7+7#
YC3NVLAVM"KLK.G7LNI<_Y361C:GU,K1N> M6M\ZACD-)5S;>I<$_D.]EUS?]@"2[?+$C@400V71>RV &+/E8[9\S):/V?
(Q M6SYFR\=L^9@MUY,MW^K7X\)& ,<.CDLQN,$X8DNVKL6AYZOKZ-S'#>XRT*+S@RX M%;I7-
6G!&F.KT%CG1')QQR;'5S_(UYMEHUN%X?-08SF9X>5DAYY\&\^UCLFW M/4V^[7M:Y\V=:[TCWX< !&T/M9;[,2
V/LR)UC+AXPGEOJ+A!W1"^; *XK74 MF8X%\6-!O&BJ//<@=CQ MLSX)G!D9D1VB_TMD*\AK/]:0/>S:EY+Z>-8-3]6
MS8]5\V/5_&%7S=?X4?<(NI$33M$C0&NR4>:XO6RPX1<*WO//O;N]; ;H$A>E M)D4$<]U<
:Q^MU:D=R6>LPCH8]WPL /7 &W2(JR:7;T07+,#6ZLEN[E?1,58 M]SS6/8]USV/=\UNN>ZX4@PAW:CL@
V*WO59),$@VY_T,EOIDUXFG:O8 '#@/
MO+\JE75-.SG@NN:F+!E+H@ZC&+K/DJCQ7(H!]=#CN93#KY8V\5S*6$(]EE#W M44+=KP=Y$2UIE)Q@?F&'SN+
[:N+^B\ DYI.NE=^@&Q?#)NOBMKLFKF:;T0ZX M5KMWWNU9,7=B732Z@N/<34)&[OF\!C7>/[2O\48[M.*+1IT4,
M_7U8221MEXF.2:0QB30FD<9"SK&0JE0'2/339S;/ M;>+!7\#E"A Z:Z:] .8G_^>2TDL2G@QW1)#I-Q^^&(%_E1[1 ,N0^
M9>?C"T K?,SKV/EF!Y,6)TU>;.3*)>5;]S_L#'-#C&E)E,L.8^1NTSI=0;A8 MV,+ 3'U' L]/"T(6:%TP.)@QTV.2;$KSA,O
\9L4FV-2"(MI2PX2=+T9M'BN9P,(%C42C &UGCTL(R5B-8JI.;D[:@(W'O?#KCE(/T.9<8R
MR=3U0CJB%^*UJL[548@\)P1N MC-EW(@;\\/B]SB\2M3%@81U*JC6?>2C?=AH6BD
M.K(,,#;.75K7&L2XSQ1BW+O1$BCRT1CAWM<(]UYL_W5$L,(Z;BW%S8;2B7?T9$6_Y)B
V%,6LF5+W]FEA!TE$#=_!8$TL#+@/ MT/>O(:*-NE;*AD@<[&9G:$::4RXV .7)=5_Z5'@[_CXLT;W,&@-K^I;?;T') M?
R%=A/@FN >$V.&GZ?+P^SQ![X&*E]G]%C3\UYCEVC2\//P^I'#V6,/+['X+ M&DX8/0.>3B5G8&#
::A#UG,&Q]^"JF>,_PUX\P7Y=[(&R)Z#>&&[M$-P;7OH M5]N/@!&;3S4L]WEIT+T[5>/T:"IYUAAL'V]ET]MD.C/-
PMZ&616W4.;9EC)^ M;V/+;:Z!*0OL+5A9<1MGGI4IX[?/OMTA6)FRP-Z"E:6;R @!;)Z)J2'W-L(-
MYMJ7FK3>@G%M;]^P_5T))IX\8]&+%]JPV6?ST11ZJ.'H :AX_(,NG%XP3];-
MTZ[UECG$06_YI::%3C28R5MSU'(\W3"X*G5V)&+X<[AO[&FVW)E[]3??/I]\4#C*EIQ?2\<:S[&-
Y]C&Q:'XJ6^H33*,2A';A>,.^Q3+!FL'T.3?43M*23[DB$I)1 MNGI=>2CNH;?SJ_+C[G/4>_#I3(*?AZ.TJ272O5:OSAYC'
,>J]H?I63P[W"4 M,,?&4GG>=J&X1YX3EP_.AMH-2R.RSRO\4#ME:6:^.9W6J\B'MN-6G#TT:/M> MJ3@W-BMS.*@3-
>\2@\/:T_>IZEUR_8#4?4N95HU71&*?O1.SE%Z1\7ND]VWW MPQK\FY8X'58\1*/7TU(,AV,DN?
VY!G.0'OVP8BX:%5^:XWT_2/X *.\),[8O M*$>V?^O- .Z\E_5C83%A>> %J>B2:GH3'1&)=0 M,JO*G#
(THPY'8_E3*H]\X8'/H3'1&%[0IK&-&-7WBCB9SQ&8VR&X(2-[?:< M^%R_:$&L;;+/?A-
_/:PEV[#)I1NOL4AL_P'X\GBZES9)^^@I.%[FAF$JULUD
M6"1R@&6J.J#NU:BIDO7$#L.TK(4I#7IQBWG7L_RX3QGPO;F$9;S(P*2$MCG' MN-^$CH[7%?2:LS9'F\V]E. .A+<0XYN
? <(FC'-JO<0G)Z,M)N=L'NAEDX"L(VN%OF%W(+K0H,\1#;P>H4O5*]R1T">/7H+L19%56\$ZO$7<<[/G+ MRQP/M
/I&/6*\I[>*\(I[VLB'5/O"&DYMU>"2=WZ3K<&W!?2-8?8MX9TXW3M MW]4A+>F>+&$4\(+ '?5M['K0C0YVQ"4#8@K?
\+#%X)$"(+[Z-GWG.EL!NBI M;.7 PFDUL)#OW5K%W5LP[7\/(@O1,P9_1L3LK];DAS ^P 0=.&=$<"!:::/- MHQU?
JD273<$>70!OS@Y;((+"HL"G16\>;X<-]76FLR=D!]AV*#;B6P(E&IJQ MTZU5NX*<),C2*K#I&B!ZQ7A(5WL)KUL
;\".55[]\D(2T*15-A>^C?%T]IM- MLPKA%#W06C+!!"> 'WZ"X^5-)":4>9#M]3*]C_>1E/T&-(G8>(ZONTF MF[?
\R+0T(&"J(C\IF@P2'FOJ3^XK(LYJ%DZY(#,8<,\WVTD_!53R]E1Z->$T MFXK0V])KCD+DMBGQ><@:$^:#FW
0V7>Y1)BCFR8:E8XO9I]F>D6KRZN85\F M5 ZW-8D'X !O#=QID(L*U4^Y,GT,*>-/G<[#,M09D+9Y #YU\8BW%VYR
MN"F_2G5Z5DW:I'U;*]JY%>9ZWX.43987J MK 7Q4 ZL.-L++VS.'4+U%([D[I,@ZD >I<6UJI$O9#,8CJ O43RVFSSA58*;K
MPB$O.3Z "]6<:I)G]V# 5K6).BC1V/]%NVQDW+6'(=I< W!O;Z@^W@/TC:C> M@N4?-
NC$@(H5%=DU)=.$0$O]Y@C$([T!X$2$$N$>LI%H: M4(S2Q!:E:&N0/_OY..%DFE3ZQ_\'4$L#!!0 (#. ;%GA1ZYAFE8
+"E M!0 5 =GEG&UL[7UY<^0XEM__&^'O +<=X>J(M5)W=/5/MF7&DCNJ5K2K)DFIZUQT;$Q2)5'*;2>: 3%7E?'KCX
%F$B1(@L"C M:B)FJB4E*Y\[X?KX>%/_^OK)D)/F*1A$O_YNS-W_^LO_^5?_O1?3T[^[?3V"@6)O]O@.$,_^P5Z&_0ES-
;H/MENO1A]Q(2$ M481.21@\8H3>O'[YQY>O7[[_$9V<_(73./52VB>)$2?V]N6;XH.SG%P2_XS> MO'E%__?V]=L?T!]_?O?
NY[<_HIN/1<./5+95V-DR"N/??V;_/%".Z&L:_ISZ M:[SQKA+?R[BNZRS;_OSJU9RE;L-].BF8G[$\G M;]Z>O'OS\FL:?
(>H1>.4\]9@4C2G$M9:?WE7M'WSZM\^7MUQX4_".,V\V*]Z M'7')^[UY__[]*_YIV92R#[*RK2S-CZ_$A]_]Y5\0^A-)
(GR+5XCW_CG;;_&? MOTO#S39B7/G?U@2OFE6+"'G%^K^*\2/[.IEMWC/;O/F)V>:_Y7^^\AYP]!UB M+3_?
7BJM]+Y&*^_$M=$R["M;ZMS3\,&#=))[]E5,>#CK>T5_JNF'OV8X#G!0 M:,A8ME#F$G%?
8809Z<2OT8M8T"3DV&!IX4DI]E\^)D^O ASR<&0_G+ ?N)WH M+W\[2RC*+!_2C'A^5E#BXO_YNZ;/^UF#"# A>'*"+.
NS/;J,5PG9<)S]DQ!C0LMN7?H5GJ=J:],).Z4=[8\29?0;I_T?3IR1HC.^S/ FU;."W'Q63GFD M9XMCEFUGXYS'$IMU4$8?
<086O?2>4FQ1/_\8OA?*>AQZ'?L,MI?5)!SM58R: M/0_ZOSN/9)A$^UN\34C3O$[=$KY?*;0[=+
K"]327L:,YY8Y6446,K"V7NXS]A-"!FZ^-[S**HV?)+L[(_BP)U![8U0NZ0VII M7??/UBZ0W55/\)'>6V.R0)P-
2@C*62'&RY9+WWM?+P,Z00A7H3B_[!BMU>VA MNW&'IG4'5C2&[+I=(H]T6DH>U>E;'N^704"-EN;_8?
N2;Y2V:&X+W4-;-*Q[M9T-#R)[9)NY(K\QI+HH?$-^OOHZMX6?.]XS^>$WNDR]QEQ5J+6?
BD,Z(6_9#/I>X)C0IC7STG53:?B4"8>VJACHW_66L[.YOE->6;@CJB MY"VM@QA:+PGV%+YX\#%<[VO2H\S^DCZ#Z6&-
$@[U*3X ,VJ67(@E[T8WZR16 M[W4W-('K2BI]"G^POR/4G=^\?;@/L\;LP88F M<%U+I4_A6H>?PW0MI91#78M30J?
0C3IYI%'.Q0@AH2Y.SAU,57?TTEQHHS.44SN%[5IM4T]S1'*X+ZNA97U@VMX7I MDEH2CUQV:C5<[MV&#R2

?]7TCR)5N?)9NM%ZL13M4:NO.U:EEWPL:FD)VQ7>"13ED01X(ZRLE; M@\(UCJ(NISQH!-T7FW0ZP$&I!63/:Y1S+ HRFK;=[(Q.}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{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

AR8!.ZK],1A+G#^0 ^0C@AP=KM9' $!!I@@.4%B_#B M5U]XO5+PY;71N[7:A'|>K]=BN' ;K,'04SG?'

E5F:MJ9>)QU$5]\$ 4^N MR:=9AM1^BNMOIOB\F8&CWOZF8$F#>);,G"[O##%\=5DQWO$"@!GJ,&;@AT- M &!*

(.H'O<=0 O0-#\% N@>&J0-?:?W<$L=&)#9 N_"Y\.;2#PKQ9\[:O+G./Y M^HNC#'<_F+L!-O)!1T$?@$D2>+%\T ?PH[D)#

*((-\&\#HWP7ZH!@O!^-8866 M$$3Q .MLVPNS1+L=-RBK"=\?O!=.HJF!_>'D_HEE09.1[P21C8,G0W0%=OM^*

MO_G[J7[;DUVW7^;H/8CSH4?8#&8 (CWHQ@P(0+P4]!E^961 VPS;:+(#CX:! M9V4TY="8(5Z-&0H+/!-S;\O#

[[<.+"'0MSU- 79E']+:KU5+2+\L%>R+-G1\ M"%AD(@;O$Z*#;=#57I;P-T0PMI\!>VY8\)U@$8'VR'KPZV"63;C9P?4-DP4P

M>K+WF]6)O[-4P"F[+Q!R(^"(^]VL?K]\?OCC?/E\D/#^&Y M^Q=H*A!1H$"!3,"0Q&Y4KK;+3P(QD>=S "[!AJ_[1]A/*

&1FFAR:EF_D2?8] M8(X;7I V>=!)S3MM$K"-8=9MOT4OX(VMG=)7# =:K#AO S\9"MQK@;OWLUA*

*M]F7.3K9.V>"OG[]W4;HG]C.@O"KY[Z);); M?.@;J@&!0G;W1R)"(*X"5<7(V.XJ$?BDL28' 98]#KX::@=VZZ$.U \-M9-6*

M1&R'I $0[Q3S)>2Y@XKTX?!?=:WU,OS],]Z8 -?81WYB!;A$^PS(4#8ACH7# M]8"'YX9>OWM@2FBF

20$#N4T(AS]^QX)#TE$>$"$!T1X^!O"]#TW1X;FAN? M.O6[??;#;WVZ.X>PHJO51H(;9F]?

&1748I1B]+C.XC.WEUB7XV:N MUX^^!RR&&>F7\43-9@@=U!?#_BL& VP$_3<81 R\H, %W/F$[H'7$01ZY:D&

MUF@W^F!_@T',V3SVA P]W9"Y+Y8=B)G##_'(19H5T1'$B!H49% >*MOL3"8UAP M65M*(?.X>L5*/LF87@2/!*

]FGCUY_8[K "?B_?"@61.F50..!'R0$^2%PT15 MX+F'&8"X.]<4:+7!"&[X"S!0,&LPVO9^=0T/V"^F 4;O[E(!L&"C'6;H7TU$

MQ7 4?P86%-I!,%#A^8&/&G],WD#;$R8X=N'\2%EY#KSN&+;^(R :4]B.8Y*

*MM@5^W*4>/X_M<6/+2(QJY8182Y9S=CD_R_'R*O+(]G4C/F*8!Q3VU;JV;"R, MU[CO0DC_G_OW063@]X!%4Y$22*

MYC0V(>%:0I-H&6A:4DTHDC)BY)',4K2J)G=$3GE_GH>GU0E9D/-

U(5[(Y_:6P,>R!."OC_8JH@Y:)]RUEMYI@DE1J+N1H:=I M_IQ/C'2)/'ZFWQTM>[XN]X62E&:=Y' :+QLKT/+HF4-*

*EM96&=:$P+75G)CM/ MDJK>@"T)XGW38HY>T9S3VTQSY84_:)?*I3(8$G7\^DF%)'N3)2N)N55]VTF2*

*MDTEQPH.61Z^?:ND)LX[/U]-2J2@DDVNQ5S=AR^/7*SU3%O!<,SFM3;B6.Q@Q MR12A2_3QZRE56,^6?*

&8EQ./5S$1/K1,C,";ZQ.CGF::Q8'-9H58?;R:CL;7T M\O"9QZ^?C;-ZWBJD)L+&JSOXA&U3I-J0& E_WS+5H(>#I507

V3+)A,A: S MW15H21X)">/10.XY2FCEA?8Z;C;9$J^#ED=#(@R3U[U6H2G4K+%'V[("]C\> MM#P:DK#%?

3PG4B3XJ\7BZ;H]'[=@R^,A45UN4%"2.D,ZF\-8]G_0V8)_9X M2#VK4B&LI+P4C.RHWJ;HKEKH-*

*4#+HR&9>KDST<9U!C<$-C-79INQ9>D2=_S, MZK#)J NGLA+]I#Z=)8KS)M[@0*TL;K9X*5V>T:MJ!S[S:)K6*

*M8F8\\+9L4KA&I/*J(/^,FYS\.U'FER; M9>5<;MYJ"CF*7K2RG-A+U>$SCR>46_;K';.Y7@J+J:!R4J?2-!?PH<31F.K;*

*M\BBW7J8E@I5!^/2LNIG,(UC1^TN[75PA5XL.L?M30U M9F@V*N92B%/EXJ(VR8[8+FQY-":S6<\L-*

*5H:"$9=$.0!@Y,"J8.6QQWM)E<$ M*30\?=K2UAF>YW+$4%Q)!'[_FECJO-BL[@I9+0JP[*9:F_U&'3HPX A*/,*

*MCI(GA71I4&A.BO5-G.=AT^,>Y#ODT(]I[@K?>.W9G&QXM:T-'DL<]V"^Z"X[M##\BA=F*9LIQ6^4Y@X=-V?=-*

M]LJ&T].57<<)G9H!1GQ:(=-#WN05*OCU,< MX=1PV13K[JK]>/UE U:7/.I!.NF /5N9SO%T,Q'7-*

\2@W^&#ID<]2$R7:J>H M51F\NRKQJ3)7G27Z0=/C'NCZJ":TBTE78,L%>ZKFLSDK!>:. .N[!JB4,= !X

M>7R!5U1B5DCPDRP/FQ[U0.;%;BW=\;UIK;9>Y(K21MAZ0=/C'BR49$L9\F-9 M]&=)+UXI+%VM#^2 /N[!N-

%=#15S7K+5@$V/GEKH=5MXUA&S M0E>9Z3FOHU-S68=-CW0[.RUVE6.:^#Q[-@E1G2J52CPL.F1KFUQ[+*\W*

*MTU(1F TR2>5+JZ"OQS]JX;U%K#7<8,VQ]N)R0_+-IB#$^"J]MKQ\2J*7BL@**

ME>&X0T\FM2!+9[+^DN%&0FM^:PME0F[Q&LZ;'HT7;V^L%J[6MP0H W]1)?KQD?5V@HV/0;#_':RL@6C/$UWFO,&

MG1]M!YV@ \;H/%N\V M)Z9< VU/[!N24L=)I5 S1'_5-E.D+Y12/NCM">CLT2V"2+43N)#3BIHSQBVO MIO.PZ=''*

I!ZP$KN0C"7$#<-LS;M<7FL%38\[N^;&,KWA\Z@V:T4D4D[:L(! M4WL"DLFUERPSBY0[E:?+1L>VZ'H=HN<)3**

*[&Y0([8^=QW!=J'&\.V;)2"IYZ MW .I5J\L)L,M*6SJQ!+8>U[/'@"K[00H#T9.BV5ZG(N3Y8;1B!N)I)6Z1>' BFK:CZE.@*

*MF$SEI7G!5::E0;L_&^29! .MX1.@K): *,P*],ZXL7J5\8B8U22I 9L>/;53 M:4^2/9^OXYIGS%<&;;O3(0^;'FE8);'J-*

UPNJ^,MV]QV&;8KUTM!TR,-_O2 M5&VS0U?H#B6[D;/JF\PZZ,"QVBQJAC-D6N4J7NLU=6,K,0+1"=ON>WOA $%6

*M!G @F[Z6>:D?=H*9Q1&3L6JEYQ6AZW379;TIE#+6"6;6Z79796:17V-F43\Q M.'0,!M4TF*>'(Y^%H?KKD*U:REA3?*

5.KC5[6("@N >FZ^^H1P VOA%U3:U9S M3XT(G/(@Q7"'4AO7T"OINC:9;M09?]H1KW5[#,.^KP+ID7%L ,

MV)S5_NU_^%PY'"@NU /S, H88KG3=I&]CW[;2>;(A \%^ MMB$CP7Z&(2/!?H8A(\%^AB%'I\#H-06;>*

*[(A$S^)B%3._=TA_V89V0@Y4+#" MW%%8XRD\JB?;D6^WT-?9HO^N01N76N_AO#E*Q3?CA__U!_OA350"Z<-D1 M)*

[X@!I_%;AN^[6EJ&-:K.X;RO2LMT%I'>:T/2&K/N'("D=6^.-NVL]@F1E6B.L\O%A.>T[C!G6N0:/4J'E_?/E

MO>R6%CT'"UF8=VEX(OS218Z>A8F,B&?T[2H! >WW1"]1S:R,AYVI6M#\,@E M9-JB-

*7Y42U*T[':O,C(E[]+"0*;DDRQT=%A]*#2)K(V7G:@07,L#1K2+4 9G MCY#A\;#+;=7UO35Z]/%UU=X9Q5T&5F*^QH!*

(3MJ]+>N&5_OJZ MGAN7+VMS'HTMW%R._[P,_MYX5;^COVW;D\U[@6>TS'^ZS/\L:TMM9W(1_T+K

M_4SK3:+U_IJ9]2#K39UKO2]NCGVPWD=&UOX]NT(+L.TI4^V-,!#TBS2\Z?;_M(Q@V_#W3[+,J&_=BL%W(T2(/X4 !D*

*=?O,ZZ<%=/\9U'.U?5>V5/=?+T5R M(Z[DEPKCO][M\.L?BJ)IH]%U1U&Q+6VSJV^]NUWP\'*IX$+,\;*MS=CGDT]*

*M;ST!7]J4M]?P7NVG!?F@1:%7(/LE"G*L%.]_+KEW) MM'1?"G7M'CRJVUV/ZI0)*

(4YY0DD4W&9R_O:&7^HW;_@],4(O+3L.K(=].?E M9Z9D:;I9L-6Q$V>F M5E6_.C9ME4K+FG>*

<@M"B>RM<&G;&$P.6_681-B%LNA]L"FZM(,^QLCA0)^7TL]N<,/,+4(I2RW/N;\$YV

*M\'SQ9^LGUG:"\.,FO/OX83*3M]I6;SWNL\5_[B.@=Z5DP]GC^B^-]U?O%BS7 M/ULO@8;=(]($V[&*O:TGMI+5&I-*

>EPRV_.>I@=>8QNN;3F0" MU"&Q;E;JG>2T]\4+B5QY/LUV5W#?OS%<;$DB3]N(@!A"L*4BV!*9-./9X"I MA(6*

*M>8\S.NMAQ=H*FZ;5FXHMEZEXO$3@,') TC&682YGDC^XMB%(>19(>8!(P1=1 M:E-*

+J:K39!21]+),RLD,%N9F=6F4&M>9X_!CVW7<-#3((]#Z?? M:N^,>@ S.N<;#S6O-

*LJ$>G=I0W\XIMFL)./ZM"8KRU(FO;1R-']INSQ?2*52 MK6P[*:0S^F T\O3AO CL<@)&#Y@8S1(HGX< Z#D*

""7^D'P_LGS?[0;[I\$Y M\M)[-CXB[;,4)2I"B1UOE.:PYINSBU,%>PPKY!6M711]O+7HJK[<36HZW+.3

M:,]^4#+#K2(94<EGP>B1_<6#*X_,5KRBF/B&FC3J@J;+*9>7"#(L MW$;&|*

2%8@(L/Y\RPWO&8E"O/R81[FUO,2<>/KVI;2'@CJ$ =VWU[)-E?)NR8K MM++5]38W\]J&I)B=+FKDS!GQ[:5C

*0N)"DY/D#&.N" O&0%7 M9!04 5>D+#.D'Q&3 Z0?=[FQ/T!4Y92MH*A<'Z]9A2Z>LZ?5OKMI#9?2Q;F2*

MFBK[A%JJ940V,9Q/-]DQU60#6R&);(4K$B]NK?.WQ\+3Q(Q;SPLB;EPFL'/; MLOPO41PB$;P@N-4:FQW?T 9>-?5//?

*ES1G#54P;OOR$ M>=05Y'K#Y6:&6/*V;EOF&R1#KR2"AJ$4BDK&*))%R2:$#0@;'JF) &Y@10D\&<-9 M#L$-@AL$-X\3-*

2I;S$)-^N043Z\W0X+KE1>2^.FZMEI> &RX"XT+TF@M%8:X;=$H# M9<+1(<;P"&,0QMQOYNO1).SJA0[.EWQ]4

*E#N=6+>\6GJ.R_4-KT_D+?MP_E MW3R\^QZ:GBO.C00?"3X2?"3X2/"1X#]V'O/V@G_SK&4D!/_ADY:1*B8O_FS] MQ-*

I.$/#<8);MH3/'$8X>H@[5\QGW/ ^ZKU"'M7")1,Y,Z>LQCD\-X[SJ9K' MK/*9BU=Z8U?IPM@0)FTA3A/=:C60)LSVM*

*[LM:KZ:G$V,)T+FJK05-N+7&]M+C\ M[;M4/YDTYWE=G"7I^;8]V$X*56"M)X,R9T0,YU 56 1&"(Q0_.&[^.:E.G6G*

*M*W3&>'KH=P35ZIM-^?+XUFQ+1I8J#,5%JD>.O.W,VJP"?&,1OB%\>RY\0S=: M("K$XU*

A4!7V1V$\O%PVB@UM2T5L!Y0,B'0RX.%C%I]?_BMR_J8E%;V%V-K8 M6[>Q'0]6SL4->:Z9F.:9#-/ X\/N1AJ6YMF)TP

3%EQM1\62'(ZRB@A([@I(M4%81B>D=B.D=A<4B=-/;9UMH)ZEW1C,VZ0II-9W0_G_VOK,Y=659^_O]%93O M/?

*7N7==X*X! ZYR[JH00.8-,^$()28!0 @72KW]G%$C"&'N1;.M4G;5M/$@S M'9[I[NGI5M9J=T!>?*

*0MMQZN50;J5&+*VK$F=')W7!\,1W$+)< L-,Q["C(*

*%OXXX+I8X:'O@4?A&>+/ M$/MPO_XR^_4W")8<,P$*KV.-Q!5+9*4L6:3G2VM5JU[=!!"; T1.TE.3$4>Q M86M2G0R690J:*

&1H MPNG^+>.G]_+#R>;W%ONH3Y&->)U]RW;/XF.(/%G!>T M=

(M3(FJPDCXLG\>*R48YFQ\R/B[=P_%/2J$K6B_6&@ECV:-1*HP&B.B65 Z*

M"CN4).LVC6.C=CU%%G,#32Y.V12=Y/G8J#;J8YB3AH$EG@D"#P^10G (P>$;

MW07II(;)FM3)+1"BEEUCB:R1KDQN@S?M-4T5[&%49(O%,5\C>;J=S5,0;V U M"9)\3B#)$&]"O GQYAO%C736B@G:

*<,BRW()<2N^0C>L%*UUFCU-M"Q);;"ILIZWEA^E>'>(-S)%)/)/Q*\9_OCW<.,&>>ZOE-> F\0#K"O-F+AB'*

*M>6NU]^AH>)=*QS\E%//-%WF;=.+[B^OW7V0HKM]ED:&X?I=%AN+Z7189YN]_MET5^.7_D'^/J-;W[0U%B.TKH()*

*MK"*J&R4R(Q;X<,A)1F0.0S@1?7CD=/HYN>B]R(11IX@$EP%%RP3.XEY[_"_[Q99%71,Z 4##V!&D3 M=X$RY*

*$!@OSK*M$52\"48IDQL\B=<"481=RW;N?_7[N2W:2Q17E=TXY/$O3EEP*]-;98)\B6VB:K\V42;<52IH MA$5V?*

H;T"!!3Y9;1'9)Y>!E5Q'UR_N:_YD36-I\".53TK5?AJAP4*S@T_>> MZW#&TJ>_,/3%47KP]{>R&/H2.Y-5-"#{P)*

*:W*B,A>AYD$V<9H9#?(*!0]5 M)$WTWP/LT.0AV! ;3OV'NXAP/$7&!HRZ_W=+YP]0UAT)?P9R;:BPS;?KC/Z0 #W3\"9./_*

M@B,B_QO!G&_^?<#: QG9[K(;"8$?O?%XG]M U>&1A:39G'/DX83@!_T$.AD+ M&CTM,VVCO2R-

*&DPQK2WZ<"CZY"+$[M<@#^$W^XDASF-$7.SS2)+KQQ \WB'!QI4E*F5&$;ZQE>!R/CAR,Y9J4;-5%FF*HEZV)K=7K"*

(Q$T#M4DPK5&<&1@HLQK.69GHUV:Q0;KI)+K]PKI-1P9F&BW4UIB M=I:F&9%+RV:Z0#:6-

*5&!B<:S8OQ5YN09XR*X_EE8H'-TJE1'P].5$*1_DA$ M2%:N+GA<&6!IHJ]2_5@?.1RIM>B!@G0295E=MTV"PK*

9FJSWX\&1W+BM<3R9 M';=EP9.#M%%5)K#F3;+)%):=5NJU$UEQ38&2 3+0XZ^OF:!5' M:&\[JS7S25CC,#*

*(@#1U!U5NR)IEG*GF:\BT,DKHD^4"C P0%$NWU&@''2WD M;*O;SD@BWK?'<)]DX?,+$6) M.M5TA*

M9NS5CF'U/GGD[8VTG,EC[$J:L6RZ M*>F$#A09.2(C"J&TYW)59(N-U4+-M LZ/0!#T>#0A3 =Q_!YM")S\UX34>)J M

*9G4X;%J<"C.3^);IM]@.*4M9_%1H=9,.$,#HJ?GS.)JCA@Q!E,3R,@JB8#(244& ',P6TAC1\Z^\,X&*

*:%&&S2G&831E]1ARLA6EC/'N-UIT)! F+ MQ(HBWTW+*YE>)@6*1HU6B@+4.@)53#8L*7-<1?*

67%!:W7T:XI8V0Q2>G"L#DSG+Y0@:%DUYJW M6AD=?"?Q.B/IY)5D4;P-&I@:(;<5-*

*;DO))&LLUYDLFDD%D<0+5;175_Z+3$ MVZ*RS.=ENXNMZIF!D,1U9VB L$EK76;CQCR'T(,!^=JM=DL)? 'K400FT*/U M*

9HF!%86[6JKO!XO.SG-&1H0K9::Y%)#8XDB;8:2\%EEM.YEG4)1 =$JOU;F

*MG=>XG6&S$EU:MAK1=+%&P:$!>3&J211/%&HUI$T;'$9F% HI.[4S-D*PY{GL M)6.D;<,Q5>#.#K,Q8OV6#D ,1]Q?*

DJ4UF].RY3(KC2OR/([TYRF]?IC%0'/F MF-($^!]F9DO

*GX1FXC:9H07>EE)T7G[R#:G.)/_::A)JF'KN#%.2;^#JR:KU<9RJOEOE^OE8T+;Y0OQ(GW@O,;'VEMRC_YIV B*3Q MBBT*

CCA1$%U1] 5P$2<%6F*4\O)]7%OU^+(L_L#I*7SP+3([_X=W?X=_^5P MRGN9YU&[N1?*

FU:XJ2G^\G_872Q(=_VL/=^)LRU]WW%R/MES=H^ M3C#B8!G^Q'PGU!7M,V]_X"^)D['H'3]LY_DPNC4$%/:#>?*

]O41@;_>7&#Q: M3N^Z[5XD9<^#XP:FKMC6H0=W[1#ESD#PQW,CJSLAHS\^^3@92@X9<2-

&O'2$C0FSZ68P@7T)D>@0^A,CT((P(D>E!&$&^ MH"=SX4)&A-#TLQ@10M.C,)Y(4-./ (G\!

<$#QEQ.49\M.;.>U'7VZV.:!'\, M"[<*M7[R^3.6C +4H$?_M\3]O19^$-?8M>]Z9:RA67QW'F,OV$D#Z>X\AA4F+L3=

M]XS:!1^)N:&@}H&5/"2!FS\1_/"[Q# MA1 WB:?7>"*

[\B9UU+]1LO>*KI/C>.]EAX(;"N[G4N#NO>Y0[4.F6]#B[7_KRXQ'7221^T&,55E'Z3H[2,*Z/#BL_T8\QTCL*

M2HTBOE+:QX]2YW">V7.]DOYS6[MZBQ'-31?1V>RG3,&:H:>-->4HK&R(8E(P ;RCYW_VH+93[Q^#_SY7[.YW4A8+_&

*+P4P7_?@=]CR;Y MW_Y 4 6/4,1['0ANNL40SO./-"T*S_WV^?1 <;/+Y5,\WN"?C6)G&4GC--B[*

*M*K_I*+47.&.;OC9LJV1{P;.%N*(H0QG'D)E1[_K<79:[WT^>$;Y]<$SNM'D M%#$M#JSM.S>E%^"5P!1G2N:1&)HU2S*

$FI,8EEX.Z\O%:"$4QK"5!O[T.Y%X M3L:(0 0M$H;%'S8L?B<_,T2!QT4!GK=56X'-Z[&;IK;2@[P#FE*!*\16]SR*

*M"#2LV,8@3R2+3880X^*DN9;*O<((0 ,!H"$69@>$J!">Z7Y?#OX(,?W!)\"/ MNW]MW[>_DQW9HA1]IJ=-'FNPF-*

92)7J=UNTRW+@"3 P7TD,"0^ /Q--N&OP MY%B X53WX_!<^ \C$-]OW5_R7/B!]X*M^E%0^P+8[.T,,R-&Y:)T:\2N%$Y/*

M"]EHKERKWS.^D9LA[&BZ-$NLV\8+=/*YCAZT4_"^ 86>R9B5W1D?J!:_5 X M>*

<##]A!,;A0FJ4MM1J@+45K.$F)VDFPV^:(P @A#//U&\1!=0G3YIBD-D;\" M1/D4HL"J;J<016_+"RFVMN-

*(=$3WR$22$]HJM%E(8+,$ .7O$%%"1/D.N2*A MQ7*YP-BT1%>]ZCB!R2J=2%&)=H=,B12 $!@8@WY//'Z]P-*

*B7U:PLT2DJ)HA.ZY,P^^9ALV_N%NAZ)%A_G"MNNPI4':9=]?&PO%F?#]*Q&E=@ MHF-*

*+0O*E7"]'WC551TK/\E@Z5QDPL_2PT)KE:5D'9B$)0UGQYUB,##-UPL/.*

M,%/G:P/!I\-0RU@V.HB61V/$[@QS_43=+#:B=4 .&(8:WF$R!!FZWQC#OX(M,?W!V3J/O8=](#"ALW-=Z]*

*U5L:Z=K>EE)@QLH9&+ Q, "N60,.$G:^>L$/K MQE0W@!Q&!KHFA.DY87K.]TS/>9#P]$;=4D#; C'I@JBNLW*S:C-*

J!VN/7\76 MHB'>-8XQ9[A1/Q;MXD@;G67LJ8P-A>6BCR)N[4'L&4DDKAC^(':]$-1Y"MD MY808Y< KA)2?M>XP%>*

<;X,A[M^3=3"C/&\;[18(I)2LF_6O,!6Z4@CI!/OX\V=6[&M0Z#_U'"L'V5I,YC33SO7E.%8RUH-TU MP!454L52BD+

*C$J\BEI-@:(2P]%G4MGV',""UXZ"U-U/F8P_FP,<2-;(8)\ M103Y='AK;39[_+*VH!&Z2!;6IM#M%F<4A!4"N*5AAD|*

('\+KCUS54HQ)&=L-;C LD# MQ[CN@"H?B&V5!JA>2:0UAN6PJFC%2N/!JVM^.'?*@%N#7O%.V=?0FZ_9;;>E*

*M6YP248--7F%/5_58*YXPI>OR*5W[F(D#S!1T&Y+]++EO'.?W5WEW]FUE<=U_K*

*M(VT07;E.C*37U)A=D5EE6ZK6Q7%:8S@B@/0QCX3CYC.%7O%<2(L/C:,O%D>&MS*R[K_0;XL*U*

MPU+,B7,H@FT(MNU<;(UY+.M8MR!'"7CS+)[\#$2\)S\A1#R:XEP!(M[(M+K[M4N\#MOZNYK_8:VPT=\BDW/YB-*

@@"S6-3'1&II(N\BWF@PVRF;"P@&,'8$?0D< M"S::"?.B/A=/NN+:DH&E#?*

*8>N1"AY(-9*0+X(^64)4J+O!/+=%M/X>BS^P.0 M4_P__PPNY#'>.GG*74/PW_N]T/5);H5S^YPPA5*X!$(L:;QB"Z(?*

*HCPG#EVCHR='\1MF9KPM/B+7X\[M)W#S/4IZ7"]A:VT.SM*2R2NZ:1O'[*VZ M;IKCV58__J;QV)A%X^O?%IV*

*M.K/I]LO^0??&OODB[]U[(A3?4'P?_JPNE-]0?K_T4=^C"?#W.A)\]++_[$OS M)=(R1 YXL*N(IEOA/=$O7_K_F*OH*

X]!.#&D.B@E![V=RM?:HCQ)^07^2N$IR=QBH M_EGK_A(GAR&"7.IB:=\0.DI>9FA&2FB+M%B>Y&L-!U:

*(I]_)J_2)"A'E9ZW[M$8]V_WVU.Z3?$D7>NX>:FG:J5'JV;LB$(G_%C^@.V2/BIE25L]*2)L?3+IGEZA :KAP_^N9: M\R.@X?*

YY-Z$-<<<'H$14CR6@IQJT9K&P.:*49R7*,1.<,F; I4B$))?"_?![3 MIMEH9*!K0IC#]-5SF.[7XC$\.;A =]\EK:P&V*

"KR5AN(K9(M-FD4U>K=WM. M8$F8SO!QOS&9R\V2'5_7VDA,2HSZ:-+I[X@_D]?9!<)CQ9^U[C#=Z8MBR?#*

M4)P22Z56>0UGHK/5:[>8:[;U7!T""P&)<24$%/"A<01]Z/6=G]HM@8\ E9 MKB8327)=U5,2OX*

*X0C[]3H0Y3R&0A,E1/PA6/A#AJDMY26?(JH*LE-@Z.9S7 MDS/6<6V<)H_0M[G*:5B8'G7;")??:C0RA;U&PVRH#\6S?*

*GR+7R>X]>-;_'YJ M&SC6X]>JI*84;:Y;\JH_FE9S?:J=;ERM<_@Y$2XYQI%VLET>L#-[FE\-[=G<*

*M@HXHZ:1./9/)*P:XOKCZA!AR=FCK*R'(I;DMHR0UF9>6.MLL=J=:JCHK5U8+,&3P:3G\/PHA(9S.K]'P'*

*S8+AVJ@IB:*N)K,37+I M-_DIB B[NX<0\59ZRMV7>N_\E0>!A?2A%B>C#B#46(]2N@GFLG,.*Q+_-*

X_&J"&?"\4UQ:CE15;V:(X8X ME\0%[+P[%TT+!I3-R&(L:B)0$8[#]^CZ3X]GR-PICSXPPA2 M47<>97 6?

HGRIZ\KB#%:20^S>W7-6SPPY. '0$A S C,&U#$CYA3]1#" MH0+EP;'3_*?[SWN&4X&OV5T7H#-\JP1U*

ZS;=&7B@,V[M 'KEDR?\E- 0OB% MC6PY?9Z'BKZ X\"0L';>2! DNE(O $[8<._PC?L/DEW7PIY&JF M\U+-.1US6#?*

*@%.>YYE@4@HE0@$AE #%)<-A MN/.DC9YNI,>;K[>4D>8\!NB1*T&0988(<,:4 &3^!5?U-^S^K4/MI3T)E[Q9 MG**

48/N65$ M.M,!_') M >@Q#D:]A(I;6<+U-<8PH3=:RPJ0N1_ MKF(&DWT<@59PK-^5Z\1(>DV-V169Q94ZQRR[Z?*

UTZO@'?.4#W_C <][WC6NZ MZ8#TQA@F7&.X K;)ODED"BUV(:286:Q>?B5J@VFWO7CZ31(OP:3J"."+ HD# M)?

PZ%/N8XW 7DBWI86I0D08J0FC%GCGKDSB#4$^_8[&7X'VX#Y$ M?4T5=-'=(AQH$398XIIENV8V^*.TV5#

*!B2"'4P&"W>W)?BAN^, R@/^P'W9 MPZB]AZK@#S"NY)N.*P_MP&9W=%=SO:4#W^@?09K[_X)_?*3C%6#$0Z=Q[,'4*

M)EX $M'8G1 1 V.*A/D2VR3J_-K$QW!7] 7+'FXE1$;3OV'NXAP/$7&!D3A_V[I_('S[8Z$/P.Y!F"KN-]=N+/S

*M/@);JJ/O0$%HW=GXS8UGSOW>$:.3*N P+ J8LPT'>_S;?KC/Z0 #W3\"U.;_M@B,B_PO@#W[S[P/6'LC(-OBRD1#XT1N/]*

*[G-^5&E^2P?MU(#?,G.<*DF%!6> M:=:H/MC)GEP";$;JA5YVV12[%%.T^\E7K8-.-7$!1L8/1[:D:!/K+ODN.U.R*

MA$1V%LTQ/,X/G-)3PRYDT,:2'4V'ZYJ4U7IE2DP,O#,]D3BF.*0J2.8;]& M>C'&I,Q1'P\^L] H-,M#HDDP4K2N5VOS-*

E_KUONQ/G(X.%\7+$9+7\ M:('+]6Q5H\#(P#/%!8MSA>U"5,L6ZS658O-41P^,S#/@2JLTU*AIS!5';-K M;-*

*>4E.:B'P^^O.],<)(!Z:+I)F.\;Y^[U!OS/) MO[::A%IFLFH'QY=RC=*I>A\.12|+X\>M7, ^P'>K0%7#"!&Y@ WHS MP6G8U,*

MXX'=[\[;\U2?77]5W/;_=OU\N%6#/0QZ)@3_R8\^=-,&W](46.=,],O?];+NV=>IFW7D0:AKHF>4O?L<^3*

*MI36;T[+E,BN-*_(\CO3G*;V^%WQN\F-1L!6Q.H3-T@\[MVM"8T,M^#<'#EO@*

M[2E%Y^4G7T2Z%J5ETH4%4)9451UWR&YQ/026L @,S2EXDV78XHU$Y3,15L]Z M]:P]YP#NI/<;>G[8.]\L@?

007S>6DE) ML)E_WL4/OJ7:P@M-M /'>M3\|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}8-M\.\YF8A=S_3[>>+NVGF/(^T/0A;/1'P_%=&""4^JQ8[Z-E!HM)Y;XV-MPBTB6P'*

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}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

*(FX2)P&[EG-_D>G=/<7GM-ZIVD /L*P @X,X$T>'4 M'@5@0.,/=RF 3.)DM-_?*

*>#TI0C@T0+,\30('4S3Z=KFMY)WQ2P4H/,%:(HV MVGT.LVA&1.(*NV[9!3,W.BU D(.P Z\!Y0+N-D<#7ZMW>ID/.*

*7N'Q%S+(K6 M);N8_;&3<&O#N@2\NI'#NYN9U(_DI)A3E=]L_@M$G>B'M0ZL@"QT^_M>B$&NN%4UM_9BTZU44LQ**

*[MIT[FJ/#/F1G*M&,3<&#UY0FJ+ F6=&.?U MF7^HIFO)ETA3&FG2$#A+T-*X5I3B=(O,'>V'@H F_FU&S*/3*

*B:,"/9\DS>D M@>NH571+C)"^WW1"C_>W4<_2 H &L,3R'B[Y5AMX+FQV3FF:#48TQ*EN !M; MBV2 ?0%H&RTZL -*

?"!N[>NV:3P+]:@]1V0FW>,$6\+$&1&#_F3ILT<=# MRV7G\2^1JA98W',DV()]/YJCN2ZY8P6#WR%/1& K.HUO]:GEMW

.O,];C3X' M&QFPNER6EZ')[;XZ]NPZ^'_!5T/:8 Z)L>U7]MNGE[RG;TQ2YPOHO__>W[8V MIMT^.0Q@W@-

H^/H]Y!ON0C&KL*^DW -;4!EV@96,\!H9NF%,RC3!!ZP*+2X MY5'3N3W@26PQ:U38(II-*

T:0PY/0L\+VPV#&'^R:=NF_2ROQ2]"-B^<'$1/HE M%EMA";0QIU?5W@A&T$Z03SB$G[-1QZ&\V[!ROXG]4;-HMZ?

+3JL:7@$P"0]# MQO_>CTKC6\/TLKUJWLRQQF([R0CN]H/BA_UH_FNOS\XF2P1V@-2-7_[AW,ZJ MO+KBF'.",P(6N-

/&AQN'"%__BE 6W,K<]'&.H?_#W:W/ A[N;]@M&_BNR\[-C

MJ!\2$[:7W""97OM([VO['23]#]_I)^1QQM*GOS#TQ=FDMTTV8^A+[$Q6T8#L M

T,"K,F)RER$QV&039QF1H.\@M:MX[/X'9)>L.2A,4-L;1GN(L+Q% $Z #@ MOULZ_[;]JD'-5O;L5^\C8+$X81B

Z5"577O)LURYWSO"=%(%'(9%T=WVI1[# MMA_N/ "/XO^"(R/\"387?_/N M07\ZZ%Q^VI#V#>0/F-/8#0SH!]GD/^;L

*MW'F3DM3YL$PGJQBCTD7-% P=D^I@DTK@+XD[;?+HT4U>'*2M 2VL!<1>#%'" M+"9BYN3C<<5+TZ^>&59;@K';*

(,!\2S/UQL!@:!B@CI,OP>I=Q[;YC_D6;^WR M5XD9!#S4#P80G/8F9]KJEX]]G'9EWW1S]GP-

:N/5,,.A2^Q(&C@IOF>Q[Q/! MA6T6^[:#M/N"S?#-F_Q'^U[B^21\B=1LP[0YUP>#WPT^_<2$':?,.<)TIOK! MESMNGP9

=PJQ5G2^/3+@7(9 Q_;>"D9N'NDMQH4S30VHU>1=A*(7J<\V(A M0CLOVTP !AE$"!DF%! ;3-*

]+6/!/E$>B=M:2(BT@H^*>#'C'3H&C27&?P\=G MZ!Q);;GB2>/F(!/B+YB>'$[RI1OYZCU8U[VU;;WSG M1,L/?*

*[PEJ>^\7(*1\ 6@$9!!>."Z>:GW]^V1VOF2_R)9MK\V G0P%<(XE#2 MW!-$0Y2TYTW,Y:W92? !@PG\",JFXB=0NQ$?*

*[^#1%7GPZW0*A-X]+M1]^3== MY7&YL'G-9Y;S=8HP)0:/>\T5U#;:>-9YQ4NK2A-,&CS.&!96>-,+GU$J>1)J.J*

*M:'2)D%SBDZDX;\6JV2D 0DIL>(>^1XV*5ZVS:'!E:RT7]1;1SE-Q MK)Y?0*/BG>0;&#F5!-$S=OW0I^,Z;*

*5J*T3'E&XQEH#DPR.FS;DT>'"5MW1 M+&>#/'6^'GRB]SJJ24<(A'!$=&.;WSC.=B\)Z_-%-2^3]*

MO^E/=L!3QJU1GI$(B^VLQFV#J%/O21EW&)KV72KO-/Q4U"H"3%G7QC(E>#3N

MG9[OB"SP]A5O\P%_,QT!4&#^C"F"UX-M:FH &ON;AF\K.%D64&0%49'5@@EUG_.5#0HED#FAOE4@'ZB5!R^4CD+RK

M0=!6! ^6O W 4[L(-.ZEH23N)9Y JW]D U-%-U;/;V0K!9.'"O+342#M!M8(M3 /FP_T_N9A"HRYNZ.XN+#SH!J@JB8:1S%*

*KB5'S)*5=$2MIB>K M2CT;53&(3AR"@3\G64H&:;UM@WJ67Z.X+E$]U3>@+ZK[N;E;<35.7KBWGU: M=+'"*OOO&*

*6=*YKZO ^T?Q=2/ZMI?W-^N#[A5.A/0R@QUZ3.ZU(2D.]23[F R M:&05,L=@V8G8KL:T5**

*[R\4.N.^F)FE'7NM))ZJS*6I:L2&:QF81I9(F3FR78 M/=[7#HCB?PT\ ;0DN.T\.*

*[D'BE/5)&+H*TYQ,CN>M7,LK@%'R!5G\)D(-/'=.5TRG'0Z#/,(^6M_&N;: MO9T\=/[G1K[PW6-Z>L]HND_8ZW"A>3 18%*

*I1X[W@>B !:?%^8BS\TT27@/ED M6J+HQ"ZAX2%9X+= 1@*PU5P;CMO+F>6!H#M)'9OM8Z38O,X#@1\8.C "8>TV MU*

*V50-.,FSHIU\!M49UO /V4)"3> MW\V]R L1 MI+M+9S]!_1U:.\NN>>2T@,TZ*1FAR>O]LFSR*]Y1$;O.GO!V'-*

@W0^NW01]R<^$P.ZFE'U- MS1:29:N#$(6BA5IDLZV95T7?'!M+VN54-,M6,QEMT4VN2DWU#7US3?-S(?C#

*M(51I>P?I6I=['E\"C&&J6\IG\B;;;*A(944KE5;WDW$4#Y-KV]A==1NZHQ1% MYYT?J\,66(#ITKD&*

XM'):6"3H1R56FJ3)3DQ92(P7O([(#9F!, X(AS M2;=-9149B(;H@>[A'.>Y(=,M[/PXIN<.\?M&=R.O>I8OL?*

*#DA^*P3Y'.!Y: M:]!_7/G0Y!]*N5/C(KRMVFZ&$RR5N9&3M+2&0J5\VF.^;'97Q[,R)H;^RTU?1Y1T/6L5-J*

MP[B6[BE(61>QY(!/2FL3-2B8#'SJ(N:/BB)\ M-C\&WT9CFI;.RS")@Q]SU\V-^/4I^/6<3]T MU/V;

(&]YZN\Q9IL&M!GJOU6(^,0Y,>DS@=$<)';UQFQ=+NIESUXH4^]_.TW<+!RB9_G%&C+_+ZW2U(!U:6=[8-/'*

*MGM%8_!E!L",%@\Y@7<1EBE/% K@HL*B (R;[%WJ.9_VXL]_+']H[3MC(]N:\ M!M^W%%2=;]491KS-5LF;4;*8SJ2ZA*

MN!T[4CM/TK8;ZANC?;AMBB-=C+#Y_^>4 3OGV=_1D4R8-;@]5S\0T[T4I.E! MBN%Y0'D0%8T=&)K

*2%8E6X7OOXMD;W./M\+M5E-Y&%'7K&]WD&\U9[*TG(TL M K.39?F3YV>44WFB.JRY9*]J+I\/('17IL?*

*I.3+6EVF)E=IL5!Q,^E23!S*_M',D2_YA(.YZPSW_H,P=\G_?KLYS,F8/8>LFMV(NA]]>QUUPK:0HMICW N_0R*

M.QG'Q=$9.>T[A?3N+E74*XH85#9-(NTV;2SB?)$K8"<+_41-D8>BM0"NHREJ M9YW+^M#JD4YS$+,V)SK: MX?

V0MRZFGC8'-Q+-N)K;X_B!1;:WDT:(V"L^;MFE<;DDC?I. M'>:=]XI@))[F1UK#C"M,.SV@S3'6JC6Y.MQ0T<.AI"(C*

*[14;S'59'DAO>:3 M*38SZF/!AQ:-8@_E9*W%KC*RSBR;;;TK4F!D_'D]YJ<\6Q?*;.SWD1<+PI3*

MJ9!;@)')P#.5E#Q.XET&P9^V6/2$UJUX#.#$XUSXJ+7>099F5J:Q(5$V6U M2O7Q/GXXLE9-2;&8@N=DNU=M-*

"NCFBAT%_U8'SDW'9)P:49J,=9%5$]% MXM2L@Y&!Q9?&BTK"[N<(ICA_+65J5,Y>)>_S XLOX:G8.(DEDDS5Q*IM)5FT*

*M2OT1&!E8?'N:DX;KA?T*N)1=T*U6LH%@\.W!Q:M%5$J9*W&_<$-=[Z(].5;M M4?UX<$E%<:%5^@EAR6;S,LEDJ5J_-*

*Z3Z1'#DBAF.;*1D1Y'B*_(.5V(Y..DN MP,C XCM"?UKN=A(:LAJOQF0GOYZ6"#@RL/A9:9JG>SP",LZ*E-&MYWK&R,P*

*M,K#X5$8I:.ET*L94E>ADK*QC2R8-Y[E9_,=OUU[CONPG(Y0H>9<\I@<)\+Y[MN)T1!\;&K[W*V3: ?*

*>&]3*JWSK@SAB0*ABC!@BK>V1%G<4N)VXM+92@_->CJ M&5% FO;CK&>)US;0>L,C]-*

*V+W+CGLSW*X5(%_!V(C>8]MY(D^#FZ[J@R9D77 M\]C_\/-V,2KEZ3)X@!-J=5G5EW8C*]:??Q_)A/WA^OKG.L7M|*

*M_J;#=/.S] <7!<)"\2+9*XF,NI2+6KU.MR;R)PMP7O8@';'*%31;;S+RJL@; ML_5*JB<6B^,BX]'$YC"*

<24D_^R1U/[P2WWX"W?KXXW0G.,M\;4!' M%%YL<"JE[EL7[DT0Z(8_>G8-X]

[/CJK,T,3FWCYD3#KS9C_83'^=&W=]P_(MAD!N](43MW6B-IL2X7Y%1V_3\&H^OUG4T?"DT:W;>PC^OC3Z!0(<>-

*DKDNN; M^VG5IF?YUJS1&-QA;*SC[AN+KC MA\3=CEJ.#DQ-\9?*

_P^[$H99Z05T8Q^3=0.E^N#H8B0R>!UB&_U8_1.RN^=/= MH/#D"Y(\U0YJ)W"Z\TI8:68(@,2GDO]['%#

[ZEQOPA^=J[\;9/5;LA5RY@:DK MMG48=NM 7% M9$[(F9,V'6(.])-&0 M-X_)FU!M'I_HL4? 7,G95 MJB0_1913O?

-27B=6SHILNN6%HG%YT8B]Q,@O)AKN"6;PWU!.OK<7(J^T(7 MD)QP*

_J^TG/##2@TSD+=N+QQYJ56>,X-.EU&G':Z$?_2X9?2G>U56R_Q%@_W

*MYJNCZ[>2(,IK+F6&@A,*SD<$)RW"6NBAY(22\U')"59;/&KW'80VD3?"'?'MT M1O$-H??H\$]H38:*&1+B!$*AR&.*

[FE?..[GE=\#/1IGW;$P+Z8L=Z# EP&2KT";_[G$ M:MUSS/LNU[G]*

*<+!:_(4X7&_D6E4A_:)FCW2+ITB/U_'QO"8A1;K&I;)*DU3K M^P4B\3^\0NI<]ZF(%FT;!IC!YCHH_N37!R&TN"I-*

EIF)W)S+:;5:3$P)%!9' MP9]^X\]X##U2W^P'*>]P ENYU^!-B$X7>':^]>Z/B?)> A5(53]0*@*K#;R5XA4*

MET"J;8SU@U!5K_9UBLO5EXPM$1U!--5*M0YKTY$.5,6Q8%7WOT.L"K'J^V/5

*MS7R^QT2G5IF)]ZK3',_2"UWL+.=\GQ%O[?+)U+P^7G&I*6(7XJE5DT/;+=NI MAXE!GR^!!LL ?;^L$)}TNR5,?H5!ZC!:?*

WE"O'>/(#RW^N8"\)@'-$FA)H0 M:D*H":$FA)H0:L(GU_TMK-#("M,30MCZ ,_5IB=<.SWAE/-*

*G9^49VZ[D47DV*I6Z.4&H3>NPJZ63F!!{ M3B1/F5-.*.X?IX_#;W^8U^?C4HTJ OT6'Z%SQ=5;23H8@"(;C8!-9]S>,GYK*

*MF3-;QW@=:#:=8C[6QB4BF;!Q&I@76&!$,(T:Y'!*L*IL#>8&=$7VTYJ?L<] M^";8#L=IC@8;SNQVJ@2FNP(<[4T.*

<2>/US1!\.3='::?2IP,>?V;A[HO\9L&FAZAO:YN-VO#M@6J/VK# M!K]

<,W283UDUFB[AMU].2R8/ZR2NO/9W#HA=NH';!?!Q,&VM,H,V-6>B@X6E

*M#96X&J,^VW6ARZK0MY0^1,T=S5LE"$OZ@(_Z$OLBO)A>Q8Q&A4 M95B";@PK^KK-IXL4]$1>@I?/=D7Y>']*8_.VB.*

*[N3@#>I[H!!W'*7F--51=$ M)8CKGX=UO],FV*EXA3--:2C!+L! FR38_SC"NSF9$?!\L*BH_ZNWB*6G;#!OQ'ID!H<]*

*[0/MRO.F7"1-KI]@VG)T MO&(%X$=*<&2@"?F$CHYJ"9G &5MMMI#N:M0N*_4^%GPFBUCC"LY/F_**7K&&*

*M,2<(:GZTI7VMEEY*5*Z)R6)\O S]:A:Q"4LA2!JE"B;&DY7 M2BH<&6BK7EEK&74"8(>AA6Y_EF[6%*DQ*

*B,#;U_;K*9J@(&(6*@WABNZ8_4G M<&2PI[R5Q-IC-HV1B#CI8R@V&%=7(FQI'YAH17M=Q&NL("'M=CZ?ZR-&%%LM*

MCG6?EUZC\?XJA:78HC=L\(PE2AB=3 R\,RBW+17-;::8F:3I,:)[=E<&L%G M!A8_+_>R2"(SF[-*

$I3"96/6N(I='8&1@\5E!>FTIS!)A,'7>GJY)9/K:@R.# MBT?2?"TJ]Y9U)!N+8HE%$UC2@$^T)*EE\VPS2U9$)3G)

*<<2BGPB. MU*OY+L9R10P1QTLLN5HD>E4,C@QR?*
E%L=A4C0S!TJ3=U"9,N8_6P0"W<:13=M0X1]7M6I"/9<^%"OM@"MFY;9 M' ,,2$&<\/MD!UO\Z>-NAV"R+(?*
0>0S%B58B)BV]_13@@BA0UHEQ?3@,O4)# M0"3H>R2W@9E3A6W(ETC3 BN,N@#)[]:I'4^'FVO,+^GN[92^.5>-
*Q9NRP*K++ MS0BSA#]?H?OK"4\/.G[< OIK6[K<+M$1AV8#+'B1WA%L!FV_0=!8(B MP)4(^WN::8'_.*()]W(=[&-*
*NYVZOP:@Z-<0Q^!KL3_T7$'?S;VA! O/":;[. MF5[;4R]G_\HJU^3'HF K0.$8=:KH*U'T[+^MGNWR;K?Y^-;XJ3D[M:.>064T*
*M%IWU)"Z+NDRDI_0*R[(7:A?2;U.2\!G@I^7ZI[I14"G^!V[S3.>3 MLQML)L@7DORS%IO.S#,8)\(>(A(QZ*
2T/0@C0FAZ$$:0+\B/;&/U<(Q 7V(A(QZ#2T
M/00C0JOI01@16DT/PH@0FAZ$$2$T/0@C@-5$A(RX'"/.OQ5[7H3U=JLF/[#J MR\4R'WI]FQKU\<^6J,=B+_@]VZ]?*
W3HI-1$RF[J$^.D/EVLKU^JW4E6_+H[[\[\&/(>, M?B
*0/V1TB,U_'$RZB)0>8=*Q;MR7[3B'OF#XE];/8$>YD,L!+B,O!/"5N7RY M9K=7WEK?X'*HN:'F_DPN7U!SKVLKO:NY?]*L-*
':!9J7?W@#[1LXQBGZZQR;R MDHS=LURG^Y:3#37_.M%1\W$5_%K.T!W+:3K/;+QQZ?QSFG?OU=RC'DK\OD51
MIY>J=>(>\CY2J9-MG9/KEY)+G"S.E'=N]#3]FT E[]:, M>;>CO$O-56PEI>6&P/7>[QW'RE@,FNEE15;
*M27*RV*NCZR&;&G7:\%HF[E:#NTKQRA BOCY$('['83 DRTCL>YFVJ^?+VWT:8A8IZ+3^"S9RS,8->3I@OK:-*
*C0($<33;Q(E MKU,N,G8?\0H!(K0AKE[@\5(T15R1)4V1PR2[72Y6'12,8H6=7N H!M1M2S& M#5HF:$,=YTU,*RXI !"P..-*
S[#I=;D,;(H2(;P 15[8AVFU)7,2D!L-6L5Z' M$P8XDK59V&L:![Z\IW M3GC*BIIH<(H3,^($5=(DTW)K>GVU@.TMP?
*M^)S%GI>S\$9S?>6T/@>U_'D+R M] I .[6G5?OHOI*EM-&A"P6Y*';G$W2L9,3NZ/;HGF)7+:I6GM98%7XR6'<7*
M;O\/XCD>QT,+(P2,$#"N&6XZ#S#05G61C.>R4YD0ID:E9!6R8^0.AU:".8V) MZ+!)
*(VIF/!RT&V(/7RZ\QASQ9P(/UIS_FLE'-XXNW368YBM*Q&EMXE=^?;.H MJ^C7H_UR"4R'"}UCLCML6TWTOL<.^^B**
*W05=!N65KW+UG'5$/$I[NOM1' H4#\Q)!^TP\/ZFUY6RJQG.4T)NI^!V, MP0S5G*CJ_V?*
O39L35[$X>_S*Q35/4_KH)$RLRS[^OQ2UIBHRM5C775 @>C$B(0?(Q% M8WX.D\\4?$WA4^#U-1XC_^,$R*
*M#IV%*_BJPK61BL\5KL$3)7521B?977=I<]%C(GH^&M*'%W TB](D.NV7:R5Z MU:V%S0[_&,Z/054 OU$LP-*
*#GTA5N/E'I?'-L3[/1G6VY.P"Z&AN*BB1H *^! M]4J'7.'5Y^AL>+"$D@VY'$'DX$QXMWOA_VQU9700"$;9J-*
HOF[&X3F75&[,8 MH_I2D#1]%'KHQ;\$92&L],TPFA!C>\]_./ <;@Y$P M8LN]QV5JK1KFE/>:#,DM\L]LI]Y>-
*[*54GQ0F40RP4S%:S)D2XF'E-R\2J[S49,KLVE\NR,==H]B6LC[BG O]DR$KT=F0'H8XMC'CB_UTL[Y>I]9]K\F0Q7B[5*
XQ\P0="6=ZVDM$ M4>ZEOM=D2&50$&J].2TU2B_W3_UGO3D,:IZ3(=5$D&VUH[ET>L8/1"'4EFO+
*MIX779$BCWS&+RT)YD38C\UI?6>4&:8[WG S9JJTC:6YCQ?Z:.5>]<43RBMV6S27]%F*CE3*TGZL=Q8H)5[*
*MU]3C'M>/H^7#(%VKII?L;*A6U2H\<^^:BDGN>1#OQI+III*:EE<9(XK(!:W< MOR9V&GQH<9W6E1H&-*
*EQ_SPX;,M^E2[CF4T_G5C)M4O)")T_F:%*O=:XUD5N&&1H7AGAI@TNX]<]9?F0.E M,N=&JUI*?PY.X_'[2,4+*
*[=1AI3^:@G7[.!'E#:0A]NB2M=UY!*_>>65^U]/H4 M ;]A+AJMN7B?*
0'>/&#B]_]!UMS%LIA^XYW1S.6Y+2GI8?.1Y6+KWU&2#[:NA M2)L?-;O=8H-
_CL:C6L4+0X/S6=@K;4'4Y]V[A=H971WY=(AYXZ M[1E#F[W&TYSFUH5* D1-?*
(\^&@^+HEF4JNE\89Q_;C[U'2<[,@AIA,ODK7PEDVVFAGJID,K-Q[.]^K1P>A93^8 MGF6CS"39&KV,!
[!R[^VIY:RAZ'Q;I&>%^N-3J9=54_>>DX7#1C[RN)KGDW0P
M%&PI,3IN#MI]+SINM%[TQY1C:L,,9TOW^>A+NIOATZ%T-BY%1JDR\]33%UZ\@1D]M>;+A[S68"N987 5
M3+>30]Z+-S2>2E5QWA6#=# ;";74:2J>$#P%S31%R[ENXD49E;2&6IB9Q=:L MW/?
B#OS\7'B>ILT@7Z]V>P_U;&+AQ1N412:S E/C^E914C3+7FQBI07*
*M7KRA.^A&YF%#J356K=JH6$B7S6JWXL4;XHTR'1G*CX^C?(I-<_7'%9?H+;QX M0WHTR72?C66D4:JV:E&Z-960&/?*
D#6:,"2'M82K3^>:@$7MXD8/1^19OV)DN M?GSBL#U)^!USA]G3VHL'1Z$>&B=L)T-0G15EK;8(L!#;V%&K6)"2^F%;*
R^ MX@!:K@00OM9T)8#P6=.5 ,)G35<" M"'\X[FD!<0.-R/SA$OYP7'\XKC_=GS(] '5QA_A^YU->'^$[W=@ M!;?
*41?.W525"J5- M*NI*DC#AE##=6 V/Y7HO5Z^.:&.43[S(CS$S7VE,+M#.*A+N)(T7\;E&!]>" M$,ROBME$EB>#?-D*
%SUCA_1+DX3/"OQ!ON>8N_)>5L --44:/Z>SZ6#^)?@D M](I&0[] #]QE<=@+Z>E"I2&-NEFM&PN&B@6>#.QE
S3+^.TN?5;@:P7OF:CR M7E; QQ_XQT7FZ9XV:45)M)1A8MJ_P"E_&#:K:CWD7&C]!**-=/|\+)2LD;S M1@-*
<..IK!3XK\%G!>V:EO)<5A-KC9"95?7JD2R^KLI//:_YT@4,A$8P%4RO M0L4(74([_"31W62K5@C>,.!<.PLO.
*K=+:\;I]L5=(-319)?PYPZ^"V'J0G M!U#$!_T[MP&?LQ5-?(E#OE:0\(5X]D><.AO*P5P;=J!7:PV+;^>&*?II^)(:*
MCDH/]QQ?:X_RC'$!ODVO!N&*H>6+C6SP:?"PRLK/9;-"ANO&8_[@.Y\#_$4A M]]?C ._2VHYS@%DH9 Z:4G))FU)
*fV<@U'M?)IPL8<34E'8MW-#8_$OAN,+JH M,?T7M4*FY4:C9YEH=&,9-SX'\'6 C[EPCG. PO2>6V3+D'KN//6,U MO*
'N%^JK&IVGK11:4XO(KE5N[D<\V3\+1<(A<\XU>R+DX?/ [XD#SBA%A![M86-F?
B55&\D9NUP9,5;HKB\0U=&GY49!&V0S#:&>6$2*\U8V&[0GVK(!CHO[M$VUO,1?'JAQ:WINJ[8D#A!745$&W0'PY?
*H;.28=,?;'QYM=WW*N0!!_Q"&'^ M[V;'T.+7GFP^>U#Z?()%KZ75]9 1G[)E^@)RH/4T$7OY;)&A5Y'YNMT(JR:& MMB*
3;L\SR=)G)U=&7^=B)V\:,[X_EP-#8379:6F&:MQ;"%VIBY@$MKT0B;3S'I<3 :IQ.C^P&GMSN8 M[\21-
*4D^X_$9SS4PGI,I/)V>$KY?+&M*8_S2ZTJ#?.)YV+H XS&CSW&A M&BNO1]G1T_K9>*@5I\.*->&7B;%^%M3-*
*94$Y4W(9%K^@KAJ"0OQI1T8A77M> MU.ZIML!'EFVFYGRF(+GT&/-SI;M> ^EQ7P?:]W6:)5K$8:S]&.@UA4I*ZQ7NY*
MU7V^@/.K&WVNMJ(AB4]'FM5NZSG[^%S(PQA2#@=".3\0ZM.VIU?KTN>Z)MK> M4>EHIIT.YX;EYBB;(L"WVW-*
QMP%/%$EWIQD![E\N&%V,@.N(#ZF2WAL,2Y; MBYW'M_V-$ITN3@. ^W/YT/]&A69F?3=N3?
*'6J7"9X4AX671E.MQ0^1+([3BR MN9@ '3ICX,HG;I^XOP9Q[PANJ9,R.LGNNDN;BQX3T?/1D#[D/Y^XM4ZH7%*B*
M=:41[/3FD9<%GS$Z(+C!HQ(+,/2Y)/=M92;]!T_5_6/?A37Y^&HV>A;W!;,A
M#H_>6O!GNY<4_F2[NYRKLHTT+&J0TLTQ^F0%,Z]A.#9,P3;Q M!&P\]GH @Z-U2@9JGZ,=H]UJNR5YP
8N%U4K?/OY%-B=J+S MUND/#,R>MLS'3BVR:J6# ^=1HGONI<;C#M& M)
D]LJ&M1X"+TH%8_$QMA:Z!KBY1>!;_(N/.K)2YVV8E*7DN=R5<6V8Q$_TE
M889#SZD^S2;B_*@P7H>"U<5%F0E[7L=WLP6>>(PO1 MJ%4?XZ/2Z$7/=1;WT40:^$SXQY_(721\GEHW4-?
*ZS:KS*U@WQ (_HDU==:'K(=>A6&-WUW 09FK+:,]6!Y$4:;M>_GA4'#9+/R M-)F7PA&1;T=!M8I%HH%P^$SE^Y?*
*U.G^B%G6K*M,-,8>/Z4<790_7H2UMLX>/ MJ$REX:R8B@A<.RUT4_W4<#)J/K6A93U2F6)WS!E5IMM@'C?*
*HT]I5F9ZP/OUE MK.FO[:4"9OF/KTJ=@5<2,CBB2JFCN=PSA41\9!:F?*NN-\1I%!HA(54JQ'(! M+K+?*
@/;GER$KWTGE.ZE\)>SO&/J0JZ0Q(/%.S2]^;=0T96L=Z+GX9*_T3G%]?LJWONW.X M3L-*
*V$^MBY%G*5%]H=ID8EYY[^>%@?),I7!KW$)LUDPF)ED*E5#M:*8>+,M]F M:)+#%6&B 9KQ<[A\]YCO'KL<,*
*[D.'>ZO4KB&J:YL/$SD*CU++2KM9N^)7LT6 MP&>0"A>]"^],?[XO[!-;F)^^+?/9][7;Y+QV:.8OC<:CD.*
*M5(-0C)IBY\@=Q2N*_9X#&^R3;#CH]7%WH*Z)/[JFAHT7-2ER477SRF)8 M>TXUS/N%D.LD[_O/,B(1[FX_F\BY;7N6*
*J$CN/OW,;,_$,U4@DD&DK*Z*9)[MUQC?XT@P"X7,05-*+FE3:B\;N<;C.OET$21XK%>8I&E$8W2D4"I/2]7IXWJ,*
*M2(Z^VW?"?2K)G?"V8R]LS,ROI&HC.6.7*R/&"MUU_Q*W_3S3E(SPPMVGS7Y3 M+G9*JM#J\S_^(,/K;"3'[9#<9;0Z_E7?*
7\"MJ%$#H8LPRJ5]O8=) $6&SV.SD8TR:36A/H47*219XG?,030/4,CL$P>@DL2!/0 D7B-&ZHY0#>]>(P8M]-,*
*153DC*I9'\$ZM*\;J:#BU+>J-$" M4YHLQ,%SR:@O@#4QNXHR49]/R4@.\XWWC[PB8FWMIFEM7'QE-*
]RCRJFCB0NJ8BE7K>B(COVKKJ5Z939=.+9O4AS7.T ME.+HN9B,5OD[T^GLCZXT'2J0YZV4/B.]0=6[?39*?S?&= ,,Q=*
I.BT3:\2 M/DE\+T P=ZP_L.H: !%_99"O#PB?-7TO0##T783S(7$%D/!)XDH P=Q%_(&K M5P$(^B[L0^(J(.%#X710>&?
2^JLN)K\=]/6.%3R3"\4?#7!+2'""$M+T7?2Z MAP"
*<>+;DK8+Z3$;8Q<%;M>/(WQR^)R!E]MRM#O]Z%F"_KTG]$\YZ^K*2S-?D MKI#R;^*
*.?/WN&Z#&=]#Z3CLV]FO!_ZNJ@DGT$20EFH+BP_T\='_U*F(.H8 | MT6715Q%]%='7 WP5T4<-7T7T%A7II:2)LN[KB-*
])1RS(/1_@WU4Y/.D4X"\K M GW%\ IYP:<.!28:W@U/B\6U3OY4X+>I:#<,Y[(FBS7Y]\F4LB^+",9
*-75ATCTE,OBJW:MEI9?NX%8R#1V:. ^#^ M 88_,_PCZMU--XD\R:P M0H4.A:-3,9G.T^M,/,*T>:50:8>A-VPT$&+#@5*

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}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

M>M4NG1CVIF.)SD|>&]SC.CD4TQ6@W@A0;SCN#SSV9>_UAU//3[T?C:&>E7KS
M|WMY]:PEY4:^GNIVVR&Q71:P[(UCZMT/EOJCC6\H6GJVT<;71;SOC7^>AI+? M'0$]!27O$?!2THM9SN1H.3Z2^Z-
@7%*,/A PS@B_BWV'(<9'[7TK%]SO-'V# M;NQ/] N\5BUS71SO:[H*K/R.8PI+]EE[K-Z''@JC6;E0:^;B>E[-+MI,Z!.<
M!=^1|*^S\OJ4+@6?\"_O97@#X8=,3JL-9[566EJ^W+_TC=Y@(&+"/[^?X3L2 M_I>6^&^J&/]NA'\)!\4;"/\^:=#50;J13)?
D1I=^2]VBT7M,^&=W47Q'NK_. M*OI3.C)NB^Z_@6]CPP1V:9\;5%^&);E='LG/N70GF(K1IHHIGW@WHJ^6NO\'
M5]K_L9<5S3$"@'A2N,D31(S&+RYRE'Q=OYR^.=/:W^7?L,)/WY>;M?3P/VA% M?2!14TVR-
A;LH6^E+K40H-.#H5.RKIOH]_(Z'B$9)>R,: ,M /8;&VT&3# MD";4%/$D6:347@]M=-*GNK(NFKI.?EU4#8EB&
K1$SC!%+-+/L?I+KA5GSV. M;2')K^_ZM18+>, ;[- 8:)*$GX]H6J+&Z/(&.B7A0]:DJ2%!Z<;_^Q<3H7]S M=(#|
12+NRVAY5.GURY)X<:&]?_]EK?N^11J(.'L\U5?^]5PX6H9HVK)PM0Z
M>DE"4<61Q=@[[=&\VHNV7E:YALPO\L_-6FIM3BR9)$\00?#&D75M6,;\H"0D M,*;H]89F2F?
2P#I;SUS@NB2D:2A=]"52**C&$0+]W\ZIT(4]@/H[-ZL5>EC M:3AAY\=!0YWBOUX+RJ/7EB;4@S Q!6U%A0(48%|
1TZ_ACR M'+AE#V];EX")*IMM2IJ.R:8+7VL2XM&>6T7+[T&T+,5 6]^Y\A>8D'M$2Y[MUAK
N,,CG#];ZEV[9G9TN2LC^-60.E?JU: O++^4=6=%"=T(KRBJ 5 HX6ZR
MCUA.M:]*XJ"U9I=B.ECDT\SBA5T,F@NWHIDK9MZA:N)WY["(19M'MX-T3EFU M*@@1PN*O]CHM%9%P;@M-3KE?
IE:+T2K^F!VR#6F1SB]^_(D&HE'X=U_U)-=N MR\J>&VEQ>[?H;QU=YZ:1;H":"AHU%Q13HOY]#JV>U]NE'@)0Z'0
ZNA-EJ^4 M0]%&+=+,=A_S#)V6^A\'D-4;"W90%K22AM 2*1Y/<">V>>)G7%=+/(C)BJD MD^',3%_S\J(^[8-#@*:9
Y!Q!041[@= .U)DR010N<$"-"8BTU) W\L31,F& MJB$R1\2]H[RY";>,OL^0[YO6]PZ#04^E6:-2*3/X&
M8;R.XK3Y=MAR4E 4J9M8V2>R%GJ3>I45S,ALM>[0TB+2BE5?RIS8YG_\X0(< MA_]]E=3=^'-'@$O@H=_H)CH$_-
YP/WI+FE$" M^G^$I;(HP8Z^#D-YCVO!]?XRW,11'I((+SK)QI0MT/E1H5QM/ LOL0[B(;&[MT'X8D4 QWR#
<+L@6"IU&?U'M1-JC+)OJ=Z76@%\S6V#G_I8II)>2 M)LJZA!'!^=+A!(PG3A0JA14;TIE80ZY'1+Z9SRU36@7CA$>
(:4>N$+U,60%\ M)4$<>*#)W04-@ET;Y^_-@5V[_3]=>6[_%_W"?KNH2((&_MG!SILYV(SEG:7I M__T$=S(;4XECEBZ$-
FG+]&>YC[S+'PC+HNC++ M'TV:.%@_LS_#OF3G0U67 6E_$5MB+L'3MY[K8 #+W&%T0G^U3A9B[D)O!!62
MO')'DQ%H[B5E+H&''L D3/3@/JS =:'($\E^#W/'QG8=()&-_T,X"7+\H 8: M<,5_U571DT[@SPBO$?-1?KM-
:>NC'W_JX%0&;IT$)CN!@1<640A_7,ATE 0P MP(((."Z") #;?+@-Z3T DB\1$Q/_@174_R%K&7[Y

T.SBRB6(X& (?'7B\ M#6U$ZI9W!MN QSTYEH?F_%&QKJQ/%6'U2YY@-.J EVF+,6XX#&:10%$85"XO
M0]S+RV#Y97TC^J^,:+FC/'/K4B%/9^E1O,#2L:C9Y8\9T92W4HT=,)<"Q@7U MI-
1]40XW'IGHJ#F(1^1VXBD_$3]@/F$/[?8Y='[2);J0JY62;4G9:PC8/6'+ M/(Q*Y3C3;-.1>JG\3 _33+"\.&8U>;O-JD9-) -
IP*J(C"0,>6&*_K9$^SZ169/C$F&L(M=&TV<@^\.BNKX\"@^&/635(X*!=2>0 54F4 M$*/NEB9U=)L0*#-MTU16RS;'E:(?
J$M"*#S($"6D4LTYD+Y7@CI>54FNB(H'>MH6,^ M3&)">V'+&&$*_%J:F4@YI43 :+F'=
R,&'U3[@H3D<2CL'<5W;&$8V+V2HAJ M69;V0%6ZEI<5F=_6(T^EH)\FF6-'Z)XM@&-C6A5D/W2CUXR5"Z?T% *VHNJF
M)NW'2(,J)HP"%#EP5WJ+N#IM@(^AAZ7',A2CZIM'EKJH?]*&B%F0S4$ MA1+&P#* Q?0O#)'"ML5$#SW*?
2^DR5W4022%JE$ M0T'V+)T=C%;I9*TDY$,?;L#ZMPB46Z]7K2$;*XPB<;VB-()T8I3K [U' ^%+ MT?LU@:N8[Z5?
*J88;>3GU7BXO*ITM-K%V/-#R!QI_4+EOC$K#;10T6@]5V>(M/8=#3(![[V[]!A=0B#H4C.$B6 \(,*'R]|64@#8-@?
8A,8$8!%O"(&\&P](M]"-R'8 7G@5^D*S6V72R$ N5G];+:EU\-YUB<_X0U"U=+B-)96$%GLJRI#T" MX_2$?;
(]ZS9J]_UG.I@NS@8A[FE23B-2/229(=J!V3!FWH<41PNZ;J,/63]H M[Y,N#GI91N!^>L1$-Y6=3!Z>2
M$P&N+]!_5M9_0=^Q6,7P*[^D[:G5]5"E#97)%OIC,\04J62JFUR087_RAZT(QN("8A6.5H/"5AUX2HAPS8!J%(3
M05GI,E:Z55.C>L@2GH#A@,T,V;#7(6,#66EDV=0*1NJ4/E!-I8N,,_2]8)>T
M#)^0/I@59JJFD&A#600KT#W%*S8T4'*WL?FA?*$ M:%CV06$5>1N.)B)[RUU;!Z?A)Q,3_7#_-7FG1&Z%MFFY+%-
(%7(9,HS+8QF@ M$$(CVQ$)D"5TB4BAA$NTT0K?O#PFQ2R.=8K,6AP!%E8(;2%03('*KR&P(3 [MR;?V,YSB2,C<5X?8]
1S&$D_>2K@OZ K0P> V#$!)QB0"&8+9!X$%54=P?LW M&'A'-25D\9H8-U:J23P1A]=CJQ?A#M5'<$#OE4A22||T3
TW*,.8M@E6HX>1 M^U>Q16&!@P2IR#-3[D)$W,9:EQ? MNO189$E@' "G=7"-
I'5=9'5(;L_6'SNX\1,X7HV/)RDKH2G,""L!MT$O!/J+JK)A?G/5@;
MVNS(WL'NU>E;=Q<@>"+B*T"XB)YKX8N%5@[::#:Y();U,;#B-RT ,4;2J9G' MA^0]YCC(W+4,PQW=?
_=;T&%_D7QL]*>]KPD3PC('>- TK&8%4DJSH; #E5%\3;/C#1SK"[#G$ZO&ZL M(@18X54(<30=J\E
:>!HM;PF(B#/!$QP]%KHJ0'D(PDZ^." 0:/W([P)JHL) M8:BR"O)H#0:_/)7@AH'+]C5AK-N8COV]B-T&#<'$?
^BH74S9%*^LH8@2I*#E M8;1>AEDRG_J-KDW5]2EXB^X!P@#5ESI2]S6D3^OD'87:;\)L*-C=D6?Q*7(!SC$%17>4 -
U* MI'".CLB%W!2%;@J_8/.5S7 QF+MS@;P0RWC$*D -DNQ4*MO] 6R,O I7C"C2
M$HMZ'C%QH85V*@I4%1Z7$B%#3"C6O9+G+*>V4_ "/USK %RQBP: JV%[X*&VULF0.V/MS_!!&8:B+V MO=
(1@\&/3A9KEW+5/P)-61S7@1#<)&(7.'T&,TCXME[ED^DJ0M10C/U-_5-' M:
(70$3'GKJQ9S1K0<\!#WEE124E1@L9J"E:)).(L7Z/7D@V3Z5M#\"F,M=G*"S:#$ MZP*"4H8%
<+3&P70,7*"2#6U.D$@AG!?QQK$5 M$5$4^U4NM@)*O&4Z.#S%X>1; -Q&QBU$/&62XCO(!O)-$=6[5$L2/]HZS!8]
M"38RZ*3_+N[&X_CQ2-LES.^FNO3+_L/OOSK/CO,JNN/@=-<_@6<-7P'L*J@(M2*LW?O7DI=1U>UILUR#13[;;)9-
EX<@="U53/_]C_NZO3K'3VPH#"6WW2'>K MV%YSJO_WKW@D&O^]VS9KIX-5YR3[/>ZFLUPJ/*@#=21P>5L=^.?
I)11F.5Q# MS3"_K51"Q!">7H)UOD$S/QVI4W=+G7T5PI*!6(/;\Q^>YU2._$75A$4<'KL MA4:!SY%#
O=U,T1@>UUDY,HZ[FN A6<$B!Z'-:Q3*0.S))CM:GV &#[@E9N@-'I4.JCBU"T*8@GQ>K?JIF^U4P
MP[0D.*%C:>,;$M7^1,,:=J1&8T1'; S4HZ8ECD!7521XCC1!>J3B!.@(X\<6 M-B@CH,@A!0]]I "#0"P%LU"TBF@P-3Z%
[!RP5. $%H*@'P\D03$&*VJN*I"[M@>NJ@5TO(1$%7<$4Z_R4+O0DRPZ>8LU'!-,&2R@$#X$8J8.GQ
MENS=$NQD+PHY ,Z9L^3K<6@CS8(HN-B3K"% 2K8)@5@AL.GI8(4W7T[7D3@; M"WT+4*Y,'M<519!0 Q1&8EG
(,5H""X:=//XI1(D\(%/0QYC@8X]9Z#_@[7 MP68@6]/ZDH'QYY
I@('101(%X3C63B!G9"!K=OXVO@E)!\XMZU96B&5PX$V1 M5]A7A$/$2#+#74I3&>$*-
H)@9R*P"G2;9)THF@C&CIJP=Z'6U6"E0?=F1 [] MV' '3 3O"BYN@&NP+@OA 72]Q-
4+$\AIF4@]&=^*CEO86[\/4!U35C"NJ:!> MH"L&;W9T<_)QE]5SAV/SER"F '6S'6Y M6N1)*1FQ\!VE
]]+%ZDO/2#N!&"%Q#UEZ;Y?*PF,+MBL2, $2OT0H[5C*(G%0ZX;9M5P:#Z9"'K.C
M2.MF9RQC[0P=P?;T&$0)Q1M"NR,6A@TWHD6[5A)_81T=_OWD'ML!Z!(G0E>P
M3B7K[O.,Y6X0E&LG'*.;HHA,F9ZI!+Q5^]UWHX]?[9TV1[POV][BF;4NBO_:;KK,.^(RT M1&)3%;4IZ((VY"U=_MVLD
(CKN5%@IJM"U;HM0+>R0VX5A-OT]V M*U#_YEQL OTO='V&8+:P^GN:]W;#,A;^$6?
BY\XN.&,JW39.>XKA4S?)K4"X%4:2?D3Z)+A[RN_X>("5F;IDAQ;?59R4_>15J MZW8JXD[5=@"
[']S49>R=UWX#_^3I<^! FB0O&=/CY3E8AJ;NF@J@D8). -S MM:_7U1YYVU5 CO5/YZ<+1));67WO@5[9X[T)CH
^XNR>F:=;V[Q/;78)Q0=0 MUB_BE5:V%MR9QW61-$C8AP+B#7*S(?8LD;+8B0&9$6A_'=!?L1M1DR L[%:G
M#YQMD^[AH9ZZ;A64=<_/;0TZX'Z#E7/ZQM=L;F7K+:Z/-VIZ91(Z!A#W5,;O(QOFDK+TKGI;6<##JC5S668$;1V&O &5.
M>QIZJ:.;@947HS?J&Z8JB 9)R'20P=Q"$+#T-CN, TVFW.Q5D_J0]J%JJT.L M=D\GQ!P7#_/ +I ^VG0?
V!=LAZ5=^W%XD3>Q0B+^@:>PX6-/.<2AG)4DQ0GG
M=^E3E:0KV7P%WB<.K/B%M+/(.:MSE3CKW>L^009N[E07("WW75<5.LE5<=$W M7I4C<1 -
X[@>=*FT9BMIZDI0#"N:!;^_W0IZEO:S7ORL%S_KY96LES-84KA2 M@B2W!KN(7V)6"_F%9*2P]1G2!X&&&$5V1?
M>D[A#:8!,6:M4-'%7CG%+/8SI/ M ,+O0]L"P8U@H"I8(SV=U8D.V0.0E=@S-5+ @QBB)D_=A1)OE-6.(HM'D<8#
M5,V5W;@Q_K'I!+K4ZS7?IZFU=LHS70JM*) 36K.[WG3".VNPP3_JN< M MRB'(0F9<^:X+]T:;TG9,B^A4VVX+,NO
&1*V\56HGGX/3Y?%(2!L,H" QY!< M'QWL(3)XB@TPH7" IEG7! 9"INZ)A7OZ&5X;V(Z4;0^TBM]Q;(AR#=_#-9IN M#

*{)9ZG_,VM]!%CNT*2]LV7O=F88=O:"'9@S_@.8@]=;V.NW5: M=3-(Q(F1>L(EAU.[,#23"BF)2*'S?4[#^=OD)SEK_*+/2=[+23:C*S_&1/9O MW]Y4V>N]*1R@L@/X'K!\IO80<3QY1#<0<9.< $2:063E(3(S$#>P=)3=N#VA*

*M]2.OW=ZY\R7DY5G>)6C-8:C$[Z.:)(B%"]LI>R@%9D)S4L]C)22XE*F-U;MA M-P$KZ@T%X*2YB/4W09R9Z,\[K-4]3WUG,"R>AP$5(I(T@F>!#Q%: @4=G!J M%,D/('U@2&4)^F0L:7WT)SN+PN58"P SDT49SUE9@HVK$@W;;A(Q!Z4-RJ+1 M'[[>--SQNX$@7USA#UBK,'JE"&,[-KOS8U8G7&=ACT6U#;1.GP?1#?'[+Y+ M+A*

JB,A@#QECLXZ50.PIS1#]=!>6@/D[,5JL6JUQY!!3^[U$-UBYR99 Z%' M!>,]I.[BJAQ2#^[%ZVW\(-G#@!\V7@1>0X=/9.U;375NB-F_,7/G<]G^%5WF

MJ]&P#^9$I1WV37CR;@3M;Q.KWO[;K82KC58UM1CJKL)I_[YD+P#SVDXEVNEV M<."WWX2S=U$]LN"D\='-T^\3.1DGVF#LIS,XJL5B]$PBV^VK@4,[DX,L M'F^AL;2C+.9K"'8VS%R3TVX>(5>Y!P M)T^_?H\RJ+<+=)*

<(J!:4Y[S,^MYT!U_?+)QA6!X60HBCP"NZ4@_W^L/A;WD2 MV/="[^Q.UMUJ,C B8BUXNFMN973<\+6@;

8V=AISL>Z%3+H MV T@WX=:?%C(@0Y8BC1+QK@>XE0II=8!HJ /6K.J!/#76#23<1(6W6Q<$ETK M+GR ^WY[^77Q!G&,[6!)"R\RH!)K(%TAT/Z"BP@1';#(7S&#^'[(7P_A/_Y M(7SAD&6'78[;LNC-B52\(S]55<#N WI!!LQYI5WM,.*

*#"NZ;SUR"^HV#RF^P MLPH>_!(*VR$I>_%Z_ADQP/XJ"8W92A^#4.7AC5D)9)8_XPU99-"- -X*F2'! MK3PC0[['ZH!N1W<=.Q//58^U7KCDVGW>M!CJ<"5WHH:>V-ZMV M336P.\\?*

*JG2XHW:3IM^RX>T<^DUMA3JQ.#9)JX=V^81,W0^R_;$!MZ%J<89= MUX;7MJP<-/T75.\IIJC:74@0'W"Z>&<3//K#P>*^LJ"-9,0[]BHU7$46\(@@ M=!W&W,7N/.V %[[>KC0APX2AI8[C5'"6H-=@E[(U2]^]XS*7$_782_=T#60D#.$JKD'^4$ M&XS>^R%V)$.#SPZ60+*A$/JR5=3-W6^NQ?/J(9*&W'V\LU&/WX=)Q#EU%F-[1 M9P_SFDRI4Z.0<%ZZ9%*

[<+V?W=.G#UW=F^O+$8=X?P7Y.0O(MUW/;Y3+6)Y:

MA>=XWU!W3DR)P\7G).A&PA66OQC>NE6RWB43N+>7>Z/E>RT,;C3TRX*

*MC=D6V/14LX;J[*7E'Z'-.P+,&H1,R"-7;C./9!QL'B@3$P02P:'"*&!X.8VK1 MZVL&J=#%\V4)6W9LW9ZGA@.?*

*[!8:Z(2=H+=O)D/M52B0*3'(2H5QM/KV;/? MMKW["BL,O/9PT@P9_M'M'!7S3S1_71D]M<;]I2Y]O<6]O:V-Q*

MXXAG(M<),C$F"EUY@SR?2O[Y^">"\]C,3BL(4'R);>^5'^9U.^X+N3+KUQ-$OO7[M];OVWC$ MC5F_-QRF9OTPM1^F]L/4GQ^FQJSP;1ZSC9QU.[GB+B=-P-M?AAU1GJ+5_2!N MW]OD]9M3.LHV,M;;6W7 %

*[55LK,5!D86%.AJQ]\LB)]JZUA1.*2"D7CR'4-U M=KK13,#&G4!YEE<<>_,RR,ZS'0?N$WNH85MSCYTT0/!E6>G?*

6X;QVP3G?E[X MWFO)!&>DM#AJ"7'$V<5<9!*:MT>NMZ?YP2$VT\HAAWK+/Q8^VI<1"^B =T(E

*M*7GP/6%O]H2]SP5VD/G<4.:?S?@GZUFA0X@P#KK:/1X'-5&M%75CN)COM8N-\ MX^'XL"\]O"F'(\W6JDWW:+C36?*

\#KD;KWFP MK!'05U10>25N/_>^NK.3.S5+WF"->@.U)UO,=&-<879*1@3>'>YK51]QK,A*

M_M$>]UC"EGMHC]IFSC;Y>V"K1:$CU>RB NM'ZJ8HSU&=)J[B&V53N7.@Y^C1 MDAO[-

*V^N:W1*ZW"%O).'Y\Q%VJ]&=(T5H.W*5>MPF\Q*K Q--_4/+J5DJYA/*

*M\'HG_N90<(]D4GAWA88S[%^Y^WX#X)]1N@L06%AB!\-4(ELJ'<*V2VQM+OP/#&&U_U+&$VD1V2-^,;%G?)6F*

*M5C$1)'B.9<-JK\"78SU'"*CV!MV57^![M),T^,%Z0&5JJAFXM:+=G@"=8)&(X_5"M6!WL'ZA EV8F>B#V7MLI45YOQ-6**

*M[G8-%]*S%H(45T96!88TGFNJ'-]^#IE:U2(FFKO41GY;QJ8O<_8;X?R;@K6MTS86PCNRUD M]J1":">N@MYO%\$Z-*

=2X+G&#>Q2T>%8H'DDGQ2IW#P?L[B"_8C:9!4S^,$ M\6W2V@/IN:",(JU:<@@(AD5A_FU';VP=?-..V-

4/&&$O7(W<6[GKY#S*Y3=B MR=7W>Z>/\8[PA1=L:-P#VUZU$3P(_(:M@;>HN-0_&7N:O,6BCJW^:5L.7Y!P M-

T[X7__JX7_V,L'9MV2"GW%L!';\X+BKW7VIC/4GJ@2]C1#Q?EYR^>Z%;&>: MASR;Q$4#T2C\&SO2/,^:1@DN.\G$

6GWERYEW>]B:EC(6B@DV)& MXS3,XP(V] M$[DW[&[>#R.%^T?*

@'@/O5YME<$3]C'!K3A4$;%^W18A261U6)V:=AH$QKF[ML.,FQ)$CQ

*/ML*UIHQ7\!5@\H@2[!SV,J4$J@&HY9ISS6JS_$Z.N:? N[5\7 M\==M*LYUP8[RAI7CL[+KI9U^D$2*8I?R_HZVV\:*

MCU!1W$D36YJ1!P8'+-F+6[00)8#4;SNEZ#U<@8[!#E@_LMJ84 -$;>@U"V@7 M!S_?"24XCX#?@]"Q?=)

[CX/$T@#1[OM(A /(K9VHN'?;V"HL4%9.1Q@P_$RE M2SJ+_:+ ^84AP91-#F)A8?,$TC,-K))WCZ&ZN?*

*MO8*__L#^MM+AQ![>3L;I.3M4%X6'8)-NTH#P7 MTSSX?LO;LK.-OSCVII/.)B"&3Z+I WE*.NN0L"T1JH<['!\6K'?*

*4/=K_'(S(M(/"LF\$.*P\Q#A(8&6P;]AFJH#!9?]['=)3;H5U9BGNMSD+\R=HQ";1MZ#4/N MULJ]LHHW"-'KO&M+>&*

<;8[$6'^JYO;.(ZQ-GH7WN510!#V%,O=D9$JS"_4 M#<0/S.D?I.+88$)O!@UJ$[CUX0AH*"=:.?*

H<_8&$\Q5C/O.CI1GM,MX433' M)NGBFL(D:/RFTI9R_*DNIMU+2DGZ5#;.$X3U/$1X_V8X]HYSMVH"(P(\W&/I M3?

*Z&@-/E%BF:,IA@V-; J:#8*M!=#A)%U<$^@ 9>;M^5U0Z.#I_.!8CM"P2 M,%D[]]DE]TEF_<29N^C6!*/-*

*I'+W_'*2ENK>AVVI$/N%N)+15LGV-IT=5/!9 M2<0HP#%]DIB"GBS*4](`L/H8]2TQZ@TI^R0,"HW$$!?,%5-VQA&6AM($*

M@0RS?L/LVJO?B:U4HJA^$+-LT+"1U4?51U4)>*=^'VQ;3&QVLVK4TV6#'] M[[*ZG=X9@)9SA("JAE[?=:U&J@:2_6-*

GJJA52;/IHK$U6M--(A9-((U8_WW9 MB?8^MEX/MFXL1IS"XHSXL'(YD:V%8WV@=Y+09V /E;M.]J2-G:#9]@01XF%V

MG^*ME&(AHJN7NE(126)HUM;@'09Z]&[85?,DSN:*D!6BSJ5=9QVG"S67(1@ MX*",;G>*

5Y2@E0HCDG0/:V:G:IC5WOAG&LR\Y@0HV1"?Q:7$-%]7N]3SZO4 M@^,P#F7L,F-$!&.UB^[#P3M(_9LB?K_I@*

1=YN>RAC4=[,BP9YHX2.G,&+ # M:L6:CYL^;FZKS$-DP1N'U0*2DX$=HP94./<17FU5,[];,/G6"NVI/)7 1>52

M6TB""4[#0PM<1233O?DC;TR)A^=L==`9?](;.TH<&\?I_=!7!D[ZI.F3IBTV M+//4E5CFMFR/&:>

*(&&V2L^R,@Z2M]@@]6)Y^B^I\Y=_'PUU3U5+I<>#G(#KM M.8%AQ)].(9T'?"HZ<9+8OPXB7.M*KF)Z/!1/F HX2T[V;5 ?*

#3?LT"//UNFA MB94/I]S#<<9Y)-2Z\'6;L=J5O)I=2N$J??'1T$=#"PWQ;$YT^R,RLPS0:=.E

MW9D2N9FH8JNU>SA%8F]6@05DTZUP@94B05VZA_?:5PQ]%"0H.$;F$IA, M4N=H3YR9LB(MP509@(?

*5*Z0QJC6T$K2=,A MNJJXW3_.AZ34E@0=<)JBA[P,[)@5W@XHJ8>XI>$K>#[:>GKKM_TJ"!5U4\/I*

MF=AC#_F0V,9UQZ9V73%6P?7FF383561BYJY4-_3AX?+D&,K"DP^C M[6W6 H3\6@"_%L"O!7BE%N#319(OD:[!

*0M5;EB3PF+'J=<4287DW6%9X,U: M&.L\A$!.P$'H?0X2W6&*L>EVOG<0?_+F$57ON^GM#DD91^]T]=XH(;29R]+B*

*M;*V1WC5SJXK45P3HSRY[WNRNKN*RT$U./%1L@ >5#-D&AY9&]DA**6Q=AK1V MP[Y5E51X.HGL]J]?^_&QI/6,W<*

:CW(9H^,-="N?_]42_TW?Q=_UW#>&NG%I-O.N8[\I3KT! MR@3>?UF8A")WL;,

)787.1M0N+O0R8%R&:Z!^Y!L8BDR>"#'UC" #E(/K)@? M.9$%>Y)5IR+Y!5R!U,.X\R3@BMYXG[J3A?

&F2]KK@6(7U^VW(OGTYB<7! W M[PU8UBTP\^UB(%>QI U:7#O4D5P" Z,OMHI-3<,^GD/I0U9/4,OAB!TV&N[*

M2>YY;WR$#65"3%9K&*MA@%.W^.&WD58%V%HE_?VL7#U;(.7(P=V!;\LLQVU_ M-U$=I^T![K[JR,(C_V:?\>?VOJH?2

*M()QZ.F AL@XU*3+ZI:RL"*_7">\ JK &L9F>';9VL]_L41N;I%$+[S:I:#L9 MI*_5%.#?_459@=5@RV*$OSZED=*V<0I0>6-*

*KI4\PG+<-(";N6]+78TE+XZFB MKB0I:./$9V_UG0<]K"A;L3]$7_ ?;AQWP.;I''OA2#IS0V6/OJ=Y0D M+X@QD+4N*CR-*

*:&AN>P8DG/H.F#X*V(PT$ MI7?9&+B/R]>+RZ3]C(X5,ZN?'^[;0$P3R""#L+9B)RI"<8\H3$'YI:29*5O% M&%8+-*

*H)ZN'V?A=0V?FYC[$$DAPSRE=/<]L*I&S[:7B_:@A%C*F#[4SWITCD^ M/J)<+Z)8];RKC85K;;*

<:%K==`"7B1O)D3BE,9I0G.?;!UX@OGXOCH=;WHY1:? MI$/;1B&#!%C21L$KY\5JF2_HNBJ2PEFG2. -

*I2PXU^::L=+W*ER2Z4E6^-). MS/[_V_O2YK:-I.'OSZ] .=GGL=^E: *\Y4VJ&$E.E-B6;4DY]@MK" Q)1"!*

MX]"17_]V]PPNWJ(H$J1F]J:A2!PS?5_339VK=Q-@B.<_!)DCN^09':%G]!E M*

MY)^N31A0.MY74#SYBLF!MS%3H'X^]2E5A8)A%'6]/&I7 M"-?G;.?

2K!.7I5E'+DOT8A'@Q_1()L69S%7#CLZWS(ER,_HHCHI'Z]CI&QT MD;^FG2A8< ,(#81XRR37$

L9)GFBS2[%KQAQ/LM=RW/CWM>.XF3L<7^UG-Q ME6W%Y./X(3?$'@9RZ$ /]XHP&7D6=Y)IBC(U-D\$

*"%5L33"8T+SNGDU7VV+99J$F<0MNL&U7M=3^>ZD*U&U*DP@I__^OHJG-= MT=^D4Z[B%26BM&_[8Y4<7V' !((.>*

*M!X#:RC?\V<,&@@]XZ)V&5>:!9JANP;87N8:*N GZ*O9?X.DM+8MVDYV1% <6R MX]H*EV-E*

*29R4WN!+\C[3JK!W128_,1I?D)F; $'>8^3S-"R01A$KC3*A$TP MX:>-:82:20V-A%M'^\K%\N^$D1"Y3(Y9QK:[?CS-*

*@5NVG#@A 8\U2Z2.9;=? MJ;63&2#;Q?RVN';_N""9*756:)>>GR0YG\MQ?92&XMK[TTX\;>S&FQ\?*

Q)SE7#)XG4TL^FL$H@N6)(L]/!"R-*(GS8#-^ M1Q]'%N8)&]0#ZI6U6"B@2 0"?:C8AJ+P>1$W7Q

Y5M6!,P:&=JQ7:0[MF.1G MAH;)#*. +A!>,0?23D.>OR#BN\K1!46CBD9GT"AW?"ZPRFPIV M<3#
(]JLY)Y>>71S++VYQ<6=6,98'N"%TL MQ99+P>DIDJR#/%TGXY_E)&;- M,^EU;[JR_1&@_X.#A>38P >R&Q3.
<:+JLV3)XV3)& ?X;$2V5*4$CS)9"I$ MA1A?D]3YB",$L7> $H,BZ4XS-S,8'TH(8>E_1.-+8W,D'0
DAJE*^/;!^O'N,&@$:+/DP(J_I7Q/ M!XPMAAR\S/%DP=DYP$EKQN.8%PNXQ["?_6,\AGD1- 58$*2$E;[MQ-$AW,7E
MV0E=R'N^F-K;$M/$RWN<-6FHK(G*F]BLR9*L"0-Q_,.K+M>K=5UOU+M-LUGI MUJI6I=MC?:/;[%4:C8I9MZQ6[94
Q&9';=+BZ0!KK!?;.6[?*,D_V^2OT M%))I@E",Y@6989PGO"V##EF.SLVBIB430QC"T0CMYG]X M$)
<.Q%#W4JCWUVMJD.RRI.6GGY(NET811>C(4J&.:E@LCF$P/]CD^;S%<,F)
MK\V?]!'+P+=*"8U"R112+R?)6!1Z>3%&W^2X=UKRI/J_2?--190N7EJL%&3T M+@F$3<38A#$AGU-OENO5?V5A-
!$VR\C%S//QD&L2N-Q?]/^=E0-;(4A\1<'2CR)8>D;!TB3:^[Q&SW91/[7U=6G!6)<6='TKO+",
M&)X/1,^C@;8/E<=L6\E])>^GY;W,M,1'2L;W&N4+M3CE6&!],"]3I2"4@I* M*2BE\'*5PE-Y?(^5 I9)[(L":$V2@M!?
T_\J+$]CN:JP?.A8/J&*IHWA^0#T M]$2 LS)'1^0(2-<3"LIM^:W2_H>I_5OK2HQJJUQ=F.O8#H\L/%OP6I0W1@%S
MK>!-$#Q /$ L(!>4RR@6.#ELH!1*57T^J;#T[OF@4..3U\D)[#C M1A;'^^9W;L]F/?]+BL6/(A-[CHQJJA54:NB5D6MA[C)
[40B7VS<,>FRHAOT M@GDS"O8P#CFYM5GS.!\[??-YO-,=>-_/Z8+NG8M9K92,FGYH89;B!.$5?>\X MA%
(OM1I51=^*O@^3OFNE:K.E(H1[$B&M2PJ!9FD9(=FQ97AY;> M:)7TQD9EUTL)[NR:$A25/XK*C;JBM
MI!LJEZ#X0_''G%BMT5*QVGV)U;Z;,1%+%7.J@J,#WN3+B2T=^!X5M1[*)A6U
M'L@F58!SJ_GH_R0TCV,:Q;*]3SP;1]2/5"]J4*4B@]>.A]42[7#:Z"@^$#Q MP2/Y0"_I]8J*.>Y)S''2BLT&(%7H<2*A78FK
XM6V)4-BJW7DJL:-=TH)CA M.9@!X:0;*GBJ&$(QQ'-H!Q6;W7[QZ61R?0]CM*KV5-4.;2NNVU1Q7<4>BCU4
MN%>QAV*/1T>!JRH*O#=18'CF)QYJCA<$6H_W/9]+,UD+V?VZ9[3V S6;=/6K
MP+>6%_4]CG>]KXT<%RU5*OI&3XR^S B6(NM"D;71*%6:+477BJ[W@J[7 MM!^;0.3-%QQP?
1LR0&!A%O8L<4P]0Q0+QV[EIC71U*V%EVM?XWE.JB973T1N MNP"C\+C:6+B=F>.EM#L6:-\;M7)#@P4X^ NVX?
H^^P78WEHX!+M[Z'.NC6 ! MPT#C\$Y+FS=P&F>.TH-P+&4)7A:,N8D=O9R'LG8:^=AM88U'EK0[#@\SO8$+ M$*
!;S.V9+OP@^OB"^';.SL%QWW[GENQEJA48FD:,TO>;9.74?#]
M;?:')ZUX0I@1H<%:%VBSUI0(^]_OVHUF^]VDG)R0OZ(.>(; M.4)3?@4Z3J^7*PEU>_TY9-3WO1$1SB?OE@$L JT#-
&,AW:1B:$HV*EIZ6;34 M+#<34HI @ E1B6(/7A;YG@FRCFMYV=N)Y0_(LZ%M#C&PX4061TF>#[+MOC63)#8
MML5"3B*?:0/NHHCF@)<';>Q[Y^-$FTP]D*XQV8.O(BSD!Z 3R0PV('I> &\ MVD48.-X L:_!UYP!]2ON4=PCN*=2;B?
DGI"R4=';*S#/.S0P"D1*BI)VJM,S M@C-#22B&8_4]AX[*\VG(LF\GZA@0L[K0=V_-KFI0;LW.:L<'/1_*
]86))A>3=0CBAICHH/AH MNI,O\7VM7$N#0^@E?V_4,X;<>O$BT$ZAIWU?K92-IT:>RMK5D"=K1H7F+]WA
MND$NC)^-?1O@"8C16 A>5R\28@RVD*-C\:.]P"/QA6 ?@TB)V2P)\[X'#A M5T$8:"P(/-.F+X@?AL PX%(..;-
,+W+#A7OI1R[I[* D'4HR$P#1')^7O3+D MX,@-;7@2+C*(QF//!^\M J?/NF6NB3>.[3%W@/_*VKFKH9S 1Y,%P9S TX;,
MRNRNSTR,U]KP0+&1>%OP>!%$)IX3_V:XTW1@*Q@H'T[(Y2I29D;L/D=6P.38 M'B%F!:.6J605?&$T)]?^/]G%IZ4?
J*,_SC.;&1V-10BSR")/.!'/0#8S1'K MPXN/F7/"@*YRV:[7--3]1*OJBJD2MEH_TO+?$[%6$[4W1]E0":%NRB]E;?%
MWU%")/G2"PBYQX0T^Y;CTV>+4$,OD_2 /^7.:GJYMB*J3@#L/=\&U/S"G5N. M2@W1Q-
S@:!I7.CP4R2]^CUXV6I/2MI$*6[81XGBE ??W?WCUW95GSM*'RU7: M%7&^UP>MY6)\)$B4%/LQ0TP+68
0=@3(R1@G F'IEWE,3R%0_A&@_D:K]#^
M#5H5[WPS@=H)&DGMAH1"*LYC]\L8^8T$HHBAX0W1:*D]&&.)BT!SW\@\>?U
M^[8)!B,.02!\M69=^X4]@)K3.HDS\X'?PX9"%%X?0;XRFH[7]RY!EY[ITBH9KT<8/:UR M=3,V3VM3)@_:%; 15/$!;,("-
=S';"_2N1O:P! 6!F%->XRBU8[WJ@%P03G) M8,C.Z4:<-]UZ>4CV7)*772?/U>R*U*;Z9^:M:38>^]X]&) A!P,27*+$MIXP
M8_.6IA5-&)AVOM>3A@%^D*)P^0V7;C4W(U\8:3WF@)G'A0Q<>EGF+=83X%4\3W/L2B+CCNP
Y$_P3VXZ*0^/BO^G[>]\[7EX5[D GL1S-$): M^H<+"@#: 9TJ-OV0?:BN$6_TV54\?"Y;D# M2"WU-
#)!N>12U@L\)PJW8'3.L/?!PO'JIQ8S7NXC:M/ULEY34-\BU.<79!J* M_(N ')!GBB.*@(AE==@*$4HTO2Q$*-
%4$$0HT5001"C15!1$5,I-0V&B)@ M1"R<6* 0\3A$//:P^K(XQO9VW7K$KC<7,2CT_DS/P2]_>%5_M:
[JKY.D9Q4N3>.]^'XS-@VAJY^N2@K$N*>A&N:(_/T"6 MT<+S@>AY%-#VH?*LDP!:,44E%)02N'E*H7U
M>5PO&_NM%+!28E\40&N2%(3^FOY787D:RU6%Y97T]1YC^82*FC:$YX/0TQ/Q MSO18%C%##7"MXD M]<=*-
#R6B7?=8G=FXZSU^'776]E%CT-C-@IWW5[Z&=H>MF=C>-<[W7@CQ&:U MU$2C=G.-$(O0:'XE6U4?2J
MR%61ZPLDUZ5%V >QR^W$(5]LU#$=J6K0"^9U;-O#*.3DUHHP+7:.7[H#Q_LY M0S![%V)IZZ5FJWYH$98"Q>
5@>^6P!N-4DUO*)7!+YB^'#O*-RHEZJ-#;U4 M;VUT-+JB\
[VF\]@"/31"UTO5V@;EN8J";LF&HY$J/UYY(=BBWE0N>Z^CH*UB MF:?%*UG9:P="FOH&
M,W$JC/OL%9^34R=4P>>++4E2%72'LDE%KH>R246N![-)5?!9L$WN=:A3I*O/ M\J.\]CK"6; $_+XZ';I>3M-
KI6JUI@(UBA->.B>T2O7&P9T]5XRP99OU$#BA M7FINDA-49'*K5F$V3%GT
&5A+=HB95=VIM0/+N5BJ((\Q0V*&P0W;+S;V(&3 M@>*% ZYB-?2-&[S[00E['=C-U;!.9N?
W.L"K2EA5@=YSQWWK=17W50RB&&1N M.+BY<7=1\4=A"$85L#XY2MQN;5"!J"CQ<^_M$P^UUXX7!&^DF:SU>-
_S>?Q7 MR.[7/?BU'SC;J.M?!0ZVO*CG\/UMJCPKLK6#?6VB@W*U4JI5-]E!^<7&M!1A M%U?G-ANENK'Q*R/>2R&?
&8HM%Y2N+;[W2*+7K]8UWP-\/TB;C\6W(&L; M18KMPGO#XVIC$RM]EF"GGA& "T=_Y29&T>2OA9=K7^.94O8F5[\
JI/;F3GB M2KMC@?9]LUIN:K !W_!/F#?ZW706,E78)1KX9!KKNUR;00K& 8:AY=:VKRA
MUSCWE)Z$HS%+\+9@S$WL*>8\E+73R,?6#H]_8DF[X_ LTQNX &:,3=C2[8+ M/[@NO@^^O;/#(;VJ#Q=[=_AB-O
YQ]:ZB-B0=H$4<.>_"B\+AOWW,KD:J56*;&S))WZ^1E%*%_F_WA22N>D&Y$ M:+#6!=*_-273_O>[=J/9?C7[IQ#23BJ
I0:GHZ&71D5XO5Q(Z\OISQ%'?]T9$ M8)^\6P:P"+0.T)&E:$G14H:66N7&++)&DMU<12:AI"T1*BI)V24G5W\/..+-IU[K-
=YK%3?!EX8?0T_@]]^$OKH5W7LJ*'VP3^]MI%V.DLJ"D,<<#TDJHC=^/ M;4F78&$P^,[VK7FWX]T.7@? -8=
Y#Z')83<'P%[6+B('G)@R]LYF@4&PDT M&F%-$L)(GRN>1QY<_(I5+& A",2_&9%A.ISY&" 93A!P%<&=(<_G" 'EIUL;
MM4Q5DR [^#0#B,SL^<=Q&"NSJZ$@#8,H=\"/>CYG-T>L#R\^
M9LX=>PCD+H%D:GK*AO&JJD*RE8WVO[3,YU2VYN3O_5$&9)()1!F6O"W^CC"< M?.D%-B+UV.<.M??
&I\^6ZX9>)LD+?\J=U?1R;454G0#8>[X-J/F%.[<*,WX.AT4F)WT@C,FPCQ/%*&_J_\.K[ZX\
M^68"M1,TDLK7A$+PJSF/C[&MM-L+TV[U-I1KJRAI M Y14*5?SE"1J[%,_+*84>]/+DGFU,=-W>
M7;)JWC#$N!\XEHB!C1V 5]-[T+XWZIF@!P5_ MY&L.D2T^!?>("IHYFM36GB\?U._;)A @@A#H56O6M5_8
["ZUDFB:1_X/4 H MQ#C%1Q8$S!Q& 0_#H)3$*^"-WHWFF68$X#,?T,."];_G/3]B\"*]I(DT\$20 MY'LCPZ/V:,QLG[C)' (Y
M_O!>!DPZY,PR MO<@-%RJ0?N12O!H? ||#7O %(R.?!&S$M3%LU;/BL!\P/2SQ 1ZV>U-["9$K M&B\.C=>"ST5'\8P
V$.ZUI(TQ&FU&#O/A MI5*,_\/81R&+Z$//LQ[B^^F5EQ>G>NX+>AC>FTO!_W*J?187%2+IM:X!GYW= MV,G-
;MR]"3]_KN0<(U[/>'?"A@>SOO%$&[Y$1KS1>'(UV[01/UB^P<5F_S% M,*$)7&O:<+-Y('XN%Z *4O1V.L\>K=MF96N
7^W6;_=LYK&*Y'P>'82[.5>(%53 MSW,L^/&#_2VRK=B?.6%CI$WM*P\ W"8>'^LMNI_HR^*F##Q.9/@F?T4#Y3@"
M0/KX:>IGP1MTBA(K?NG56V'1.1FL&4$K";1+ 1STKQ+X;;ZT>G')]Q]<&S*0 ME?V(*!.Y0XY]0^LUYP *=/XX<1O?
B*X%E@$'$541!>_I +NF.^3[#]P [M,1/ Y/.I>TISUC5]'1DCJ"#X !:2*SD1DMY+<^Z.S+G3 @;BJ244TZAA$]
M_=`/2J*DPJU(@^^EQ"X2J^PXX*B#7-P:*>RN^G_QNIY0J"YS937MLR"\"TEX M:""#UT>*A)04:"6339A-
@<#)@C7@2PBE!K(PJ,DEZKERH50PN& MH%EGBXTP4_#0HVA2!"W?]\N5X$&0*R)^\7; ,IL ,L:D-B(%YK<-(%V3.FG
MILHYW&N"QK%HA4D$#&M\8FR[(D9':WT,>.XX;1T@2Z(*-_7>#M?(K6>W"7O_
ME;D4E*N*H%RQI<5^%B:U56&2*DQ2A4E+"I-V? Z0!4/MO>/=!=MS?1'1N4ID MX5&"VKBU+?
(G^T@0LIHYP/S$:#1QM7U<[5,/]1T76MX_(EHMEH%OE:R.U&T* M]LFQ!
(M"+\\/]$V.AJ=)>"I,33M@C4/>)'OC_@6ZPD,!*"7ZVV%B"(@PBA7%G;T4)C8FFBJ+.P_H1"A9-,+
M0X22307!Q,+9F@H+C\/"(SL_+G4>MK?KUB-V_9QF>J%W#-XK?OG#J_JK=7?? M+E<7:J G[[^U*-

* *

M#%YM&ZS=;9D]UJW5F=D%C.E=@[?KS;JI-\Q$LXH[KLSN7W]]]!JGP=7'ZY/N
MS[]&MPW?.7<[F$*8O+)S">"PSWO=ZS^N_W;/1A^O:^H/OEKG-M?]Y<'K'[BZ/?/WRY_>D+7%F;O/)O{[+E=CYYYV?
VQQX_,QMZI?=^ %?6)Z_| MT[CW_?[G]]I-Q:A;_>NN_>5=?&E:W3UR2L' ?O\ZT#_UCQKG+|_NVE&-T>_ M5._@RJD=M?
Y;^6KT6@_O;XRS;U]^-7]]JEN_XC.G=O0A./^M\7#?,,Y^OC@] M_[\:_!-
;^(SIW;T\9>SWI_M(J:]L9NU]Y^Y;I_^]@&?.;6C]WZE$5R?5>^O
M3\S1R/WIZV7KSAMTJ]W*Y)7G__U\;9_^^9MS%ETX%\W6?_|>]\(O<.74WM^? M7C[XWVY/JS>70__W6\/]^J5AXI53>
[^[Z]UW!J/+[K7M?ABW_QG_|NLO9_CV-MJ;WKOYVUOEQ_:[4K?[3[/P\OKG_OU>_OX,JIO3N]BO"J?_AM[/&/^'O/7]P
MU_N[@E=.[;TY-G_OG;0__O?LC_[?'[JGEG5K?NUT:]-[?_BUO/FY\; M=?;M\U_6Q2^= 18^3E[9K79ZP1?CFUXYN6SZYZ.?
__^A7=PY=2.?N6__^&_M[WZYO;;O=6OP[?0?]_HW?/O4C]I_[G3^,AY^&]YK%?"'3__]]*G5_=CH M73/W@EN??
K'_:_TY>*6Y; 3 MKWMQ\[EZ97[5^37_A[/JAS^JOUY??GFE\WHQ]D2B:%1F:B UPSPJ8CZ?K/@D'V6&
M/R#RN.BY^$AF(E")Q_R24**FMQXVF HDVR?>$>@0V:H[4^-:ELQ>Z=6/]'G%Q++2 MC/PNC%
[2O;=8R5NP11)CK4B4JXH)1$];XE[2I$ MC;AHP2ZJHJF?A:A@*&DGP8BXIFQ&<%L@1>+_5(R_:OH
M30NTF:CC3F+JK_4W5(O#ON5J(&++T9R:)F^03CCGF+H%*_,2G%LK#*#ZI,P
M*KGC&38"NT54AN1X:P8@Z*K7QAL9J5EZ=5Y+GX=\I-4J+323< &B]0[NZO+H MMV)3\R.:\8MEX%ME^A
S9J9(R>43H],YK^G,<^C';XV3D6(/:9_ZB1;X(HF] MH %^M:RW_Y6%R$2C^TR*+O-*Y)@^,%H,I?
CO(WSTL4@MWP%S.M_N)47G/QC:\5)/M?,>GF>Y,,E.P MH;TOU1T[WWLG+N/([UC)Z*+
(Z"\S26D9496NACZ^UZ@YM1:?:BDR:-B(:Z^O<*;1FTW1@Q#J>PR4 MUZ>R,%-(_TT!1@K^/09,I@!DH\IACT&2+8K1-
JM"%%1FZ9D]ADJFGF==3;0S MY^#*LRSMA#+1)>WSL'Q:_D_/?_OCZY.AS?O:)0T0I)E>LFCLS2,POK-X3<<2 M-
=MB*^L7_G'3ZIXG/:([]W;0O7T8^%T$FH 90,PJ?Z0C.=V'&^?GZA%XC=<7 MXS.K9@X[]G^KG6R9H*@-
C%>'VDB4!WYBOM_5FS^=^36O>W%]='G_8/_4/HN&
M[[]D^B1I;5$4_Y^WN0W]^&B4/+^G,L,)W3$21'W*#Z_L>V1;S^',I8K+#':P M;@#+!O081]QZ[[#!J[C
U#ZM_S9P=#L\:_2\7S_T/QM_\,]8BF]\^G%)S0&5
M:B0#'<6),E'R0,U^XPDVXE3")'[WP5>;1O@E;.K1A/GL/M;T.L6457GL1*\3 MB]5+HJD@UBTRW[&!]W
DC>AQ)8^J.DZ^6(J)<6\T"IWJ;/C]V/9YTE)1GB<" MH;0/KMD,.(VQF$>R\7M?;%N+7%LP\35\Z%Z&0,
[,M[J"D+N_#CK]GVM?^,>* M$?[3/OHRO/[=O@:&RG)_)^A>]-=F]J;1Y>59\ZX2G-FG??N7+RW]VV^M+Z^H M5^*(.
<$/K\X_O<]SOQN-+"^4%TQ+YU29=P:###H[-[(S"5UH V('K*AF!_?!' M8U0S_W1[-
P^=3^=_>KQ^U/<&KWYLMO'85\S%,:A^3+@[9QV\I1J>'908K9>U MFI!,^[%JM3G)IJDL-5DYR,E,#/JDG.[)%>3=ZO]*O,
MZ#;K5=ZMU4V]R_1>LUMKU]K-9K_&6KW\05@\B=LX^_.7\Y_.KRZ[U4:K[JR] MX/;WM')CY=/*$IJ%:^V2PA]/5/!
I.J@3R(8-&7;=^U@B-T! NKX(\[LS9H% M2GUA.#GB>/#(E:=SQ-$?\#?X?68TE^V:GC_VJ$FTAGTU;1?/2M @4^[&4Y$E
M ?>YU3,:9KMK56I&MZ8;O6Z[6:EW]9[1-(V6V6"LL5$"W5@?QO-/IV=_:E<7 M6LQ-"7HW=; @*YI8%'IYN43?K''V8-
5P0JN\(/#X=N6@Q"[+-=;STE:/N%2; M"R,)*P-)++[=W6M;RW"!JEJM-!:85.,Y8P"X*3(DH*U=:"DY+]]6-@#'=?Q,\H$/-6YI
M_TM,KAM1! 7'\0D(2VQ&(Q0U)/'G_ZWC_>VSXRQ3:TM0AE6(OO>J3
M5W[DJ8+81IL'0JK1'#,_S4;M"HQB4L/TOVO&#W9,,X\X1TZM[T0]_A]XW;DO
MN$74"DNQV'M=B&MJQ._Y&Y(&E^:06Y'#%=FLDG4K]EZ+KT1>$L5(5Z#8FUTL M:< !HHE!M*. M
]\;$%O!%@J,+C*CQ>":B^\/#XBN;) M!N#07@X&$ KZ_WL4]@IK$.%NMVO_/$_Q8G)F[RC@YA& @_8'\O#0>^R+_K?
M;Y$7OEOZ.G'9!%W$9_JP]\ 1-B:HM*N5>WZO5RR]/ Q'L\#\R/WAG0M/!;ZW
M_2#4.C@)C)J(A%YVG.L'VZ3Y*9V!S^5@D]X#_=+CX1WG+HXRH8&I;DA??_)N M&2
RT#X/&;Q!Z_QKC/E#WJXRY@]YNT5.X3QVNT7R!%;+ MV!A[G;&A:RUN>J(K^A'VE\.FN_P@C/N=9V^,/=/#S?
[G+3::=8TM%>LC(M#KF5I''2[$I%93V4HZ2PJQRE%[!=Y2@=\G:5HW3(VU59CSU!U$M2H"KKL=?H M4\;|
(6]7&?,'O5UES!_R=I4Q?\C;55F/G?DP5;VL%\V>?TG6^V[3&E5]>X=2 M3A#N?8 \I3*\OO;9MUW3'C-
':Q,C3F]Y/"Q:&T=^$#&1_#B[-X3@*N\K#.>CM*@_GD+>K()Q#WJY*5^P)HI1[MHY(3A21,9;H?
\G:5Z7[0VU6F^R%O5YGNA[Q=E9S897+"4-;["TY,:.W.Q8+D MQ'O;9? 1/JGDA/)PE!I5'H["KO)P7A9ZE8=SR-
L]U.1$8081K(+7QM9]AL-H MJOV"C-!GV.X+PVZ1C5"%W8,V0A5Z#]D(5=A]7B/T[?[%KHVR_F\5O'ZQP6NC
MH)7UV/[GR<'MU[TW:7P;_\"GZBWMNGQ9/BEKE]RDI>C5>D5%Q_??\5 AED-V
M/!1V#]KQ4.@]9,=#85=%OU7T6T6_#]\(52&60S9"%78/V@A5Z#UD(U1A5T6_M\Y#3*WKY_-.EBG]O*?[=GMSLC6N
ML*M"PBHDK$+"AV^$JKC#(1NA"KL';80J]!ZR$:JP]T+"TR'ARY-?5$BX""'A M*W;ON=[H03N[#
[D;8+'NI3GD(Y;$B%5D=D^-8N7^'[)1K+!/[T$:Q0N\A&\4* MNRHRJR*S*C)[^$:H=#ZHR&Q!([,G MS#$C1W1W^&"[-
ST60362%716G57%:%:<] M?"-4!0,.V0A5V#UH(U2A]Y"-4(5=%:>=CM.>GKU7<=J"QFE/>=]V;16F/2@+
M6<4"#ME"5M@]: M9H?>0+62%716F+2*BGL&5*8@9O_V(\I[OKLCR1(6Z%78/ MQI!7V#UH0UZA]Y-
>87=PAOR6]QND;R %?R7W*Y[S+P9^%[D6L??]>E_/[_
MH?/3'MO]AQ&^7XZI)0'^#ZS'G>G8OMR^"O'QJ6>@XDB'[!DH[!ZT9Z#0>\B> M@<)NX3T#58E=Q+BY]L3>,R-4Q4
.V0A5V#UH(U2A]Y"-4(5=58D]78G]^>N9 M"N46M!+[L\\#0)MJF7%8-K**!ARRC:RP>] VLD+O(=O("KLJ4*L"M2I0>_A&
MJ(H&'+(1JK![T$:H0N\A&Z$*NRI0.QFHK:D@[:Z"M"<>K$;[S 9<.T?4,#.T M;[EVRD*FO;
<=KN%V=/V==C7DFDD7C_%B.W.QA1?W\6++@X6X7JBQ\9@S'Z[2 MPN&\)_>XR:('A4&(D@:
[0>\CFN<+N=LSSMR'K.7Q3FY>O.')X/SS66S$X;!=V$QX? MT3>K@*.^.CAH_?$3>IYO9;V]R\GGU8__;P&9%'+!GST?
JRX"S>N# M;6T'&K\? LY#;T\Y".M4=%?]]Z\UBMO M7MNW;_)7_D@GGQR>?1;>?99T9C>%=DD6/CWOI$-N8
(_SY@@/#=CWS7#H9 M)^"EG4DBJAIE71MRGP/) &U9G(_@ OBCQS,WH&LGB.]+Q'R0U\X#4-(8*%.# M![_W_-'_?
J8<.J$6?P5OM>SZ2[M@+ M.%'Y)3=IP7I+T#S';R+?#FWX_>S>'#(7G-J.&>+/>KM:*VD,?%%P,L$-+0%_
MF'Q,/("WUQ7SRUK)OXW_AGQ@EI@-N]3%@<#B!S2KB+[8>*__:@EXU:@"12OI_
M>&6U+G:3KOU_LHM/C_,BRWO^\7<5^M^[S*Z&W!X,PV.#F';CWH^9S='K\O M/F;.'7L(8C7;+M?T?
Z620JX*X:"!_6RT_Z5E/B,\IH Y8O='&9#EE:BX+?[. MIU7%7WH!=1]]CG*O5N.3\\]-^$J0R]C!' $?\]=U?1R;454G0#8>[X-
J/F% M.[<7 M7?BU4J_)7Y_?@";JT8V4?'JY5TJD]CS'@A^39?[G;6_)E70%8GF#6Y!&;[61 MLWDG=_Y8]>@#/?
YM\CV.485@Y55A+@Q$?Y#4!E6!(*?XIJ6T&Z^T&E"504 M7?@!%!$&/7M\R)P^J@5\$(A%
[HL+Z,D^CURXBQ[(HG#H^;!/J_P(XSL#'02& M% S("Z9@MAP#P3N\//?0-SF*GR;X:;43^O'"8DDD2&:N#2SKYW/
M9]=7YR>7)>W\TTDYL1<7T4RMW*J_'**9QXO&IB+:,\R"(H!JAT 02OF% T&J MQ(.%PG,K).FU2VI>VM[-
FBL"D<[')0^>GA>&,29>Y.9>2T0+RV M31%3<+#8,X*@=@@[-.'7M\%;K>/T?6YIE\RU?,^*6D?RZ?EDO9Y"/_YSUM[
MBV)(B9F]L&E>IA'S#'"X&1H\[YV=L_-B$KF+_I]V^1^ MB5JFV,@9);J(.+5];H:>KP2$$$A!*0+P@
;'8P7C]V;==TQXS9UJ&O%G)NU 1 M5!5!51%4%4%5$=1#-58*!SL50541U,=$4#^Q< B0^]7S!]P-N*N"IP63, ?-
M5_M@O[P<@V6N+%!R0,D!)0=>C!P0<=/WMLM6=R+3(P,C0P.3,P>&5X,3!D,2YH=&WM77ESVSBR
M_RI8SYL=>TNW[!RRQU6*)2>N2FR7I6SVU:O] R(A"1N*Y *@%?_:U8;+M#ZEK,)E^ZW[X2V[."$7,5L02C"JZ.
MN1J2KN?[U"7?F!#<<<@GP>T!(Z1:*;TK56LGI4JQ>'X&;5V$+WEN@U2K9?BO M5JD=D\J'1KW>J+PGM]_(X??
NQ9%^O'5ST?W?V[;Y[NWW3U^O+LA!L5S^4;\H MEUO=EKEQ7*I425=05W+%/9#PNC>LE3PS*W;OR4(V<
MX[+C>9*5;&4?G)_A%?@_H_;YV8@I2JPA%9*I/P^^=R^+'^)Q97#SL_*T=_F MV9YG3\|/;'Y/I)HX[,^#$14#[A:5YS?
J%5^=PIMEN#WSS*_BF-MJV*A6*K^? M^M2VN3LH.JRO&B>E#Q_B2X(/AM-KGB&M(9A#%;]GV':B5SGY@ MT9M^]%
[?:T&M_2O8Z:IZWF.#<^V?PUYCRL4ENI9 MN0?#Y]^ADQ;(+!,SO<3'HP_=DR&5I,>82]@ORPELN-L7WHBH(8,K
M9JA[S**!9 1^Y/ P2 XYY$?$]12!1J#'U"'4M>$B7(4G\%TU\1GQ^JE/J2%5 M^J9@ RX5*""\BBHN"73"%_P>6B.>
();G]DUWJ5/:LN%L>4'/8=!A)%S^E 3Z MZ6&W1UQ*H%)NN,.;$LSGJO6_VA??NUF/'+C:UQ&[/[*84 XYL#P9B^?
ZCP+22Q5IF2&"SYANZ=S2Q/:*@O6I[C MB<9O%?W/W%V'NZP1 "T"?YJ[K3_1D)[#46*F/3XK!X_0J3M;/=5&2+-7VSH@

M%"D<41M,6K_/+'1MT.* >>HP7[%1CPE2+Q#M7!ZB@=HBJDE[VN46F,<5!J$W-MT73WF!JC??^G-Z$#
(+0[9(+Z+%#6Y-M!?*M20XW/Z(A_=D'L*"'+^KQ@Z]<>_=4*)"Z6P@'1A3PJY#M19H<[\(* YZI
M=5#JH4)'2X)FUT*Y.)++\;AR\HY\HI(Y!=*!:.PO&#R@,U-[V\#&:*BS\[$T-M%7WDYY15*.R"]2$&!90-C "U8.@FNQ
K<3N@CC-!D*!; ;WT.-)9H(UF?!U-MQ\"&(6,[4-T)X2P[/TKD@OI<@27\"YGQ@2B$00U8DV3PESAL$%\A3#$@A1
MF!ASD'J;],%;=L1=.02^HIHQ/2(C1EU0.$D@A"<0J$!DHUM.V4$JIZWTF..- MC];KX4<&?^L]DSD/BN ?[!+)XA>"&G*(
!MR!"PI6M27B_S%.V8A_^7Z',$, M#M8<80_*[H\Of;MVLU-8##LIOT0+K64"]&P(_)#+5IAS;[Y180W)L79M:EOC
MVD3]7<44^X&0-35NZW@(=FTZNIG&S1<>@#J*2,0'G8BDEH7V%-H$G)'CLFE\+E='>ZI,-O<0$UQQ.8>W8F
MAD7AU]@OGPN=LD^!3]TXT\N_/0:^"#8"Y;*-U]4)>O_!YT(.D82/NK-<8A)H-MU W"CK4!D
]@4*Y(HETF7.B&2U$O54NV0'NE1QE_J$?-B1R:[("2LBQU"5SI]-M3#9I/I2BUE!3U'S<@L1R%V,
(FLC\B&EU!HJ],1W%SF"JAJH3.J)]DS)$%*-MF*L-(0O3@G;\<@KV;-N8LI3X;03B\,\B'N^FR-3>SPC-X[']1@/KQ#
MX,W678S%=6&7C>WNZ_DJS[("(9AK,N!__ZWZKG**BP^BE@N8#,=H!P:!Z?A< M,.,]H+<]
<(%"T!SMF,UUC#>6EJ'1C(JC\^Y/4$D*]D3>&9]D/G_M4$0?[H'7,Q >R,B,*"76^:1OA/0@:U/TA=05X17EC"6YXFAV
M+9-/!Z#C@M&?1=J'.*=!G3&=R%"A/WPHU8Y_/^V!>\U$N/RH,K-&:3]7/CUD-M9Y?"7&JV"
/C'@=N#K@%;K>=4&UKJMJ".(P&$Y5!$6I^OX4E0K@1FL3ACC-M&!?:&&
^R]6!#H0R.AUVR$J#$J$^AC;P!)@8HZHF]V5F%?42.H>:-73DDT>%-M#<%G9*D6ZQM"A7VO/P4_7EVWBA
T]!S]@@IL*D*N/I'+R-*Z+<[(4UP_!T.-MQ.D'\$HGZ(5A%B/:*!I%I^3SUUMH_1='F1],=,.3.#A;"%1>H**9-PAN[KD7
M2&&>$4SJW7N__[QCW_K=&@A3':BC.(-R],_MHB:ZNN_Z5UQ7IYU#SR,\G]P+6FDP;P2."$\;4.X.%-"*JI\2K#O(9Q/!>[
M$QBC*ZX"Q>:S='F8\EQ1KVT^3&F&,>N*H&8%M8K(,(Y%I4,B3:7Q]D;<'U?V2ULG37#J\(J13='
MVV_+&_D"7&\0(Z)3Y[,Y;[.2XK!W]%@DDW@S1,EYA\,TF7L#S_<&*B>[);&I-MZ;.5@VVTVS-FMMB;%-
-72(]*'LZ5^C"\'BX-&@'.6N@$>&8>NZWS[!J3.PJ$-M66<68TF=:1%%'PR!>=\H2#_VO9-/FFR^&E+WL9!>#;D
A;KK6,%U(>[W-MYKHK5-^^%A-/)[6A"^Y)E6386NR$GBV9-M#Q>TJA<+9W!$Z8.6-*O@&U-MV-EVH4O\'5<7=
(=>H%$K6R!#E(AR>'_5&N%DTJE-/T^*L%8D07?-R/78SAX-M>K[Y0.ZC'U=+QYO4X.=\!PL.D\MQLFHQ)CU'T!E%:1,
4Q";EN%1;-M8%06?A"\+8;K(5!((63-FW([3%$!.;F+;@#8Y*:?Z"!\M+3#_I*(HU_0+1]_'E@EB;C;NSI/$G8>-60">.:-M)#
(MR+-*!FZJP@QO>$UY?C254:J_^STY@.&LA#;2("ZAJ=8_SCWXEA0OV'F4<8PA(_.;TSOTQXH0P-N-
$[)Q+!@QNA5Y>9ILUME-7P>-MBT;P(8>%9)_4]{33EK/I!'B#6Z(E[I=NJ'!ZA1U6"D6X=?2V65C_6*I_S%FX-M-1:6E4-4?
5G$C.>L&[_9'_':?:#HXG'NN^K^(MN99>5R^O-UYRI+[0Q*KUL\@'O)S7#IYT$/&6(-M(TS/ASC3$"?
RBOCKT=R0YPB9(^1J"-G+$7(S05(.FCEH[L+0YZ-Y#YI6#IHY-M:&[]J.>@F8/F%H&FG8-
F#II;/^HY:.:@N46@R7+0S$%SZT<[!\V]!@CZRGK1:K3Z:=U]>]53>Y_=C;G:1*FS-M-.:.#5G'2K>E"S)JT>J_2D8EKRU;\9:?
JK(KIZH\6Z"W;)7Z"ZZO/,F7;NW?-M^LI:SM1]6E]Y7,WYF:^OS!IIGZPYL-A:A*[5,D3*2>.+;6?&Z.SQ=.VM,F!U
M]>MZBCKD=EX%$AJ0.:36,+E?__4Q-3N,I\949EIXWB#W+B)C=-C@*A)46^F-MCG96X][I$]PXK3=/KS/X7)WDK&0-
N5"3)$7URD**UAOMKW;R],MLM]VTR[R3-MV]1G3Q#:7#DZTK1!@F6F_>GA*^%YGA(/?L97HSHUOF!TA
'M_%EK[K28C>L!-MVC)IRA9@O=KD#O=JM?1^_NUXTWIZ8WIXQL1CI?\6G=
(4CF.UCQ_.%1_[:E']5_<7'>N6NV[9G>MA7CW'VE]VW#N?%Q4(-,9+*4%-M)\W$Q\Q-,%54,#3ZO!F
BDQGL%WROL(2I)%]3IS:$CL>T]-8M+,FR0#K@P/6-M!&&YJ%2UOVTI9;;:T$XK4NX9IKV^6FW!.:E7[KW'\7R]T^B
EQ5LN%$MKIM@-ML<)%*I"2*SR_#ZZ#Q1[Y"JMY8O;_X7(A"U18G_$7??"!-D?
7"ZGU;K2==%O+DGKZJY]T9U61^\V[SZWNZ39()#MVW40WO^G-FLIUJEZV#A"74%C-10\:6B;GB6^
2,+)XO[H5'C+M*X.F<-MRVOC%D@?0$F'%X^#4N&AZG_AP6S+Z)PZ-4E02I1REL!X)4/"LI92G:F/($U!
MLC[5I4N@12DU%3TJ33U#:M\C=FJ2L?8)IZ8LL>4%KBZG/>W/D$H16_9;RR/1@IK'-IV'\#H)8T@0PE-)/()<<*$G+?;-3K
MH]\6^%0&,5#HF[;-HZJ#3RRG4"(_LNK*HFJ!!DQ6-#AS2+(N*8_UBN1*?&P-M"[-'4^ISF&<@$!
[5+4WK>BWY:'Q&^2Q,F.9TG1=?Z+,&-95X?_YH4CO9J>SP-M$OFJ(;+$I:5V%&,*84').7J6&Z=-G^F^+\BS!:?
_7GOD,A!Z/L5H0N830_T(-M->+JHP8PXKJ0LY68P@P'U@&.,"!6P3@*3!>IEE'IHP@:;$W=T3=L>IEABI<9C-MB<-
BS(\7F#3%8!)%G<'8DGYJ0*)>LU]<+G3(-E/',O-\RER,]1:7/M;G*WDCDY?FKFY-
M5YZ+]]6OSNGWSO9,G1)YNF(^W(2'2L3P_TZQ%-SU#-M(.?";"#:)DQ!2H\T$GJR)QV<#3]0(]K*\"
<;HN0Q*6U77M,AA,K",:2*DO-M]9@:HV5%ZSORL$9@:/"-:L<)$QF611E1A:&"-H6I+FD3J].Q$E,Z5%<^A&:!
MX2!+8D+@FP"4\Z0,:>S,#P0-SPT/JZF/=(?F$P4KU9>&8,1B?NS4P]\P2MB_M5(&XPO*I81JZ_-@K&-
,^%Z.PFS.)9JX]&0XZ-PX,#-0H#]V?K:=;$+I?@,>-MH2;(8D;7.27C(SI!"0?WU0I"^<9UN"".(Q!%G6.+6B^8XB*&^BL
MMSL=\N-+^ZY]#P-N X;,8";J-DA(Y-I.J\Q(6#4R2,07X-MIHDIWILBTQQJ^]'2TE-M[8GES^$SFF;L31$-V-N>56EEV4IO
P'1*OO*LNH.,_JUCFH.(1CI#\\5=MA8-MT885I"==M<$LKP=YD3X%##M4/LC#@^&/IX](*&SD/GL"#QS?YK*-!NY(K79/P
MK8/\%3)*T:*M+M@XZK,-"($HY,JU2NE=+;O,\CWD\-M1^X:XFH63I>K)%A%X-MR,"?$U';*J9J"T_K%4?;|
[I.9ZFNOIG)YN#8$'YUVNG.?JXA:1-M<]&^R54L5[&])G#;M"Z/J'8V3EXA$S)=/'P[I&)$2?/SF\V-Y"B;H^Q64YCK
MXA;KXAO/6PF7D1^>P)/9F-F5-%S7HSV:Q<37,UW5IG;^\R6CJ5=7WUZ8Y\-M9BX3U"%?<;L@:0="'^:P2/O67(]A;N?
R+!&;*K>0=VSC'=O-1O.YA,2>[CQ_-MSGD&RB.77$B5WC0<'D:6.-PT/H\D/OD@W\>^X_O87[0F7/H@R-YKX=)SNCQW
M"B6>S+/D(-1U$?3BQ;1W#+P>)"XI4Z28K0Y&=7XTU@]1S\6C>X_;C\%1N>?9-M$_AKJ$;.^?\#4$L#!!0(-#2
;%EO'@3__Q(-%A^-8-=GEG#$P9#(N;'1M[3T-4]M(LG]ECJV[A2M;_B*!-2SU"'!>V") M@7.INZNK5V-I;,\B:W0S$L;
[ZU]WS\B6;&/,!FSOAJU-B&5IU-W3W]W3'/^E-M7&Y'-Q[Y(F"?.I\O6*#\="BBA/E:|
2NCF0R8!T5QSQBGX76,@S9!RV#OF"L-M5O7>>[7Z.Z]:+I\-AN-9O6-77]FNU\ZIWMT-M^]G5:>>?
UVW[WNLO'R[.3]E.N5+YVCBM5,XZ9_:+?:]:8QW-(R,3J2(>5BKM
MRQVV,TB2N%FIC$8C;]3PE.Y7.C>503(,]RNA4D9X01+LG!SC%?A;\.#D>"@2-MSOP!UT8D/^]\Z7PL'\(=B4Q"<7)
[LJ&)\F60P5^&J%E[\.)O-M/QS6JXVCXPK>;0&=VU4_%%S#$LG@:':#%^W;BR/J@S@*/8,I9Q$?PDO^[U-X
MU_BI>E!M'-21)?G)J=)EQ&3@&$B>Q+$448]I8<<064#;EA7B(B)!S],_BV-MI]60)0,!5^R^=87/4R,8_%/"S8-XVY5[+%
()@T4-7!XR'@5P$;["'?AL,HX%-M4[W"]JY(!3^A++?K2)"##\!$UA&$-1*SE/:S&E&:^BGH67!YZK\,MBXAXIM)N-M*
6Q,G<&08@*(1H*(T!!,P:89EGW4=>Q#X-+[O5\]Q-ZR.-#6Y-,XUCH7UN-MQ*ILOQXLNZ^"XL[)1ZE-
PEI@N0*R7HEB5S$Q(3+JA01@@*%;?2T$?O]Z6NG)-MO=W4=OR:&M-&8WM)1BAMS<;
[>$:#=@8@S\\E9G%3[SDH'%C<#'D8EGT>F_F=-MW#EAN
6[";X.L:]7CX[3;:D",1'^TJ1'RKX*E6[^4*7_CF:_#64DFBD@I/%?-MDPVC92E8-MHCGD-6C$7D_XJ-A188%VNQ5Q
M(H9=H5FC6F+DV^RB@ML("JP]@>X,%&D!H^Z8D.B*9(2Z'M7W/]28]P'RSD!H-M'HLTD;XIL?/(]^9USX(]W#DI.?
YDG)V!O1MQ+4!SZ]B!"9;E'CP;L!]DVR-?-MQF-GXI#[9!BZJ0'<#*C^A!V\8Y_X&%B0M>Y%E(H2NQ-/\&RBHA+[W&)
UWJ-M[:Z3]HXZ>2*6ID:NA=;K7R("P\C.T=B3'-PE^+IP%POM/X$:0W"3Q\!$&5V(-MH])'2M:91@)9BT@:V_"*
(BDNX'A7FO1-M_\?(-8)-1X2Z&-$X"?)(-4N&:.(\+5*PC77R3@'.T$,ZX=6*BQ(ZQ9/!$H*
MDP/+8Z<\E@FHX=^0>$(/#0/WBCB#%&!.TZ+'A+1&7PO\+J%'$E1M('KPXB"C-MNAD-O5'R7?)C,SVV<
MYRPSPS]X%UOHG*QFQVZ$CUMK7L^C6,%PSV+R]5/[IMVZ+15$^;H'JVM2^*7'
M5/A:E8\%J&"V"E:8A,%WTO_$2AE:Z1D:YMP$A//BW:E@A+2*/E?/950N*B+.1EDD">^F6MKL^T:%UN_%;2$R2J$?HA7I
M/-CM2W*U@+F<"2&::V%B(#LC,R/8Z>6MTWTL2#7*#%YU#UP#"BJ8,G4@:1,F-MJS^Y.-
>!!/70'S_U#NO!;A^=,W4)]DD"U&MZNA>IYVT.NRZNO)=9!FGV\NFEG-M6AD(X,Q))H6Q%D-@&V/3#&D"T1-#3'D;GT
"4VC-^LJQY3T/-M4XZIS,+[2B[WZ@L96XU@4HPUI8C\,0+CM"CX@$A+U.O^7:1&H0CZJ&3S.T:;
MA;JU!^&5&IDF43V7)/\FNKOZ1EC3[BXTW)'*;/;"_"I85>GST$'7A6MDY(&ZB2B;F/NXPDCS
M&""L>5F,\UJ9T&DP.:OT;8A"U8UM$)=.7B$X_B,NFY0-^5Q?N=$X-N6*MNU0HX,X6:&-H-S5@M^5>0_0:_)PQ,?&;?
+!>V__X*]'-M7;!N0COM4YTK^;Z5DK_[4C(I#6;YY.>=Z@Y#_>&V??(9+4SV.9,)RUF8"@4/-M3#2S?

QR]M)6V6@WTFTJ39D\^B&"14EQ)@CP&Q1NFR8)OPLQ^I Q!A*7UL. .N$NO76\"PWOFL@;@8F)V M8N6"])GL>P+:<['MW74T*X]XZR@PL&U6+RX5FXT"N=$$.)5RS!JKC=YT.]ZX^O=R->B>-ZZ>NT?
9.EQ4Z!:R4F'RG19+/$RM4:;$(;=+;F(8N$OETMZV+%,,_TO9@T-P-K5C+T)6)WN42UY,LUFSN M[EM>1C:%>FMV:\HY-/4@;:X5E(01@:W!%MS)%;)4S5.QU(T6/M!^&GI-.O*.S2&P)L MI7[;%X1M$2C[^_-YU=DBWQ;WQL\AM 5B'3622)L)I
MB+WFYB$GJ]]U.Y 5<+W&8JCK-2OT:Y'V)>^?$^X+T<=FL1<7["4P%.1X T*<
MP=%&NPN6:T6U7?.JM6]7]YBO6@]ZVR,A2X#*L,AB,-IFH3PXUKZ=X*:BC]Q
MT.8=SI36[.+B>CW@O*^RVP13'K<)^(%)B7U09LJ9M>I/ZY;259FLWO :^WD^ M^X!MWZSEL5_4(#*(0MO\]
[5W_P[=R\I(SS6D]4&\ MEM< X%FR^Y2KL:P-.A;_$!V+];>.Q;>.Q>^[8_%E$,TS>W$]>^BG=CU>MVF75LAP2KR
MF3T/6>@<.X*/L=)8%-Y0NW'^@%+N9)P]6SL]J90[S%E H'C:GZ2<1G_8(251 M8%NI\ZTH=:]1:&NN>^_F^TYV4D'9-
W=2: MDA]!LF<;]+*&JB'H(0V]1,L:+L1C*Q-)PZS0XV/=/&9Z3B3Z6%0LX1>TV/C MN;>+T!VE-
1G'B*6M@UEKH9L2$2PXK\>N9D]"Y0];//[CM!O"- ML]?>3A%P,&7G8O&X,!@//VMVHW&7-&AAVFZP> 6R**
[O*#M<>B]5:JAWPO8U MB&"6&)[K<,KH3*NX ^9YG#-J.:))$ ULP!*TM?Z-JQ24.XOBLCG"68(>JP MR#')&4_XWJ1=
<7K=L99EQ,DIXT=VZFAZ!IX8:Q(]NX9^T#""1E]H88^_$O,. MCJZD'Q:=SIY?E?@X<\\2GNP'L%*(B.
M96!0_47!SPFW5U_)?DI2\5]H)8Q+?H*J9&1&AG/'@S&%I+=1G4/W(RQR367 M4:.L&L:AR!\Z+E#2>
JGS#&\^PEI]A,9WX2-<*O8QU73&WEK'L=V@MN48';^V1+M]3:0X+D#">JO/I#@,UAD
ML!D\$N"6Y&80O%F:+;8T]>_D<.NMKV*Q,>-2F/TX.3!@R+<&-S!6AH>FQ"+P M 1-I1Y*54$?2^1\;YH'&KX
V1K,X3U]/QXDF=.\6C;6#8[J#7UE(QA0++)3'RI4 ;3Q:],=!_2+7VG2395(I5$I2SS;G.!96 L7@7?\4 =L1;
M.5,VDAXJ&D(Z!;AD0^G)@*HL:XYC*S,QS#33Y*9$]07YN71WKO\:WR+ADZ9? M:[+$=]R&F4C;-
"AWE5*1@UH63[(2=]# 8Q^+_![:5HMBHHCQ@L48=\Z/;:A MTZ/QUNFQWDX/DMFW3H_7:='7B]3-T\!T?-+]O6\
<]F^O64TB_3JHTUQV;.6 M+I(!SR#$+CFP(%T4->?@%^=74FZ-?JM1,#=S7Q4<$WM86T)(A5./>9H,P.GX MC28.8
\"/$$D,*L$*:_4YSI/J*WP&^9'_\^WNRZ3IW]<_;/UO^T;&J':NFY_ MZ9R?WI;8^>6I]_K#]5=MT9U/UVU9@\\;
(K\3D9>9K&!!?.'1"B3O:QA;D',J MEDXM^##.C:=8ZV'"%52%<%I&\8MA=,176"GM8K?GJL5LP55KY=R7VB_9*[+-W
M!G]?#^#')+Q98Q2Z2)[IN8*<@=/V MU<; VNI>S^_"%"QS*%JWG9O6O]J7[=,6.[]I7[0NS]C%^>?S3OOLS:-X0^2/
M@4@QNCY\.KU5G@D/YI!%\[V.N4.,,L^;L\0?A'\W9K\HW1=XGG@^I[AV$SL' MT6:MZ9G4$*TJ_:))QP69FFU(.2[.
<1>#Z.5I[-O)D"A*7R?JN;\G=9K57F_. M\-L3A/<*A.J)_&#%_L9T^A7L)_\/4$L#!!0 (#2 ;%EM=2PT3PD DU M 8
=GEG#,Q9#$N:'1M[5MM;]LX$OXK/!>[30#+ M+W'2IG(:H$VRV +;;K;GWN$^4M+((D*+6I*RX_OU-T-*MFS'K=-
U>FDW0>M$ MU) W;P:71QZ,0O?[\8_>?ZRL]I[_>GM;^\N6"OH=O\]N.AV+T>7_L9QI]=G M(\US(ZQ0.9?=
[M6'%FMEUA9AMSN;S3JS04?I<7?TL9O9B3SN2J4,=!*;M,[/ MJ 4_@2?
G9Q.PG,49UP;LZ]:GT2_!*4I8826D8\OAEK5>9)^"QU/S1840^5 MJMP&*9\(.0^?C\0$#/L ,_9137C^O.U;\+R-
3C7'S3YXG6L4W;18[5>;,9MR& M>]+BJ%CW&-U<&7:I[E08=)@4=AYF(DD@1_F?GYT>]0;#LR[)>MM8'DE@D=() MZ-
>M7@L5E[("^>+:%#RNKZO9?(\@5E+RPD!8_S'_']E+P9WW3GU^KK+VD@5$M/N!PVHZ5J0N"RC$^!
M:9@*F"%\;28, ^Z/D&F-0SME'*)2V6 S8+]@#JT7P!TN51C%@!!:5C0_ZOS\K/^B-]S\?,N-*]-L,FJN\ MW(9
#C$8P_6<1";\!APB%F,:;$M0&9Q2$MYH#A*(A49N@F+(5@QJ@]'*,(#B MC)F2/I;]9Z"A&H06,!$&"RB9SK,9#::
V"G8@&*L,$K1*-&\:8;A'G/OO?WW M_2)O<'_D 4M%CKXEF"Q]V4;8H3C>UHW[(D\!:[DR+?)8EI1%$"\-Q[41:X*R
M4('N)J02@I&[+J!8H<"L38UH3QRE:I-$*5$ \;<0)&XZX_2)NQX*\Q&*SXAC?LOAZ8"4D6N*"&H M%/D>-
I&WWC&NP>$"_2R(UU"U D.E19B,Q$EL@LF0$B)=)\+$4ID2^U&:U$IZ M@!3(XB#!9L,.$ \)
(,"\TZ]N<0>2X^[I#6:@CZ5$B?Z !_V3 SAT7?LGB;_R MEX((;>Z!2>,S2E,-O'K\D"X{3Y2N3)3B1'55;J(8):BZ[Y-
\WL^_"Y;LVC\/ MTXKFN8$?.6S7E\6W8O@2#+)%]*:K;U^&6IM*;\Q+LWL7JH$1(&RJF7Q55:7& M
3!GD1DI$Z(4Y&X93U,4H*1)W5&#* MR(A$<"UH <(7?U<9#$KDO)*=WCLIP2 MR*./3Q-:+(;_"L"$L2,C/UQ'_"$\X?
%>;0CSG=.>!MPWSU5[HQZC)2I2 C, MW*C<[76YP4 @#DH(YS]IT8;X%]S[@DC!7=-2[#E@.LSYL%D1;7!85WINJP45
MI2X0\\:1F#C&;:I3P+'9,>3(321"'^_01BIQ(LC4/;PQ]D2!V?\)X \,\'@K MP*^F7)8NVY'W(4V1=XHI^LW?
KE_1.+:K[O0A2\)5"?(0W^!,F'A62R/>=Z;V^BAG;Y%7%T=^Z$ MYCTR+?$%%
<>E)FPTBO,=HTZ4L=A.9[@XEHEQH#_]81(]V-(E19!C#ER3KA3' M71JX PHZN\C+A5Z'7JN,FP63H>SI@@(25U:\.3/>\-
W5%G4H=->YG8*,\VH;O,<02^>]"9#>*\4(TC>;9*FP6#< TX MY&0BK 7X3!6)%'(4NI\(U,\-QZ(4]/)2BP @[;B M78M-\
SX#1$I3\\=E7(;"W<07I\;WBL55/M5?QIU1Q7B"78TL"A"6]-&M1W! M+AC]B(VV9W,&]9PI)P@MM(I;3%7\
[SQAK0K4MWKBLHCYP8NGF/^A8SYZ=#&/ MW#?56%O;&('@Z #&L'N$5 5[VU-'D4^5G
+QQYR/JR=ANF(0,"FDF@/>G67* MTP:^DDHP]/="KCO;@Y)>'G&>>=VBX&C5F-\)R-YN%'V9-Q"]=$+*X#)7"WB3
MF/DW6JBE 4Z'R'K6;K1^A=2%U]>PY .A&N7XM'/\X]-J%R(\L@H65I86^@#/'KV?-7E+/^R4?6Y M&C6?
M5^GW_;FF];Z=B]4GRMU5]VC1_,OD>SN^2V6MO^4M9XZ%7ONL[!!?)W MN*
(O!+_$[SNM.1S<'R"X@\/Q6^*MHM,0,JN;B$NB?RRW_U!/>)- M@Q%TDNQ?O[NLCKSW_Q;_?
5/VP;5_#H_;]PVU#^_(U_4^WE/@QX**!BO/%KOZ MY1=.Z#Q!Z;!.0(UOK:S>J'8\I),4.035=9VR5KXO4S6M?
%UF_:LX!1]#X'=' M/+6@0SY5HCXC>_FJF2I]6\^=AOFO^+CO#)W_#U!+ P04_" T@&Q9C#D% MUV@) !C-0 &
'9Y9W(M,C R-# Y,S!X97@S,60R+FAT;>U;;5/;2!+^ M*W.D=@-5EE\P)"
3JA(@M;G:9+,Y<'>"ZUEEK$W6L83P=B@WWW1'>SN=_M!<'R$L4[J3JH(V6#0P[_=_NX> MZQ^$PV'8?
\D^OF?;G\]/=ESST]].SO_[\]W^@)UK7AAII2IXUNN=?=AB6ZFU9=CKS6:S[FS857K2.__42VV>[?4R
MI8SHQC;>.CZB$GP*'A\?Y<)R%J5<&V%?;7T^?QLNM9'_M$Y@-:[;BT@8\DQ/,1_*/O%+"6A_CE4EFPBUQK+
(8E6>7J1Q+RX:#[BX[ZHVA MO?(>Q(H 7:$;N0:[I67]Y?\O"7DBM)6)C#BI]*ZEO%FF=QWV@5MX(?LG<"P*
M(XH.BYPLSVAZ.C M'K7UVK%\G DV5CH6^M56?PN29UD-\\6S*7G4/->S^1Y!I+*,ET:$S1^C.UA= M
%^Q*@^7>G>.Z\!"X@89GZO*AHF\%/&HY4]>J$8Y5N-_?"?6GY(Y(Y[5.'60 MA4BC62JM"$@]
(BS43/.R$>>PNX]^M2)KB09=Q*FX+=1J_55S_E5Y_2,-!+%T MSK-1VU_J(D"7I7PJF!93*68(_#:5AOU>
<0TOS.:LDRB5MD@'[" UZ(%\$O[-$ M:303K,2*F:BB-'O7Z*T(A\+S8;]#G-)0R7LWVK.)R@[3P44(RIHT'38NR+J M+A%
(ZNB1H7K.LH_52^XFAJQFE(,F]DGHL+!AX$I6)-_M_OQL*(_NOKYAAN7 MJ%D^9Q= 7B;0TCO>@-J;+580KE#@
I""RX+Q8LZJPNI*8#5(](XHP$Z"E9;@.L"8I"I4P-R&5$ SVNH!BC0*S-C70'CM2U;$6588&P)\"2-QT
MQLD3<9.R)%,STX!3BXDT%D35,DZ%7FY(V6EAS#3"7)'V"69_"69[-\+L?,4F M)/'@Y*)D9:($$S59N8UBM*#L
M'GXU9"YXLBO_H83942 M\12R&)7)V!T6F&IL9"RYEK0 Z9,_RPP%C5092LC.;8W+WBYN8HRS+";%,
[.CA:4*;W>"OL:"&B,CHCWW $\[O%^?C#7&^<<"[O?-
M0^7&J(>G3&5,8.9&%6ZORPT<@3@H(9SKN$$;\"^YMP61@NNF)=]SP'28\VZS MTK3%85WJN:P75%:Z!.:-
(S%1A&VJ$\"QV8DHP$TR0!\UM)&*71,P=0]O^)XL M$?V? '[/ (]N!/C9E&>5BW9D?
9$DX)UR"KN9:_CC@]ML$+W]X_64TN$9'1%Y MC2>N8U79FR78)+_P16M!K#SY\OZ)C1N^[UQ4>$U GA$-
_@3)^X5D?'/,]=:^ MBAK:Y=?$T=5<"\U;1%KB"RJ**DW8:"7G:T;-E;$HIU-P-]^]X;^B..N/&;3K+P$9QM@W=98PC\-
V"SEPAS@O1 M.,BS5=HL&(0KP)!Y+JT5XD^RR%B!HU!]+"&?&V0; $?0-I04\)LH?..5XH]*
M0GSG@541N1./G>]Z"_C#7S6I%KETD//#MQL&5NPW^V.XV7F>@XUB.NQ'$
MU'2R$DD!IZUYUV(3/!/\@HB4I^>.2KF-A3L(;\X-;Q4*ZOVJ/XVZ)@OQ&!V- M6"2A&\-&O1U!%_@^L-'Q;,Z RIDJ!
[2@%;>8.OE?>\);)ZB'NG%9^/SPQ9// M?]<^/WYT/@_NFVCDU@X\4#@Z !]V5TBULW<\=93%5&530?RQX)/Z)DS7#$+D
M9:;F K6S5'G:P%="""5S_3LAU]V:GI-='G&5>;9%S;#68WPC(7F_D?:E7$+UV M0L)@F:L)O$W,_#LM5-("IT-
D,VL]VJ!&ZL+J:UC*X;F9J$?9. ^P>OORIS>S6 M,-)Z4:8U/JF,[F>;,-\!X3(<(RH>A',H(0OOGRSJ.=CH[+*BA%YY3Z61D8S
M%"1#]Q=ZB^U^)T#5SIH&'O!.>O,8Z%]?JC]7O7#-'CXP-6O]]@^^HCE:0?*J M9;XKK:]ZP4'W<._)"Q['BZ*KB;1OQ6>
[GO5FZ[S[CS\FUC1[;SG,2WIRP!T M-.NAT-=?7]@I/#QD'Q!*W M;@UW_PM:WAK)EPX-;1(O-UU=CKB9:==H:E)?,

MW7RR9WWW\X"F\|6%BN)4-LSO6M>2OV8=D_!.>7C1>N/%BL? M%L64\[\FA#'FC:!\ N2/!,@'Q=Q)*D7"WB[VW[_Y:X&[_W+)I%Y^Z._T(<< M2XGH!._U\LZ_%G#GFE#=G]XQOM8\-TBX>GBM&#Y518ZIU Z;).Z_LPJQ7U
MSH=DRF0A@OJY"5$KW\2IBU:^B+/^)9^23T3@=TD\L4*'?*ID<_;V\K"[-UB$ M1E_6=Z=L_LM#[MM(Q_\'4$L#!!0 (#2;%D*:.4%IP8 '#,R9#$N:'1M[5IM<]HX$/XK.C)MDQG\2I(CAC!# M@4QSTX0T./?
R4=@RUE18/ED$N%]_*]D&0Z=IKD=2TDDF">A]=_4\NRO9[5\, M8Y#$. E(B#
[X5Q]1R(/9E"02!8)@";5S*F/D\S3%";HB0E#&T'M!PPE!R+'- M4]-Q3TS;,#IMF*M7#.*)AQS'@E_7=H^1W?0:#
<]UT,T5.KSS>T>Z>W_8_^Z M&>3KWMR]_WC90S7#LOYH]"RK[_?SAF/3=I O<))127F"F64-KFNH%DN9>I8U MG_->^71*,G1-YNB63W'R MKI[7P&=&!(W>M73OC/Y#8#7069*%-#"C$UA/R=_*C>(5]AAO+#(G6L4Q9R$T M#A8Q'5/Y]L
YM5L-UW10VQJ#"=,GD"T_:)1"N>XJ43V^N];DO8&M_[EQ66O MZU\.KP&7MZ.[!K6/_.&S2?P((9TFNC-
'9L]$HT%/"9H;UFFGP*OGZI2T[K"$5.67UG<#VUU):4#8@'NP8D*
<51K"S,6,CC'$'&$%9%VFQOJS5W(FU>5!..!4&**6:OJQ8JJ6D=! MLF_Z!$H @+Z,@G$TOD<#@)-;$7&:,;
5Z@R4\457P7Y>T:%[I\I,&^1Y! ? MY5_!
(S@GAV%9BK;)OB)Z00KGK)'[!SS5[J.EW4';4HIT.!9I"_,RJ77DQ#R%4TJ9JNW6BM%$CS0XM&S'E-#:V5='L4
MA_+5E6QQOG'JL*/V"#9A\S!EK[%6G*143847F@SEJL5L3D&2%1JW,)YSL)CE MQ#9M]TW5B6QAMW(\J\S/8?
S;F8(1O'ODJ#F'5%8\S MSF:2;"FZ:Y@\@(S' R$_&Q?_-YW 0V9W3+OQ:O7GMOIQTSP[?C7[[LRNW?AF M-/Y?
SN8)M*YD1#ODYU-OSV,W9(?8WR>5]@]7]K9N??Z^C*[)MU=!/#1]NB>XV^YW86+Q.5ZBCY(R&I[H$?!-DK
MP%XHP)X50[V8D@@-%B28J1P2#?,[7T 1'+2INCZOZV-WGPHXFW.QPROZ[W2O MAS>")@%-,?
M2[*.7[5NWKXM>'A,>K6#S2?1[]KQS&[D[VLW]_^YK2OK"4])<
M[6LL8YR@W[B8D"0CR6M*^A.A<@]2TJ_BZQ5;+Q1;/R ;O5@]^BG2NB=).O]+ MHKF62.7"W2#@LT2"*1[*.\L'3OD-
YK[@M'*I&J^>Y:Q?;U-/D;CP2M]1>4=N MLZ&XL%8R,9H0HRB7WF;C[;RB:N/EO.T7_U(\(49^N8TC282'[SDM'\K^>F8>
M.RLOE]?9^EW!_(5"_89BYU]02P$"% ,4 " S@&Q9XI?S?]80 ".I0 M$0 @ $ =GEG&#H;D. "ZO@ %0 @ '5$ =GEG&UL4$L!
A0#% @ ,X!L67 ?^A[%+ G?(" !4 M (!P1\ '9Y9W(M,C R-# Y,S!?9&5F+GAM;%!+ 0(4 Q0 (M #. ;%GA1ZYAFE8 +"E!0 5 "
;E, !V>6=R+3(P,C0P M.3,P7VQA8BYX;6Q02P$"% ,4 " S@&Q9]F=YYX _ "(IP0 %0 M @ &&HP =GEG&UL4$L! A0#% @
M,X!L623CQ:W@^0$ Y(L9 !4 (!.>, '9Y9W(M,C R-# Y M,S!X,3!Q+FAT;5!+ 0(4 Q0 (#2 ;%F;4)8=^Q0 ;D 8 M " 4S=
@!V>6=R+3(P,C0P.3,P>&5X,3!D,2YH=&U02P$"% ,4 M" T@&Q9;QX$__\2 !8?@ & @ %]\@(=GEG#$P9#(N:'1M4$L!
A0#% @ -(!L66UU+#1/"0 "34 !@ M (!L@4# '9Y9W(M,C R-# Y,S!X97@S,60Q+FAT;5!+ 0(4 M Q0 (#2 ;%F,.077: D &,U
8 " 36=R M+3(P,C0P.3,P>&5X,S%D,BYH=&U02P$"% ,4 " T@&Q9"FFE!:<& !W M*0 & @ '5& , =GEG#,R9#$N:'1M
64$L%!@ + L [(+(? P $! end XML 68 vygr-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0001640266
vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember 2024-09-30 0001640266
vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyNineteenMember 2024-03-31 0001640266 vygr:DrDinahSahMemberus-gaap:RelatedPartyMember 2023-06-30 0001640266
vygr:Facility75HaydenAvenueMember 2023-08-112023-08-11 0001640266
vygr:NovartisPharmaAgMembervygr:NovartisCollaborationAgreement2023Member 2023-12-28 0001640266
vygr:NonProfitAgreementMember 2016-01-012016-12-31 0001640266 vygr:NonProfitAgreementMember 2016-12-31 0001640266 vygr:NonProfitAgreementMember 2017-12-31 0001640266
vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember 2024-09-012024-09-30 0001640266
vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember 2024-04-012024-04-30 0001640266 vygr:NovartisPharmaAgMembervygr:OptionAndLicenseAgreementMember 2024-09-032024-09-03 0001640266 vygr:NovartisPharmaAgMembervygr:NovartisCollaborationAgreement2023Member 2023-01-012023-12-31 0001640266
vygr:NovartisPharmaAgMembervygr:OptionAndLicenseAgreementMembervygr:SalesMilestoneMember 2024-09-032024-09-03 0001640266
vygr:NovartisPharmaAgMembervygr:OptionAndLicenseAgreementMembervygr:DevelopmentRegulatoryAndCommerci
2024-09-032024-09-03 0001640266 vygr:PreFundedWarrantsMemberus-gaap:OverAllotmentOptionMember 2024-01-092024-01-09 0001640266 vygr:NovartisPharmaAgMembervygr:NovartisCollaborationAgreement2023Member 2023-12-282023-12-28 0001640266 us-
gaap:AdditionalPaidInCapitalMembervygr:NovartisCollaborationAgreement2023Member 2024-01-012024-03-31 0001640266 vygr:NovartisCollaborationAgreement2023Member 2024-01-012024-03-31 0001640266 us-gaap:AdditionalPaidInCapitalMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember 2023-01-012023-03-31 0001640266 vygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember 2023-01-012023-03-31 0001640266 us-gaap:CommonStockMember 2024-07-012024-09-30 0001640266 us-gaap:CommonStockMember 2024-01-012024-03-31 0001640266 us-gaap:CommonStockMember 2023-07-012023-09-30 0001640266 us-gaap:CommonStockMember 2023-01-012023-03-31 0001640266 us-gaap:CommonStockMember 2024-04-012024-06-30 0001640266 us-gaap:CommonStockMember 2023-04-012023-06-30 0001640266 us-gaap:CommonStockMembervygr:NovartisCollaborationAgreement2023Member 2024-01-012024-03-31 0001640266 us-
gaap:CommonStockMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember 2023-01-012023-03-31 0001640266 us-gaap:RetainedEarningsMember 2024-09-30 0001640266 us-
gaap:AdditionalPaidInCapitalMember 2024-09-30 0001640266 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001640266 us-gaap:RetainedEarningsMember 2024-06-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001640266 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001640266 2024-06-30 0001640266 us-gaap:RetainedEarningsMember 2024-03-31 0001640266 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001640266 2024-03-31 0001640266 us-gaap:RetainedEarningsMember 2023-12-31 0001640266 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001640266 us-gaap:RetainedEarningsMember 2023-09-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001640266 us-gaap:RetainedEarningsMember 2023-06-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001640266 2023-06-30 0001640266 us-gaap:RetainedEarningsMember 2023-03-31 0001640266 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001640266 2023-03-31 0001640266 us-gaap:RetainedEarningsMember 2022-12-31 0001640266 us-
gaap:AdditionalPaidInCapitalMember 2022-12-31 0001640266 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001640266 us-gaap:CommonStockMember 2024-09-30 0001640266 us-gaap:CommonStockMember 2024-06-30 0001640266 us-gaap:CommonStockMember

2024-03-31 0001640266 us-gaap:CommonStockMember 2023-12-31 0001640266 us-gaap:CommonStockMember 2023-09-30 0001640266 us-gaap:CommonStockMember 2023-06-30 0001640266 us-gaap:CommonStockMember 2023-03-31 0001640266 us-gaap:CommonStockMember 2022-12-31 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001640266 us-gaap:OverAllotmentOptionMember 2024-01-092024-01-09 0001640266 vygr:NovartisPharmaAgMembervygr:OptionAndLicenseAgreementMember 2024-07-012024-09-30 0001640266
vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember 2024-04-012024-06-30 0001640266 vygr:SidneyStreet75And64LeasesMember 2024-09-30 0001640266
vygr:DrDinahSahMemberus-gaap:RelatedPartyMember 2024-07-012024-09-30 0001640266
vygr:DrDinahSahMemberus-gaap:RelatedPartyMember 2024-01-012024-09-30 0001640266
vygr:DrDinahSahMemberus-gaap:RelatedPartyMember 2023-07-012023-09-30 0001640266
vygr:DrDinahSahMemberus-gaap:RelatedPartyMember 2023-01-012023-09-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0001640266 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0001640266
vygr:Facility75HaydenAvenueMember 2024-02-01 0001640266 vygr:Sidney64StreetMember 2024-04-012024-06-30 0001640266 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001640266 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001640266 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0001640266 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001640266 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0001640266 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0001640266 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember 2024-09-30 0001640266 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2024-09-30 0001640266 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001640266 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001640266 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001640266 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-09-30 0001640266 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001640266 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember 2024-09-30 0001640266 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2024-09-30 0001640266 us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001640266 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember 2023-12-31 0001640266 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-12-31 0001640266 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001640266 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001640266 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-12-31 0001640266 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001640266 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember 2023-12-31 0001640266 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-12-31 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2024-09-30 0001640266
vygr:NeurocrineBiosciencesIncMembervygr:DiscoveryProgramThreeMembervygr:NeurocrineCollaborativeAgreement2024-01-012024-09-30 0001640266
vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember 2024-07-012024-09-30 0001640266
vygr:NeurocrineBiosciencesIncMembervygr:NeurocrineCollaborativeAgreementTwentyNineteenMember 2024-01-012024-03-31 0001640266 vygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeMember 2024-09-30 0001640266
vygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborativeAgreementTwentyNineteenM 2024-09-30 0001640266 vygr:NeurocrineCollaborativeAgreementTwentyNineteenMember 2024-09-30 0001640266
vygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborativeAgreementTwentyNineteenM 2023-12-31 0001640266
vygr:NeurocrineCollaborativeAgreementTwentyTwentyThreeAndNeurocrineCollaborativeAgreementTwentyNineteenM 2024-01-012024-09-30 0001640266 us-gaap:OverAllotmentOptionMember 2024-01-04 0001640266
vygr:PreFundedWarrantsMemberus-gaap:OverAllotmentOptionMember 2024-01-09 0001640266
vygr:PreFundedWarrantsMemberus-gaap:OverAllotmentOptionMember 2024-01-04 0001640266 2023-09-30 0001640266 2022-12-31 0001640266 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001640266 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001640266 us-gaap:MoneyMarketFundsMember 2024-09-30 0001640266 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001640266 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001640266 us-gaap:MoneyMarketFundsMember 2023-12-31 0001640266 us-gaap:CommercialPaperMember 2023-12-31 0001640266 us-gaap:USTreasurySecuritiesMember 2024-09-30 0001640266 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001640266 us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001640266 us-gaap:CommercialPaperMember 2024-09-30 0001640266 us-gaap:CertificatesOfDepositMember 2024-09-30 0001640266 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001640266 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001640266 us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001640266 us-gaap:FairValueInputsLevel2Memberus-

gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001640266 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001640266 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001640266 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001640266 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001640266 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001640266 vygr:Facility75HaydenAvenueMember 2023-08-11 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012023-09-30 0001640266 us-gaap:RestrictedStockMember 2023-07-012023-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0001640266 us-gaap:RestrictedStockMember 2023-01-012023-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001640266 us-gaap:StockCompensationPlanMember 2024-07-012024-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0001640266 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001640266 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0001640266 us-gaap:StockCompensationPlanMember 2024-01-012024-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001640266 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001640266 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001640266 us-gaap:StockCompensationPlanMember 2023-07-012023-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012023-09-30 0001640266 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001640266 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0001640266 us-gaap:StockCompensationPlanMember 2023-01-012023-09-30 0001640266 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0001640266 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001640266 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001640266 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0001640266 2024-04-012024-06-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001640266 2024-01-012024-03-31 0001640266 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001640266 2023-07-012023-09-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0001640266 2023-04-012023-06-30 0001640266 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0001640266 2023-01-012023-03-31 0001640266 2023-01-012023-09-30 0001640266 2024-09-30 0001640266 2023-12-31 0001640266 vygr:ToddCarterPh.d.Member 2024-09-30 0001640266 vygr:ToddCarterPh.d.Member 2024-07-012024-09-30 0001640266 2024-07-012024-09-30 0001640266 2024-10-28 0001640266 2024-01-012024-09-30 shares iso4217:USD utr:sqft iso4217:USD shares vygr:Program vygr:multiple pure 44038333false0001640266--12-312024Q3Todd Carter, Ph.D.Chief Scientific Officer545420480010-Qtrue2024-09-30false001-37625Voyager Therapeutics, Inc.DE46-300318275 Hayden AvenueLexingtonMA02421857259-5340Common Stock, $0.001 par valueVYGRNASDAQYesYesNon-accelerated Filertruefalsefalse5462558611252500068802000232835000162073000159540008015000037140003341000841500033000-48000-291697000-261182000330310000236320000426041000351281000246290004614000737230001599470003024100025863000911378000-29507000-449880006795100045790003429000143340008567000200000220000300047790003429000145540008570000-9001000-26078000-304340007652100043000-1770008100058600090440002590100030515000759350004890000-11500015000-29000489000-11500015000-29000-8555000-26016000-305000007590600000-0.16-0.59-0.531.85-0.16-0.59-0.531.78578511104386483857564413409621165785111043864838575644134261072438613891380004527130000-219000-393512000590200005199318500018500037441743955885000311160003112100025040002504000870008700012401320000-269468000216961000198348100012280001229000628286234441800041800026270002627000-1000-1000-22208000-222080004375940944000490791000-133000-291676000199026000127252415000415000225002795000279500011500011500025901000-259010004390916144000494001000-248000-317577000176220000440383334400049750600048000-261182000236320000325007800078000324520214500220001930300019305000777777880009346500093473000344580000-458000-11330000-113300005431813354000613850000-506000-272512000340886000259589000009000056549714736390006390003959000395900016000-16000-10141000-101410005447211354000618538000-522000-282653000335417000276429200092000422931000100033550003355000489000489000-9044000-904400054542048550006219850000-33000-291697000330310000-305150007593500011048000810800037200003106000277600064560001832000-478000-143000-641960003730002996000309700034200-3423000-145900015560007040000-538100032360000-1698000-2102000-404580001626000-781000101679000336600025010003346670001949750002703770002900000-67656000-168476000261000182900093473000193050003112100040200023500011344100033185000450040000-336120007039500010047400011539900066862000267510000 VOYAGER THERAPEUTICS INC. NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. Nature of business Voyager Therapeutics, Inc. (the “Company”) is a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease; amyotrophic lateral sclerosis; Parkinson’s disease, and multiple other diseases of the central nervous

system. Many of the Company's programs are derived from its TRACER™ adeno-associated virus ("AAV") capsid discovery platform, which the Company has used to generate novel capsids ("TRACER Capsids") and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of the Company's programs are wholly-owned, and some are advancing with licensees and collaborators including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG, ("Novartis"); and Neurocrine Biosciences, Inc. ("Neurocrine"). The Company has a history of incurring annual net operating losses. As of September 30, 2024, the Company had an accumulated deficit of $291.7 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities, funding from fees, option exercise payments, and milestone payments, and cost reimbursements associated with its prior and ongoing collaborations and license agreements. As of September 30, 2024, the Company had cash, cash equivalents, and marketable securities of $345.4 million. Based upon the Company's current operating plans, the Company expects that its existing cash, cash equivalents, and marketable securities at September 30, 2024 to be sufficient to meet the Company's planned operating expenses and capital expenditure requirements for at least twelve months from the issuance of these consolidated financial statements. There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company's business, results of operations, and financial condition. -2917000000345400000 2. Summary of significant accounting policies and basis of presentation Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission ("SEC") on February 28, 2024. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board. Principles of Consolidation The unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary as disclosed in Note 2, under the heading "Summary of Significant Accounting Policies and Basis of Presentation," within the "Notes to Consolidated Financial Statements" accompanying the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Intercompany balances and transactions have been eliminated. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, incremental borrowing rate for leases, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Summary of Significant Accounting Policies There have been no changes in the Company's significant accounting policies as described in Note 2, "Summary of Significant Accounting Policies and Basis of Presentation," within the "Notes to Consolidated Financial Statements" accompanying the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. For further information, refer to the consolidated financial statements and footnotes included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission ("SEC") on February 28, 2024. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations for the periods presented. Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board. Principles of Consolidation The unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary as disclosed in Note 2, under the heading "Summary of Significant Accounting Policies and Basis of Presentation," within the "Notes to Consolidated Financial Statements" accompanying the Company's Annual Report on Form 10-K for the fiscal year

ended December 31, 2023. Intercompany balances and transactions have been eliminated. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, incremental borrowing rate for leases, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. Summary of Significant Accounting Policies There have been no changes in the Company's significant accounting policies as described in Note 2, "Summary of Significant Accounting Policies and Basis of Presentation," within the "Notes to Consolidated Financial Statements" accompanying the Company's Annual Report on Form 10-K for the year ended December 31, 2023. 3. Fair value measurements Assets and liabilities measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Quoted Prices </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:center;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> in Active </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Markets for </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Observable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"> Unobservable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Identical Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-

align:bottom;width:45.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> 1 </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.23%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 106,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 106,492 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 77,920 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 77,920 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;margin:0pt;padding:0pt;"> U.S. Government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 24,655 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 24,655 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> Certificates of deposit </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 5,461 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 5,461 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;margin:0pt;padding:0pt;"> Corporate bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 102,083 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 102,083 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,715 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,715 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#ccceff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> Total money market funds and marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">339,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 209,067 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">130,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.51%;background:#ccceff;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#ccceff;margin:0pt;padding:0pt;"> .

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> Money market funds included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">65,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 65,589 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;background:#ccceff;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;margin:0pt;padding:0pt;"> U.S. Treasury notes </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 103,044 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 103,044 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 31,075 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 31,075 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;margin:0pt;padding:0pt;"> Corporate bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 23,970 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 23,970 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,985 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,985 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> Total money market funds and marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 227,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 199,708 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;">

</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr></table> The Company measures the fair value of money market funds, U.S. Treasury notes and U.S. Government agency securities based on quoted prices in active markets for identical securities. The Company measures the fair value of the Level 2 securities, certificates of deposit, corporate bonds and commercial paper based on recent trades of securities in active markets or based on quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. Assets and liabilities measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 are as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Quoted Prices </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> in Active </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"> Significant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Markets for </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Observable </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"> Unobservable </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Identical Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"> Inputs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 1) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Level 3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.23%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 106,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 106,492 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td
style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> <span
style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 77,920 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 77,920 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:middle;width:45.51%;margin:0pt;padding:0pt;"> U.S. Government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 24,655 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p

*style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,655 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> Certificates of deposit </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 5,461 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 5,461 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;margin:0pt;padding:0pt;"> Corporate bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 102,083 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 102,083 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> *

</td></tr><tr><td style="vertical-align:middle;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,715 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,715 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> Total money market funds and marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">339,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 209,067 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">130,259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> .

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> Money market funds included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">65,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 65,589 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;margin:0pt;padding:0pt;"> U.S. Treasury notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 103,044 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 103,044 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 31,075 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> 31,075 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;margin:0pt;padding:0pt;"> Corporate bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 23,970 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> 23,970 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:45.51%;background:#cceeff;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,985 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,985 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.51%;margin:0pt;padding:0pt;"> Total money market funds and marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 227,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">199,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,955 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.97%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"> . </td></tr></table>10649200010649200077920000779200002465500024655000546100054610001020830001020830002271500

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">4. Cash, cash equivalents, restricted cash, and available-for-sale marketable securities Cash, cash equivalents, and marketable securities included the following at September 30, 2024 and December 31, 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> Fair </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr

style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.16%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> As of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> Money market funds included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">106,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> 106,492 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:43.71%;margin:0pt;padding:0pt;"> U.S. Treasury notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> 77,846 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> 74 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> 77,920 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"> 24,644 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"> 13 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"> 24,655 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:43.71%;margin:0pt;padding:0pt;"> Certificates of deposit </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> 5,449 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> 12 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> 5,461 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"> 102,077 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"> 55 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> (49) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"> 102,083 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:43.71%;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,724 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (13) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,715 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> Total money market funds and marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">339,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 158 </td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 339,326 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> As of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 65,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"> 65,589 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Treasury notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"> 102,966 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;">
81 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"> 103,044 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:middle;width:43.71%;margin:0pt;padding:0pt;"> U.S. Government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> 31,068 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> 10 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> 31,075 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;">
23,975 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#ccceff;margin:0pt;padding:0pt;"> (7) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#ccceff;margin:0pt;padding:0pt;"> 23,970 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:43.71%;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,985 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,985 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#ccceff;margin:0pt;padding:0pt;"> Total money market funds and marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.14%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 227,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:9.4%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 93 </td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;white-space:nowrap;width:9.19%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (13) </td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#ccceff;border-

bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:middle;white-space:nowrap;width:10.91%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 227,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ccceff;margin:0pt;padding:0pt;"> - </td></tr></table> - All of the Company's marketable securities as of September 30, 2024 have a contractual maturity of one year or less. The Company reviews investments whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment's carrying amount is not recoverable within a reasonable period of time. In connection with these investments, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors, considering the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss on the condensed consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that is not related to credit is recognized in other comprehensive (loss) income. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in general and administrative expenses within the condensed consolidated statement of operations. Losses are charged against the allowance when the Company believes the uncollectability of an available-for-sale security is confirmed or when either of the criteria regarding intent or requirement to sell is met. The Company held $96.0 million and $44.2 million in marketable securities that were in an unrealized loss position as of September 30, 2024 and December 31, 2023, respectively. The unrealized losses at September 30, 2024 and December 31, 2023 were attributable to changes in interest rates and do not represent credit losses. The Company does not intend to sell these securities and it is not more likely than not that it will be required to sell them before recovery of their amortized cost basis. The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows: - <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> - </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.78%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 112,525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;background:#cceeff;margin:0pt;padding:0pt;"> 68,802 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;margin:0pt;padding:0pt;"> Restricted cash included in deposits and other non-current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,874 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,593 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents, and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 115,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 70,395 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> Cash, cash equivalents, and marketable securities included the following at September 30, 2024 and December 31, 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;margin:0pt;padding:0pt;"> Amortized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"> Fair </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Value </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:51.16%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> As of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ccceff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> Money market funds included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 106,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> 106,492 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#ccceff;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ccceff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:43.71%;margin:0pt;padding:0pt;"> U.S. Treasury notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> 77,846 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> 74 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> 77,920 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"> 24,644 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"> 13 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> (2) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"> 24,655 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:43.71%;margin:0pt;padding:0pt;"> Certificates of deposit </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> 5,449 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> 12 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> — </td><td

style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> 5,461 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"> 102,077 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"> 55 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> (49) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"> 102,083 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:43.71%;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,724 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (13) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,715 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> Total money market funds and marketable securities </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 339,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 158 </td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 339,326 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> As of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> Money market funds included in cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 65,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p

*style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#ccceff;margin:0pt;padding:0pt;"> 65,589 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;margin:0pt;padding:0pt;"> Marketable securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:43.71%;background:#ccceff;margin:0pt;padding:0pt;"> U.S. Treasury notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#ccceff;margin:0pt;padding:0pt;"> 102,966 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#ccceff;margin:0pt;padding:0pt;"> 81 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#ccceff;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#ccceff;margin:0pt;padding:0pt;"> 103,044 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#ccceff;margin:0pt;padding:0pt;"> *

</td></tr><tr><td style="vertical-align:middle;width:43.71%;margin:0pt;padding:0pt;"> U.S. Government agency securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"> 31,068 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;"> 10 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"> 31,075 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"> 23,975 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;background:#cceeff;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> (7) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"> 23,970 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;width:43.71%;margin:0pt;padding:0pt;"> Commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,985 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,985 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.71%;background:#cceeff;margin:0pt;padding:0pt;"> Total money market funds and marketable securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 227,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:9.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 93 </td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 227,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table>10649200010649200077846000740007792000024644000130002000246550005449000120005461000102077 style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.27%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> . </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.78%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 112,525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;background:#cceeff;margin:0pt;padding:0pt;"> 68,802 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;margin:0pt;padding:0pt;"> Restricted cash included in deposits and other non-current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,874 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,593 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> 0 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.02%;background:#cceeff;margin:0pt;padding:0pt;"> Total cash, cash equivalents, and restricted cash </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">115,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 70,395 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td></tr></table> 0 1125250006880200028740001593000115399000703950000 5. Accrued expenses Accrued expenses as of September 30, 2024 and December 31, 2023 consist of the following: 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.74%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> 0 </td></tr><tr><td style="vertical-align:bottom;width:51.74%;margin:0pt;padding:0pt;"> 0 </td>

<td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of December 31, </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:51.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:43.76%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:51.74%;background:#cceeff;margin:0pt;padding:0pt;"> Employee compensation costs </td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,927</p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"> 6,614 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:51.74%;margin:0pt;padding:0pt;"> Research and development costs </td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> 3,972 </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> 5,225 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:51.74%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued goods and services </td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"> 530 </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"> 4,229 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:51.74%;margin:0pt;padding:0pt;"> Professional services </td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,013 </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 755 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.74%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">11,442</p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,823 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:51.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:51.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of December 31, </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:normal;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:51.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:normal;width:43.76%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:51.74%;background:#cceeff;margin:0pt;padding:0pt;"> Employee compensation costs </td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,927</p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"> 6,614 </td><td style="vertical-

*align:bottom;white-space:normal;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:51.74%;margin:0pt;padding:0pt;"> Research and development costs </td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> 3,972 </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> 5,225 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:51.74%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued goods and services </td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"> 530 </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;margin:0pt;padding:0pt;"> 4,229 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;width:51.74%;margin:0pt;padding:0pt;"> Professional services </td><td style="vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,013 </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 755 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:51.74%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,442</p></td><td style="vertical-align:bottom;white-space:normal;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:normal;width:1.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,823 </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:51.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.82%;margin:0pt;padding:0pt;"> *

*</td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:2.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:18.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:normal;width:1.65%;margin:0pt;padding:0pt;"> </td></tr></table> *

5927000661400039720005225000530000422900010130007550001144200016823000 6. Lease obligation Operating Leases As of September 30, 2024, the Company has a lease for laboratory and office space at 75 Hayden Avenue in Lexington, Massachusetts through January 31, 2031 and a lease for additional office and laboratory space at 64 Sidney Street in Cambridge, Massachusetts (the "Cambridge Facility") through November 30, 2026. On August 11, 2023, the Company entered into a first amendment (the "First Amendment") to its existing lease for laboratory and office space at 75 Hayden Avenue in Lexington, Massachusetts, pursuant to which the Company agreed to lease approximately 61,307 square feet of additional office and laboratory space through January 31, 2031. The Company received $1.8 million of leasehold improvement incentives associated with the First Amendment. The Company gained control of the space on February 1, 2024 and recorded a $26.7 million right-of-use asset and a $26.7 million operating lease liability, accordingly, which reflect the leasehold improvement incentive. The Company's lease agreements require the Company to maintain a cash deposit or irrevocable letter of credit in the aggregate amount of $2.9 million payable to its landlords as security for the performance of its obligations under the leases. These amounts are recorded as restricted cash and are included in deposits and other non-current assets in the accompanying condensed consolidated balance sheets. In June 2024, the Company vacated its leased office and laboratory space in Cambridge, Massachusetts. The Company recorded an impairment charge of $2.8 million to operating expenses during the second quarter of 2024 as a result of the carrying value of the leased office and laboratory space asset group exceeding the undiscounted cash flows projected from a planned sublease of the facility. The impairment charge reduced the carrying value of the leased office and laboratory space asset group by $2.8 million. On August 2, 2024, the Company executed the sublease of the Cambridge Facility. Payments received under the sublease are included in other income in the condensed consolidated statements of operations and comprehensive (loss) income. During the three and nine months ended September 30, 2024, the Company recognized $0.2 million of other income from its sublease of the Cambridge Facility. During the three and nine months ended September 30, 2024, the Company incurred lease expenses of $1.9 million and $8.0 million, respectively. During the three and nine months ended September 30, 2023, the Company incurred lease expenses of $0.9 million and $2.7 million, respectively, for operating leases. As of September 30, 2024, the weighted average remaining lease term was 4.9 years and the weighted average incremental borrowing rate used to determine the operating lease liability was 6.8%. 6130718000002670000026700000290000028000002800000200000200000190000008000000.09000002700000P4

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">7. Commitments, contingencies and other liabilities As of September 30, 2024 and December 31, 2023, other current and non-current liabilities consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-

*size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> . </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:51.42%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"> Other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> Lease liability </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,979 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> . *

</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#ccceff;margin:0pt;padding:0pt;"> Total other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#ccceff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#ccceff;margin:0pt;padding:0pt;"> Other non-current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#ccceff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> Lease liability </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">38,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> 17,093 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#ccceff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td

style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,001 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> Total other non-current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 39,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,094 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> </td></tr></table> Other Agreements In 2016, the Company entered into a research and development funding arrangement with a non-profit organization that provided up to $4.0 million in funding to the Company upon the achievement of clinical and development milestones. The agreement as amended in 2022 provides that the Company is obligated to repay amounts received under certain circumstances including termination of the agreement, and to pay an amount up to 2.6 times the funding received upon successful development and commercialization of any products developed. In 2017, the Company earned a milestone payment of $1.0 million. The Company evaluated the arrangement and concluded that it represents a research and development financing arrangement as it is probable that the Company will repay amounts received under the arrangement. As a result, the $1.0 million is recorded as a non-current liability in the condensed consolidated balance sheet. Litigation The Company was not a party to any material legal matters or claims as of September 30, 2024, or December 31, 2023. The Company did not have contingency reserves established for any litigation liabilities as of September 30, 2024, or December 31, 2023. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> As of December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:51.42%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"> Other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> Lease liability </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,979 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,200 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"> Total other current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,979 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> 38,368 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;margin:0pt;padding:0pt;"> 17,093 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> x </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,001 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"> x </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.3%;margin:0pt;padding:0pt;"> Total other non-current liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 39,368</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18,094 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"> . </td></tr>
</table>69790003200000697900032000003836800017093000100000010010003936800018094000400000002.6100 style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">8. Significant agreements The Company's significant agreements are described in Note 9 of the December 31, 2023 consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2023. During the three and nine months ended September 30, 2024, there were no material changes to the terms of the Company's collaboration agreements with Neurocrine and the Company did not enter into any new collaboration or license agreements. On September 3, 2024, the Company entered into an amendment to its existing option and license agreement with Novartis dated March 4, 2022 (the "2022 Novartis Option and License Agreement"). The Company recorded collaboration revenue of $24.6 million and $4.6 million during the three months ended September 30, 2024 and 2023, respectively. The Company recorded collaboration revenue of $73.7 million and $159.9 million during the nine months ended September 30, 2024 and 2023, respectively. 2022 Novartis Option and License Agreement On September 3, 2024 (the "Amendment Effective Date"), the Company and Novartis entered into an amendment (the "Novartis Amendment") to the 2022 Novartis Option and License Agreement. Pursuant to the Novartis Amendment, the Company and Novartis agreed to amend the 2022 Novartis Option and License Agreement to incorporate the grant from the Company to Novartis of an additional license (the "Novartis Direct License") to a capsid discovered through the Company's TRACER discovery platform (the "Novartis Direct Licensed Capsid") for exclusive use with a certain gene (the "Novartis Direct License Target") to develop and commercialize the Novartis Direct Licensed Capsid as incorporated into products containing a payload directed to the Novartis Direct License Target ("Novartis Direct Licensed Products"). As a result of the Novartis Amendment, the Novartis Direct License Target is now deemed a Licensed Target under the 2022 Novartis Option and License Agreement, as such term is defined therein, and the Novartis Direct License is subject to all other terms and conditions applicable to licenses granted to Novartis under the 2022 Novartis Option and License Agreement. Novartis agreed to pay to the Company a one-time fee of $15.0 million in consideration for the rights granted under the Novartis Amendment, which was received in October 2024. The Company evaluated the Novartis Amendment under ASC 606 and recorded $15.0 million as collaboration revenue in the three months ended September 30, 2024 since the consideration reflected the standalone selling price of the license that was delivered on the Novartis Amendment date, and there were no remaining undelivered performance obligations under the original 2022 Novartis Option and License Agreement. The Company is eligible to receive specified development, regulatory, and commercialization milestone payments of up to an aggregate of $130.0 million for the first Novartis Direct Licensed Product to achieve the corresponding milestone. On a Novartis Direct Licensed Product-by-Novartis Direct Licensed Product basis, the Company is also eligible to receive (a) specified sales milestone payments of up to an aggregate of $175.0 million per Novartis Direct Licensed Product and (b) tiered, escalating royalties in the mid- to high-single-digit percentages of annual net sales of each Novartis Direct Licensed Product. . 2023 Neurocrine Collaboration Agreement In April 2024, the Company announced that the joint steering committee with Neurocrine selected a development candidate for the glucocerebrosidase 1 gene therapy program for Parkinson's disease and other GBA1-mediated diseases (the "GBA1 program") under the collaboration and license agreement with Neurocrine entered into in January 2023 (the "2023 Neurocrine Collaboration Agreement"). The joint steering committee selection of a development candidate for the GBA1 Program triggered a $3.0 million milestone payment to the Company. The Company recorded the $3.0 million as collaboration revenue during the second quarter of 2024. In September 2024, the Company announced that the joint steering committee with Neurocrine selected a development candidate in a gene therapy program for the potential treatment of an undisclosed neurological disease under the 2023 Neurocrine Collaboration Agreement, which triggered a $3.0 million milestone payment to the Company which was received in October 2024. The Company included the $3.0 million that had previously been constrained in the transaction price allocated to the program's performance obligation in the three months ended September 30, 2024, accordingly, which resulted in a cumulative catch-up adjustment to collaboration revenue of approximately $2.0 million. . 2023 Novartis Stock Purchase Agreement . Under the stock purchase agreement entered into in December 2023 (the "2023 Novartis Stock Purchase Agreement"), Novartis purchased 2,145,002 shares of common stock of the Company (the "Novartis Shares") for an aggregate purchase price of approximately $20.0 million.

The issuance of the Novartis Shares to Novartis pursuant to the 2023 Novartis Stock Purchase Agreement in January 2024 resulted in a premium of $0.7 million. The premium was allocated to the development and commercialization licenses granted to Novartis for two programs pursuant to the license and collaboration agreement with Novartis entered into in December 2023 and was recognized as collaboration revenue during the first quarter of 2024, upon the issuance of the Novartis Shares under the 2023 Novartis Stock Purchase Agreement. . 2019 Neurocrine Collaboration Agreement . In February 2024, the Company announced that the joint steering committee with Neurocrine selected a lead development candidate for the gene therapy program for Friedreich's ataxia (the "FA Program") under the collaboration and license agreement with Neurocrine entered into in January 2019 (the "2019 Neurocrine Collaboration Agreement"), which triggered a $5.0 million milestone payment to the Company that was received in the first quarter of 2024. The Company included the $5.0 million that had previously been constrained in the transaction price allocated to the FA Program performance obligation in the three months ended March 31, 2024, accordingly, which resulted in a cumulative catch-up adjustment to collaboration revenue of $4.4 million. . Related Party Collaboration Receivable . The following table presents changes in the balances of the Company's related party collaboration receivable and contract liabilities for the 2023 Neurocrine Collaboration Agreement and the 2019 Neurocrine Collaboration Agreement during the nine months ended September 30, 2024: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.94%;margin:0pt;padding:0pt;"> Balance at </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"> Balance at </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Additions </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Deductions </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:59.67%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"> Related party collaboration receivables </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> 3,341 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">. </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 11,895</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> (11,522) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 3,714</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">Contract liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> 75,240 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 1,592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td

style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> (42,050) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> 34,782 </td></tr></table> ‌ The change in the related party collaboration receivable balance for the nine months ended September 30, 2024 is primarily driven by amounts owed to the Company for research and development services provided, offset by amounts collected during the period, for the 2023 and 2019 Neurocrine Collaboration Agreements. Deferred revenue activity for the period includes the recording of $1.6 million of deferred revenue during the nine months ended September 30, 2024 related to fixed transaction price allocation increases, offset by $42.1 million of collaboration revenue recognized on the proportional performance model during the period for the 2023 and 2019 Neurocrine Collaboration Agreements, which is classified as either current or non-current in the accompanying consolidated balance sheet based on the period the services are expected to be delivered.

* 2460000046000007370000015990000015000000.015000000.0130000000.0175000000.03000000.03000000.030style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;">‌ <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> ‌ *

</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.94%;margin:0pt;padding:0pt;"> Balance at </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;margin:0pt;padding:0pt;"> Balance at </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Additions </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Deductions </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:59.67%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"> Related party collaboration receivables </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 3,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> 11,895 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;">(11,522)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> 3,714 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;margin:0pt;padding:0pt;"> Contract liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.08%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;">75,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> 1,592 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> (42,050) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.81%;background:#cceeff;margin:0pt;padding:0pt;"> 34,782 </td></tr>
</table>33410001189500011522000371400075240000159200042050000347820001600000421000000 9. Stock-based compensation Stock-Based Compensation Expense Total compensation cost recognized for all stock-based compensation awards in the condensed consolidated statements of operations and comprehensive (loss) income was as follows: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.97%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.84%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 919 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"> 4,495 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,472</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,959</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">5,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:45.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,434 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">2,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,048 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,108 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td></tr></table> 1 Stock-based compensation expense by type of award included within the condensed consolidated statements of operations and comprehensive (loss) income was as follows: <p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.97%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.84%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 2,021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"> 5,587 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> Restricted stock awards and units </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 983 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> 774 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 3,454 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 2,339 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;background:#cceeff;margin:0pt;padding:0pt;"> Employee stock purchase plan awards </td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 78 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 83 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 237 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 182 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,878 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,108 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr></table> Restricted Stock Units A summary of the status of and changes in unvested restricted stock unit activity under the Company’s equity award plans for the nine months ended September 30, 2024 was as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr>

<td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"> Grant Date </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Unit </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested restricted stock units as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"> 1,370,897 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 867,558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"> 8.15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (423,362) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (198,076)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"> 6.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested restricted stock units as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">
1,617,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"> 7.56 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;">
</td></tr></table> Stock-based compensation of restricted stock units is based on the fair value of the Company’s common stock on the date of grant and is recognized over the vesting period. All of the restricted stock units granted in the nine months ended September 30, 2024 vest in equal amounts, annually over three years. The stock-based compensation expense related to restricted stock units was $1.0 million and $3.5 million for the three and nine months ended September 30, 2024, respectively. The stock-based compensation expense related to restricted stock units was $0.8 million and $2.3 million for the three and nine months ended September 30, 2023, respectively. As of September 30, 2024, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock units of $9.1 million, which is expected to be recognized over the remaining average vesting period of 2.1 years. Stock Options The following is a summary of stock option activity for the nine months ended September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"> Aggregate </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> Contractual </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"> Intrinsic </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> Life </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"> Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.21%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 7,425,444 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"> 8.52 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-

align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> 2,325,226 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.21%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (86,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#ccceff;margin:0pt;padding:0pt;"> 4.11 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"> Cancelled or forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (793,242) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> 11.69 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;background:#ccceff;margin:0pt;padding:0pt;"> Outstanding at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,871,328 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">8.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">3,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,604,321</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> 8.51 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> 6.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> 2,777 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> . </td></tr></table> . As of September 30, 2024, the Company had unrecognized stock-based compensation expense related to its unvested stock options of $20.1 million which is expected to be recognized over the remaining weighted-average vesting period of 2.7 years. . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.97%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.84%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,590</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 919 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"> 2,472 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,844 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,959 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,553 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,636 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">

</td></tr><tr><td style="vertical-align:bottom;width:45.19%;background:#cceeff;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,878 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">11,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,108 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table>15900009190004495000247200018440001959000655300056360003434000287800011048000810800 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;margin:0pt;padding:0pt;"> Three Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.97%;margin:0pt;padding:0pt;"> Nine Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.84%;margin:0pt;padding:0pt;"> <i style="font-style:italic;">

(in thousands)</i> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.19%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 2,021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,357</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"> 5,587 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> Restricted stock awards and units </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 983 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> 774 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 3,454 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"> 2,339 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.19%;background:#cceeff;margin:0pt;padding:0pt;"> Employee stock purchase plan awards </td><td style="vertical-align:bottom;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 78 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">83 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 237 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 182 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.19%;margin:0pt;padding:0pt;"> Total stock-based compensation expense </td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,434</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,878 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,048</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,108 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr></table>2373000202100073570005587000983000774000345400023390000780008300023700018200034340002878000style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"> Grant Date </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Units </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Per Unit </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock units as of December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#ccceff;margin:0pt;padding:0pt;"> 1,370,897 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 867,558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"> 8.15 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#ccceff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#ccceff;margin:0pt;padding:0pt;"> (423,362) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (198,076)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"> 6.68 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#ccceff;margin:0pt;padding:0pt;"> Unvested restricted stock units as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.29%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,617,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccceff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#ccceff;margin:0pt;padding:0pt;"> 7.56 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#ccceff;margin:0pt;padding:0pt;"> - </td></tr>
</table>13708976.658675588.154233626.231980766.6816170177.56P3Y1000000.03500000800000230000091000000
style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">- <table style="border-collapse:collapse;font-size:16pt;height:max-

content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Weighted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> Remaining </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"> Aggregate </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Average </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> Contractual </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"> Intrinsic </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"> Exercise </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> Life </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"> Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.21%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"> 7,425,444 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p

*style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,325,226</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> 7.79 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;background:#ccceff;margin:0pt;padding:0pt;"> Exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#ccceff;margin:0pt;padding:0pt;"> (86,100) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#ccceff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#ccceff;margin:0pt;padding:0pt;"> 4.11 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#ccceff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"> Cancelled or forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (793,242) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> *

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:45.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">8,871,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"> 8.08 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"> 7.5 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> 3,756 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.21%;margin:0pt;padding:0pt;"> Exercisable at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,604,321 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"> 8.51 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"> 6.4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> 2,777 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> . </td></tr></table>74254448.5223252267.79861004.1179324211.6988713288.08P7Y6M375600046043218.51P6Y4M24D277706 10. Net (loss) income per share The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net (loss) income per share because to include them would be anti-dilutive: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-

word;position:relative;"> </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:33.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:32.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> x </td></tr><tr><td style="vertical-align:bottom;width:29.35%;background:#cceeff;margin:0pt;padding:0pt;"> Unvested restricted common stock awards </td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;margin:0pt;padding:0pt;"> 22,500 </td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;background:#cceeff;margin:0pt;padding:0pt;"> 22,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> x </td></tr><tr><td style="vertical-align:bottom;width:29.35%;margin:0pt;padding:0pt;"> Unvested restricted common stock units </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> 1,617,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"> 1,312,727 </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

*Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;margin:0pt;padding:0pt;"> 1,617,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 714,164 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.35%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding stock options </td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,871,328 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,745,593 </td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,871,328 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,695,548 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.35%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,488,345 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,080,820 </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,488,345 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,432,212 *

</td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr></table> Basic and diluted net (loss) income per share and diluted weighted-average shares outstanding are as follows for the three and nine months ended September 30, 2024 and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.48%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr>

<tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> Net (loss) income (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,044)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (25,901) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30,515)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 75,935 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator for basic net (loss) income per share: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> Weighted average shares outstanding-basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 57,851,110 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:center;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 43,864,838 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 57,564,413 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 40,962,116 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator for diluted net (loss) income per share: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> Weighted average shares outstanding-basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"> 57,851,110 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"> 43,864,838 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> 57,564,413 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 40,962,116 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#ccceff;margin:0pt;padding:0pt;"> Common stock options and restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,648,608 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> Weighted average shares outstanding-diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 57,851,110 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 43,864,838 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 57,564,413 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 42,610,724 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> Net (loss) income per share, basic: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.59) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.85 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#cceeff;margin:0pt;padding:0pt;"> Net (loss) income per share, diluted: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.59) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.53) </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.78 </td></tr></table> The pre-funded warrants issued in connection with the underwritten public offering discussed in Note 11 are included in basic and diluted weighted average shares outstanding for the three and nine months ended September 30, 2024. The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net (loss) income per share because to include them would be anti-dilutive: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.35%;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td>
<td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:33.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:32.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.35%;background:#ccceff;margin:0pt;padding:0pt;"> Unvested restricted common stock awards </td><td style="vertical-align:bottom;width:0.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#ccceff;margin:0pt;padding:0pt;"> 22,500 </td><td style="vertical-align:bottom;width:0.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;background:#ccceff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ccceff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;background:#cceeff;margin:0pt;padding:0pt;"> 22,500 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.35%;margin:0pt;padding:0pt;"> Unvested restricted common stock units </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> 1,617,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;margin:0pt;padding:0pt;"> 1,312,727 </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;margin:0pt;padding:0pt;"> 1,617,017 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;margin:0pt;padding:0pt;"> 714,164 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.35%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding stock options </td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,871,328 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,745,593 </td><td style="vertical-align:bottom;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,871,328 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,695,548 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:29.35%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> 10,488,345 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,080,820 </td><td style="vertical-align:bottom;width:0.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,488,345 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,432,212 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"> </td></tr>

</table>225002250016170171312727161701771416488713287745593887132866955481048834590808201048834 5 style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.48%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div

*style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine Months Ended September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.68%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#cceeff;margin:0pt;padding:0pt;"> Numerator: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr></table>

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> Net (loss) income (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,044)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (25,901) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30,515)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 75,935 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator for basic net (loss) income per share: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

*Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> Weighted average shares outstanding-basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 57,851,110 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 43,864,838 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 57,564,413 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 40,962,116 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#cceeff;margin:0pt;padding:0pt;"> Denominator for diluted net (loss) income per share: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> Weighted average shares outstanding-basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"> 57,851,110 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"> 43,864,838 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> 57,564,413 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"> 40,962,116 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock options and restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,648,608 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> Weighted average shares outstanding-diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 57,851,110 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 43,864,838 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 57,564,413 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 42,610,724 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#ccceff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;margin:0pt;padding:0pt;"> Net (loss) income per share, basic: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.59) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.85 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.3%;background:#ccceff;margin:0pt;padding:0pt;"> Net (loss) income per share, diluted: </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#ccceff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.59) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.78 </td></tr></table>-9044000-25901000-3051500075935000578511104386483857564413409621165785111043864838575644134096211616486085785111 0.16-0.59-0.531.85-0.16-0.59-0.531.78 11. Underwritten public offering . On January 4, 2024, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering of 7,777,778 shares of the Company's common stock, par value $0.001 per share, and, in lieu of common stock to certain investors, pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 3,333,333 shares of common stock. The Underwriters agreed to purchase the Company's stock from the Company pursuant to the Underwriting Agreement at a price of $8.46 and the Pre-Funded Warrants from the Company pursuant to the Underwriting Agreement at a price of $8.459 per share underlying each Pre-Funded Warrant. . On January 9, 2024, the Company issued 7,777,778 shares of common stock and 3,333,333 Pre-Funded Warrants for net proceeds of approximately $93.5 million after deducting underwriting discounts and commissions and offering expenses pursuant to the underwritten public offering. The Pre-Funded Warrants met the equity classification guidance and therefore are classified as stockholders' equity. . 77777780.00133333338.468.459777777833333393500000 12. Related-party transactions During the three and nine months ended September 30, 2024, the Company received scientific advisory board and other scientific advisory services from Dinah Sah, Ph.D., the Company's former Chief Scientific Officer. The total amount of fees paid to Dr. Sah for services provided during the three and nine months ended September 30, 2024, was $150,000 and $450,000, respectively. The total amount of fees paid to Dr. Sah for services provided during the three and nine months ended September 30, 2023 was $157,500 and $541,300, respectively. During the second quarter of 2023, the Company and Dr. Sah agreed to a fee of $50,000 per month for advisory services from Dr. Sah pursuant to an amendment to the Company's consulting agreement with Dr. Sah that became effective in June 2023. Under each of the Company's collaboration agreements with Neurocrine, the Company and Neurocrine have agreed to conduct research, development, and commercialization activities for certain of the Company's AAV gene therapy product candidates. Amounts due from Neurocrine are reflected as related party collaboration receivables. As of September 30, 2024, the Company had approximately $3.3 million in related party collaboration receivables associated with the 2023 Neurocrine Collaboration Agreement and approximately $0.4 million in related party collaboration receivables associated with the 2019 Neurocrine Collaboration Agreement. 150000450000157500541300500003300000400000 (c) Director and Officer Trading Arrangements . A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act," is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or our other securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, for diversification or other personal reasons. . Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative

defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information. The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a non-Rule 10b5-1 trading arrangement, as defined in Item 408(c) of Regulation S-K. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.53%;margin:0pt;padding:0pt;"> Type of </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> Nature of </td><td style="vertical-align:bottom;white-space:nowrap;width:26.13%;margin:0pt;padding:0pt;"> Duration of Trading </td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"> Aggregate </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> Action Taken </td><td style="vertical-align:bottom;white-space:nowrap;width:22.53%;margin:0pt;padding:0pt;"> Trading </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> Trading </td><td style="vertical-align:bottom;white-space:nowrap;width:26.13%;margin:0pt;padding:0pt;"> Trading </td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"> Number of </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Name (Title) </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Date of Action) </td><td style="vertical-align:bottom;white-space:nowrap;width:22.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Arrangement </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Arrangement </td><td style="vertical-align:bottom;white-space:nowrap;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Arrangement </td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p

*style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Securities </td></tr><tr><td style="vertical-align:bottom;width:13.19%;margin:0pt;padding:0pt;"> Todd Carter, Ph.D.
(Chief Scientific Officer) </td><td style="vertical-align:bottom;width:11.74%;margin:0pt;padding:0pt;"> Adoption
(September 9, 2024) </td><td style="vertical-align:bottom;width:22.53%;margin:0pt;padding:0pt;"> Rule 10b5-1 trading arrangement for exercises of options and sales of shares </td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"> Sale </td><td style="vertical-align:bottom;width:26.13%;margin:0pt;padding:0pt;"> Until August 15, 2025, or such earlier date upon which all transactions are completed or expire without execution </td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"> Up to 79,000 shares </td></tr></table> September 9, 2024true79000'*

"

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

M4LWM(&K"LZ83]0TU2V='('2U$I3G[&:L'[:%XD$3V '8I(\<=O+G<(.M4.[K #B@=?>4 :VL/-^"TI!]J
MLM4^':>^0!5]=^]F3:JQI*!/Q])'C.@H%V$^\JT\.I4]?IS;UGZ&7;T=/0](M,*]XO&$[3/_@4'F].@]3/]F)ESMN"-
Z$NTUZ&;,"&'RAH5H?#24&&]7&V>C@ M%<$!E. BX4A]!B]Y"[;HAW826?+F:><%=[:56O)W5#G/E;$D;LQ VYP'
MMT]06HM^N/'([UCL+*?8WQ%G1QR_>&',(/8ZOO,B?+VZ(6Q?(MO?4!-D[+;,
ME!E&86;MSK!!IY\-9)#1ZPD75'K*/S0N&)O\H(4Y/PW#;9*&19043!'GBDJV
MCK##DDT8"V:,@!O#BY@E5N%7.A'STA0/JN(V&@PN8PJ;5+IS+/XK[:;FN5X= M)RN]", &A?ZVD(%!OS=<YX8-:_W9D
M..XW)TQHD=XP&A2<4,5JPBG"?7\LF, 4I2JK4:*S>T*LW MS%@>:(6R/H-^5^ %&08H,M2C[]>8G9'G 1Z4
2X55"!XR];1]#=16J<[#; ML!^]C0B)8(?Y378V0L88[;%'T(N$\%\>=FD88SK#]O=^1*GSM,*SYF&%PCE>8$!Q<
MB)/H91SP%Y67?!ZH/3!I$H,)TF9LU#X%TZ$TITE9+WT,HTO.&^5,^6)%/ .^ M;-K8L+6MX\A(A37R5!*Q=DNX.?
P=93!^ZWZ,]K;L-']?9]>HSU:X)./1[MP42(GEJW3-\.N\QNVJ94P.9TK;9E$8FC=<($.TE6)SL&"5PVU],NX[8J ;'@
MP0KVJZ@<3#WMKKK<_E7>:TSQ(M)?I4.U,Y'R![TZ:U+]7<-JKI+IK)CB)?M1_>QT#'76<8TPK].\/ZH-_,(ELE MO?
G@9IR0Q I.?)NV0:%LL5R!$>+UW,!"WWW_0[JC_G,+]@Y+:!Y!USO/*>R[M5)CL)KS*S%@DB39,.?/ALUQ,)67#YMA(
*K1L".V7\-L_79+LV2#2;]<:&+ MRMS00.5DGZ!5H%X$8(-6?UO4*JII]X8+/@-T&)PGD;/B)94%L_)BT$+<#%KP MW
G7UX-LVH2*O_98T@B_2YC?DF)&P HCN,&(C^5EQKOR+J.N]11]9X8,;19H M!86FCC/"@U;Q34)!Q0C=J>[+.D. ::P@!
[^IZ**C#$*83[&0?J!>CF[])A> MKRJ=U+4(^O:%&=2#+%#FD.EV!)Y)UEN-X3G86ZJ "&^>6K9*R$:Z,"_$$)/B ME
ERX/YA)2I+\0WG?+\9S*Z+P@8?PMB+_8FV
MF/L3GR7F#+2A!A[UI#P[K!JJWT0X5HHSVRUFVP8]V&)>E09T_JA&-8&4'@F[
M^(J)'U)+J9;=&OU@0Y2VY@)]TV3;=/$SGJ8%^^O7J_.^.NKW" :AE/UFT^8MVJN"O/&3O,(\W;11[LZ
M8X'*UWRO5WG(LZG#=56/$BWCH&IUEJ33[)/H/=)CRS0E"H2JQX[I@H=Z;XQ]
MOMO&,Q19>_X&\A<29AF.T7;W$(4^[;K"['[G-%O,C9;@28FY<"PMD9)X]REY M\D@6IK6*$,NB;D?7[I0Y-C#Q9FJ[-
NYQ&^(QH^UPTQJ/N8G-=R_"N)K49_R/ MHC9>*!Z&5X0YDQ 5(AZ4@"F%M'LE&Z*5U4.-D"L?<2YYKG=A9":;GH'=
[M>#_M,_+@0:MN;/&=%">F2FM;'[[PCG:CXRB>>@#K9O3LAC!-VXX2-
'%XSO^^8!"1Q;^DL2ME^&+U0HK\X2L"P$;Q]Q\)S(6 MVI4 +IXZLL.8M)N%0&5)C@6J1!0?
LFGAX=]J'83HJ*'4"'MBKY@O%AH@I@(2 M.C@!\YE]36Q :"ILR];G_!ODHP66OQ#VC9'J&V,-9C=.3/'E/6\L-P[-SQ1I
MH0#G%. G"EM?Q*WW B%83PNT%@C'_%$5H=9T!KO+/)(]$Y,]X,/62?JC_RTS$R,/8H(*/ZYL']FW
7K6.DG1'Q)YL,3['27PB?G&ZL7+PQL'U M0^:%,=MB*A84'Q+2K[CP.(JP<<. M60X&4$.+LJ84&KPW?GB/8WR*1%4\&?+
MUG(G8)408)6+75KML);Q\:LD*)&LB&4K'CQC4]9!/K2B%3"[)H]>'/Z#[]>?
M)7&:1&$@\ACBX$845>"_7J_R#70OHA/P3&O>8XHV;(S:D$9ZHP0A@MZ9M4; MO&/""C_P:4;QNJ>3LUXNQ?
6J.CI3'6XU-80='VK=:F>T1ZW@>FZ+K./=4+YQ M?(^_9NB4NMSOCNX<3ZFHRWC+'QVB8_-A1V?
+B0ZAK+6#K#CKUM7.0[5K>'& MHX;,PY>EFXU']OSR:_@8AZO0]]CKFB5'M,U9\A4J[13FA16K [K=UC8,=76
#@HZ^,@RTM8<;_%I2#W5U1AP],>IH@SU&NZEBH#/O M[1K9NOK,SW];Q['6#O/R8'-HS5V8DT<2??>#E06M801N?
IY\<(K<,?!T=H(= MNGHZ'V8#J7O #5Y-N4VG5QRE5K"9EO?DA1$KXWJR2L@)J_8*I[3KG;_&P2YB M]PP;+7;?
\HJX;E_8,='+ K7EF4Y'N!'23_S!BY*<"UMHE!ENAVEM=-1CS X' M/(?
#P%48X\L,;]IR2MM[P79Z3:V[1X*R"UQ'UQ5\5"W*9K=F3!#G,LED3J-* MEPWE :?+-:M?
36V[5FI]^L\QXELLT1W[#9WGA@)M*IC'@XJ;^W6>77L\B[GR
MTO?)#@=7U8/A9SM"J#+=IW:=_6"#A[;F!V=X[9W@@H6^Z$.#(N> \%=66,"9 M/[.3@?3&V[/H.E::XL-UMJZ>SZ9_J@
BMTC7"&J<"?A(F<"F#4?CACB CL$I M]!P;L!(W4.,Y4'.YQ#>>;-NUHWO4"#:^-.LDXT.]!=SX5L@YU.%$*GCR$(6/
MSDZRKW":8EQ/]NX\#.SL!-TA=72N.VA;#\@.JR7W< =FY!>'MQL ' E.KKC[MR&5%%D/QN!];%/,J0H\X]FN#9-?98$\:L.-
ZD$5J>T9]","-^F%J#-XKJ;@M M6"W-BAG?'4G8!*Z\J>.JHI..13HW5OL2>0;1TK[%VHO"S./%X.9BQ4[LN=9B
M!M("S9UAID(213UY.=VUJ.VK6H5I=8 9^OJZEG7:6UL#K[>N)_M0;XU?>59K MFD^KC9R1[I7DW8S59:GM)[PDA-
W^9<+T&:C[4(9JB.L41^BM;M#'I_[*S%\ M#))X(8D9L('9GD7@($.E'7]BH"QO?8LCCQ578B_+\0+8O+#WC;?
7N6H_FBAL M_#!C,QE2QE&$BS*&]!H<9JQP>EZ2WI?8@PZT4]D47*K/)-3:K38HUI) M/H-
@ZU!L:+1)@WFRJC\!D8L@'BI=(/FIB$(.]Q, U_:#A%87'F&%(%G18JYR MQX#?
TAPVOG3I*0.'JBU<1.B4>$QEZ1+B]O;*,LS (-MHQV;P]^568+BZ1D6&3OBEH^AP;2N^9BB
GLR)C&ILT79TQP@!N%$^EI MXBJ.+!"J)$*%2.)9(DDHUJD0BU7O%T.YRXL[(VUZU7'#QR!YV/%NVHZU7$5#
MM.'&N'$-!R?G9JV3>1GL+;O%GFH M>S>.YHY7XM-I:W;AHCCYYB](?J$PD>'X9O<0A?[U:H4)>^VMY?A;JQ?,*.RI
M=7D0WMT%^&EX#P4&>VR" KP*XY /+>6].+MO?UO04V:!MIP"'4@%$QNAJ1H; M>W2;97 VCI2Z?
68;GN9&E/LU1E2&D(Z;]8! M#DAA2SGLTJL\>D'=T05V*.OH6T]+5[>'&[9:4@]//)>(+\13 'OT6_Y?UR/U MI*K?
T)6G'VXCG(ID/(F5B^#]G.+KU46:A1LZ85"=M1\U@AV@S3K)(5EO 3<(M%7(.W@Q)^0982=!)=-G5R-P\&S<;>UC.E2V?
>. /UK+;Z%)-L(_B68;@.KYE*2]L M'YNO!'BB7^>3789YP(:?22S:G"AK@ %A M5?6*"3N:1Z201SRJY>:1,5!&E'.-
/=,&M0*7'\NJPU7J7Q?\=?6!#6=:&LOP MU-H!+MSHB3W4\ROJIRT&^2&._STMUHM8L# 0"F:GFK2L_4
MWC0Y?/PG#F[+DN/LL]8IC0EZ,./=F*6JNC8CB '/)#*BVN 4(^]A%WGD(+\H M6V-^391&&+L^2__BZS_"83.GJ/@4J
*A'$YXZ1VKW9Z+R08@>= MI95W&GJXE^-+H$=%KWNN6C4(P,3TX;907,SLZ UW=C= !R.+G/9ZY[;7@)!T
MMP("AZ7MM0*_LQ/L8-?360[P]AYP@UI3;@,;MZ(NIB^>0^ C7)S$)\7OZGJ9 M=@(LW[^VN46=C=&XCR: 'U34+WJ49
M-=HZ2N?C=Q1^#;/UV2[-D@TF_*1",JC8:TW?AE&"B;\&K'.0$]B7#-S9WQAE M1F00"?2*B8VG#QO)C%NR>:=J
M)'&XJ&=>11-1+%?PK%7ZE,5!#_NF4I^(R^2R9EBG)56&O.JH%F:$,/!X-F:[M6B"/I@HX@LWI-CAT-<*U(UJOE/7 +
_(%YMME.PQOL/D*?2QPKH1%X.7!F,G M68]Q^]J7$S"1!3RU3\,,L\>(!/;>GF =PP,\!P,+G*(]Z*JI#!I[39]#QG
MR+=GO"A"J:)*-?(83CB>K,L:,.-\2,@QM$HS%-FXS>;G)C[=WU"3]CQ$MBO+ M7##%P3?4C#
<6!9D#%KDPAY&,'AF"&$L.5(WS&$GZ!:KD;UW.<"78S(BI 64+ M9Z;?6G6JJ!Q#\M0!9G!F/YY5P(85)[?
MDO@)IQF6TJSX"PW<;NG2S\(GW1WJ M@:1@8_H8^]1NW@V@ Q=11VEC)+2\;)?OI:Y9W+.C.;3+A9+S]'@00MQ;Y?:Z
MWHI*5GW"S AAV$%GSG9]ME&[J<(-2(.ZF1KY4+(5*Z:5?L7AXYI*N'S"Q'O$GW8LD24'U+ZY]?UHS270
M!UBH.99[$)I#N Y1Q\2V0,$7Y8R1X%RN]<%_G;&*&9CP^I*?O U>?@T/CUY;FL$$CRZ] M&"ZHVL
+^4Y)AQ]&5$01HXI^8W3-'3YVN-XMWE+[K*DL99KDH9[GR<8+#S-X M^_:%ZZ2]+5!XKG9'F.
[<7WR#/BXH#_%RU76*Y(F2#],;BN4;;_G8YD)-["+Q/%J?'6.4 M*&.N>XN@(-/4]\R"CO:
P]'7>DGC4LO+C1TE+@GRJB,^NU$ZM4VN*UUS M#HXOK3368;A;)R2[QV1SR8]9^$FK8KG7BP#,T!]NB]K-%.W>\";)
(W08/%/D MM3<.*Y>(.R::GZ9;*>S]O:83$69YW<9^< M8G']!P=-
V#F("DQ(&&F5W!JK)07GS,M$\F$X0K&]LM".3#.Y[KON)AZ
ME>5,/^'L'!,*^%Q]=G.QO+:HJFKZ.4X>4DSX/+O+ZL6MVB[J66_+$]-M MVUV>'$[-$^Z4TIKF0Y& "8BXA
O$'M.NA!17H=&+4L[O42$IJ^9;RHJXL LD MBXNXO.B@YIS#&X)L=DEGKH=SV>/C)ZT.L".\6]?#A5MS:
[A1I2'SF&4(7W,< M594T?%S5PWGK=2&/%6_^:^,FI2&2L / A+WJ3VL.IPP97?CTJ>NZGQ[D@[.],S
M3#+^KDZ&T^O5.=XF:=A\RJ;7 W8(:FA;FZ&IF\,-1AVA!P\>FVVY931[\)
M^H[J,%E4.!#4G83JAS#VZ)K.BRYC.G_@VZ4MRRAU:]@AVJ%E;7.CN2G/!60D$7580=KIKX8^DK&K;LQ(I79
CCQ^M5@_;I/14C;?ZH,2=P(A:P0V(* M>\IQ9)(^W.";1$N3$>MV!?;Y[I[P3<9]=1FH=1[8V@%V0'7K6GM[6-D:KK-K
MR#SX!.OEW4M44$=QXNQ98IKCV MLT,]>/7Z0@[EGAH,]WI$W;YBACS&;:],_+$5YU#UMU3=FVQ9A@(^3=B\12OR
MN_K #GNUN5LZP UL/;&'9^'DU-%#XFKGU*6&EH)SL\&$S>-OO"TF'4'9 MW!9Z,+9H6_"AH:0@Z]-
W!%U'W.J:,O(.HHZ!ZK9S5P[W9<__FN("?7G]?X* M/]&P:-D0U>T,.R#[V: Q%ZRU)]R0[2G_^+PL5%+G!^:?
EG]UN*E:JIRG@O$= MHV,[M.Z:]J4QDTCH8Y'&@- A,(.XZ*7&-.'A< .SU)AG0*8<$-ZTSLC:>\S$ M^=7:-KKZ61-!7X0/#?
=VPC4V]MU-)S)@'9K;UB5:3J-H, U1!^<)YB M11B5E(MAJY>B]_CGO.Q,N[M>]:ZAQTFX&7:PAOV,LAK&?

D95UY]TMO7M7>_M=7Z>KM*_OJZ4WL350YG/HKI;Z'9>-KGR3T+Y34UYHE!^[K>RKSK>
M6K3$>B9P8\'^EFYH7\%_T=&J]K.XJ7WE]G5(KE"U>WP>IGZ4,(66#RE_3UKQ M1>KT@PT VIK+T=O9"6[HZ8L^-
&X$AP62C@PJ+G0%F?-Q"&;*NT@U>^58FWBNHD1:JZ;]L.K)_;3$XEXO1% M*/#1UZFIUA *-
PZ[19YDS%B@^R3SHDE"DQ$>-%R.5IGKA#9'M^&-UI\<';P] M[EW,\HZ%[GV*>=V=F.2> "/J>BAY\L*
(105[IM:3A\NN99I.1]B>JJ][;93I M[_77BWO(/GC?^7:%\Q6:;;4A1'(=L4KYF'C\2]&TE0:9>46Y
MKEW:8KZ+QGP00%N3P8%1,#Q9)>0DI2P1'_8JI@O4A!D@@&)RZS0N*66#^,/0 M1%$E_; U3(.FE;*G6
QFAA,R#!CH|)T^F!*P"NHC]?+4"%U?O;*BBGU6?.Q MXQ2O%E_\+<5I-JJ:H-BQ#46U.,$,<=Z(,D>-
FW<6H5FU;>#86G/<4S@2]+=']*L.LCB?[JS"ZF/SAZW'.WLQS MK/<"K45&]+UP Z*V!P6UB>9%PL&H
ML3D\F2T4F*C\&#"NO[|O1 M"W)#UYR=^NSC(N6"8EKH=&,9*WNV"D"MMH-^\<*8;0DIMD.Z6P,&R6XM2SA4 M-
P4.?!J"#W70^)5G%9LF5$7:J66T>8CQ+5M'&S66]4U+A6&D[QWL5?O4QW>1
MEU%#$"ICW2ZGF$ZU\;WW=5@RA#9MF#@VB05[Y SI$9[/RG"<>I.>)DG"("X-
M.HCB!7K@BJ$HBEI1MC*M:=TLG3(X.\.>$<0^:I<.Z0]O/$N48+FL"Y&N'G MAW/-
ZKG#.2;/9#CW7M@QQH^,^11(9];\G734FV MQ@3%U']VA/!W4OC=0!=1=['91LD>XUO,T:0-!ZQM4HG!V2' XHNF-4*7\;!
M.:N0FFS9-A[+^%6$:N_.,.-UF W*?5CMGL"W9?OK,3PU@Y]*[DD3I_FPS M.Y)Z\"A%GTX=UQAG*&#O!M%/DH$?
Q!4JHCH02_1YY3126C#583]C$M0C)=;EN].(RT7+*HB&[T(MJ,Q?PFQ-!]TDQFA/N2#*+_\3:QXG9.-%*-
EB0N6FBOI[GTH5KNCL-W[$Y'N[M)VCVOMF<$RI8\8,SB1F_ZY"BG)WE29EE6]RV^I]Q]/XE28+JW5S5[$JO!WR<
M[M#V$)P5S>>!R%W"&\H'\#;)CGHG13S\E4TUL(2V#[N,O;%*\34,.+@^,IFX M9Z>Y5
NDP$4U("XJ1'0"B%,9MD!!3I]#8,%A2N1K/[FSI/*Q7SC9U!;2W)!D MA=.41I<7?SYEZ^K'V6IY>=9NAIS<(/X&G M#W\
<0[':O N#&._O,H)Q]HE.+5!%+J: MCM>??A!TNX+TJ!WXR&S6[" #8TM&TC+&VQL!C34MTTS%',5]P0X*=
MU9";5&,;FK5O]>H6>]%%2OT:%^L+U1;2NCE,^-'5L[:1 MJ6@+=U78*?'@?7A*F!WA,-)(T$8%<3=[F%-
KZ@4!+]=$]5WEP2^@-C W\%.A M?8R#]_-UT2N!MCE_]A BYCL^_,\1%X7^4>2HTT5T5,B$0DDH MN]-
[B\8J6"'&"PEFB')#5XUVL#\QL6B+9I7S\WT7I3$]6 MC!TZ_6#B96_-Y>E,9R>X\QI]T8O4YX3(=\7!* M9R6:
[W8/?'"YC/UDHZI4=]0(=IPVZR0'9;T%W A4R#G4WPIR2-!SLH0PK-(U MOQL3(:&|]RPDXB;QH5
MQ1B&&_5R$'._XO!Q35=-2SK >X_X%F_$423_\!Z3S1LMZVB1F5.DZMM%'<3= M-.82WSTT,1;Z!4^4,T4E5]$",;X
@,&";4I3>+DI2&D*,3_)CDTQ8L.O53\Z M#R%\3>U%IPDAR1?:[M;+&DLX#B4$$RC&VZ;<$1Q$!?
CFX#B=C(5&6'%"#P4K M1-A1_+NZ45W"X)%C=TO0C8D.D/486"7.J&2-&&_[.X7@OK MLR2B[!-FHB>\)(2J*S8XEW'_-
EH4']_3GU+/Y[=([]D=4=5BMO6 M-E",/% MX3^X9':G,)/I_*E9.^05?)P\63,>P*["&%]F>*.ZQ&68!4PXF-*>M;=Q#-*'
M.\!.HJ7+H95)@[@X;I[? F;0S284;X$A&E)L+81CG]5>J6J;2159G&PA,R&. MZSUUO-
#7W0LV>&EJ7=L/;N\'"%V)T!1]W#"DQ6!3%(5P_Q6='\Z+2DNM ;D[9 M:"\5T=D)>!AKZ:R1D@2^5(2FW%,D([FI<65)
<0!I2(@-97W:# W+%!=J8/)G^;(O%S-"L>A@O3'U,5Q,Q3G:I6JVFG1?] MKC##=XC^U>MW>OV
;QCVU6+P_F%9S&XCQL6;+&!QV!Y,1)UQT/X%FR 2<]P;G'M;3-VUR1]*/W-=SL-NQY/^IR M9]|6\\.CRY[&B
*&36,V.SYR&4H1.-2:TV_X!7A>6/FPO.A&<.-/1S(<]8J7
M2T0VMN*09]%>U)G2HL#D55N3C@Z%G!F;2H"$"$B605V*.9<#Y8*@0A+[,.[> M>!_K+ND&ZG=1%FZ/$E-
&D'DF<'Y@ET$ GM-X1!'JJ)$1D-[D5-D-X@>,=JQ" M/H/=U2[;$5PB]BJ)(I$/ENY\'Z?I:A?5T)BALY]L-
ICX(7OWR>4QO45;]L?@ MG#-LS#5EGF*DV31K;1IF/X813C.ZC+OQ]DR//#72SB(+8;F#"#:,GF,^?-Y7HJ\:N.=_4H;
MARDK#/'Y]#\011&["S9;+UXC[Z$440I4*[2/!P %D_W):A@N.2(0T0 M)[.)A^/W&_,Z8T"AE59))]V+$'N>D45?
B3>42)8W[Z H;>O!4K0U>T('&Y[MJV&HN%[,Z3.LW>8<\AV!6N:2N_T!:W91)Z-]*DU4,+,/>M;,4"DK.0"K--RL
M^@28MWQ\)/S5WGQOX1#:T_OD%-_F4P!6%:A&Z,8C6=R<"3\UPQFBJU%;=T*R M$6XSQ7&SN@^-
[DOQS)Y7"+,0,^Q\$^]HIIWFVQG'$^[ZZ+ 5XL$8&!86CV< ME/*5&\E'T^L4W2?
HE%U;S^W.B[/52>:"NG@*$+;E*_OV].M&GS:9OY%+L?37 M(1;%Y1I>Z.EJ"WB4Z=)02LEH;@@D70.K"%@*_?+--WAH/%
(MKJL'X'#2T[8ZXV]M#CS$-(4W?K240[[V$G*?EX_1I]:_.3@0#M)05 M%DPVR-5N
M&4T\:R8R:Y3K4,D0]I4G+&B;LT%;Q@=M5VAVP#B1R73@4 MMH(=8O, $=3A9-,>)9I-JWMU0S:GCZ[C L%;
YQ;S!T%O,.%; M;C1ZKQ^B\)&[=;J,."GZX_5**IBEG.*-(088M$;;J 2TP92 @]UXO8P#(1$B ML?
WC0B:4E$(AKQ2*I[E78HG1W>[LSZ7YA)4DUDCBC98U,TGL7XQ M!A?<>$<2GX0QKN?Y%,54[[_0?_:?Z.
<9QG%+X>%A= #\1C+5 ON 42 P^\H ME0P@;Z@\KWO[^LU[5(EWD--VO-AV8:Y#2QSD)RHJ)5M))W1BCVY3<.>9 M
E9/PR3U0TRQ)KV,?1T 5?28!52V:=L BDW-9P-_K<)/"G22.TM"L.=97&'; M)+:HR!NKG)B2[%55-
9'^5E5,I+^PYZ>#G9]=DSM,GN@\JR%CMZ49S CMTHN% MI:H-O$J'G9(.=;:<*,]9R>D.3TX=XWRLEG@N0-
J8N=K5%KP;JC4\\,7CAJ = MLD5]JZ+4&SM3E,]]/5LTJS5+<%/D/1D7S2Z4E0 M"%#<(T49$\%R,N2$5C@_4O#=!#
<8BGM43=HU-0(<>$J=CJ\I%"V !YE:7N.; MR[Z7KM$J2KX@.7FVO-WFZ*Z",;V/[T.ZJ) ZG5;;9JTL/4L5\ZK7OX;9^FQ'
MY=E4M5_W^>[V;5DUY\ R@XG !*)Q-JD_'M6' KPIZT@]AE^2%NS$,W4%P]IK M$,4)4<75*!:\%S:)>8I-
T(0&CDQSCMDLGYTJ.7H(PZDK^#E#J6!7<:!*5([@ M'C[/=AMVSR5\PF=>YJ_;Y?!?](V? \
[R4WV,0G"55B<$A;DAGP'H[C-&)#' M6UD;N8>SFBG$&U!XPK&@D@YQ\4YV6U0)R-:9N8@+) O)9LP%=4=O! (U>65/
MG_%&U)Y2ZLHHI%4EFP9!*!YG3IJLLDQ3W+R\U>T($]CZZUXEH>KT KXT[J?# M^#3%,/8)?VB+0H+?/+'P.$\4[C?
HEHS=]\FA+]/LL4D3"QGX%LR4<&%%1@J M$?=7&7&18.4@A]6N!4Q6.BBFZGU!3;LG8%3KI[U4LT"G&W!& +\.R
MS9*-*C9VH:V^@7#?BG#630%NA3QD@@P6_GIIK+WFG.G*8$!P4RZX%PN*QAP;!I+8VDJ\0.W/IW$%BXF<)>Q
M3_6A@T/&T^"O\EM'#8FO>CU@XF$/;>6I6TMSN!,W':&'U\ICM%%)'!743:?* MCO?
@QM19W3ZS].+C5%JM#K/S9$.IM2V^/#S!=K0W-[\M=_%UB^.T.26W7T_8 MGMU#>]F_-;K!]?
(^P@_/+6Q^#]B%A_^"8TR\B*J[##9A'*:9N(NGX^.Z?6%[M>2\+R'ZNU1&NI_<3?
ZBOYURXJWLU/H[P/".AG^'@CE7*^QR'67I[]|D+R5O[MP/9N+8T/T%O=
:XWZXD]U(L_QT^4/M\O*]C42BZB'>/G),%E6L4KZKFBWA>/ M!"D/YR:=K40Q5Y2]%$IQBL\1;ZAVK3'[52D_2L])Q+I2-
H]=%Q&;%]"A&,5]HYU2B0+9 /F40V$O[20UNL)-[I[RC^X&C)S^1/V,Q^<2_J3;-MK9/$[5MO)R-RHJ?1,W>F^:I+?
M[EHR5+KX^R[,]I6?*8R(@M+NOJB2_SV@SMI^. ,Q_&?J$DLO0R MON%?HO6O[HC]MSJ(-7\/=L:P.N]O<0A36?#=?
2,NBUEZ0?]@CN5TN+^(" M+Y 0&4DR(RXTRJC4*!=[@83@B**3$-W1!L5LOAE.CEK[V>+Y7_E Z S/C]A_
MJWC>_#W8P?,Z[V\1SQ46&(H:@MQD\VC]\C7/QV(SA]D/"5GAT"72-DGPK8*M M\MNP@[='[+]%R%4; ?XLNI1]HHDT!(
W__U45GNV,%_N+/V*P\^2+H:\ M1\R7$>?TR_S@A>2O7K3#(X3>TKYK0X7H[Y5R\<*?43\%H>=<88:"GT%,Y1S
M$_LPB/%#C"'B'-E0(D:G;Q45 ;O#/_&OQ_<'#?3^B71:UH$_\RZ56B]3'W. MQ[_3?[%-)\,!>SB-I*PR@9C$/_-#8HM6KI\?
=QIZYM."^E$-O+E!?_F^U0G" MP&_2Q6GU/Z<*!DUD[&[7HSAF7:"$A!0"O0B%_!%[\7[5H>:@=^DBX/T?PXU!DT$?
VF:'V&7)T(N5Z@.AS';7["4 M.?#<1[\ &U'/0+>$-93N&]U_!KR'5K-
2M"2[%LA+$RHV2E!EY^9"V/7_F3HO=4S2^I;L#$*MHGR+HXZ>08QM MQ 45DUDA$?^'+07"^%&L/-
Z8_JJ:63Q3S&BQIQ$@:*#_#*.[3)']^EJ39IR3[=YQUOCL]}3_8X3NYI>58 MGHP9W,">7N7A91^K=SC%T-
Q09PEA4XTEWO)DHCH-R8DRJ5T\H2&08-/ M4[.MA<\W Q(3U&!3,?DFH,%02:N)4&&!A'SSR\J?S-(UZ]0? 9U[(38[-CMZ
M/W2VUXL;$T%_(4FJ>H)O&D[/>^QIL:[)T:>!S?,=?]J4A3_"'58]8W^A,LXK MCV%"6\^]RMEQ(L KW@#UW2S -
>+KYCX8>H]1'C2W9 F/L\;/)66-0F61TR> M+SBJ51W\ME5%<>YA+"V=#Y)==Y ,/R[F6C?5%.*
MYPLE(VQAK%14P0EQ5L\8<]Q^A_]$E_JWX !2OGD<,;DQ;KU6C[V3EV=K0IM' M,;","&,<2WOMO4XQEAF58.;CF?
EOH]>89H[]C,>U"8SP#=6KZ;)>82"GD-)7 MB&>.*H.^$Z/ TDN"9XPMP^PP/S "[IP,4!1.ES?]Y@U/-
;F.BX\ML$F+X&,'6T:00_GO:/A("Z_?O M7G-@8'_Y6WG-["R)>?V*G1==A2NL* BCVP=F$/;2F(6.5@>W#A\D/J]2PGUY
MR+KJI<0!,1:HX&'YC5[7>CN;KSQTH_5#[WWU)D/> M8[)YVS9N6)<$)H0"^':.YC1VQ0 ^OW%D# .G4G,$&?
644&6RUAI8UB5YWB S MXMLQ"3(#Q'B^(#/&& 865.963LO'1\)3XR^IM&&^^A; M+ILZV@-?-

>E*/Y=%T]3ZE/11R:"Q,/$LMCJE24G=7-.G !WQ@XD(UBP]4:)%SP TX
MNDZK,P1XE<0$!*\P[3YNJ>A\YFKU<8=O^PD'ZP\U?*//,5AY="%GXOJMA66< MA4$8[;+P"=]A?T>HRIC"G1_M
AQ\H([+C+<3VQ;7JPN/L/VR] 838;M],X'E MUU!5KFI:CK!#WX*UY<"?D!WA].]*XDTJFBCWQAU)^51FY7]Y&WP><(V
MQWL9N=9MCI%XK'=W.%5]YA83#9(;=NP%8CS0;X*+$P>O'C>Z8P\H?,0M56M4 M;6&[N9:; M9!>KEERF:,,.!:,6-
#B3$H3AAH9]4S/C@HY$/NRD20)2E:HD(45]11[4SR# MN1;2^.^[\,F+V$X5SV:>II:RYR840"NGI1A.G@\ZT)]9Q+
[812*E7K[)I)V M9]B0U<\&M6=VM'K"!9V>\@_>7ST&B#HGNOK*>1U.4.W @B4[?-IM,&%!_+.+
M4/^$L\N8@C*^2M)T^>2%$=OPOD_..$[S"=XZB0)JJU,O#7V%J?I3@1W\ ZTB MHT!/$G#A8*@B@^,!9RBBK)"7T77
QUVV>VG+*E-'7*.3G#!A4%>,(M\CT+. MUP5.'&1HBM*=URL.C'*2 U>Y8X8PE!9LS!AE(1DY!A&"BQ_CU#%6J%'P92L3
MP;F>:L29NYYPN+'4.8Z331@SS&"WU=$#-T5\"#K5G5,G\Q1=VQB"GF>'.B8 MY_E@C2N8.6?K>]IZ)D S&
<8$N1V@H0R=UQ&>@L#?>F6S.6Z2I303O4^.DQ.D MJDD*BQLA#!N)S-E.QJ;Q5.&BE4'=A@:F) (2,A2XM3Q8?
9T76Y,7JQ7VLQ+A M#C,.)>F<8!L HY[)>]Q)GD]$$54^VA(?[N+PR$QVL@MW#RG^^XZJ>_%$_[EG
M9E&E:S4WA0U&;?K54O :VL$%C%9I!^<7ET01IXI^XW3=/ I,90F#T"/[.R_" M=$;"HJ0E9ZVM/7P';=7TT$L;&\-
VU7:1!_LKI<="XZ@[C*T)+U8,LWUZIX. M(2F=+5.X;\W1TNH(W'NU=:^Y<6FLO\J&\-
UVVZ1!^?)4\HG)>G\BI&3&?]T.GZ. TR^L#R,^!$M M'PGF"P07$7D6>6EZO?K58^N4[)K8X:^JYX/M32?F?
\:F@&U>/#PV9"B:,\- MP1]V%-^#G%?:.,/I: K3'77T*XOS*-H!+\K3)?7PPI=;*B_;!439&J,-IXK"
M>)60C4A*VV*2Y;4QLP11.4Z$((7/IB^M5O.9RA -BJ'?!&V[9U:VM02P&WL5 MQO@RPYNV72]%)N#I
G4[5<<6680NWN M(0I].A]88>*HRDWC;*<\+R^3],\\]M[#Z;X D;QAK]59+ZJPX]R0U3KGROHD MX:*&*<6,S[D7E'",
(*SI3S@J+') >^+;70H9BPLM.7PB1AFNZHE>@, M<4L57M-FM?
1EQ^<5_'&*XEI#]X;W87/8X-.EI^)$HM86+EQT2FSD]&$AGC.O MKN8XBNS)M+W.YQ1HR_5D.6FNX[,1Q6K/R90?
EM"EJI4WE!;LR!YEH<[)1!P" LGVDJKIZ;[V25MF_D!:P)%CC(5J M"#*$$&
D&:7.8$3)N3)4R:DC3EZ&D'3!]H/K'P^_1:!8ZGQ(R 83NECS^3VD MEGP-94N8CJ^A7;D":6X&?'G1(?
3PNVNJK(P59XAPR9%Y+\OGH%*&V=[NNF(B M[0595-$U%VGGY#R,O?6=MU;'6$,;P-&ETJB,J\,&P"-**>[@+2JZUJ-A%.
T M?(PYBGMI$49GZQ#3*:4?LNA9A3ZZ7M%_,5F@<_(2<4$0E62!;M8OS^W&EG$[M,(TH-3<%<75&]9:<[UX$8
;K<%O4Z^GJ]H8[VQN@P_"%\7+&M)OEAJWFXHK$\<,D5 M77N@A/]7':G!&MWFXYUM>FN,]U?
P4X:U)3<#J1(+]SG$UG3?LPI/'2;/-L!23)[J&'W46 MHM@]4JD5/(5I0O8?,+[Q]FQO^ :3CTF#DCM,*8CA"<%4_1VC!F*
(R11V-#,8#8W>2R;RKEK&&!"JZ(LD4Y M7YXFS#G;3T.Q;YRE[#FY0Y6.8PY&[Y,@.*-:87*S?AF\5._$JQH"AL-6W4K(
M:VP%'-;:9J9T*UE]'9FQ1X)_OAV?7V&VBUC36*%!.75%'25 M]/M?_J7X2]I[_+_\?4$L#!!0 (#. ;%GV9WGG@#\ (BG! 5
=GEG M&UL[7UM<^,XDN;WC;C_H.N+N.N)F*JR+4NV^F9F M0W[K<9S+\MFNZ=W[4D%3D,QMBE2#I,KJ7W\ 2$FD2)
B3=2VIVIJ;(!$/GD M@T0"2"3^]N\?"[>W C!P?._O/YU^/OFI!SS;GSK>_._1>'LT^5/__Z/__9O M?
_OOGS[]Q]7S0V_JV]$">&'/AL *P;3WPPG?>Z_^U?0F[I_@/]I0%WL?@?-+8+^#A?7@VU9(M9'T/P^4O7[I\^/'C\\
<;=#_[<(Y:.NE_V=:BEL#_^K0H]@G_Z-/IV:?^Z>>/ M8/I3#R'J!>3;#!_9%$<]S)3^T=^4/?WR'U\?
7DCG/SE>$%J>O:N5^TI2[W0T M>AO]T619]W2CJT;?H?_];K_0WZ+G@&LQYIXI=PO01__REP%DL7?YK\[!V"
MV=]_6JWG\!/&_V34/\'B_X^;A"";_QU[TULO=,+UO3?SX8*_U,/M__M^3[3 MGY6_MN8 AN\ 6DL0A8X=?+;]Q1=
<]@M;LT14)M2_-!3S)41TQ1VY]KTI\!"K MT5\"WW6FF,97EHNQ?'D'(QJ2,O5NI%"/UD0E7L'2"[+E8O WJ=,@6/[VV R
MFRR1C)BB >+MM;]80O",*C@K\. 'P3TRN L@'"3^#I@(W4OHV[^_^^X4S5&W M?
T1HQ$L%JNAS)L)R;07O=Z[_0[QUH7Q%'0@W3F"[?A!!\&B%Z,_)["H*' \$ M=60M:TR'2"_18F'!-2*:,_>0(V-
;:"ZS;3]"DYDW?T)*L!V !RGRE!RD@2<(M J2+VM.FH _K@.K.*./(,@ MA(Z-AB#^!=+$>&4YKO7F@CL?OJ
R7RWX.PCQ#UZ '4$G1 IKA(>X3NB $+$7 M1F!Z^['$-JP9$KFV= CT@%@))F^N,V\^W'-M:2&YOU@X(1EE:
(;!=@:M+6,K M,\$"/#C6F^,*X#'/=[18_93-G4,@P)116M0B'':9R,(>.Y9H_ B8K"A-:G%" M0+CSD9\
?'E'ZXUFGDAQBSJ$^X8<0/@#6?$0>$\1,A?V9#8#$(V@1A*6-:M# MS&?
@8M<6K13#]2NT$)]LLAAJ)"2]T;8YEIO?:G,P=QTPQM%Q2Z.!'=STVZ; MG4X!V(CNB@$.J !4*"T:[KN)H
/_UXSQXP2(7]JN.3Z="$E+&S;&OQ,@:6F[M)NRFW2!;ZKAB-]6V;1HSCX^# (38CJ1,2/+[Z<1[QA,)]DN)4R("$7&=:+.'
M4- .JEE44@3F&GO=9B4AWOEHEG4=8H/CW?Z\^-FF35)7H_X;X#"*P)+6I '[MER+$HS5IN$'QN M2Q
W^"F"]KN5^JD\K!KVQQQ@001]&_E*:'BX:'[PXZB&70%Y$#)_V72PT+0) MT/R(%R(D&,0+H66'@JV7G Z9LQ1._SV9?(7
QOTQM]O(=-TX;H18^1MPYN_H?\AM9-.H<4(7)EV[($Q@T&J$726@#LSW-_]078 M4Q*7C_]"T"!(W'N!@Q2#NH?Y-
T8./%K54((AF)["$'P@4D[!=/M3)\0?'(T&J)I]ZFL?1?T9CMQ2WWZL6\8YF1 MU*YO9[KCXAL1/F30Z10XL4[17W8Z1?_X?
NTC$S-^"XCCMFD).7C _?M/!;__M(K$K&[Q>48L%/4G_^ONP?SDE@>'ZZZUN:'&.8[:<%[4W3Z*\Y
MOF3Q3TI\69(P]4_VN^-N53^#_J(0H>1K/F.G?8C&Q-]_0G^+ M07G_@$.!A> M!=+_-
T(F!T!W_0R6/BQ2/Z5DZ_!GZ7^BBC,MJB!VWXE]Y I=[!=MG3*8!$BT MT=>B#>26.3Z:#:8W:&(N446F7.OT4-W[1
GG2I403Y5WC@L>H\4;@ 7X[Q=I M#?1,'4]0'VA_1G,'=QS+WRT%D7,+RJ6%>(,"7%N,OH,G4\T,-2@ ;PNA,MD M?
XWU/Z0HIK=4R_?#+DJCK0H.Z7JV/^RF2E^R8XL]6V"Q*^9:I
MB$>*1#F7&I0SGDX1=$'R/VBA"$ZIBBDHVS*EL$J0*&2D3R'7Z*\3^.K_*K4 ML2O93F54]'^S^CO1IPMB8"?P"?
HK)\Y/4*J0O>+MU J+$!O5J%V99[KYY >A MY?X_9UDZ]1<5;J=:JD78*$7M&AT/XC$$%D4-Z5^W!OC*3F^@5KL
QTE>W*=W MWZ.O_?:+M 9RIHYO8%>[Y$XB\]:G9V^O>$^[/;]<JV!G:GC&]C5KKF3LY"7 M]>+-
=PLPS_R^-8!7]WJ#MMKU]88(MQ_V.SY[HNQP%!7+2M$?#/N&[B\Q=WZC M AUKYNL(8@'CS5_,%(1=%%
=G.+BK5$)MQ ;U>A8,=]](BXBU3#8<0&]7H6#OC36-XC18N <6%I5NF#W89-GI1 MNRY.6/,.7+=*'>E"+=-
"9=3ERS.R>P+?<_M@07I$1JTHJW1 9< &W6H75!OXDAV?;Q#/RGRC2@E6Z,,GOYO=*%V99WM81S9 MPZ:-5-F6ZJ-
*@HU&="RH\5W0Y+Y'+HJ?/EN75&J-CFJ*LE$698G]MR_JL=_B M L+YGH"V-"S\]P7'AV[;1W[?-]]+M]Y(/]+BS@]*C##AJ
?AS.28DCYZM:?TS6$2?)[U'>\6PA M4T9@'8W@PE!)!ES.MBQ6614J7*,"L[/P>-Z>R_=!R M]?L33]!? ABNGUPK3CV
?.XE7L4C"TDU"O0J7:("MYS4^U\Z/,U\%A'\D^\W M8(GW9+9) !]];X,.@6I/YTQUNJ#T^H)2+Y:)T'I?
M3U(WOGSYB1QYC/._S.9 M?4.3(0: 8A!*ZV0Q&VJ[$RW"(O +2KWDULK%9Z&)R/[23'77VJ@L4VCCW83"
MV5^YJY=*D8AL7O[IRHJM:M;JI&B[E%%(WDE[$-I(PO;20:]@FF$:*384IZP M"-
ZMC>ODR:;@R5KCG;F*=61A88/IP:+/@@F%74RI9%"_EQ!GE\\#2.=#N]I9'"\&PWZ_W51I
M(K>@XP]C3,C^K%M)&GJ%SO&$4U1!YQ\T:B@W+ME7WRNFE<>IDPD MV\>RDB=DMN]E42W#OB[-
N(!K%#!$;GYR"=VM7XVG3:8(" MB5.FW[)BJV0:73CU6QAAQ2MNMW;'4Q?12L/^]XIUC@A, G;+/HRG4R<6X,ER MIO?
>M;5T0FL_X5I%ZL1A)/9J_5!/S'A:26+ZZ6VE!OB^"- ?JGAWAJNB(26XX'IK04]-*D&*81N MP,RQ'?I]D:J*G6-/39$%;:
(:L].1QY%Y9=,Y2C"*V*TP*IU8,T ,-/((2_. MAUU\44Y,*7$,R4_Q1#3R#E #.T>7*5G%H$ZRBM[/F0_^Y:?#3%Z!:#>X')P@
MWIV/<)0K^HQ>O1"DE0DD/9^2Q=[FN5FF/1%:9=-L2VW-5.V2< '0^E096=GC M9#WC*'Q'!N[/G;4H9RB%9OR5"
M2WBM4I1N>;?"*]}T=5[+59)+>!.SX7XVYRS/4+/#*J\KO82KYMH(PSBYE]0X M#((P22UJ/\(<8I1Z Y32AT2(:C]
;"269CI4.Q#L23Z[30Q&UT'DC77-FT[; MWP:367))&_V6A"JE3H/P.5!\(L2Q%77&FC=UUX>>/^OM>M%#FNAE^M'[&??
D M+[UM7XS!&X0V.M*,CY]L-V(SPN\ UO])\I_5RU M1DNFV9@*#6;/P<1(*VC[2>?$LTWRD*2![JLK*2RW?
8CKPR63(CM(S0A2A@;.'_MWB ZNSY)UI-(0!WE)75,4R"?5HH&.:^P4F/OAJH)\BOP$(N$G\\73B>@\'# MSZV54Z2B5M=
(4D?<;L7IY1!D-?P9;"Y.6D\%-@&5G&>K5_XN=*Q*_;N2G25 MA8BBXN?,H,"C[_E9P3<)0%VU5"!OLH(@S(B
M)9.EJFF$J*?E/%MJR]ZMY#>;')+%F-*FE=)*765,#:FE.IW*UR:\-#DXAM0B
MAQRG5'F.@IW[M=F@<[P(X;#;9+X",Q\FUQU>K0\0W'X@Q*=-5$E0+V:TK*047^3:7^"H6X@PU32,)QU*\KG12'B83;_=&
?K5#?JG-X_?ZJVX6BOK M/WT-_]7 M;_M5(R/S4W=':J0F9:JK.OU0TJE7O,:JZCDIE!T69VA8C+0: "Z=9-,-58I5
MLM&A+;9AV^U80KP*\CV2'_C#H6W3E]8Q5J%TO90HDUE"$W6;NE#V%>#9B;[>
MSY8S5H?,ZBA$NLH)#4@F):15O'&9ANO$72'3:MF%1V2X2@%U0ZL:Q6BV^_MHK8GLS&$EC>/]S?

H3GYA66.UR./Z8(%Q^0'^(",*0E_K]HXW!:,8M%'6%RVSZ%@%,N0 MI)ZBW@@P25OEP!=IC$DT0=/ZDL1 HL["4'}\
(NM!;L4!9IN5SR29H&G=+-UC MVL?I!M/1N21;*?G=A$@9W'X :#L!-3"(NYWN<$>(Y%+?OQH8PJIXF F@54E#
MYO%*!#V8:<>+C%&1]I2%Z[] @&]836;/Z"_0L4,<7[(]NBM:KI;7,(\BG*:G MKHQ2'T-3HNQ[+R8XO](W-4U1?
ET=J:0ARI M#DNYM!*"W35>/RZ=06M29J]R!L7+B\%P8,"3KK54S^F E",@)95L?2919B(B MX-B;/D%P%^&@U-
_('EX8<%J99HV91Z$ZSHI8\27TX)7Q5]W3R.US2?.O&2<*5.X]YZ%S/EM)G92@%* MJ#R2M')6GANP60JX-M.F6JK-
='W2%66+"C-IL]H91=OH7DR^OB8DR
M:;7NF23;J%Y,F$F9ZLU("7!M!>]WKO]C:_X9,@&,^/$%_Y2#=7:V_(8W<>]O'1L9VZ*R(XU.41+GJ$0XAC6?'W&@P
M/#/D&*]$XWM^@RP46G_3&8$R<\(25W)7P#0:2%1KGD,5,$@^GE.^2YG9>\"; M!9[MN"#C@+_ZC.A7V"@9GS*-
JKP62QDFK;]VP[=CSK#QJY\LRI1/<;?9 .K6 MXT0W '7;=LK(DRYRI P[+%)?)E+_BM4&L >
ALG]8FDYD"QL&9Y&+*AR)%)] MF*3&_RL/.!C;-@1$TPN<:/M/HG6<"#&P_2B^$OD$P<*)%L&]MP*)DF@^5:W&
MCF24 6#3")/)13%,/S/'V3(ZHRI_?2IW)6"Z8S!#X".YP_>1:<1X0\HXVA9AL ME8]$% %8T]#C"N(IMY (;
(BGAAL0_V*WN0TO&*ER=Z :03D73\VE+3UN;;R M\B.#3@PW&KW 694D5F6IF@%M=#
(8]H=:Z=%0W2S\802AZ:HP:W->A;Q&2HDV MSLN825RR$[0PO)B]=F?)(@*'IHO#BCE*>:11'@[D)J*5S/0F$6?SVIT7YT
< M!P&@>O'U&NLLWR3 TG2B$TP_9DOUC)/F3V;(R2PD$&.MSC*EB?R2EVL&>,V; MJ?S)6M?R@Y)ZG65/,P2D7OA4?
@Y8B &,D!".]>:X9$7+0Z"]JH?)(180I-[7 M,X!&V=W>#1JTZ$;F^@=(*!XDI%ZE,F!JPX$>&,S?G/#].@I"?P$@/[=*6SE
MAO'C(?7ZB/(P7/9 H\9A>)UG5T,H!%WF,.2]4 H8\8F2I-A/SL9-(Z2@V$\1 M*+3^.0*TC-G<+K3_B!P(,H=+8V]:=9K'WD
6P%,$H-X7"B72HB!VM!E,8O?4 M]4^G.3B^6O!W0!X4W]WR8V5<4=TCV6HA)'DOGG=VI6R&(A1M *;!'8(8'XD'
MD]E.0GID#%?=@R10L% >&)'& .=E M0C #-&"I..F9ZQV9Q8V.H!L9DG.)5LI&-J8]0!X%PEO3^(6I\C>HJM8$@CYS
MD)14"J915S^$\K?H.3TI#*[X4!;VL\'P3._+8J9SN Z<4M\64'X:6XQ;G,#E MFX3"Q?:1$O0+-"RS/TB5C',AYD_L;3?"F;-
N/^QW_)SF MLQ6"V]D,4+>)U';"-/+S;B<9@):$,= BVLM@\4&3LHQC32,'\P\Y'IFV#W:[MMM,E2"\H>G
FZ/BQ$31D*%JVRU4;1E%10!J.V/9 MNX4T>0LMQ\,N[V:VO,A7W1\@Q:-HU%=6N09)AH5)>_;R,POBY.7N'X00?!H
MA>C/R>PJ"A D 7L:V=,3]/^]3[U=4^@?<6LX6>S;KCTC4\5.X-SRDF0NNYRW MF-
TDG7J+%PH+KR>S%F7O.S+%QE&I\]1$_N8"0M7$B&V]Z905.@'/2 M[#[/84K.\J8D^3*V)<'NVSUK^_'>,OEZS_*FO3?\?
5QXF>V!D<:G ,&*Q*@E
M%13[LF4\>$5*OG+I)_ALE4TS)]7:RGBS]654$N:AQF[<60XD3W=]1=X4^G16UX[RH+U7#N[2.::.:13_I
M<&,\O.SGAE.2Z.#4>+*1PO7G:5@\$"G. M6F+9D+3;K)!]W,F;Z\QY=R.&>;-"&NOYZ=:,-"NDGU5>PGXAM0;C 00! -GM
M]LJE17DETP9TL1;2H[>&/$K>GU:TG/ 7"R>^/1J'C;+(YA>U&P8MA] M""T#64,$ZHCD [9[UT]NOFXA['B-R67
2D3Y^2+%8QE MW.8G/"JGR!_(M&KDQ+_K/+EWM.WO,W!Q9I5K/P@#9Q]PD -1NU^(1D ?(XH=^G@ DTK.;H].3@G@I
M$/9^1O*_M)S2+,]M"+L!4G#1EJD6PMZR*<,-@!4V!IZ<;569+\?5?:!6MZT MD5^EC_28YA.JW:.5W&'\@?P6-"*?HC?
7L20+0AQ3+?;6Y*&>_ZN M985K KJ$90L#EEHB[KS3OT,;>JS53!F!G$K8WBJO*V*'7/O$B7BR8+A^16N< MP+(S(:
<,0[,@9#!IM;?$S?;";+M&3J8T""HFU>IJBN\Q4/K#OK[G:,&4X<^K MP\R%A(;BMGMJ;A)4O/DMHZ48(:Z>G,F(+>
[]O.G*7TRU+@+#C!$+!Y<#Y _U M+T>#B\O!:#A2;602,NSU<1W_665?V"IGQ]H0C37-C\WRZ2-O9QJ(+ J[R0/LGZ/\9+
[/T?H[; M-M:E%'RK94O$X=GIQ1DFC7*W\L5^!]/(159QV]'X25"T_DC%(27ZGT[P.\81
MQ+LUQ+DB^JJ\]R;R&Z:9&6[]Y@V-?'S:O6 6=?V&UW"=YPV7E#LXQIL]"9=Q M_ 872*JG@PN1Z?#B\M3Y::OD"
(5IJRTCFFFJ88&\L:)7V+=2V=:#-G6RA;8 MDUQJIM*)K7%[G6**'#1D+;>U7.KBG7D&^9EG_V:7\9.&M"M>6Z*4?*\/[S0
MZC7G>\OI$E5M=03YG36PN!EGNT[#= >$W'18'3RGD-Q'C3 MHN$^R(EJ$U/(@RJS4E[)-%/"KX*\&:DAL=1
DC.U1\E%\?6\%N,R;S&*[WS(MM@M*+G^HO]JU3:Y&T*,Y!)E"IHQ4-C@+)O=J:4I&H;:'+E]1V\@?V5T[&7\X
MM(,RPK*FZ(U##WGEL4O&H$/E;RJG^HUGE4?4H=U/TL%&7\'B#4#:(H2O%=/T MSJ["O/I%B$XEAHB-G,
(7AE9@:YM>?Z _ULF?J"7\@@M;G4?T^Q KY :2K]M M&J%$D&)OQT@KE()\0%=+/O6-44<.)+A'?Z5-4?F"IM&JUOS$*!9U
U%Y'!9Q ME/#[:-=1$/H+ ,GI7NIP;\VTN*O1DK'Z+E==8;26$-FEKOW.U:[]"N\'\R[^
M1@6+/\HE8>.WA0R\+;S9#$7_=SFZ.-,1.+S;:+U=+%U_#< +@"O'!L6OVHU= MT@V2'_P9V#Y:^_V)Y"
(OB!!AV;>V!7\O.Z OM1LS"(7LT!P\1GA?>//:.^>\ 3_]PRY5*/^Q<59^V(_]%L->:K@BQNIFEQQXT,$QI&/UK
MIUWTC^_7^&(H@"39SJ.U 6A(K1B6;E&@^&Y(:5X!1IDKFN*6KDTE%5L,UGE1GWX*]0%)WA"3L;"&L]+
M8C0*2YJDG68P[\=1L(O;YJ@'P;%Y+;.Z_)*5^-B'')NG7^_L*A0]3EVQ)AZ(7) M>>BK?P6>@0U0F6F1G\#?
2NLY(E)N"6GM=*7/+LQ*QI,QB7O'OI_?L:>E,/O4 MBWM"KE:G+U4GI:8]W^M9/;CI4))>]Y/Y^_URDI\-
+T>#T?!D=#*Z4!X:N^W> M(PAO $3VEXPQK+]M4#F-0]_RT <(7]OGMO&84XW-*S49U='85*I(^FQ[_
MB"]H_/>UVCUN%N1G22V0F7A%E9*IA[X71J]@+$U4ZKC8(>, S,0[L+GL>'O" M%/^T=-.M29.F$8U3PT7+/<%@&!
(Q\]7WP#I.^'87>=-R1A07-DW7PE659P,' M$+I3XS6??I!W3G)!A""8S&[T@^-%I_V;$W+O(7"CBH,[M2FG3B&*
(I*#EHG'@>2T!+&8;'B16VT(I%08T4ZL !^:!<6_*@S85D**YW<3;KVX1)O\8,K'R/.1*[2.D=&U<"G]4__X(R: M
&+0GJPE@!7T*2A[I T'+K+>]E%__G&UWO[UGPZ 2#_OZP>P F[96HVI4;Q6[^^*A+XC)LA9X?-D#+Q6[\R2EG6%
(QW$/P1H47B MFLU!H=4TEC'&>"=-I:PA4YUJZ)/Q,M!L*.-@ MY8((S:I7VJKJ'1#?RA6=YUP][*2FKKXP)
(XUO+8@7"/<"3)\(:W9NJ;QKY[2 M"[:G:PNO)/>YUM=[:9&*!46S")TAA$XZ00]F68VZ."9O&N.=OKK*"SZ!11V$
M^J'EYLBQ>>JX78_'%]_3+"K)?;OL/'^[C/&=>;YGYNG-XF8H3],.?BM-PMOT M&M/=%_:K-
'<<2UW3C!J;SBBYX3G%9+B?,^Q 4+1^I=974<&JG$-D!@4/CI'- M')$Q^JG$H_X\>:0C8\@>-
T<<:G4@I7ZE2U=;GBG,L!BB<6FQ[/JUSZR*O!8Y MA6QSYBPMX>@M)T<#D8UY0E)J<'@?"3MHJW[YY12TMZ%E_N.
[VZYYEGE$Q2G MK4?CLO)]Z->]R 4CI]0FWH8U.FF'?K9P:CA/$>%@&+(H$)ZT0[^NA:NJX)R, M'0A#]"PQ]
<9!:)P7C=9'3A=C]E 1BU91RS3BR'O!E[*0G"]YUQ2F!-)8.:-=8Y M'DF 0VI@F/(ME[T!M8?W-P\"R\68X,>IG_!R
0G+=,+*UE3G""<<# D9-O)) MZY71+?66 _^%"[;*IE%*C'_>0':ITY\A/CI[V#-S?=-XU(!K/XZ*PI2?7:# M]@JR1IQ[QR!;O=-
\:@2"4?H]!FY^C] M:CD>=O8H/DY%Z2P ^U7^9HY-76$E:KM2]USSMYR8?=VW]\0 9.%Z@K,? A>
MK8]ZFT=L;9M"N#I4X=Y&:@")5%=(^6M0=7'"*I%%RTS;1UJR0=+4I1K%M/3
M"'^>2LQVW5_,IBR(CTOS]QFS3=>XR7BFZ"9C5IR>/R.MT.XV[G_L$&\UHJ$R M')Z>G_3[H\N+BY/+RW-3'B^3=
<1HJJ=8JA$AQXORYF>=,9%,48Z=I "#B(+V M$;)O26M_/CHWU65_D"I98C9JM]E)+HE'1,*AH$('"WF:, +3VX\E\((:V1L&
M^>P-29,]D+1IOK^1]#CU=O)U!#$=JR+&JNI]3]YW[9\.+D=G_>%@I'R[X7:Q M=/TU ,^ +"?
R?:7(5EDO.QB&@^&YYO/;6LK(6XAZ@NMV-BB;D DHR*(!A"0V M;CGN[OF-&/ 4*/+NN<1N?6O MYR0R/T%_!H*
=/X.5,T2Y96ZQHT&4K?^M1PJ=KR^4<=)P>?(4N6\O!;-'LLT4A;/[D6LC7>%.\S$-_R:HTS_)1<H:9H6
M&7245VQ=.1FTK7SSGRH+EJ0TU1E#3=.T75=Q'!2H$%[,K67*$NK%F7I@_1)" M ,*+
>K5\#RV4H7WD5FJM$:!%;#O+:/J2*U <\/SN$M5ZLJ6Z[2.&$05DPZ* MHI@[RR9O$%P,_FFMI\ ;KX"'7V&A*:BL?
$<5Q2URZW=@R1&D6GX M)V4[HWIVZ1(&7!JQDA3,@-\ ]H_!=(S,D34'SP#OG6U^^0K@XI2)'-7-=)0W M-
05/*#4R@E*4S8E209'!C-_RMMPK'T+_!RKWC! MVJ>HU5 6MDL$VWF[^")8 M],UVUHG4>4C1%41_L7#BU ?7OH?
AB=_1&'O3":Z;"OCACH.Y*'C[YO_;L M] ?CRWP^_F;/W7W4_$"9E$CX_D9:)N8$4%QM?%=^O)]*Q.N[J.OX40[\P#:$
M%NKFIMMXS4[Y-7G_"74=<9;UQ4-!'S+-=G%KNL!15@-2F]]2PF>/DUE*Y))X MH*RIM%&D<[S9&-'I\U\R>-H%4-7FI.?
LQ73.,:NZJ+CP.:B:R00Q>U&8N H M>"<=9&6Y_Q)]%*<8>>K]>$LH@7.$8^,_MZ+6UM&PG=YE$3*.F,4BADR,10*/BU
7P,7)#9YD[EZW;S)%S8B SZHTL'I9] M=5P0A+X'GJQU'*F3>(C,!*.V<.168[1$I>: M$6="6D-=>W!L?
*>$(8ZGHHIIZA.A@CT'LPX"!L9N@0CZ-D2>==8F;H1Y_8'^_M6"=_HI9*TO'4;.H J"(2&4%;P,? .,YEI@',U.:_2 >UA-3:W-
]G0')KX=0M M^/X!7B+\YH3OUU$0^@L ;S]L-\+[GSA)!_K/E/[R78V63*.>= ;D22<*-V&RZ?GJ7X%G M8
-49LI#)WHK1V()0:P-AV4T4<=SY,SBQT*3P\']G?8@+7ULTU,-/5DP](I7 M%5(_>"2N:G EIZ0Z-^!4Q5\A^9V
NC_P$OKV[T\1M-^MU$]K','D'IJE"\$D M?>K%G2)WR)-N[0KV_J>U6/[O'NE>;]._U*^[<7ASO!5>.E>@?R.I"G(2$-
[A^M%:%+TR02MF"B,4:WA'+2Y@VD:, M9[#_#T;L&%-9Z77=\N

M*FF22IOI)A=$Q"RN>5K=.NUC!!58T8[P2\N:HEEM]IX?'8T'-!Q$*+3C%:5- M(0._3ACT6<=@BU!.*L;U&?8^RJ%ARG
MI\)7V"Q'4L,' ;M9YJ#R_>J56U5=TQ0J0BF455TM*"2DG6E#"&X]"I4P.=5N2D*!5K
M&P2XB05[@FB9Q$^>XG:.E!*$F9(L%0V)-E[@(W@\=X.%$RTF7BPUW1R55CAT MZO"#(^@!R&-D>5[):?
@)PYL.%Y=E@\N8Z*XQF*52K?E=4T6(=#^OE$;=*]9EK;@6=AX<8EXI_=QA M5Z'@>)4J8K0A*$&_^D2HH$E00O7P-
CJOU"/Z?0B US2I5+:= R"),%C,NZU@ M6D:R ^8/&S+&QVJLK MQP]L!W@V".X]F\7V%]4P25O-8*<:=F:QI2I._"74
[2Z_.B4S,EU3:_2RZ6: M-_2XL&;0DRZS:=[E4@,5RVY<5=!*OS@)^A/ M(SN M@>W//>?/W/6">HT<,,T$ B;HI/
0[0/BG$2@&O#;3SUE\L/CU6-<&K#33LS M+I&33A$:3B*X.QO<#[MK@$Y-H\1VH#L@#HW"
<^;WR2$NVZ1IY'LI&,]=]>SCMPQ5&X=.W/'4)]-9%-K MWJ I0D39'4-5X0WZ9S]%FN,-;ZA6N,EQ+R+#
(/11A$M3M<(@]&M9<>R$$(%HXG!M_I*21 ,UE;?*='K[::P;YG MY&N(+49QIJ7ZT*=3;4:<'QWCKN.V*R6(?
HZQJSI/$Q&BF^?X<]]6QZ(K34#1 M_-NFL5 $DZCSF 8HC5OY'$K4N'XJ:YNTI8-*#6O2?P**@Y+#1Q!>1Q#KA^,T
M];8IID^6QYIQH2/H-AFNA>V MX96B^.;0MW^_L@* TWPM 0(2-YS^^^T'_BO@CET>G9SF8I?
QQS[AV&$E!RXR&YDP[OONXD> 8NMAG7?A &Y/DR(O/F;@DEOEE,HXBT MP]'9V>"T?]+'+]%D5EBJ@Z))-
W/L2@_MJ_6N3"+*^(<%IVRQT W;-\T 2M!\ MWN3)1<_$)UGNT=2Q0)8.88@E>$@N5Y=$:Y34,(TSOP$,>KHMZ/YXN',_!
(+!HG*EN%W5>7W#JD9GB4#HR;:$/E$SBF3)9 M82[1>O#\H*;M:C"4O6?!LY*HC-61>YJ=,(UTU"0J6"ZIP,60^
MN5TL77\-XHV1^+6RTCF$6MXTY2M39)Y#?!@90@3D%X70L=&ZFW3[F^>$P?/+
MMRH7DE[G2(@&.$D(U5$\E6%!TT!CX$K)5%+C2*7:* FZ0**12%58TZ!^J B2
M;MZP<;14[&1+0I!*6<5KKC@M);+9A6(F:T?:8HRILG$$DJ/0@N59?7@DY[]6 MG&ZI\#ARSUVH<11YQG$4N?M:7
K]Z'@06>LX:G Y.+WLG_4O+L\O^Z.^^NV# M=AY$ZK=
[$C2O[""RVBQJV\XZ[EJ6JJS!KJ51:N[4KN4(.;L7QUU+&BZ'L5FE MGP3*%-IHL\HL4K1FI\ >BF>V"0A:,CI;&WI;O^(T)1]
[Z$!%Q&L)WC!^/IN M>?&I0?#H>RLT','TV7?=.Q_B2J))6JL3QA%:#L$$,ED#,@0= M3-.VWSLTL/Y%U*MM8&4_?
QQ86@<6@S+$9M?0G^Q 'IA(J3/@Z!Q;N1X3.H2F52F[*-ZE\?4;<.;OZ'_'R!^VYH#X MWS?(NMQ9#OR7Y4;
B'T_GEYV9B8T<&.PL1Y:>>=% 6X&#ZW.C">%-#=S<.K: MJ^R07YK=GS)O6'/V+\.(LQ/$B/YQ;!LTMD6HTZBP.F7E#F[-
_QZ%M M]M 6H4X)5ZLZ.6LGNW,18KUYXYJG<\=!;?:@;JQ+02FG.S^BN[>R/HYFXT9S M0TU*WX_NT'C>),"VW-U-
J*K;)9YO^_:1R1]X/>!X\W@Y M<"J:\@6?Z R/)=!+(/E9D3;;ST('_WP/T%8^9*$M.\=J<]#?;5J,-&_D(9 /"VA55?R
M(UR.YH&H[<1QB!@Q1-AU4[)_M3]N=.:W2>5%#&HDM^ES)+>),]HDWSIFMFF8 MWV1X.;PX/SF_4'_NV,K,-
F>G:%B>:369$C1?L#J3BIZ)UUV;9;8Q@!=R55:P M=*H$PT0UU\?&O,PV!I"NF@0U=GY$X6)
($A,Y^;@-4+XR199XYDP8&4*$Y@<+ M:K+9F$ MQ9.9) 3;GLTF665-HC (+6_J>'.)MU=*/V8<0>401B S^>%LI;_&
M+KZ[8^-Q_@$'9M<5YFIVE]D[$AG1H#& MO<(+Y:/V@9*V>@XK'PSU$,_ECP?0D:8N!X<1YFH4299 M)ZV(X7E2-
E^9J,?':A_3=/ T.7:,^'0>4(C=/O)8XKH>T M9GRU=6G4T@36I@^:1@HYI@PIV8'4,+H8OWZ#0<
3>M>^16TR1Y3XX,T"Y(\=4)RM2?X#^V4Z*L6[JUD=%4%9$ MLQZ(>JN&^HU[-!?!^PK@XJS,G*KMB2F\KT]'BA4T $9C
Z@;8$.?(6C8E.9: M4MN3(]GEP2AA-Y0R_8_G5R;7GF*JP7; MQ.2V!Y].\3@0#-$ P];$9G2H29KX",('/PCN/?
0[@.0@H/#F23P].3G=SY.(M&N[]C/X5_*7GD,9[2P![6[>_,2(MQ;$NTW!!I *UXQ6'*>T&UWV1_WS8?]\ MU#\;#H?
ZDAF.O="9.BYBP@J- #M";', W+Q);1 M4,1'L@/G7/OM9B[M%GB8\L$Q<7>_H;!7Z^(&RG(@RONB:914P*D\D57CR\!J
MY3$NQ2)4)ERLJF8:OU2KFI5L%8@9DDWO&?F/T+'QVPTX_41I2L7"LNV@0X4R M\CIEE]5,17Y#GGWP_/*-1Z'9.H>A6
:9#4D_*"D!:F<4RR?)Z MJ$AI*JIYTRC31I^R'$P)9TZM8O)XX4<>;<]"2-NF<5@JG82SMP1#J9$ 0_T[MC%=6X-
AC;WJ#TG8KF +,UZAH8A]CU5@1!2B#=8I]VS6,@)A20N MC$1?8=>3@#$.0^B\16'LE.8CQE(9A"@$;-ZP:59-$BDE
740?ERRK953 9]1 MI+5R(04@8JH"1A'@>;8=JE[6ZQLHBTL:QISFFQZ57KO36^&%IL8Y==#]^5.
M^,^H]J1TEQ1?)I*@K$KEJE=S;O+-0Z+\0%\.@?<4O;F./9DA$>J6I/F>G[0O_5B#+G'9A?KJ6M_57^F.W@+P1X38<+M"?
Y3&3A<4S5)[M.!CV1_JNF[+AFQ^VS(()6KJX.D[HL9#.U+'@^L4B;\+B#?*2&&5J>5-4SJV]
M8L6SR]AJ[>_DPZ%5D]DK6OP$:$0@$9'1.T;AF[MKA_BQ3!#<"&UO'%N%023V6\6WB,))_ 9KV]+)@MJ M>>,
(47^RX)-1T.:1%G-0*&GI+%%2PS0&*F1D09FS@N4Q1+BV7!=,K]:;&3@IR+7>8&\UB_P%0G[8:JY)0$-R
MOG+U^]R[G0"2C;_"8-&*=XPY7&(*.JPTAA*%PR;S9,/VE]NQ0DN95:NMCI%) M' 9*SD8;KJ*STN*WJ&*)GIQ<7
M(^4&9)LS@=;9JW7F-TQ)]#C:,LV@U-)9@6$1AH6)J?%>4=N362I2NN0,L+"L M:5H7IZX\%=@!,%'5Z7!XY'H]H@[M?
I(&J#0R@+,5T^C!KL*\^D6(+B:;&&7% M\@@BZ-L0>4[7OHOTYF,7: 7&]# (H#0&JWDY7V$DFK]S%*
M$F,0R)GLPR]Q4LO9G;\ 4[:K8$&B(2LD1O+9= M@G3'2R."\P5-TWQ#[92KN\[J MFFD4T&#&R[&0>K-?
J]E/01"G!0XRUZKX"%74@FG^2]3U%DYT\AR"S6=R+3(P,C0P.3,P>#$P<2YH=&WLO6=W\LC6)OQ] M?H7>^\PSIWN-
\;U(<(=9 D0P&2'2%RTA%2!+2*! ^O5OE20RMK$-MK#I=4XW MAE*IPK5C[;WK[_\W'^G8%%BV:AK__)>XQ_^+
4,V%=48_/-?ED_E__]?__^ MK[__OT@$4]O)>A%33-D= H,'["&.1Y+!E8"EJ7J.I:T5&4 M@D<(_#Y^C]\G&"P2"?
I*2C9\U#0>5DWNBY9D+5;S@$^AU^%D[)XDF<1^:QY84U4&V*/9P_)IV%B.D92$ M1R-
]AB0C=#0N1R2)HB(*$8T!)@KZ?2D8^="!BP47S+ ?7#LRD*3Q/[^&CC-^ M^/V[+]F]>],:_Y^\(;*VBLJX:V;CF;S>
[G/4OW6I,X3OU&/_?@@JR:SVUU MI_6,6K4E?K=+15X>@I$440W;D0QY\Q3L4W'6#VZ_@OGM_[AJJLZ=B WDG9?
MO^\'YO2W:L#A +10OQU+,NR^:8TD!ZXJ[(A@(G@\0A&K?FS+.5P ^.7.Y*>+ M@;7SIJFYD ; KN\J_6%/ZPLR2J;=
(D$7NI:[]%\, Q M-!")1.+W'"%RU2N0E>.OAS_LO'Y^@,>=/M&O&RB^ XD07L>G]AJVR @9W8&S M>A3.41_.ZJ]__QX"2?
GW[Q%P)$PV#0?RI7]^.6#N_/87!CT< 1-7G?[S*_@] MXBS&X-?O?_]V5$<'__[]>_5?OZN>J2S^_5M1IYCM+'3PSZ^19
U4(^*8XP<* M'SM_P9?^AC_OM%%4>ZQ+BP?#- !JH,X?4&_\C^JB@(,[R-
LD+$D&4T98<$,+1AN=\':XN5OI@0*5Q$.RUVM%ITH#:30V&1R%)Z3>+FG73M%V9((SC>@$<] MI,S12'40-
[=90TG!_B#;A^Q?!?8O3(5HRGE#%RTPX70N(\0U8%I4HI7-T19@ MT2)>?DX$*5($FA0ESE)\JR;:D2:7*EJ9S#R6CU;
X+V38J?$H*5&&0EWR7B7 MFC?Q)B?,/F=2;]VH*F1?4+("A7=,66M*N@LJKH.H#@GJG6DQ,ZW5FUA"2H@6 MQL-
JTBKR%2FL>_6&>9$=B2#=7FLJM+BT&RG/4Q%W_(9YV4/) K;X.&#[6;H& M2CCI+!.1VE!HJL+@G9-
1@*R.)!WRR'PY_=S,%*XK%J(DT<-' M@FB".9=QE?C@U[\TC5-QBJ+^_KT[P]6,RU /LU1Y9^AIU_(8JDB(A ^PAKF%
MMGAQ*>2,;*DDJ,.R-F5P<9HTUVB#8NJ!A82C(.+)Z%(PS+)D62+;KI:9%B/(MVBA'L.-27JQ-U=JO?_MP^F
UPF!$%QT@!^G96:3@""U)SQL*F!? PA]H0Q9K MS'Q:J5@:H4VXQH0SXD^ZQ+(B*1*__L6AU(K2.!F-?N9X4R[$-
UQ.U98EO0,D MBS.4-%1OUT-64I95F;N,QI$% O28LECF6P.10D..1 @2ZEN?.=YTH-]O!IR!
MW]CKX0XZA<\75CK<(7F,KN:(N]VCQ22&E# M;K&H1-H@U1\-JZS(H-
'6J/>,-79TK%#%B8U:FJN)+.SE5;1'HO;*0H*"]TFV9)4?0KY+$,S-(G3\>>$0=@FO"O9_3GG;=L%RLYT
M'7X@$4^38H5+]4$"?TI,6@6(E7_Q3YOG1\7\B1.--1Z=/NG$H_B"3IO)^GB$ M]_J#HQ/]O6LS>/U#_178__Z-
3+,'V[.ZX!0PSU1[0 ;-/[]L=31&M.1_-_2L M842DD959?3^W%:0N_=[KT_O3-EW+^\NS>1^"9?(FL \':-^+*=.%#:PQI/T%
MXE ;EE &KF7*%C3SDJH(W*%W>8-.> -P:J)#3CF2A\R 0GJYHB%'^LA9>JZ MU#,1:YH"=F !KV5C!O^U"/X-
YPF"KJU^LE/,9_*VP-='>'F1TLN-SNS7:DK MTQM6?ZF*ST> A7G+"8[Z0E+YPJ[:L/_PJCL;#-#0_#\5^++Y6%=EU?
&'ABDJ M_-7SL/V"J_=P;/5^_8LF__#R\OW]^VC_)[QVA=:CZW[P[C_++Z>_7<[QW /H]?*J#RL."W#']W #"" M?
J,.0142W2+@1G.M8-1JJ<83M+ANX#TO>'=7_7+(I3RE_3S(C0:&>UBM QVYTZOHD09RN_F"QDXNMG_Q.CKV2-
";U);88:K>(*%PC-/5 MYG)>;\C7AM#]-?HX)D]?W%__'GOFHDBD(GCT+#QT;1] 73Q0EJ"!L/ECA9NJ
M9<).G455A^]A#86;N.H8C3RY0,2[
6M&DE4=3B'&Y*0%W&]V"@QW)M],V7BV3X..KWEHI62:F&#U&OR]>@Z75BNGKC"%^-@!!DAXV?D8+ZO
MB8@B!K:R_>!?)X'-@+3>5YWU] -PC=LC3;!'V8:VF':81658K$K5T/*KEW?[M^!0OQ9V(: 0GX/].X$ZP:> +/1MW.L?
>DUV^5II7>BH.^'HB D1),:*ALSK# MLO<;RM[?SH]JR>OMC'UH.XVGI;U(IOLBGB6IR3CVU)R6E=!IN2'N"E^"OZR;!
M4Z^>U1,YCLP^@5:%-I*Y\@W[E^/@K[[?FPKOZ?,N#8B2\-O M=-,
[X*B#@:M+CFDMO$#KT0A8LBKIZM*;V3XAMI>S7C0KE*9X*S.4TP.%ETJE

MFRH545W*5VR[4J_):%=="I671T,MPBG:H&,:RA M"1K8>V3+NSU;553)6B#F5^E[\60[I_*5*;!873>]Y 8?%4$?
Z5Q99802$=-: MPT14%9/-@B&'3LBM@R&?6Z@ <\^LU,>I[-DEWIS-/[O&EP0T5/$2)P)ZN^DY M
+TYH_5MEM"3@1,EW7A)"QVD0R@N0F"S[)S9OFJS;)J> MSP3W./0FYF_-8QW8/9H5"M)P%E"
(C:'$0IEBVWR65105=2;I54E5\D9*&JN. MI%\ Y#Q+%@=L8:!SJ98.GLK-8GH1"9U.M&:?+ZW>AH6^N'S?'/OTZ?;Z7IC@
MQ;%_#KS.*U17J!E$%X_@K)RG<-UU4E=Z/'I#BB_TJ;6?\K.YY#N/FXKE@5BH M)+.<4)E:1$D>=>0V'[KCIBMBFB$[?
7J3S_-S*>,":..EF6:S@#&U5",=KXN/ M7*9="BV:;S@Z$4?'$RG?QF&WD@8#L)1+";[=:<\OBC,G[+9BJJ,ZM>N+QY,
M\Y(R-_9E,1WGL$P.$3$A4N5V*R+R^.BIGEW03^EE?1%:]A%&1'R=%A;;DC6)
M=9;/1Q%!SZN@2!B"*:A\=VG;3'=6>+SQB#=(C5-Y!'4I'O$AO?P0$0JMX=-V M3%UJ]N.L3S"C2*K3O2'B*O2([4C Z-
GTB'$GVF,3G,7A$MFVBT)'G72BH7.N MAA81;XN/BUXD-I3:1L3'>82K)..NX<[2@E1,1QBK3C$@?D/$&WC$J8B@SHZ(
MRVB6Y_0;*D2?S\0)@L"!T,A6^4&5!.#G:*GG,:]O'LNS:T87].OTI@-GH47+ M8RWUY'03G5;3N5SRD@LIGHV86&**%G(*\
(9NC=;!EQ%HLHV/+QE.) MQU*)9\1&A+EVD__DZ5\'"MYKSC_#TSNY<3)3+"99K2!6RJ.!0)"Z>.T*QV?S
M]/.4R_G8_K[,T\=-P:[,(FP9=]F>D9['AFIS>./IU[O;)_/TH3JU\9;M&D*E MK!8?IVH-
;S9N/#VD**@\VHM2,ME.:*1""G7R*5WDV8O3Z9=._KV^IV<$6B$9 ME0?
*Z#&+%Q3#+"ESJ,D.KQWOGRW0SEF)\#+QM'V^:#$4'6T)6?=)DQXCECYT MKWV;OTB@A6*W3Q9HNJ"-
%\NL#?!1U&C-LXV" /)7K\I\O4"[# J$7*_.X%6E MP4T6+355(^<:$P^?0#OGY+=R^,\BT+U T6\@^Y@@[>>V _U2)
M1EVF:MB9@Y\;=$*,+Z9CB1L]@1'>X"-5A;]V]^I7B+30;/?),BU=KW3(^5P? M&P7MC[9[AZKEN34QS,ZJ.I\QQK3 O-8
9OW8% M]I.Y^D7&PGW#$^/D&K.33"#+B?QHTJQ&7DL]VZ'*6_< MWTLX5L_+TZM/=P=53]M?P]%#L]LD\O" MFK.-
TL*6!N7EU>_\U_/TRZ! RN@LAS_5HMQH4J0*3-0:B(60^9[.//GW!CD^ M(]!:
\QW)":!63UDV.RD9KCS>!]K;]O81C]IQF/DX344H3"B!F6AHE4 M-%N_]FW^(H$6BMT^6:
-4D5WIJEX$<]6*^)3CI(+:O?J=_[K!=IE4+!8B!&7 M>BK4-:DI4B4^8]1;CQ?W$'_IY-
?.5_(\$]TVE0<=E>9)CB>$06.8ZY!ZZMJ= M])\JT<@+>=??NL$OB[1B=Q0A9]-JGZO,IZZ4H>LU5KWV??X*D1::
[3Y9IN4B MHWJ&T!:DUEI&E[0]7I),[MH]ZU\MT\X,@_,5-TDHBVY?4&,-C<_3F6XN$1_0
MUK43^D534,,7FWZXJW*J,\M;%7> 9XMC5:E&N38QNNWJ505H'N[J@"\0F9'+
M#K@*QY4)ISA.YJ[>??:)NQJ***7#;4UU(^6>(=@F-\E+5DSJ#>)EY[:M5Q6E M<+BK.ML@2TF;XSAWP!OU&(OK
G5CP5=U3GFXJT]S:;(LU^=]'&@I]E$=&417 MN>WJ53GK#WCB)3U]S8J$A4NK)=&%^[R?.)NQH*C]7AMI* $]SZ8X;#
M"RK9EJ,MG)\Q-\'ZM8Z+#;6R,\E24"6*/<>C[5BJ# UU;XZ"H3IVG1=6)VHC
M@AY$VP+!D=,83SPMYV8K?!=+K;T.VS/<]C>^,,6PZTFG7N0LV$KO-SX=KW)255XO^IV+5$NC/):8IK
)YFH51TYL59'")T0 M".&5)E]XF>C7U0L^7ODQK'= JW+/+8U2V0P^&0BM)IO"4XEQZ*3A[0[HMV#_
MTVMB4+5,V(FSJ.I048!L *FEWI5TR<5::?-O %45 RQX!RZ/$V-@RRA= M!)(-UE%05@'@CL0TN!9O*
[5)R4X\XJ'CP"NXG##MU769+\\[[&<.'Y+7:2NM M&M*0EX9]7*X.O$.V*GJD 4G.EF3T$CNYV/YE3^/?_+
*,ZBG!46NFV.A0#=C MK)9H:\7)M3&V_37Z."L[?7&WC8W]U?V>DIL('XKI1K;3'M;ZMN;V-35/5\>-
M>"9TC.^&XH]47#TSBH_?3O"E* :S=%+07$-Q2&]4 M" F*RX4^UZFYXH?@CM7\OPXL_=)O4Z6%WO1)-=Y9< M-
H$7RJ.QVI"*\[8>.H!>0]A=>'32<]PC MPT**Q#N/IC*2K.IP>C$F)RW@9K%38+@KG(Q$@VVUJYJN+=K]X: Y*Z6506@Y
MS>GG4B]-^G*'4N06-LYP*/6RZ?3&L\DH[9_2!1L??XK72HN.7! FG0G3&F@&
MOHR%5DEYZX'D[F2_IUET#M?,,QG.*:$SS<[D,:-5F(G4;''=I^$\M%PA-!G. MW\OI\@PVS,F 47HRH>,N,2R.JJF.I;:N7;/X?
&QHKZG\^-J];4?(,-C)#>SRK2V,+K["6SC]ID_JT&%J%(YS8N'H7 MR#/8J*JS0LLN%PVA8HFB*46(A@%NV/A9SHWG+N-
1FMED4H"&2G0H6F6MMZ!J MT9N^<25NBT/#)".I5E/279!AX:\Y:[#EC? MI-M98Q0N#9*FH?"H$]51US&_%;[[&*<>
(ZH0G0_,,K3#!T^ST&I#I^W+!L(O M;,S'0S).V-$C(WEA2\\PI.-8V$Y*? $,E_,Y7?9ZV.]%K:,1L%"#J@17)GA:
M5F(=O&+D6WC6U,H=>\'WIN$MN'VCT@]3Z1$0_&#J),)"G0+?L+QN%@>"="+$ MQ,F$
UD!%)219$KX0!V'5@4\!XD2/YE$GT?"C4[#0*=9LX!U2XJ246QZHPLD$Z&25KI[D1??
&OU]X=3[6FXN%8:3DGVD#44]!]DVT\E M_<"#D0(6@J$,;0"[TD^#L6FOIG=5"C7>)\V&V")*7"$Z7,CU7L75PULY\?F-
MV=+ZGM^9LU+K3]+)0TZO851D4T2T:3RVEX[ )\H5)C4OJ-'PGH%8B@ M-
Z2C&5'"!UI%DJ>%=&IJ9,-7@B&,1NE/L@./E%B]!H_+>?259F+0[(^B"9M+ M*:DXT)>C3B]Q#9S^)[E-KEMY.O-5
]^>7(\I9(_-H9&@= <(:C912$WGSJ): MN9'I]R73S],.KX(\0W24^:RGEB=J9J*I%_*"RD9UFI29QHBX'5Y^5QK]=+?Q MC5
OXHIVDLVJU>*:0SS5L/)]LO]8M_*A&'1C22\:R>E6?# M+)X=1MADQ6%FN?0UT-@5P?H[2Z.0BHYR2A,9D]/&
IAUZQ(_Q:E"^,IM7S>L M;]SZ*]R"0LQ=\.*C,Q'XA;FT:\MA=Q;>ZXVO$=G?WA,7!K>9\IB7'J=4%W 3 M7I%=-
Y[/5\)WTQ4^EC^\F-QKKY@(;Z([]^<5)E3/;57GCW@D1U;SM9J($\-KV\EGIQ?V M7?
S0A22O7"6&'JY:IN+*3L7B@355Y>T*^JHM(R5S 9L,+&FT?5/8"C7GO(2, M-933GBG#WQT 5OCLC1N+3*_%3KE(;^88?
9T9T6SH_,M?=&L9>NVQ+5[= /#\ M'G]<2)[UIK1WHN.E:?$LCW22">RG#):HUT3;\ _-_!#R?$O6_GG M
ESZJ9FA<@Y!9O!*DW;Z8[[5%*>AC= /.;O\3'LN##IXH\0QW%,JPBRL/C42/ Q, MIY
:+IGAM*KBA5152F9U/C&JW9C.Y\/M; [H5YQ=80)?)]6=--S2R!)&12/Z MF##M>0:$3K?_KN#[J_DM]NS5465K
4OZ7#%/7?SCI^],@46J^NF M@^:ZXV?OV2V2K57IF,!'6UFE5"!P+L25>Y^;Z<;G_NQ4+R?U([HLTD]R'EV
MT_ETR;8K_9:$R,BI6'5U,-QB/54+9%Q# 4K0P-[S+GP$&Y-FIS]UREU6R!*6 MRG5IK1LU0HN-9Q=(UI%NP MB;=
(E='(@K:81,M#*\)H1G@O)CTEA?[XIIPA5.IG9F:$RH%S82H]#TGUJV;+ MH9I%@HM0#E<0.+N>"&]IXI"0U W%
[T.QD!B)%$VWQEHT4I-XJ>[,R<>?Q+]# MM;-'',P_0XUH-9=-W,[5&6'$*"*5R9>+!2NT7L20\+R;&A&>Q(80ZA%&*T]R
M[JCVB!>&R13IEN;]2>XGL?8;C#\1QFJ6SZAEE\YRD7J2X?JTT\+'5UU+[5,5 MB4](O7I7AI133H[9E+UL: MQ,*
[D1+:5KH>6B?RL=*0/)-S/P()E+7U(XQ.K M)DYKC#"N=:]W6[}AB>YSY:!/+)K-15*-@;#0)3.M9".Y4C6TWH2P)WQ_^;Z_
MG);|"$;+K,977&[4)EO#)FC,ZN$].@]E#G0(=OB8'![H4:&[>)JF<#[?G>9& MBK54PGOP'2HY' ;OVTOEC?G:M)>F]]
(C%QDZ*IXOYKJY\)98O505XE#M\3O4 MYQ>4K028-AFF"+I"1<[JN6BE(1+3T)I&X5.VOMXV.EG;TJUQG&VI/8V+L(ER
MKFV5J@OJFK?ZNY?7^9"Z-4_IBQ[9(ZL:F7L"C03!\ZGD]>K6WZ#DS'7>-ETT MF(F2<$D-3\T7/2+6+DY$(;0:P
^MWAPJ!>4Z[X,UQLM.7$TF\I"I$Q"JC;M MB!!>Z7@[:0LWSL\$RB?6J/ S4=?
(A+!P1"=9*TQ#>_3\0W%PI93_7A5;>=F>+2:79*QK)4N/WUK#?;' M2?8K+ Z:)[)6+/DX&.+ ?M3;NM!75><:4/F3@!
7B3T<5"T3=N(LJCKLES44 MY&<>HY$F%^MRC5Y25T:251T..<;DI 7< 78*#'=5QZ67CI?GFA/)XF2WFFLV M9H-8)Q-
.Y\P)<7EU@8M#*E$*K7WP?7GHEQ<0IK;1286(AT:$94,O$U-& M
&3$GI<+>#S3#:T1\XUY*'6ZI*>^/TI7.1]/);/8RR5'6L')X?4D0363Y9N$
M/UBH&RH_6[+CO6Z;SDQB+EZ(MN*S0:N0M1L_FV]^OF3_4G027X[.ER5[+Z:. M\TV&:N-9IZR-AV929(0;
[_P2R7ZJ_OD#4!J@4^X,DN5QOA?#6X^)>G/6CX_8
MV<_FGY\NV7\R*I^7[$FB&:.BJ>A0XVF]2[6KME6<_&R^^262_>O0^8I7_NBM M;M[2H*6&&^3U@L[9
D01DT=]P";)EI#%S>43(3>S53R\7J#C][J],,'OZ?U^_M#PI>ULCR3VF\^=1)/VF5QQS%\J)6()SPRKPOOJGQ6I"0-
V1S!%DC? F:6]&4 MO:?V<0%0[\+!X-B>TSOY)V;(V):A1-4R(6:UNJ6I*5(=]&:Z(\==A%:N?/"_MK'>P\MJT;X@YCI@L,(
EZ7#E6&6D&BHD.J_P^RYF%IJ:MMJIQT>M #K3)V*H M9T GM)+E),R<-/&?B)JWWB:K-OKY1EW#':V0I*BEN%NH"
<:U29O;B?N'-,_1 M]$D;N4F%Q '1XKL$6>1'1&AE2K@TS]">:+]#\RR.<]0L6XUFM E'=4I*J>\L MGJX-![?
8A@MIGATE%ZVD[&'9]L=B8X\E:V"$]I(KVO0/*\9,:=IGG@WG08N M7ZGAV?JD-(]/Q-Z@>=V8^7+-,ZRH>:OFR28>V=
(LT\SA+J[KR:[^E!Q?_G:& M[Z!YAC9.Z4YHVAVV M0&J.NT"
<"WFAM$PUKXT7W"+"]I!P+LWS*2=E$[5XIXU'J7C#BBT[F58SM%PB M])KGE2/F-,VS YX D;6-")>M-
4I%P>QS<3JT'.4*-,\0H^:MFB?U9.E@U.:R M7*30B32E?MD1[-#ZPT.C>88YCN[-
FF>OKS.YV9S7A5&GKX!A(=E^ZH:6/X1+ M\PQM1- [-,]XAXR[A06H"ZD).5\X<5)2EM?&"VX1BQ?
2/%LM%I3+K>+.&5SJ)J%_+M)5L)+3;"I'F&-+(2712;28'%\C<'(P-+JCY; 7OWR!R*M:N)=]K><@ ML4>K2\?

=4J4@3!:*5:HMW'PYO%E]H2:Q$'KE<4+DF/Q3M:5EDU598I7N9$2%
M3HI]Z<+16PL7O0B)%6>=6K$Z9.;:I%3B^J:V=!GU1F+O)+%3]1WJ4HKB'E(*_MI$4" $2-
6T0,LY&HIYW\\N)FP%4MW+;?ACHH\7L.$EN,:DJ]/BN6M6C5J#RV M^Q$NKH?
VY"#L)/8&_\YE%,4]I!#1:IVK/A5S@COK26[!J1:5^V$DL7 LW$;\ M@U[:Z:64I8*
[LSX1M0LQVGZZN/UT#1[%_:M$.EHM.E";R:&P2&0IO29Q\TXZ M#
(K2I]R?,4OQK9IH1YI!"T[,4%+".4!ES"BT/6;4;ONL8OVX#P^/"/[[;R6ZY M'!=+T9X@&16@E'-J5VF'@5=]^<(%;!VN4]Q?
JO0\(1F9G#S6)H79W(A1&;EX M^7O>W\HD"#Q"QL_()(YGQL2+2R%G9$LE01V6M2F#B].D&8:U^)*$$M=0_55#
MX4G(_C,4R5)$&Q48LL7' =O/TC50PDEGF8C4AD)3W;I[N6E I\6JMDF31.P!/O*!%]J3 MOB.69XU:U\&?
9EJDN^CG:ERKD\@=SM%UK ?4_NVO2R/>#;S9!1U^F@6&.5.-8MZ=NZ$X7 MOW='?_HV5"US8$DC<4DWN
;^>UJX<^\-XQ;"^FJT(R5E.B0'/I7*K) M&?E<:G8(\X""X<>77_A;G3_K3)=2P:V_^<02(K'>.!^_/LW_!=F.PL=\J^1 M-
(_,5,49/A X_C]_C25%48U!1 =]YX&YC\$160(O![(^'T/5D'S*D2%\:J?KB MX;\I25=[EOK?
N__F@#X%CBI+\+,M&7;$AGRL_]^_O.:VN@0/! $[U54#K-Y# MW)/QO_R!/.!C!T/_C_K_16^4CKZQ
54M&RN#&58W1Y(!W^9]@]YZ\$*O(VQH M@?X_O_[3,&78J3V6C)U^O<\/AFF-)-U_=N:/+OCJU[\-J:<#S.QC*<2*#0=2
M&.H%;I4$_S\^LF6R#B3KH6P0< 3SOWJF M!;'K?4&A(6&VJ:L*]A_<^^=Y]+QA+Z-;P_9>#/]&#\!F.BO #$>6CZ\(-ZN':[
MSHS^[NU"W7L.+N3TD1-'XKM@B M[HD$&+V%D_4D61M8IFLH$=G43>MAQ1=6/1YEC-ZK[Z/P57[')',/>_8Y#90:
M!EAO ":YCHG>Z=/\9U'^5^WZQV<6_2#!92KU$N;1%]2HX%9X>K0J8X$154>*
MP/O,3>!20M,H,+*HQL_Y=ZD']SG6"/3C1ACFW1G"< M?(C3J6,;#;\=Y:0=2##W=/S';,&E%_RW8QVA!RI^'SL;29QG(7:
(W#?D7[:* M(H&U[X_+,_0Q?/-_-+)=T=E'9K#SSR\5]F$#&0HN4^])NFXZ/7/^ZS*2M>9Z
MYR3ZH@[&IN5L"=E1S;27>*S=$OC"O%Y(TU:G7JH=P\!J17DP, $FY#%^,8)" M]|\>
A(Q.KI!P!'1>S:R.RO>CV[72^I%36#K#:Y>[&!UKEJI-["J4.<%MMS M&A4,FE(-:"]A!(55ZAC!_*'\B54R6"/'85M6UMK"8E,-
]#.1H.BU!;,AEM^> MV/I"@S%^W%[,F!;F# $V64$*_WK&(#TH!S3%;<_Z"@,=*OZ?_Q!1_"*
MO_,_H!$^JWK>E)"02\";$O(#M^"FEGRI6M*P),,'V(%>THDT.U$Y%ZUS?"EG M1FBU'6/3L_?H)?
1/T$L:=;;,YSWMXVH4D_A'?5.!)N*L4;121?J6.<)$[Q_, M,8-/G^4E/F'O7M(N4N9HI-HH] GKJU!E,%RD:CQ8$9&?C*LO?
&+5JL M,,N&DNCUH\)$F=FQ&4V.N.G;="8<)R)4+$HR-]_RR@::YD ; PAI# M #51X$)9:]]A>4.^OQQ?
^*B8^8.;2[+C+0R*6=@L"";9F#T&,@IP4S#5P%3' MQN2A9Q;_>3N3O/&U;[GK07P""P9F>&)6(F$CW>
[0HQ0A2E)@^V2,)&4@4 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MWWVE'YJ^9XZMR:D$<%GV\Q5@OP"6&](\'^04^05!MWU5$,7FLDI#LV$\%2)5 M)Y5TK&$!] ;HE6]",8VJ/N 4$2=?
QO$5,*F/!@#^X7$,S+0PTX%&._;D6JJM MJ++G;C7[WOJ\]/S?/>OWOZ^V4K=YE/OX M, 3S]_5[_AX+"KQ:9\+
<+B/!RN;]GT=..\)-W1] W%'6=W[$71D=?M*JA%>$ M7VA9O@LM75S#817% K8=_*>H&H#8W1UVA-
&^],"&.7_66J;@QXK5,&?&UDI*93(Z;<>2 M=6Z2CK=)K=33^>3;5K((YGXNTGF6\.LMQ6"]/(VO8E7ARZ!>MGWF
ZCX8[IE MV%DN.Z$L<]XV9Y$B^Z9%*TFV+J "'Q(1DFXR(\4 M>IGS68R@:D(JTKOJ>,?S(=-=3AH;3)GCV4Y+>
[+;I5(>G2"\S6:$XR&)F[D8
M+#4Z*1U;D'VH8TG'P!S(+O):PJ^AP@WLFTEWW:KDAV$"B1!#5'C,Y/JDR/E^O2AQYG8!U66 M/R\>CH9N_-
&K0],X#$=KI=*%D9)A2UH!%#)359E+R=YA7NA+XR>91(2A:/QR M42JB06G +LWO)(#5A
P<:N9;LHMLLQ,=C"\PP2Y!^] M/Y%"@X*-6=EYV(F#D6,2$<,54<$3N$@G8I38@P 0Y01@Y"@M4?*Z3LDZOJ1L
MU>*EZC#/"@N)34ZFHE)+,(/@K&VG93MB3:U^CXEK%;ZVF"TC-#Z*S!!3W6_) ME]DR59G%A]K"F-
N+91?,RNE:\SRVM)GC+B9^#\@8?\; MO\=Q AM+%C:5=.3S_WA"W,]BA>'"2\!G?3:
[!DO4&>>8'*V6N$7>H"KCJ!!/O\CISHJ]<('0V,ODD?N/U4HIKW>% M0D2L)O"$22AI]A7,E"5;D2;/H>:E)
[&L;O8D'9I7.C2PL))D:< Y?F#\>34P MKC9+;']F3Z[MJ/W%R:?ZO_Y%M?5E%./56V#R$,@:!I_5H%8!O(O9/1:FYRG
M/X@_L:%D>[FI"B;I.OP1I6XC*WKBJLB&AJ9S#P0-8)]K,YI"@5U^\G%@3&_9 MX"ML(@,;_8R2CS$%_@K52=1T;
$9>,HE06)>!1$;^P/V!XD(LUVH_]A#$R5> MK5* G:'D{(]])NV.TLNO]1X.YO#G'289"O8'Z<^Q!TD1_MY[0CB%[;VF\"$T
MBJ ?E,5N>X/P!BG9#I; ,45:V/?8:I\O?KR5VU:F BS!A.MQBJ3Z=%D^BU<=."NO(N^5P\]FZG?@F-$6VGOZ\.G/+Q/
M&P==0"I+)!)_/=O1]MO\PBVK_Y3-X--E9W!0J.!P!KME"SZ!3QP]##D?UT#4 M! EH#H.)#V/\5NF@90(?8$!J%
LL#SBR)+LG1*F)4?"4"KZ/E/9]+'MJ*N[ML"6-,T%ZIJO[$7U\I('|@38T]A=)D?=! V>H>EF:8Y2E>6D.XX]WS3B
_>1OV0X"1,A[T!3))E2/T0WI ^$$%82.(>_1:#R(H<_<$>0;8!WV*MY!TD MGA%'Y\JX9(R0@:/S/654O5\+D;0?
8BY$IMVM:5[KVVQ71]%EB@.RVKV7J.'R03)4V: M99\2R5&RS1L#V)(Z2
5^*@N5DFW86JHHM]I$E.&Y).J3WF])BWF5Y(?$2"@, MDV[F"22KQ=9 I [?SB8Z0!
[(Q:06F92H>K67SU0SJ.7!VR,92\G@#7(]TC5-T1COA0U<$1J?4'XZ]X- M4]&S[\.,1<7/7H2 /__L1?"9XG==@^.
<*+$ZE[@4+SJ3+^%@B9ZK7GNT5JT_MDN)Q8_SM,/E\IGET"5Y!R1N*V%Z:8YXLD+Z$#
[V^N.S',?/YK.63,'.OXC)Y>J0QPO)7FHG(T M:2E+NA$Q9B+U:C!/^9@G]/T!&U_.(!,7 'OTQB!/Y23\<_[I:V"4'V<#ERQL
M[Y._M\!)UX:CM.TU^9,54.B6'(42R,4H&:E(%;'?JT'RI]^$]UTR.OWNG==C M0:^#QS_/*"]A9%R)R?WJV>./-\4OLP@AY?#
<\4/%&W_#W}?+6_66]V4O[@; M/K_4LIFZ$N]IHU:=*N=&T0C(#D3ZW7S^^,'_BWQ^%3AYF=2ZO0 !@CR,#^B_M<
Z/TE:/A@^H_6-Q0UZT$-1Z#=,+]G%M_PP?#L>_<>S(]1^FY;U+7Z"7SU3X M:OA:S(!3-9': _F
IT4;DB&KDHZ\#*@B)FIL.Y*A2)9B8ZC6BJH\EQ)(_2'] M>?0X'ONHG7;ED5Y>K(<]!+J^VF[L#
[B)7L2%7R7_Y7B&/^\Q%'AXQEB;K^86 M/%J,'2;A7T27REA1VIB7-+",4I&:/138V+LN7GR>*5Q!?--1\^T+(IH:PU56
M/4*EZ3H>)_!8PE"R@+W"JG68EB_[N3:VGVNS3K)99]W +KT^[M"%$;";BNR8 MZ#UD_Y#2/*B!@.89KR
/=B;:Z@^"@7X0>0#MB3Z@Q$?!VP_2]= "2>=92)2 M&PI-51C\VKEJ$D(Q,
M3AYKD\)L;L2HC%RL0E0'_=C__J7,T="D+TU\-*->&^(ERMQYSKJ2NJ/=:EA9^1OZUHG7#"^HX5
M>T,NQ,YY+/KW_SJI*(&L \E"-7&&J[@JTMND 8CXI]Q2WP'6@Z3/I(6]"J** MWY/TNCC!>BLH/T4H'O\?;/-Q$VBT-
1H4NK5UQ+USP$'@]V3B?_8"N%9?OG+8 MOE7& 5K@7J;)H(#37@YX:<&$OZ6S4-$O;&@A#O2?ABD?U4#09XA2R-
#TG5(BP5>097NA=Y"AIOP8 MNDUV52_MF4)!%BJ:I>:GBJ-C@R-^]\]>M"0X8J>@^;VN@+(#UK=B8
MGSJ#DJGA^$88@4=JGIB45,/+[O&&K =#MM=#]G, 5&-J0AI#P?Y(Y#G(I+!4 M6[.].%_7D*&)#3M":4[W&
L5XZT.S$"']L"_^;:/P?$YIH4LU(#&-@:_SVNNO-F;2"IOK MGZ EA2J(WB%;Z&H'Y MV'\]Y"4#!O;B'2IJ],+JWZ-
KQ&RP/;W55FB&.3."Y?<_>QMRM[L;7@-_!]01 M6D%DP*#5-JU@:T<2M'DD9'*BY8*_N&AO@>WJWM2 Y2EJG!% F1X
M^2I0&8/@]+)<%+7?!R@!P[^=$AE&ZV4\H3^X1*BN'EPCTQNMKOK9=4@G?6&) M/HV@=ACXYR<_OD#H $-
A;O8Z?!]N/:I*Z(#]N/T>T-%Z[W\-H#XW.M+I^9KGZP%O*Q+^WA\:;(*^."G<0)6X4X@496 M0!%>$@=B%/[*^WE7JE_;??
$":4#NHCOPK8.AYUE"F:PO,/J^R)R@\Q@U;WG M7D+@6K&B%WKPV3$R J&A-%@S?J38WVVWDWK0^'P(-=V^(>?
A/!Y@(O%ZQ3-O M4!%HV:#EZZMSH.QQGN0),2B=(;[,B&3;)GP""?^I:KFVE\/%LLT[M; ,S],+5VCA2VJ_P[&E
LCET'>.VC,5*,@WZ+Q0Z8#7K"//6*0/MV,7M?'Q M8>& &\G=2.XTDI-\F""B6\G%;0+H"\'EC2Z6_=S MP,F/=NP_=>/E-
U[^HWCYVE3QJ&4,;4VD/!U1G-#OV_2&N(L,H:(J-YJYTG52H'[W0MN"_0)0U=E8-A>(?2!!0)3&D5^^%*H[_IGN4-^=
[KJ6Q.85O5QJI#"0X.8[,;.>&'=NF!4WS"')=0'W "S%! MPA5L]57MP\6RO '\>:/S&YU_>SI'K@7#TPS148?
J^,X!&6Z;=QKB(']ZX+HW M!J9'\D@R!D^A*DZKIH%IY!TS@'X?57B[P[R#->0EA.-%4/"[LAWWYDBX$=B/ M(+ MY=,
[RD6>_8$YP;V0LPR;)0%)\G>V^$ M=".D;TU(Z-P5V6K(=]9?:X!;I!64_I/&8SVX8C@06CWO(E]'*%S:/2'Y1Q%2_A6K[R9.2

MC0H(V[!O3SC*TEAUO#"1K0K!WO&8U]_U9M+B+^Q&:3=*^^Z4AMP:.LK>05%3 MR'4)9[M8AY$=$YJ^<+S;2$8O.LR
CLFV9!^:'OA&'[^RCH2+(BU?$G//*K6 FN*#O-,&ZQZN!'7C;B^/W$9 M
/B9I6@H@5FU.E981R=Y45'HKRV*L205.4K1([BJL#;6 [9I**II.H>M%;WO@3Y[)Y/Q7ML!KPGO=1Q
MV.GW]ZMLY^Z]F'"URH=$?5^B1NRSB4HD/=[/^27WAWZYA,-8XIXFGDDX]%,# ML:W/MY1#_)9R&):4PYL4_=%2U)-
O(S@![UJV 0H5-;P3=5V:^;JNM;YRR=Y2 M:?UD&0R5+X"*LY?
F"153K]R'BWPWW'=1GBJD6_@^(W"I>L63=J/O@I@<].3]\X1X7,$@_(#Y M<]6E.BW_\^6\/$_#-
W3D2/;R+'VK&BW;#'CYOUYVH.=TAHV"G%S?E>9G-GMY
MA\%=4E:0RAQP0Q1;KYNVG[.-5O&E9.:.Z6)^&J3W2MB[##"H?;KH7,JW[%': MU&O=L#M)RMZ0ID$*
(^K:3T/>3DSVTI&/SV>3FWUL0B^G'OO+IX%[K 6PH037 MS,_\5C4T69/AZ MVRK!=4 R#;ZB%Y3JO-
M*=HJ1XMZMJ6ALZ^I9J :/&B25P,=!SW+1.U=E MAKS21)!A0EEM^70>9-E6X==8_@[+PZ%A!.M]39!_8775UK",/Y?
M#-P[5*@M MB". M.['T^X7([#WJA&\^.Y37^[MHX]C/RL_R,C?3:3?PCS*CWH>*\5=E@C
MN/(BS6&*Z5$LM"V\&XUWW>P;W6DKY5^2)Z[JJ]T0=:A,'K"0LT^U5]KXCF=O
MW^<7^//@IR<3DBN&)NMZ1:JL(/1CBP07_B1"G5'\&>/:XJ_02E=.J*&Q=A0I MINSNXL(C_> .9%2<80AGZ>/MA&[7E
RY.]SW5:$QK^^M.A-[J$8[^6))B5DP M-I]3>APJ0*9DVRYR7$$ FCT]" ORBBF./6W!0^8+G#PH]2>AVG[^45"1
M:O@EQ[;+@@2TAXZ5T&,SU08H7$(&8S22S?VHO<46%T'FQ VC<,O\(W 0>"B1 MP+,]+7?;3()* 60.BR"(S"N9HJ
KBPI'4=KU*,EYI%-52?,&#*N_PR'?K+Q-\1K?-32JZEZ1HHLJA$B+-
M]75K$'UMBA!Z5#O>SG$9J8ZTI:!"0\P;6J!@;&JD#I"[VU<=?=-B M?7OY>FKW6-Y8'TIY\]3!MHJ$9A!
RQRC+4<%"1?;]+ZCP7P%[%3;5XP1]_#6 M>%5Z:$S;?5FN[A)H#*>:XWV=GE?P5F5:5EO^[$Z*SO5 MHWP-QU.:T1/]
($9@K!J^ 60$13)U,$6:<+!R1RHUH77=VJUM7&W.5[QROT'5
M3&]9D+!:W>']2ODKSX+;1[6W^=OO0I]\J;9&"QR5:F_=^KU5,>;@\4 F>Y09 ME&8RO,K#P
&;O+"M:6\9>#T0Z"'FIA[RCGJQ86:HEO)**'*DI[%@03HP@O; MOUM5-$:UC?MW7AF;M>Z)
[-7U6J]W9&O\S^R+:@P]M0(^OR:(NP">2+E$MLU1 MOH-8#GS(0N:;MZW.7O=!,<^?
+N)G&\8AW//W6!\HGM2#"K\"O.K*JS*S&^Y_M$$CN&GXC8/E%L/TG#ZHZR*8U1I8#1*DY, .A\U9._4X.O:J:!/D&
A04>MYS M6V-%X430F/%$S4J2PU^]^K*V_YP5E'1ZDY#9DU.K-5 PA&R$YLTBH65! M5R
M9J:E;;NC(6J0'AY43/6\UT%-.+@94!OQ%'GD>$!O_#__(6+T7X@<&R7,]JH; MPR=ZKN-SC:TE0*2#"&:G8%7 =#
/'5\)BWNUNP U=9:*?*0'.]6JX\\=BAM MU*N%[@029E>G]JUS[!C'4\D]]AS\Y3/5[?:>78E:F0'I/K]7J-5FJ[:M#7]>
MWGN]RGG6:@6]RLK>ROJEP:&,#=2G[:Z>>Y'_%UHK5-G=X]G:J<-0'0>YOLCR M-Q3(G_S:@HB'0S8$9^2U@:.^'%-
=;W/F6T.Y(_-*,IV-SK?T$3'^-L-YBL]E^ M:M6[E*-WDAP"E^>
6,7'^KNL(BGAE61$$@0R(&AWGM/<^C#KO,-9;]8P[A9Z;!9KHXUG-D;]BW M_"41
]]2A6KU*WM)O[Z7'D/_LIE0AS=V22M5M,K6&_E,OLR64WFVF"\C2BKJ%#W36T^X7#8&\VQ'@/I7L7$3O?W7"
MJB^4HQGV8;\(\-D_WX8)WS$2 M(F[L*<7/+S1S9;SC><2\Q]UUM>1]H=E^4]KW@Y+1#:7H/.+!'8^!)4LV>)XI M)-DB9
H8\NH9:E:YW+PL7R3P_XH5GC^3U0Q%D4\?6\.$KUQ
MD!L'"2L'29G(K+0!Y!B&=_4K.A_>9BO>?;G#=W&0$QD%WZBD"KE*,6,7WXY=E"L-CA?
CB2A#XN]3%;P>L$8%6_L6L3>X)+\W@TC\, :Q MAA4Z>"!+;)G-^MN?1R5$B'B5CL0^<9Y#?Z#SC9S"9"Z%ATV-@??#8
MIF?/=P$;%#M\WE-*-MP'L:=\8]6FSO%"<=_S\;W9$O&C^1)5$]AR(P]%4+[) MB0R>B'V('5$W=G2%[.A\(-CNR&,H\
(OBZF_$CXH57H!,!F.3%:&!E=AZ@6M@ M]3Q?."-NPL9A*.HGPJ%:KZ2X- (U+*I&/,N@SQ@-?2-U5PA MJ[D
&E8]>OQFT^?WUEJNCJ?<'"G?G]+//K=KH\IWK\#U1\M2WA7T!_&R^0K* MW=D.EHTS-$-*%@V?
X]YO=XB90_$*U'DLFS1$X)<.E_.\F(,CQ-QZA8Q^_VY M[P6!X'6&;?5VL]:^*P-AD3&>85.-2IT7B03%4.\\"O&9!WOC'M?
(/=VF/7#F,49=E\HU[ELGF]P=10^PQ8Y[P3*#Y_#>"XE MU/.-/.=[> 3>RTX/E)'OS%3.8DW^# [$B)Y%*&Y9A!_@0\R-
#UTA'SH;!DYS M+GP/'O.S%9 M2'Z/Y/E\MLPVO -G@B%QYIVG$)MNOCG)[^?\G??NKZV)O@^ MV%KZ%^?
[@NIZQ'LWT8G)?9(B>+-+]&! 3T6AI2=*> *()% (1HY&*0:/[[#>ABQV'X4\(8_3 M-2V:Z;>=0K;#5'&B]7
W2[ABW\VVEHF!2!^VY-B^52QG MN)36&M'BTV)@SB?-@<@!>.N%"HB;'#EO9()I1I-H$+4M=.9#N%8E<1:F+\L*7Y6-
2G\P4S%2(X M-2=I*LED'%9,'+;,/[)V7>2G0X$?+%FB.##D-'P[@1\V);/S;J8VC"Z%2(\S M2X9;F2\-V)0XTG3ITB$+I
M2>Y[30^FY33+J8A!L6VMU:9Z>BLG)6)-.*TCP)(:-$D3%-/$)]L%W\238M(6 M8:]'D,52XV@SGAG/-
)=\C-.TGJS$$Y#ZCR"KG9"'#DLU&D+6+J6Y3(O-ZFE6 M)(\@*Z%.Q,EXV0$:H.>S1,6T6TL5%6&&8K]:$,>SU
M"++*>B93RBE&'(_F*OF%[("H$H%-CR"KW39K[4Z#CN/J>,J*3]E280@)FSR" M@5X^*8^BR7Z36\0X?" FB60V!5?@" ;
(?A]/=^M1 Q^1W:>.THI%)-3K/@9$ M.AX%# ",&,,)(-(T5,#CB2@NRG2?(!>+ ;(=SRQ!Y_3GJ$.**E5*8_Z_7F2 MB]082T[;
Z.0@Y,X@J,^;]AP!V674[7:/$Z2$MY>GHS< #5=T6>X:MWO7 CO/;1?_7XU MU)4Q[^M$K[HBO5ZBB7OB1>?
SECV[U;\)^^SKYFRE/ZW^CB"7YH/OAYG!E7O5 M_1$XI'8L8:D']7_7V;>$PUF[?,OS]@X/L.?8*=)WI,OGHS<-N*3-
H*ZQV.W MC0C!1A#X/9&X[40(=N+&FT*R$<0]?=N(4&S$C3>%92?N*>JV$>?;B-<#?-YF M0'S>K!/PQ_?
Z>B\K'S]O#>)OV/E@RNN<8_*YG.-729"Z)V.KX_55C $QGF/> M.0ZV.KF_X/JL(IS>>?K$@[$#1CU@^7>I4/C=ZE*5WO?
#QT=IY R (>ZCUPV8 M-)"W\4*<%R^OR;2S3']GLOMW"-VD0 BI_)E=>^4NJ!M__4OB9/TM?#R+]OE MJV?*<)>I'\Z!-
V&3#_^190#Z_4^=Q(O;P]HV<.RSDN'G3O>26OA'?-4_?14" M9\P78_\D-
GT#^T>=GS]^%;X[V'W1^TVV.71VU,%.IES+@HH6)GG2^>$:-.3P M$>5K9\;?<,JOGH!\PSG_0&2_=N+X':?\ Y%]
<7LW9!+V*]6G=1XD$?=2KJ?WG:S'*[63#Y0M/[W-2O_SV6.(QB3]_1.8B_VMSJ'PS8R MEB2C\W#,-52GCE(_!?A!Y!V(=A
;2:'PB*1I?2:Q,T[Z=HO3 &R"I?*_N=7 MA/J%H1O[).>?7^K<>3#^_,$,:P>5P[@Z)O#X^MTKY)D:2!(M^ "R:ZF."NP[3/:=
(C>3,93.D%?/SD)L^H6#]5Y,F=K0$[\FI\##>(S?6ED3 M!XVXCK<8>< NHV0O-
63%*%*A2(J\BU,75*%^%$U>W(USH\GPJD-O(\IX]VE0 M:BGE)K[
9[)955EG9"*BA$H0$27O\!AU.2WH&HGR^CU0K"S[94DL(.H+D.D MW"S5*_8]A6\5?K"9>S%=J[XF5KL,G.
<9>J6X$*8=?=G@LLGF=%BM9#L$C0J= M($<5[,V(RC(OLY#\ MH3X7Q^\
(!K\YM;Z74ZN.4A6!@HTERUE@7L62GFE)'J@OH.%=XXZ&U[D5OBG_ M%
/\,\%5HI"W5&:9<&PX(6%XP_(M\FZBJ_8E#96O:J.[&DTH\9R<3J.H< M5-NHNQAQ0:WM9\'[%N'T72GZ@B>,
[R)I)5>:CG/%IX(0,Q4ED6%&G#L!=#^=4XR*.(,\ M :J#S!U%Q&^.N6_BF$/7'\'^&Z8CZ9?2_*YQ_\+KAKO%LX16 7N-K?
8:K4P\ M/Y H(<([%5Y::ODD/4!7*R#/68RZH^F+1+#\0#*\A96%G@POI_2\1H<=JS!T
MM73*%EHM@9>-5L?),MX5)\C=123NHO&+^+!O#J]/I M03S<808X7_S\-U%7KRJ([",U&_/C2_HE?
*IL*I+A@,-4&Y%B&5PC#>[/_W5Q"]SWUCK;BHM^:A]SX=(4#,DP Q?5$(J1!"$VA P*]_)6&[W2VZ
ME]UMYMIQEH_;3@ME93Y/965E91$SX'I@A0I*RZ.=,<8ZO4F4P#DMVL^3W DC MK3N!\Y7GDOZ3-!U.6\R_WD6,#8K
?!+,)SW 0O;#0Z?-3O>^/&/J.6??=IVG
M%>UA>7N$;$M($>^9HS9M(H8]E4KK,K,GTDLVDV.+>9:!E5DPN_0@H/SX".AW
M48DVK(8I@TD/K0BC6K,J$W9O+R8OF(1 >8J#IQ9O/]?4B8-B)8@_(FY;[N9F@N9=HUYE+/DA)_@C'#[0U$TPG
M>R#AQ8V]&6ZJ'99+[RQ/=O;(/(6?<&/OT>D EE%=A;J7IX/39;W>RP>,N)NT M%7XNFPC9,:IK:BE-
\2CA@R3F(_(4!L\VWGC:ZW@)%4QU_7%8]QV+$3&+:6Z8 MM$&[!&M_9"/%"^MU>7H^<=W5$1IV-
^J.\4O*>NUCJ"7G&PL??M5JF,KL/]8KP5J[S=$1/T)F5: M%);'67@N\?939[^\FJUI**GRQM,113]P57,1_PYX?C(*&/.?
M+0KV,'KVVZ\ MK.OZ1N$B!237-PP0$K!A%H0$3+1<_BHXZULT .^#N\YRHNM3^1%OS7I SX;=
MDAY#9[@XOUC3H)=NW"ME!UMQW_AR&UX:=2N[&T^HZQY]_-CK8-I)>!H&IT* MZQ(M[[9*+-!\0D?"(U-4C\J3QSILA
MJ="@#%K#QEY:(_Z2;/H19JA\ LG#"7'V-*7S,(]TN9BG\UV?Z5>;.G Y>L,)
MI>L;A0=>RY[N9%2"W3<1.X7678R05KZ$;QK5L=%S(RF(B3WM+$WG.8:#Z:A[
M2D==X2@\+OY/>!3J[03@U5!=U3L%TR@7)^YJOEMWJ"@A@/16$1R%9Z#N+)E5 M G,0>X.6\\ &."'(/P=Y<

W]40>B[NP4ZZ,?63WKU6[/K+W[.6=+I;'4+6Z*-M)?C-TQ;".%Y&C]AU/90X#YV8-J"^Z[-?=Y;WMZ-;GXXQ3W)
MVKEH$2NVZNM='2_NQ-3==='(>,L_"-U5WDVL[>K,'S+7=1ZX--LV]I5CL3:ME-M&Q_VY+GJNP)MU0>%?
K7H6GM=QM/&UR29QT_3,@1B&.;+(/9/&*J]"?Q50"V5-MW50%J-*0MU'9H1H5@4_'P=F-
)FG4'CEVHWGRHZFQUYUR8:K:%CX=9?4>ID4-M5]MUU)_2;;W&DA.MME*E43!P$,77Y$XWCK721MD8GL-\;+--
[$'Q>*$OU-M2X"R8GVSP(TN:19):3BKU5K+G2HF-$VV#O$\09TD#0T356>%:B=S4PC,3\%N-MV;-]
[JT%8C^6A/R2VA%SCV]HOC^6PN5J1]1',Z-I1#)^:)7-Y0GZ)$M=R-6P-M5?;5]'MY+CA??=@OR0!TT(Y&CQ=#:5>:D25?
V#W>]-MCF](GB+0NT7CP=HP6#YRR?W((YPL-%>DN^A.%\):65@6CV.ST20.T-*FV1R5
M9PC8,_M.2L"N<$@@]L^W'WD$_%;;I-9^?BJYM&T%R;?.AK7;B@/$'-D=-&FW_Y0.0<]P-'*9TYF^X_K[A6K'K
M&P781!A"-I9>04C-Q,R%"Y+Z/[U--[;7OLYRI.M3^1&;$#^@9\/VVH^A,UR'-M7^ST?-=[K@].;[G*Y_[GUZFEDK$Q-)
FEOR%X@%?]B>%D"+')1W%"QQO-NT]-MB?2B/\TMOR>[]*)#&EIT%:_C]0,E-I0L4+0!5X_>=.7Q!-Z2#RU%<^3IR('
M9AW.[Z-(M-][$+E-\BE?WIJ8?!JVNL[/*Z0(6B@>[#E7A#0]+_U'=J-M[?)OCULZ2#X?!@O7B]&C'1VOIC:?
<-2>*Z&@HWF<-2/Z;5W\)Z_Y?>7?Y3,G-MUSZ451"-1MB0^FI-)\AIKQ?XL?94'D71Y+\W>,QA"'+*RR?EE"#7!ZL-V#/@
M'5*-!)H_?).8/Y@/G+8/?"0,_>==X-M"C@Z^CNIP[$J81>$D#!6TGI7]+<]_DI]|P3Z=_J44U/\H(>&=,BXX93J-0NQ
M]SGNV]W.\/VD_7'B4NZWC_M3%X39.9BPOHOLW'MV(K\;I03NB+%%#H/RI9K^-M/YF*S-
%L[4E%B6ZL%MV"U^QW%/[H"/]F>'OX5_*-_BZZ#F^]?K#2=>-I0HEC([%1/A-V5.D-5_7-.<-M+6MQGD$H!-
B@ASM,P\0C3JHW\/I(7_%O3E]\Q:F^2VR\0?X:EZ!O'OPWK?U;-M)4Z5%F#&23M^0'718C'<"[>9^7BOZFO#
[*FDU=JANQ6E-;2UJS&-M^'B3UYTB.?(8WEM+%_9'S3>>;$V"KXES:216L*+6-TN.FV2MR#Q%XGF4/'8"-M[-W&2H;^DJ-
[3H3\8GB5XJBX'XXD%>U/)%XHJ5O4:.EI$RF48/,$<:RYP=NQ-M<$SV>-
BJ"5.Y0>/8#+4EV05;H1QJK'Z!L/609/HA:/TM5SJN:,118I79M^>"-MO6R,AOA(,:R->-%%7Z70WJ7MGW%:/A?
[Q0K$KK0!U@YNLU]S-0GLEW&UQW)>-M<7P:IG\91<%S.;=1ZP)!>+WG8]Z-M0K^WZ:@S2O$EVAF*-P:;-
\PA/+MXC"VZ_+X>,/2^RH6+F58FB(-MX>14964$B@7W*VYXFQ'V4+ZEX.@;"+LQ!FM.\8#-8^>7]PZK'>SC"<(_'#O&
(IE.?:$@=*C(_D2.X\0R3<58;T=R@9"=?>6,^.D=6!CM#OA-M.@K+)U!._BV.R5,H#?O#W-INY#]$6ZH:VJ&5;#SEW,-
%L:Z]\L-".+ZQ-3G+-M]6'+&)A;.C/I)C3[UXU%3-^-E/;D*KZ&4[XA.$)I%2=C_U(Q
*1:5@[+TQQSPBCLT1D!MDV^"G7O+/S[,TH-PJ(O\5V%%G93MHMY-M$C)K35)*B",^G,;R&
(N?,.R[$TJXE>38=\V3_9^V[8'K[C\(^.Z9RZ^6N&]]-M7_)U"RTAQ>-1KFZO-]-J%P<&VG'(V;"A(U-]$\,-M5TI]-
S1"":D9@>X,2:2PCF.Y]/XR$J?S*'G"^S$>G0_>F(F#?'#7?'"6VS'>-M2@B^V(>W@E%![,C>#R]F?#]XZ1'/I!S24).X?
M7OQC)V?$C].]]%B"%^3<>2Y8-!\D>(EU\H&64V._^X=/<)UT]9@DG?]9.#H'(Y_3O/F[
MAN]:,S?/7^,OS7ZL64+P$58NGCWAAT.2C-MGDD7_;\?!Y2?FAY_19)/1$G]^.K_Y_6[?
T,YHKJ6ZWUYIOI72BT.9X'Q%/8Z-M0&8>4QF<>?^T6Q(F7G/RG)<)I)[#F/\.5ENB#2\@+T,\[]W]RK[Y/AR(RE
MK6R15R/V1#.(!>;!EZ<_>_Y9.D6_-#UT]+?+QZPE.2X$/\SR?-2"R97-
YDJ6(\ZC//B"U3!=8&)+2:6$EQ?"1K*BQ^J&4XX/ES-ML#C2^G$M2']KUZ1\B&]\RBV\9$+[U\!5C[)HBKQ?G?
4>)&29H#ZY9CT!X@L&-ME-_)8-]^^+VE,P8_#*>MM2_$HG<_\OAZ5_^_8-I?_"1-M;Y/3BX-S'[]9[EOBB;N^TW5-
*GRG;*Y-MOY("N+]SAV*XW,N-G4?WGX#R:3H\HME?BAUS=*R6X<1SL1LFQHMM#;8JB/DC
M[9^1ZAAK_/2O>,24OW/GCSK>KUKH**$6AZ+:WY=]VS<&-4],H0&-8C2!RRRC
ML#))X7&\KG&L3,]0;$Y@LSF%SI[PI#P']$Y5;8;;H;H1#&Y8=;9T;]!NBW*\-MX/A1,JR-B6FG9HPE9+-SFWQUT0N$*)9D?
Y3PS9:XYY<=#HHV.6E5V'^R0;G^KQY*99[K6C*F7UY6IH-3=@:AL)^ABR2:&_2@ZPU=-W:%E0BJB)101!H/*AN5E4D9_
ME!S3>&.X;'@[->=W6Z[?VO$U,I',J+2B"N1ZB(N4J1C]CE5P-F5I(,:2&96,-MSAH#O74/%1J61HO+8IE'TV=F5*
(Z$5CW+;\KV-RHO:I@_&P7Z+%D5B6'IX*E-MT%M*0JB&1@5K1\WAD)>IK$KE4GG!
(*.N).S*+;,N5EI:J2+*=%92Q"A:%3!:-M%RHCPI'KS=W-GT4RDY4R.!:4;)6C_S5&I:W@F53E-!\6E-
8XND6A2]^*E$5K2U4*3">$!'4J.^DBEF-M-#8F%[_K$>?CR,Y2ZB&4]MZQ5$!K5)7V@XO59UV]KU2A&?
MB&9<%1UV%^QD2]A2H]5$&]%<$>BBGHAF?;4_7"\+-67J"^M>==?<#S#/W<>/
M/>*"\UA_X/4X7C+*S8ZM]236:72Z09JS7$2<<-M3*;KB'4JK&-,JCC7M#VE/XXM>\0+EV-1PB,-B&8&%IBF8'EZ?VD
MS/F,(S7$9LUG0X.4IZEH=F!IL.B,B4(+,6V_5I9V$U2T8Q>S+@RK-0Q=R6-M\B!<&E%;K$_3%\CHM1D6&Q7'B%\
1V:8O>E6K4$K?6I6KU8=ZR*HUER;8>CZ-M#:&R-8-XNL"/('$Z6LT4&RDA)H*TA[/]GG:\992(9O3]T=O%'#,Z4W/M3@A<
M;V(4U4^?FM'+"Q:$4_8+M!0.BZ-C43N-4OA$-*/7HN=4HY*DDA*N^#3)X>VF-M7$N?FM5KM%9*'KMG^I+AKY!%53(-
KIQ>;INEC4C85OB&+)G%:DA+H&--MLE\-M_8T+TES5R_K\D)*-U^:6LO+!E^=O7@!K&4G1L^_='W"Z?
>W[5YT7N(;+Z:?;1CF,KZWGY%:^\-MV5\6DKQ:Y[UZOAL__O-(_&O_CY)2NZEK)#__W$_7I=V=^^C.+G[-U-MUKOK?
8+#X!<*_[%PL\)C@:T;Y4XIUV174M%Z0,9NVTX)[/U:=M/?J"M(4-#-MALZ-]GH.7K\;U#^[W>EV:?
S(J7IHZ',8^MP<_J.A(36_P4JG;\5ZQ$;9K\?A-MB?\N/#'\,W[;\$S.,'\0%/\I80BM?DK_3$IGHU]*#T4EO/
!C@A^*T5ZZ4U^9-($QU&1K-HAG[\JL-3MJH5)J/+^SZ(_T\[7$'P8_L+;TEV-8&210$H
M"W]EX)V>JR8'L9+.U&2>QKG3=,,A+N,<[Y]6(9-AD(G70"9D%),%JK;LCLQ*
MH:LJO#9=V\2?]);_""#7.RMD@?:'I$2SXF(3UMP5,8QB("O<8+SM,0R(\%Y!_F:3-K!;.BMM?0,)ICM-]@2'_)7QC(
M6ZE(<&N)79IA;[7I-^WE)-23@!O#/WW%*"[/D=F[8#XLGW%I3S_AEO[[CKR>-M0+>G3CB.G@/;5=)8Q_]R8QOU9XR=
[EW)?ZI^O0LM3YX)OP8EH;_>CY:W5:\(-M_?7!_17RZ]TH^1#^>E\UPE>WN?KM%F$_8->\('BJ8NT*:46KTXM=Y7TY;R]
MS=8?-?O.J@>Q;^V3'BC#^Y&73SUN=NA,V[$',/*.5OH&1>&0"3B2!UHL^QHI-MRD$!+7888^
;:UH;1S*=WBF'YO%374-R#0G=1]VP@7"^H4W9]\&Y7%KZ+!*"-MCA0NNG9MNYXR43'I$YO<*D?E6?HD^S-
P_Q7"^=;A?*9-V/?!61X8RSHSB<;2-M3EGC0FE6+J*H'L.9^_25P_(,2\'9&<(9POEB6['O@S.*$AM#'_"&23,3%R68
M8MB4DF-[V72EZ3R)T7#/]>;V7'_,&E2-Y+[M))TB*+9AF/X@9>V)+GR?=BK-M37]<[B3(&>CYPLI=
5>?)3'RA,J8JOGO,/ESMF[XHY6R[.*V8-=B'Y]6^;5?-M%N.W)3Y]9?,8S9XN]KH-8H:PAK"^=
(+D_;#>L/)@@@FH9RI]=MSR.FMUB26P-MIA-8X]1)8/U-6_Z7]GP(ZSM(E+P?UD*UN=7K4VQN*LUJ700#;HI-
^1C6W*>O-M.)WG\),LK>!T#7%]7[@^;<;D_;AF,=!9"P53$CKDRM8K0!_/R@FNDYP)3N4I-M%CU=SN0V@'W3-
21L^@$#-U"LG)LI7854ZBNEHB9(K&[ZDUL71H2EQX7-MR!47SM^\A2O&57YFA.B@BX[Z:Y2V,'_<,Q.NH&.N(/,8?
I(:-5C49ZWD(!=6ILVE$I#%%Z2&.F/I[H?I!0-/?I*X:Q>0:#=:H/QP$P7KA&LCAM-M
NDM9(&CK3E3C+J",*IX\GA;:Y@#GX_)(DD9<5B>XV"9S4W>5O"MM<%?ENO[-M?^<,1W7M:R^K@<<9;_PXXR^X-
>'3O^XC65-+L=2,<153:JQK_)PCW(K4*Z5^-MO3P?F71+WRW":F%4,/7D]>)-C,@S1[+Q?\-]-HC9!\/LF9(F;\-LN=;?]5IC
MIXK:-AB'$<;X#IE@-CD4Q.4I--OIZ2,P^T-U+_>NY'UC]KQ9CK=A5EL!NMR:-M]44!(;?
ZN#X)%I,@BE^/^_25)/,9)TEQ^)J4OV/K8P=S)B.NP+&5HK#N-ME':1QG9H-H@RAJ57<:
(G.6SY0+M.E_9[".H#J!/S8OC'W-WV,&4.E[8O=-X[-MR-:\>T;:[(#(A(VBCRK[%=M<=S"VIJO9,E-ML.G/I
[61,PYMRHV^WP"ZB0+<*HNY3>#Z9NNDOBNI<>K/$_^YP!X*\S#',^#-M1W3O)HOP'F9?T>)P*
[477;02ZFB[VA?"&JW'M'XHL6!@B06D-D@%-UNB\1XJ-M<.N(*0SW$UXP!N42RQ$86^^+"17-N@Q(!9*;CR3\QXJT-
K^KJZXY0':48OZ-MRC66Y7:84L&AF(.B8#$'Y-+(!;>:-'H/%]3GLMWJEC8UL_7-[C>G9<*"I]P
MP5,%"'/"EJXWRP777@$2/_.OYJNN'+D9B+T'/\K4+:_V$H\/1J.XNUJ-M-;#]F,03#3S7LE(:/]3W_>J84SF1)'NX/(IF
MSSO"8\H0^X^&_5.?FKD(]G5OOQ4B=RM*?;%?<-VN&%2W>H)].KUR-V5.TZ/@-M@0IN[EW)^P;_F0[77
3\:EAHDH+08*2*55L.-2NAO)""G_OTE4#SY)'#.7#F-MA^"_)O#?50+FM#R02><.1Y4MVAC6A%%]7])!H?5.S>=FX?-
M:]J#CEC$BF>-M&YYR]X4#ZH_M[&OH<#)8MCDSW'2W&Z*!-WM,S/]D6N1SDO)-N)5W9:BX]+C<-M(EW<2[+I&$?
\=*WHE8!4CAI@9/:Y.;NI!9J\H_B$+.A/7S'FE-UG(5U<#2HN-M/2ZW2!=W52[T]NB"V4^-%C:9V0*N\MM%$5E0:R^-
+KA/7UEXTP^D"T@75T-7-MYTAHO84N^B*+5G>+?@W%-]TB*?
71;3_0$[I(DE$4"V_[NTV@ITUKQI%$]E)H#3TU7++,4IT

MQ(*CGLI\2+C9!Q$,$7R!TUAO1?!RSC4C4I_YPFANNF1IWE@5_2A!<%*L0^6Y
M$U7J/5"QSL4]'4+X%M,B;X8P5O,+_>U>'$O&E&EW%K;BUIOI)'PHN:$P"L[" M$,(W!^&
[REK\B.;,!12ZJ.YD$RA2I[NIK1C>&?D#,0%Q6C@33\1$%L6P<.8- M-Q%?.A5SZ'@;FW[E@05P?&,#OD]??+F]XIGK2DG?
N]X7ZUA^8<7AWLN#Z?VH MC@YK$AY,[T=U=,CH#Z;WHSHZW 4^:_%^LB4<.AZ(WVT/M)RN&,
[S&LMUB[W=T>,WCK]VXW%TM9@&.O.!LCUV:=Q601QCA E2WRS3
M07LLFGC2AN,#^G@)NG@]G>J3\@!/]TQ(_'97"D-\2)::2^* MT@)#9=[@$S)(#AZ<:+OL87>\(1O<6W!POOM@SA,<=
QO8C";E26!L.H4&9.N M+F0]X8.D">E)]MU@; #9X)9C@_/='G/FV&#I3U>")JP5R;;6:(V@%X/6.HT-
MDHWX(YW)/R@VN!DVN,%=^%]=0?/]QOQ34])#[NCV]N5_5/1JLD77=USJM+/" M]>E[!6'C17-*R?3PS/]=UTM>B
\"SYB%09(:'KA=Q0/.L6-D@X&E%7$$6Z/V MO.D."D:E.P3QC,">/'5TL_L'D"[NF"[N-^?T=H[X:?C8-AKJ4JY0K!"JDHL/
M0J]MD'I"%B=/+4&VN!KT0+9XK)S4[P<7$] K[C?K"6[21)LOT1MDQXBS9%A^$]#NBA'4=M$T!*09"M7JO$.ZMI@
^JD'!IJ].A3. MT!#0UP[HN^J!\6ML_PAI=JK23B!196D4]HN*S'?KB!(ED'[NB(&>L('G;4#Z M-J^2.1V#74D9SG6EM^]=
[XN=,?UU(9/5T//AYX/&VA SX>>#SD?>C[T?-AB MX[8VIC,7+>16P,OY"\4#^=Q,\0T5[D_#;-D59D/XN&1M#
VF"+'5D7_8G MA9 BQR4=Q0L<;S;M/8GTH@_>I,;?D283%,^)1\WO J^?O&(A05HV^8V^9,H: M2*P5V@"!M*Y-UK[37E
4K\LXENQ.HY]/M)<%4]\0S'I$S6XL)F+D4S-D+L>',#,%\[6!^WZ;TQ^#ZW3O3'X'K'^$LB#5]LFU, M=:E8:HG-
+1OP493.SP /F$.^31E *I8:EL,P6$8,Y(B8\.'UN!O+]6 #\L!C)'6^44(FK5-G6KN2& Q-NT9S
MC=*@O2\AZCY&,Z\'UM35_C6>D12.P,-$2)7U;107)?@1TO MQP^K[IP;!GYRZ#]^B:>2_!S?G%5($+10/
M]APB+]2A(>D?O+^-OB-Y]0Q[_H#Z=FC/@->9IXDLO_,-]#^K5*H7G0$/U+TA
MX=Z"T$I(TQ_AD1R_)_'I*\7D60K+8UBV)P[,<$-"@81R&4)Y]T;Y.0E%Z?;K
M%CME24'19IN!24ME="8FA$)_^DH2>98F\RQQJD0YC%"N"C:7'AA(*+\FE-_= M<3\GH3BC%:)O6]0:
[41@Y]DU=;LD]810N#1"H6)"(;'L)CR,4""A0$*Y#*&\ M>
[_^G(0"!O5N8#6,C1!B#,+)XJ*R;J2$DNSBDVB>H_%XS7/"GH$WRRB_EQJ[MVCS8GYS8N V#W=6IN:K
S''Z'W'RE(KU76GAKP 7)2I(Z M5VKJWC$!F0$RP_5DF-[!#&JS-&@LS5E)4$ 8H8/F?JJ;?,(,9\HQW3LF(#- M9KB>5-
$[F,%FK-&F/1R2YF@_TTNSV7ZQQ%)F2)-%>)[&T#R#D["?QUM/>?Q, MVRNIH[H$.<)=RT?2^V*-F:^BB/GQ]
(:._FB*PSJ4Q]+[41T=,OJ#Z?VHCGX/ MV_;_#I29!:[FQ3X\E:$")P#>#R]F?/)/5[SXQT[.B!^G>XJ56RE>D'/GN6
!_*2[EJ$I0?R/ MN>$HCFK$XGX0_\".7\;__-]_&Q^I[)6,^9_[I&9LGK_&7Y[_6K6 XB507#Q] MQ$N*+/FH9P9"_^])$F'?
>P].?DN#/:7"Z!]?_?^\?O=OU("HKN5Z7YYS>:^4 M6J3)J"]XRA4Z0&8>4QF<>?^T6Q(F7G/RG)<)])
[#E/^.4E'Y@,0RZFX#BX MS+WZ/AF.S%C:RA9Y-6)/W(188!Y\>?JSYY^E*<"7'[J^D:2OOGC 4@)C Y*G M?_?/Z,& \AH'OT1
:C D-LXWX#T9[-L/O[=TQH"' M7\9SG?I7(I'[?SD_<:QA,R0)&!5AE0U'/UT&(C3SP,O0(Y'C#VXR.R[#WTRW,RUM/B7
M0W<7H]/+Q;.#IZQ &/NFG_5'#6F\]G!< 5*WT*D$42V8^OBJAQ&ZK>+34H6P)&8939.B*L63VXZ-151?# MFC,UD?
UTVP_!0D"(Y.,QXD=19M>O32@P]U'0[DQ5Q#2M]H!/1.D?1?=2Y(^2-A/)[;!7 M=(6PC-
0G%HI'P(IBR8SZQ4ZYL!FTY*U@DW*5D73"+VK),[/JSVM[G/$KFP7:
M4)IK!I^-30Y/7C2K/LEXE"Y*M9[0%^JCQ:8[*WNM&>@ M.-8:@-:P2*;ES.>>6%^$T3"0Q+".JH1'C-Y>NV:
Z8CLD(]EKBHEH M9J3Z(<4V]'ZX$_"@J@W[> \=QTJQV3>M28@QQ+JD@O8KFEKFQVC/"':2F3=+ MD.UQ45E2EK
K;>T-5TB*:>56Z;1LQ2J>^M YW3K?48>1B5X^=+_L"T9COS6+2 MZY@5R6VKN]'6:>[$1#3#$\-
I0=^72=T3=LWNFL:W8J?22T4SML+[:QQ4]L[(M[$O:JK$HT5@1I*)9O=H4-2MO5VYDKBM2CP-1C?3W42J;46Q0WC-
B=8-VT$JA M6MHQ:W7?BK&*85G%Q,T@"FI"A11 LS16&T.]4:OIB6A&,9%A"I[09RIF9N"@T4;Y0EAD!H7V2
M8<%.\)>IZ!&\D"NT,NZ4>D)C10S\7FLV56(WQ/ C=-7%B\I4+3:$<#WC(UJ: MS]"QGHAF]$("K^S/!+.!
(EX$R#:YGE>+8B*:!9=:FNI:UU!00Z.Y/3?T++J0 M/C6CE[^>=@.1YSNFP94K>+O(*;J0/C5KV[D_6D^P)L>@E6%8W2]
;Z2SL5Y$ M5J]-K2YQ3KU>$_K%2&D-BF*AB>B):&:T]E1Y2/=X-B98O%R7:%):+P:I: :) MR&+NQ$'#LBL8
2M6=MI8#JWT!;),O"Q%VMA1J(J)8$ZI0K?1J:$=9#-4W.VQ M_LYN576I4NNM(K\]JW6Q]!6R4U%OWJWOK?
E"0O%JB)'BQ.^-DW<@C] ! \QU M&XQ#"9\W-KO2#@-U5T]$LV.[%[O%VEI9&:;MC3;DU)E5VF4QE1VE M98UJ%M>
(*M$'V8QB0QRW*(/%#+-/E>K)\DFP3#&5S<8DY0;#FWYS(S5Z>\TF MQDZC+\6:'8D)>$:O-2;
6YGTR%'K=6&@:X&>B&8&P=0;VD A!%12KL2*H*R'P44+5VQ7*;?"J;T:P3@IH$*+2+]LNR5Q:#J>R"
M^!6.S/8J*%3DEK^LH"/2 3:[;&W:-I^(9BFA-497!M];HHA(34=4K8_)<0"+ M'8D,NHQ8(76E@0MV>T!W)+
[!&NOT!;**#;<^H(.P.A5$.#T.C6W20GE^&V/! =>%<03-V5OA8Y",?-)MS,UQV(BFE&, MMP(M:
N^T5+KM4A/1#.*=3KV&C5'*UKJCPM=)01>P\:C1#3CML3$ M;W9Z9)>6*M4@+81M4TZ=F]=(4U&ULR[8H-
(Q9*+;HRK(2Q\O8D5D_D&3' M**G%FC1:=44^TL>SL)^*9O22VVB34S!ZC-IN1^WQ>[Q47_&):$8OIL5I/6H@ M5B5%[
\;F"&,=3=]:D8OK3UAU;6L=&\GYCVU$]O3R2*+KI**9MYTVG[@K-&FY6%- 5BYZ$#P=I M+_\C\QC3,U;=,. QD>Y3.G-
#L_-N$TMFLK[YJ)9,6FZ']#]?6]E4+'L MD=C#TOI=8\M$ $70287%)CA5H\1$-(-'0>DZFB[/ &IT8GY0$+-O+=.G9L9K
M@Y/54"VX;0F DM*<4]%^'@> L6AV$ RV[?'3Z:!G@HDWC92M\@.PBB M95*MG6?(0N@[J#?&+9V)UPSXD7B"5U&?
53A2$Y 5C98Q>SQUR;255$:QR+&- M?;?2]-"1OI2V?)=7MZNT24Q&,:'"5SW+P6@);/83M[$3V?4^?8&,(Q09UB7:
M94R3#($)M\$.+6[=] 6R>EE6U-Z6>V1="(D"6UV*@S#$TE."68-AK=H"X/6M M@'>+KCK%-+0T2T6S!@-
K9;%BF9G/&PUG3CV-C*1M; : M1=NHL1RGHAF]-DQ?G@[P?56PBWMOP%0F-!VEHD<6.+N&QO8\N8?2\9*]JBW;
M+=*/A^M(W*%*/=-GK/4(#:$LI=/'UL=A"&K:AK MMOU]@#:\@A@P:$?8%P_/S0Q"N\>RH"@SAJ2,W9IE8/YX-XJ?
>R1$V/OE]1AA M])E 1V7,1;EP;^U3T8S;>JT:4V2:DB@9NKJEPXU=VQ?U1#3KB^'2FF*XXHMF
M@_0:T9)O%2IHE,IF!M<7Y!+1MN95<[W8[QON?#G2A"@Y%I!Y6WE4P2)<2R1R;^_6SCMS"!7:%]K.J)=4QN
M=>9Z(II]72:&[=)$]H:)B(T%B8--1TP2R<=F\YF.3.0Z5^E+E97:7^TE:]BO
MQ<\],IL7UP2!3(6"+30HU)O2@ZJ]C$F!.#;ORDYA:ZOV:HUV)LUUH,S$C:FE MCSV24/+%6JO3HU9
,CQC7C:)'K:=1(EH!@[1(EH07F@M47M3"=GRF%COQND+9/7"-AZ_&!16 MK-#9 V,RF?%*?1 _]LA:B=CS
M]FY7:)>LJ9B(9FWK[(2^XC-XW6Q4XS"\R2N+_B:6/3*7KE8EP"S714V@MVM^ M[S!A=YOLZAR92]G1E)XMJ0$J%-
NM1;'?VE&C2?K4#!\H!->*C*[,"S8[#PUQ MH=L%,Q7-3B-2>==&O3+IHH"3 FNGMEMVB4]E,]/(8+>C2T.VTS
;W4VK;8X] M/5E@$,?FTND>*W&<&.VE<%3UV')3G'E,_Y'4@-@3TSV9C1U)&12WJ.*WIL9 M*IHY
MVUX0+]54L1D(]*I2V.PV=H7C^$0TXU^RZ*J4VVK/I1 ,A]PHE,66&26B1WBY MN@EK.D=
[J%)J(THPM[E2)7UL5K$:/]# =C*=FY6.V GT+AE9F)[*9MR&8)>V M-
&Y@$FJ;2VT>Q(&6&\>+O)&9WQ_NM&5!TEBIKW #SM"]U7RC)Z*905@Y:WXB M2)V:V4?BJ5;#9H2(I*)9S0+'-
R<]L!^:N!31_8/2MP,\:?*H"3A M+6*R)1OK^B9>FY-'@@0&>&'9%FD$;;166Y4H2=)\F#XUJQC!A:M);VD63'I=
MH;0N%]B=8?K8([08R45C-K9-DQ:<"=ZGI4P M:5%.1;-+C'VP[E7B):G9-\HA,I&P(C-(1;-ZC0G;41"TZ@AVN>E/-
CNN4UC$ M+WLD1.BV1P 9H:MB;*CIGC&',E]=NS9GE"3 UHMD>SD?#8GT!3)Z&9MF:="V
MYXHUK^11.].T^Z2%34KK0GL;RQZ).[CN&I$4?UHW;;J^+XV:JV(M#F?((_L' MLC!FQ_6RW3+[Y4ZX:M1LWHR7
N21_8,ZWT.ELN=)J,&7QM-1K1OH"OM[LY4VN982%]|)&=[*K8'57F6R#9Q99(3/Q6 :\>GINA^VHP M:O5#*>R;
(=XM&T'7CPKSV&+'8I2FTQQT S:4UK3,(FRP-\KJ*!'-6$SMD0MO M00AMM-/?8R$QK*XE)'UJU@PZS1FC\6KBHJ.
7SI18XATIP?9S. :]DC96S53 M%)!QBR4W]*27FNQ(Y!'5P9IE*ZV.8%?CP*,^[[=70$]$,TY3=?H%B&3,H,R*
(PHVB"7A#UJ81@6,C.A7-*K:9^$..7-LU$XP-G-56SGA<
M/\AF%",QUBW4VZHK]"VL8=M*CR_T8]DC,8(@;5:&5>0'@N%N*&4U\I9J/(^1 M1[8/Q(W;G;>C4M_NE_JHFEDP%M?
L=EYV9=!P$DT>B"0EG M=O-Q'6!20\3\1:44694=GXAF#=9CAY'(.U-AS2B##=:;H 4V%+.F.1O3 M& D@Z-
FM.KDNL]4H$:>/PD%45OI5<)"]<3T6R^%.S\JC M@KH911TQ$6+K()MANK+6=? MOWE=!)<4.3\5'B>UMNJAF/?
[DNILM6RV9#WPGC_UN8SY4#'WME:*!/T9_64' MH5>5O*^>[\;/G%MN]%Q-]_QO)/*4U9=#!7H4#\
(_%GZ__%Z9^6[2/>$_20TX M%:L6>(KC)QT9OJ3?Q7\-_D+S2/RKOT]2M/_SXP>O!-]>2OCZ,,)O'!)*QO'9

M1)}QZH(6>CHL\5V5]HNQ'LH0&/&9I*EKL2G^E?7ND%#7$F0Z"?&0(:X@H, M07[F?MD1&1H"4M-C&0+]S.'0$%=@".HS#>>(:S $I*:K,00.J>D:#,%^)F#4 M= V&@-1T-8; 8++I&@S!?$8Q:(@K, 2DIJLQQ$5W*J AOE$3 0UQ#89 TWY. MT! ?98BW-QM_V]{I^;1FXE]FFJ"GP
M\IYQ)I6O:1U\)M__=0{LTKY_HCPU_FG#YGJOM/X__L71J/_^9WKX6#&!F9L M'ARN#S@SP8P-=/7+V_WR:U+Z,W7EB}+X=9(-),6ZRS7IY3W@VK,2G6 !O+NT M_=E-S7[&KCK8@>MRN"Z'ZW*X+H?
K\OM9E[_,6N3OSEHX^ID]{5KM3T.4HFO; MKG-P]?3^JKL,5RX?JE[]8J6K&!I24'N<+YX_=?*OH79=FO'[>E]M3I M[.DH+;:YM(;7W//]U1?,WZ3NUG]6V'OW[/MG],P]9G!;]K,?'H_+S3S6]9< M-VSFHK)*+@.&=G[#XNJ&S?Q7T_7]OY-KTUW[9A9?ES+V815UP]8N@;FA&I"\ MW[14NF$["^LP#KUO9?7T$S._9W'TOAZ\<'%TY;L?MU*5F/:0OK)!N*JT%RQ*MO).B1.CIUZ#R=1T:O<\SHM#3KT/E7[=TO$.5_ZEY(O3TNS3[=9U\O<^#KM#3 MKT/E:UJ6WV?Y[!5Z^LGS1R]
[M/[NK_&*<Q;0]_R/MR9RYC>'*I M>>)SWAO\B=:@83@N%6JGSRC@0I+!7 M+PMHP\#'*CU"^Q$E?LII0#5LQ?
+_]U.M7?Z42^X]4X+__61L@R].:&MN\"3P M*>9;#_OOO[T?OXX*&"\#KRB:4)-]W89K]GP_+XMT'"4C] MDER-M2WS!9N0E+ZY&DF5.J^:_,49 "'>0P"OJA /;_+" ,0+ \R(Z2'*I'G# MQ(G^9"+.6^K2Y.7T*E>"A<@_;?
[S#I!_R&I"Y+\#^=].M"?'16K.4X'2$PLT MIS:"1YON7.AL-Z%2)GLB;^BG90$3Z,JR4;-M5H?_;^9"TL\%WAX8.U6M/3%!%[%X9,W>X M.=K3>])?[7&J>L$\2#%C_F""4T"3VL#+:ER.RL:Q5KI=E!F 8&R>7>.,9E M^.!O2 @?FD>_
T(X9,J/C'(/B[T,4D? M+*H3W"I^)2?V/V4*!^R5G+NV]@LV14N@IR:-D3$YIC) 'KDP\<1KQQXE2
MC331S9@Q]F98C^8892/%R33Z@ZV2Y-DUWP^!%K]Y;(MN/*:N=MA!27_9.2#B
M&3+:D;V4F3X0&5ON,V:QT0+^I$=L;#*2F60OA<+R"?"%,HM$B0LDKZB(NEW MC L_;
[MTN\KC]TPNML3NLMF50JCF1*.ER*MSO\P!?N' M\=9LYH:8Z3",A"NSFLP!$&[;8AQO)1G:$P5<]US]?BP7>^$-V"'P@_@#DN2L M%W_K&>JW!&WB[Q^4GH45[K#"_:.3N)N=[GUY DMGWGN!RJM/K#F'5.Z1K.T:
M5#UCH8YFZ&X^K!;.?!BHH2ZS:04\0^9)C(&5;_=4_GY]HW 3M?,?O69X=*-? MHO[[^D;A)HK'H>O??
KWS]8W"'%19+0]>_Q\K>ZQN%*RP+AJX/2UIA2>N'NSZL MZ#QKRC!)*J=-,=QY3DW3'T_Y0L-),CL..*2&(B-8Y((%2'IE$/%'A9ZK>H8# MTC[Y'C= VEB!]:!PCK0JTPA/O]FL%N!SISW/,71T^>D?Y:2!"69)S@J3[$G/*=_BT0-*TMON;+T
MFNORKHR"/FS;.4M W[::IV0!G6S[M:4Y"BBG@FVYIL0F!$1]^@H+^V!!,"P(MOGA!\ E)J-
G6Y4:G4!&DSL;#6JH]4FB(NQV*V>'V.-E;90L(Y.*Y22$PT_2 M9Q86+9]U!R+U#F2F^""YO=!> <<_;": ;?
(]@#7+L&89[K'#>EI83PM='];3 M/F8][>WF63^X\0*O+4,_2-[)'[@_^>1T@[B0Q%/%5^'4ZV."/1 KY,<.T0?> MQE#!(1[O
=75G?2)1X)QR210;&P;):DS0\@FT$:1T-%E#$WRJ7B>0DEXZ 66 M/\/R9SA)P_)G6/X,71^6/S]0^?---
Y>X7$PI:U5K5NQO,*%8[X82NYR/9E,^ MB2F3#._)@DI88G[6!*_D>"!^DSW0UB5NC!L CRMHL@
MKWJ;X,UWN%4$9K5WC;HN*/59=V'U?<4M_G[US<\^[5M87HTCS]ANE3@X;[J^ MWW'Z+[$X[\6>Y.BORW;;
(.C,!\KVR'JN7"9J^ RK:JBAF^Y0&P[J SF2,2R] M 8X]85NLAP(>+%>] JZ!LR4L5X7EJA=+6IYQ5ENUAES!
<3!&*$X+=G$TK3AM M]#"K,:>:U6 -ZEE3E+'UH%G>+Z1NFGY:H0.H\,G9^4LT+HO*7<%4+G<:'ST_I*")VW
MU%]"Z#PR='Y2GPFA\Y;ZS5N"SC7OKO1 H!@.T 3%<^)!I^V4AK:L%(H2&I# MHA>RUS9G.T*D?
W\KI0V"0Y8I22@=R131Y?)0(/F28.);TG14O23,-%'&3!"F.?A^-2A;'_G7WWR-HW5K]Q)=M+KYA4 ME4X8^(ER\> ?
Z6\L,7UD$ CUH6FW3(IM$:A?:\7\2*0-CHD\25!YEN5@M/%_[K) ^(-#EO,#^?T]GQ8Q=P///[S)L3/E_2IJM-NDC/8GC.;-
M')% M8Z($R%0"9 C@VRBN/@F KZ\^^JH _.NN$X.HC^*8,M*DADTM6@NN2%=Z?]@' M_)_
O)N/V&AI;Z>HX=8;V]9DH/"XGH"9C<';TGD*@Y<.W$BQ^4D0?>EZ\03# M?UT7B-]<$ZX7FV%D&F@3K70[\K)*J
UC^L& CL!$YS>9+.SL\0R-=9WWXB M(-]YB?J/J-[M9"0DEHV>J0QEHM4O.[U1_?>;L[TI3-ZLYM.!.Y\,)'Q>=9EB M?
2UX?)J\2GM>8'2>HV%;X]LO*1>VP%,-/_Y[=Y[; #^.\7*'FQ7=0\,46&A^
MZ4+S&V2ZW[E(D7RUTG+!/I!MYAI!39TPJ@D*9;&%?LX,24I4(;;OND&4W$9G=!;O(L2OF%COLGC.(QK8/MMV'X;'N^
[;=A^VWH^K#]-FR_?:I(LX%[. ! M-H4=XK@#KE<*:OL_K)3[P^B0$G1O[}3))J MV <[+W#I1MI#X ?
Q!R0;"E[\K6>HWS85$I?_H"T%N'_P>,<"+I[>]MF07*K M[9SZL-H3CM2@:J-= ZJ+O3)&='):L#-)YG M3[F(OD5*O-XS
]>G\O4=.(=*J^Y:/[Z5+Z^BGOHP==<)'Y]*E^ZPAQZ\&V5 M0U^?RI>NI88>?%MUP->G\O45$7^&#N6M;&>#]^N\C-
%/>3(" M-C2PB!;NN,/:3EC;"6L[?[Y[_^L)]]OV/6+UR]7M)V;AKQA5\VQ*$>. MGDRX2>N,4[;->'2PP=).6-KYH$:'I9VPM/-
!C0Y+.V%IY\5+.J\;',JE":C9 M*YPT%4'O>7ALXQ*79F.2VLX318>PLO.LF>[449!9X@U)IOO%'7)@FWP/8&'G
M8Q1VPLU66'0(BPX?V(-AT>'%/1BF-I^B5UY;AGZ0O),_<'_RR<>CV-?'EGH@
M5LB/K=\'WL90P2$$[@'5U1WC9R&OORO46M7RWJ2=Y;ROT2HQF\:Z,)/L M_H28-
<7:!DAZ$JBES6Q/%:G!.MRS9B'Q:*/62P* M71\6+3Y$T>)_3G 3TW"1W?[UD#G\37BEWY_B?JS3_NV
MM*C&H7)LJHIB.,FUZ!VG_[*>X+W8GQS]=0E-&P2=^4#9_NK&HX4H#Y$]VN:$ M4!A;J\9D'2Y6\>*4/5Q;=L*
[CAX=FK"T%):6/JC186GIE9:67F!N_N T[R7F M4-(W\:@TE#I"Q=)9I[]OZV(S2N=0YE1S**PJ/6MV-
W:#0UH7%IF>,"_K>AKP MD(/T%VRUS?FN96BY?Z'I_^XZ)+A%V/YI1O9RYKZ^(7E*ST($/(:YGQ*S$ &9
M+"U$P&.8^RD_"Q&02=9"!#R&N9\2@%>+@'/F_Z[6YZ]^MZ(' L5P@"8HGA./ MB_^T-=$UHL;(;S<=]>/)LJL@V,
!OW\;:+S^/>11DI3)KW(A>INM+KH[$0BT MS*AUKL'V;8>7,4[&R$]?<3R/H]FSN!^WJ?!@!)*F4:^60"Z74X5T" M8J7-
:94@5P\=D"/0?"[QRO_^>_86N,.JUX>I>OWXMK2\+W?F']B'=KE5UOMV
M;SM'@5GDZX;M8%/M3_K0IJITPL!/E(L'_TB76:57!AND/!A*1=\6&55=+#93
M/M8GZ3)+$GF&XO+D_|_>FRXGKF1MH__/52BJW_><{OB@6K.@NK\=(4#,,XCI MCT)
(0@B$!!J8KOYD2F!C@[U=908!N2-VE0LG4@YK/;F&)U?B%[FW#J6J;T4> M/H+8_WD6_N^9+:/K(\#O5SX:@WU
<JRP)R?,*_UO6.EEHZOBN8&^4;EAS=O$ M5Q !&(J,;T0W&G+Z+Y=T%_CI3F?UY!HCY1N!DYTMQIKT>_W:M.:6-
)QNIWOC">!6Q#D69)$C.58A /16&_$)$CH5^=>] MSIJ\@$\:K#!;E*D2PSJZ5+JP1;^;YF0V\:N(+WKO"21^
MDV>+=M+KNE8F+-$6C=9@Z[K,8%4JKBYU[]Y!D:6]RJ@G$B+FNFS7V:+8PEO+
ME#X8M;ET00=>#P$3(@3)Q4B&1'4O4:GH[R1)HH0:B&&)2D6C4M&7VO0^#_07 MG0&=\"NUDKC8J$ZEL?
$+U=6%;L'[=/M[]1H::2G7D%J9LJBE'<$Y';B4#1@L*E>W@WD:R/.G5:&J9YB21AY)8D8PR.(P;:(]'8HS<+=\&! M1\4&
[Y_";U9N L2.!+]^^7((1P?#F5QQG*VRK477[;;%5M^8,/U'K"W$E@>E*P!N.N20B)B)B(B(F M(@E&Q$0DP?>^G(B8&
$)OFMBXNT,-55.#+8TVZH+I7A=78[7EK1,ZM!0"XKR M7LI20X3&JT8G7R^["R\M
HA+V7#E(>F%@=2&G>!6&#NR[UW,'N+A(=%'/#S$PT.BCWAX#\O#^\\EKV,Y2[@R[5(.RX[*%:5
M<@??]*CRB%T.I&7USVN3W^(>;9G+S^2)R:U$(R,WIN-$PR]P*XFDPXJF)\[: MH7J&B"^) ^))(]!%?\A'YDC?8G<\!6>1
M!AQ%:I$&/,=R[V*T2 .. K9(YYCN7K MICQW\!KOF*W)=-%UM+F7K W810>PZ!H M_O??
PZ_H/**_7I3^^A8L*0"6]NT/32T":'F-6J#AW73G*_YI\FVRDG(%0?#U MEM7D>-P4*?T;MS@%0ZGYG@L'!R;_1*G/?
J$ZE^IVH2NVYI-E"M^6%BZN2R0+
M2WW2%$#:9(Q@T875UZ<9WUJYWLS2.:ZO_)!*?.N1WOY^RVMBR/GOQRS,A$&E M-3>T5=*I=8KRD/R!7$$_9@"
(VPX^H\[5MKU-FQXT,N]JU'>K_8\7F]"VO1 MQ[=*5>+$6J%7T],%@1@Z9[XQ^SV.U!);65J06DV8U:?
9>65I^5TBL$7@C5E) M.H:?HDG4!,]>LSU6^M:&>'ME_9Z+<>Z5U!R@<)J?R@(66$%=7$T_:\45I7VIJ=6%T)/PI-
O)6)Z^4.WJI- MZ[Q0M^?4),0/^L=?%,'%&(Y#&')]RO^M->L"&/(!K?_6(XV2CU-AG44UF\P4 MA59V9D]ZM9*^X"
[LE[0IBM4*]"@GS)8EOK@M]--UNQ% *3IPB/)7>>09 M3=G1R E$(X\.C?P.TQ>_S1(G2(DBSD/Q3
_BU:$ENK:P*,@.)P_U1-5K7)8F MOJRH\7R#+O*"T#U>-^[HD;J3Z?T;2;M-) M*;%9SF5A-M%F>+L5KZNM"Q_VP+-
%*R>)N8F0W@I&+C]A\+(46 (!29N+,3B+ ML."1RI-?EX/]B'S(/U?_+W.L,\U:GUROS;$@BYDX7W$)NE2^%L>:X,4D7S77
M2WS13C;)5GQ8GK,KB F08XTHU@]6#/RZ#&H$"'_/D"9[V<5";JL%O$31?"E7 MS!-NZEK:7R,RC"=
(DYG8S;M)/=O;%!JIP"((ZO:P1(Q(D @"'JHH^G4)T,_D M'ZS2K6Y#I1J#!L-X.
MQ<8H1'"^/X+SD9(*:\U1#!=\WQYA2\T%9B5X!Q 0S [O*44ERB^7^+A#$/N- M+,=+)3$BK"1&PTIBU
[5Z&\'/!=$NMKKQJ46/ILT#^$\UY##<'R4)OE3US'/L>9]'^LFTMZ0S M*TK#2X59C\OU&=M>?

_/8X_'VUY%-7_M\]WMU&AH2XFGE 4C:L329HLKMR$J M/-S]$C_^XHYC?@@W_CS@_U1##E,#4<(-M/-
*]..T+]5$,.8]E(@A]D.8G'.XG^ MM5!LE"3XNK9;LI_L,OE6@\!.)?6P-9MOQ,#'Y9A3VF_8608N)*FE/AJ(_,UKK MYK 9;ZY7T-*
Z"0=K+&%R(QW[5^&Q'R!U @J M#,&P+1UC+I/L0MGJ6Q'9HS<+=\&"1[?7WS^1.WJS@_(C,U>K-P%
[36\XD^XG1>-68(H\I!?0M[A"E!_&,7 M,#0L&-JQM# VM#\,>:-M:#L!5:UES(8A8L%L1*L[CO*6'8UC-<=+0CL("(H*
*M(H)&,H2X_TU[,]=J(]YQ9$L/GA-\#P8&I;UPIVW3E(=VV)T7R8;ROWN62HQ: MV01!$+@FMG/UEEXG->U2I%*P?*
*L&O3D4D%_BFILWL=&*ZL9T4(::T!)O2@SG[M\1<9(V@FAN/'1VA0-A=Q2>^42QIE)MZM0>=LF>5CR'G-)C/\$G>*
[LP8]S>5T MORZ49)T?!)## ,A!4(-(OXCT>VO2[SEA]\6399TOZ::0[IK:I-HI9S;Q;]ZA M]
>P,U!64C]OX"PNY\H27MR2.,,UX.PE?OQ%)&,4?L$:8D^EB(@X' 'L0;1+ M1!Q&Q.$GEF!$'+ZY!-
_&_CN'S;:N40.Q81$#/([S2H'"3=]+7^;0UV'IJ& QXTT&V(NXRXRW><>#@K=SEX,&^I=4?+*
M!EK5W2G5!]F#SY(']0I3SXD6T1:Z52O'V'-RHZ4 /),P><#%. [^?\'CN ^2
*MZ46$YL=O{4%^O>0SA7XFC2]&?')HIXM2D=9:"Y2J&1LX,.,Z#*G&AV;+$TM=OZIE\FEK4 =!(__DI2,9J] MB ^*D >Q]Q%*
[_XD7';'W$7O_21<=L??OAKU_E\51SFXCUMV&MQC4+ ??"-U
*MN6LEVH7)"MJ(,%$!C43N(NP2=.+AJHF*0&3B0]G55)BHF&N6&T@KIJWASQHZ MN_ <9Q<0-*
0&QX.^;!8\D&)&K$;GZK@.=>W(-KTY\UX-]D M#\R6P_I_30T,R 6KW]';U!1;MX(GGKJ7-3W29+XW!I-<%\5QBDX/*
*M%S(O412,C *;-XE*,2-&-6)4(PE&C&HDP?>^G(A1'0$)OLMHX^T--;;L-IJ; M@4,(I.([@T2^QB2T%3348'CR8I8:HE%?*
-3HI6HX&.K?55,RT71<#^B$O9<.4 MAZ86!U(:=X%88*X&1 (BN;&,$OS(.?:D]>((HTHTBB?B8BZ3T_41:/J*-/*
*M2AU%HH^XBT_!783"_L](YP\4Q9_Y)FBJUKRQYL!FCC8&[J"QU J68L^T_4%= MEAC-%U.%FQJ*M-*
*A2[7@VJ?]Y3:>/WO;J6N2!J0R6*B<;5ADX&36K]>)/\ Z0 M)TL_),Y4-:\V:LMKX)."A0"=.>&XB=EJT2O%XH(G%-:(H@?*
M?]',L6OZ+P11B&..*9(]!'"] $YIC?8G<*MQ%NM4(+Q"$(+2+>*87#,W:CJHY\;#U+V*^QES;-%3L'WCP*
MWT/;!/>HM=\-RMYNN:,W);L(+= YUCN76P6:*
*M"'*8:F;">\.60X)&9L/NQ1X@)^]_AFT<>AA)__)62S:#8L.QA%=E1QAA%Q.#=*
MA/1__SW\BKXC'NS3\&#/7RJ8=Z7:Z(R5.O56B# Y)\H^QMGFPW!'F6J INGW.QLD1H,6L">8F'97X:.440B1E 7
MO$WG0?)-=T4G/L+8_WD61O"93:/K(\#O7]4P!ON YKAA3T[849UDO=BBQYDT MWB*]0F]-Z&ISL(((P$
$0)K_2&SJBVC^71"B(Z7YG]>4&+7#D/1+'BS/YG* MQ;ACCK\16_D2"A3XT8SFY<1 C)?D'E5-*
*E1)U*T"!Q(^_6(**)9AC;PI!P1VS MRR\"!4]"$/^F]G^9$6Z*T_EFFW,U?,9:W76N71*UPIGM@8]9:!2?)C?];!./*
*M]XN3>'^L9G+) !(@EYO!6<3E?B@N]T4 (8)T[.@!P@NEI>]M2'8]YT;*I M4*-D@6%#!89U0F@\ED@<;^&*
*(1WYO/')AK3F*X8+OVR-LJ;G JL3"&Q?ML,C, M&9;T.ASS:.%O]"H57_"R0_H@M<.:\SP[YI. (N$SVW++8-Q9]5O]&*
*M0N/TU;-AGN.PKM)>)]03&8^A:XRT1*4J":7U=,&MUNLTF^(EBH,9#Y*))4\< MKWD_LB)1.&+%-XF;8AJ1T< 4QZ';QE%*
4>EI6\NX)1+(P'_1FSWR03\6; 93)FI=;\9@3XF\;Z[X>8_=%'$*&H&*N9])]QU!DW"+!&:I)N%G-%FH$T
*Y68CCRG&6G&S34# M5:"^$Z]O^30C@DS7B 4XKQG-A.'PH!B(/<*4('#S$LI4-0<36O4ZHL(B*NQ]*
M1RJ_1H4]>?'HB$"0 M1%Q8Q(5% HZXL(@+>\=;)RR9 M05TPYX> !;%A(P4L:.=$;%C$AD4"CMBPB T;-3;L5\TYS24VQ)
(O-W!9E-M\ M+K-.D69@SD$Z[(7L.<2'C1(?-I"C^! *"XP@OT@+I]WASQJBPSX5'?:A4Z@W M6'7$Q41B(W8K8K<^Z:
(C^NK=T%?O.E)[.YO2+\U2HR6>+8BUL9PN M=FM)C34"FS(HAWLIHQ)1A-*
$$18M1P,]V6HJ9MJNBP'UD9>R83,#7[Y3#-]4W.6@G&X+.<(3JOTB0_6^<:O01V]]-;7SP(\ M2Y63#0O>Z5ZS6B_V->|
X;'T0]).5?-JH[:_NQNHM2XU6IO%VY=().#64^4 M)KVYPTLT$=Q,1ESR8K*GTCI$/45;Y7TO)^*6/L-6>>8@Y2VV-
*+\XFU4/#?0QL SRX5'I)0;R@4T9NE#VFJ2'6>674^H+$BU?D*S16ISO.J MSH>\2J0Z7^%=(M5Y9M7Y@)>)5.*
*[CM&]_C3<#Q#P-,,);T69"('@_DBI"H"%,9[PU*13*5 M-&HKB28E@O[Q%X'"")]X8.X#X= '42*$0U\AT2(M-\A.|*
*MUBH*0V;4W<:'? AW$4A!!%A3\W6K8BP_QV^>>3A0'_\E9+-H(ZN[&%%W](P M"H]A4&C_^^_A.0 "L6"CX*2#*
Y)\HB$N-4JF-WRCV\ 6=(FH#2NL-)5VB]>J+SI&VBO-5W.>'5F;- MC8W.^)NEV_Y.F8M@#
[9\J3T2#6YA=X5.F5/)8%>&E7:)1(RA$DBC[X-;?A&- M?
D1Z^#>5^,M\\+&Q=/&NZUMBK6J4BTNC@7?:WRRM_5ZA/PQ'&'U;K4F% BZ4 MULN!M&RG/,X--
*!LRN1F21%3N.Z%R7T2O;\W&CIY>?Y"1Z.?GJ6RYG.*G);E6 MG>DB09H2?*
*R4E[F]TNI=IN+QH.'HSXXP:HW8YL+5A6H),D#&6.7:9D2)'D]%^ M(45^\(+'[[6Z5G0WE52JEYR2*BDVR4FFW.*
(O;":74VDOT5AOFE-YPLQ%U]?G M+98/]!"6N"8&$UPCUC%^,_5\"Z)XL):)L\6$*Q6DJV2,%BV\$UI/0>&@O>:H*
*M)T+_4[4/I$9DFZ)1<_M+9]!3O!1P16@8^B>Y&$L?.R.(6H%*0Z/2T$CT46GH*
*MBW'FHR3ZEZ((G6.7_3QJSY)=V2TF^)+H)^1,1DF4Q1YYH0M7/MUO#X+Z=;TK MTUZ(*SZC",Q)]5.$957B^*
*ME)F9&E2K";G"#D79JFEJ-6\,U-XWV5G?- W;0[F43ZM;?=JR4]Z(VTYDKQ"$ M8F @^S*V803YZ=<.:U\SAMW17 ^*
$:P'?"C8RBO46PH[^>+8=_C^B&B^0-$ MIY<;W?FUD_/;J/DBY0=O+%AAC/I$.'IB4:LV-\1]O#;"&3?/Y'!#Y"6:@>%H
*MFHR12<1"OQ,6>O2&_/ 4]IM#Q)=LIB\@Q GK:*39[76CL5+%6E;S4IO>H.FM M V1@?*
*OQU?'@/@4(DF>W1&W+T:/&H]&F4F=S1&_*M:>!(@N^+LQR](=^:\(PD M^+*
*[(NM$;\L,S?:\33OTSUT!4$^F!OADQHERRT]5>:14GYROH&@35/1#W]^ZY MO\'*QX?*
*P=D0@E:_7(V+:&OZL(>KO4U%_4984\5 1#Q6)/N*A(AYJ-(+E5^6A MWNXZZ=:V/6VUMNQ<).?*
*%E8D74H5.'UC:+&2O4C&*81"!%1%8$8$5;=*(P(H(*
*MKCT8$5$5BC'7&]O4UIC6U2;L7+##YKRKV\HFXFC5X#VI1!_89+&96(^7K5 M".[K+9*8+AL6!O1#7LJ&*0]-*
+0ZD-.X"L<#9 GZ\EK1(I]$%(L MRJHBPN9]$S:1!"-V(6(7/JT$(W9A!"0XTGF
+Q>@'59HNK\5/CY3ZU8>1I3M$GS,8K9JB:+M%<4+V63B01&1\101$1
M%$DP(H)&08+O.BQYQ6VMC%>Z)4FJ3(1NDQG,^*&-;Q&L*UQ%]O6$(_TJE%(ML/R8":0$0X31BQ-&HWOQ) MU?
*F0(8E4YRL,2J0ZSZPZ'S LD>I\A8$97=7YSP7N\CIKQN2#J[W28G^96RES M9EIC%G*G*PPFX_6?W\!''/\P<*
*1C1)_=ZI7DE&Y#\!N^4*N.QJWQP,@J\89$ M)X);O9(QG#Z^1?=\=WHA&/H@2(1@Z"ML6 1#EXM$?*
QE!!G@]2[1]Q<'!V7:>_MB/?IH0QOUF95POAB!/1FC=3\>M"*W_';YYY$J#$@]Z9:K@ERG9E"U%PV0/ M:VES+]C2,
J/85 R__OOX3E0X'DIK6]AC@(PI]K^T-0B@'/7 0;7KIXOK*. M274S@'>,MZ>M IT=Y),)G7;T;]Q+%@REYGLN'!R8_!-*
U7LV$-)Q/X@-3C*_R MX^:(QR>IV4JBD[#.*T/'&)H$0(FN-S]K./[&:O-F2LYQO>HN?OZ :/![]Z]> M$PK.?
*W_KI%PL<(E"/S\E!Y-FAN]PK*SI$ H8 47/%#^9! 0I!4>#0)V>0 $ M 1>I6V'CBBZH#6,B^@HW;6G#>9R\ZFLC'L)!*
MXL=?+GD@F$"6?-ESP:)NP2'-'%A$L$0[X) U^FK??BSF;+SAT73R>+E4J+ MD=IQYL_CLB9?3)@ M"+)!CP8,N_0-
*H9O9V>4>:Z87@XD#4_SAK[HZ,6)Y9_93_@0!91\9Y-LZ15. M[#;DPH*M2V9Y%,0.8(J&3!(Q-*
LDA#AK1N;QH("*P+"BY#?TIPU6-SJIL;A) MYBBS(0OK?N;"MK[Y/()3G''M$EN#;W?BW:BSW?X(_]M]63$UVH%*.=Z]X*
M@5SX]MU&@^/_>S[5^U"8R -4W2$K]I[K_\]AWU\3JG'%-FWGUWYO.!C4.$S^ MD0&0Z%I\Z&CR-
*"Z/P'M_R>9*WKC[;2<9)FF#?>?7R_Y"[42;3/XO=O SG(ZC MN9S)Z_C!C.V *VYJ(^_7[FO[SX(]Y>5#VPTB/;\<#?*
*AYP*V#3W_SW&!A/'O^ MBP1V#I0&\,_=R&@"[D9?6]DTF/6A8X"5R6OF4H.H#%=)MMSX\5(1X*$FL"_W*
M[R%^DHGW:L^^+-1_Y;/(Q@]L[,_=\:]M6SF)RP&66'"G,_]SF-S=?03@!<(O M!(XTW% M>&WG3@?D0SWX5
."!8N#Q7E5O-V"O7[X=J6/%C#\)=CUE'_"%MC_MPDHJ45,FD MI%&:PBD)34ERB1_A1-QD6_@L]^Q-T ['0SL#L*
*4T'P@FVX,*UC*SY>4?#C* MM.R.LZ:]3R:@.*/VR8Z4/=ZP7U\X-9!0,!H.C"0;YV>/H,R.\G2Z(9''+1-)39YPLIZ:YC9Q*
M,5NNIX:))B]1QRT=6TD)0%-RTYQL$45*7RA&=P5:,N]:IHWZ9-GM;85IRQ/& M"82_K[EW#1PHMG*RE,R46\T]$S:]C2>
*M,>1V9KZ2V!/]|/JE@>'3[>ELH_;XKL^SXR$O<<#!KI*B\1^/%#=65:(E36L/'-B#6\8;WJ M3IF&1!#'3:MF)]^N#<3>U+?*
*3\;7B=5K;]$H"6]CQH!;Q;2N==(L"NRI[F\6, M7GH*Z !UW#0Y;8S&U' QGFIUL5FM2U/>: 5-CX;%T1V?*
=&M":EK2+QH+GP[M+X"F)R3*QY4JFW:)KMBE?#7+.$E)G(&^GA"I'-"Q5<4>%87NM#HJ9Q15B+?*
M#)Q8_[JN;N;#MBE._7RW.L]6^>RP#)J>$H!"VJ%%R]*$C<8LDOET2:KG0=,3 M$C"K:SR?'F5PP1B5N%?[-*
#C!=#G$R*@-TM+?VN:$Z&4)=8#,M';2A-=(D\L M;,DTZ 2[7(MBM]LM%1:-07E@\!)Y8F&=AC_+]]N%\72C55?

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